US20230303704A1 - Fgfr3 antibodies and methods of use - Google Patents

Fgfr3 antibodies and methods of use Download PDF

Info

Publication number
US20230303704A1
US20230303704A1 US18/045,995 US202218045995A US2023303704A1 US 20230303704 A1 US20230303704 A1 US 20230303704A1 US 202218045995 A US202218045995 A US 202218045995A US 2023303704 A1 US2023303704 A1 US 2023303704A1
Authority
US
United States
Prior art keywords
seq
amino acid
acid sequence
sequence
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/045,995
Inventor
Yves SABBAGH
Yangde Chen
William Brondyk
Huawei Qiu
Sunghae Park
Ronnie Wei
Yu Qiu
Yanfeng Zhou
Cendrine Lemoine
Hyunsuk Cho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Recherche et Developpement
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to US18/045,995 priority Critical patent/US20230303704A1/en
Assigned to GENZYME CORPORATION reassignment GENZYME CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
Assigned to SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT reassignment SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEMOINE, CENDRINE
Assigned to GENZYME CORPORATION reassignment GENZYME CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHO, HYUNSUK, ZHOU, Yanfeng, CHEN, YANGDE, SABBAGH, Yves, QIU, HUAWEI, BRONDYK, WILLIAM, PARK, Sunghae, QIU, YU, WEI, Ronnie
Publication of US20230303704A1 publication Critical patent/US20230303704A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • anti-FGFR3 anti-fibroblast growth factor receptor 3
  • Fibroblast growth factor receptor 3 is a protein involved, in part, in the negative regulation of bone development, being highly expressed in growth plate chondrocytes (Sarabipour et al. Biochim Biophys Acta. 1858(7 Pt A): 1436-1442. 2016).
  • FGFR3 is a single-pass membrane receptor tyrosine kinase with 3 Ig-like domains (D1-D3). Binding of FGFR3 to an FGFR3-ligand, such as FGF18, triggers ligand-dependent receptor dimerization which leads to tyrosine kinase activation and downstream signal transduction. This signaling cascade regulates, among other things, chondrocyte proliferation and differentiation.
  • FGFR3 is a member of the fibroblast growth factor receptor family, which also includes FGFR1, FGFR2, and FGFR4.
  • Each member of the receptor family is a single-pass membrane receptor tyrosine kinase and shares the feature of 3 Ig-like domains.
  • each member of the receptor family possesses a high degree of homology with the other members.
  • Strategies to develop FGFR3-specific inhibitors have proven challenging for this reason. Nonetheless, it is important to develop FGFR3-specific inhibitors that do not cross-react with other fibroblast growth factor receptor family members to avoid unwanted side effects in the treatment of an FGFR3-mediate disease or disorder.
  • antigen-binding proteins or antigen-binding fragments thereof that achieve effective inhibition of FGFR3 activity.
  • Such antigen-binding proteins or antigen-binding fragments thereof may be useful in the treatment of FGFR3-mediated diseases and disorders.
  • anti-FGFR3 antigen-binding proteins or antigen-binding fragments thereof such as antibodies and antigen-binding fragments thereof.
  • the antigen-binding proteins or antigen-binding fragments thereof, such as anti-FGFR3 antibodies and antigen-binding fragments thereof of the disclosure are suitable for treating FGFR3-mediated diseases and disorders.
  • the disclosure provides an antigen-binding protein or antigen-binding fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GX 1 TFTDX 2 E (SEQ ID NO: 157), wherein X 1 comprises or consists of Y or D and X 2 comprises or consists of F or Y; a CDR-H2 sequence comprising the amino acid sequence of IDPETGX 3 T (SEQ ID NO: 158), wherein X 3 comprises or consists of G or S; or CDR-H2 sequence comprising the amino acid sequence of INPNNGX 4 T (SEQ ID NO: 159), wherein X 4 comprises or consists of G or V; or CDR-H2 sequence comprising the amino acid sequence of VX 5 PETGGT (SEQ ID NO: 160), wherein X
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), GDTFTDYE (SEQ ID NO: 295), or GYTFTDFE (SEQ ID NO: 296); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101), VDPETGGT (SEQ ID NO: 297), IDPETGST (SEQ ID NO: 298), or VEPETGGT (SEQ ID NO: 299); a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAMDY (SEQ ID NO: 72), TRTYEGYPYAMDY (SEQ ID NO: 300), or TRTYDGYPYAFDY (SEQ ID NO: 301); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLLYSNNQKNY (SEQ ID NO: 73), QSVLYSNNNK
  • the VH domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 6, SEQ ID NO: 18, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 10, SEQ ID NO: 110, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 57, and SEQ ID NO: 58; and the VL domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 7, SEQ ID NO: 19, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 7, SEQ
  • the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 63 or 65
  • the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67 or 69.
  • the VH domain is at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO:
  • the antigen binding protein or fragment thereof of comprises an antibody heavy chain at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 63 or 65, and an antibody light chain at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 67 or 69.
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NO: 71), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAMDY (SEQ ID NO: 72); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLLYSNNQKNY (SEQ ID NO: 73), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NO: 74), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75).
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 6, and the VL domain comprises the amino acid sequence of SEQ ID NO: 7.
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NO: 76), a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NO: 77), and a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGAMDY (SEQ ID NO: 78); and
  • the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NO: 79), a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NO: 80), and a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NO: 81).
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 8
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 9.
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NO: 82), a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NO: 83), and a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGSMDF (SEQ ID NO: 84); and
  • the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NO: 85), a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NO: 86), and a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NO: 87).
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 10
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 11.
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTVTDYY (SEQ ID NO: 88), a CDR-H2 sequence comprising the amino acid sequence of INPNNGVT (SEQ ID NO: 89), and a CDR-H3 sequence comprising the amino acid sequence of AREEDFDGFDY (SEQ ID NO: 90); and
  • the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVSTG (SEQ ID NO: 91), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NO: 92), and a CDR-L3 sequence comprising the amino acid sequence of QQHYSTPLT (SEQ ID NO: 93).
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 12
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 13.
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFSDFE (SEQ ID NO: 94), a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NO: 95), and a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTMDY (SEQ ID NO: 96); and
  • the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY (SEQ ID NO: 97), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NO: 98), and a CDR-L3 sequence comprising the amino acid sequence of HQYLSSYT (SEQ ID NO: 99).
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 14
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 15.
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFTDFE (SEQ ID NO: 100), a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NO: 101), and a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSRTMDY (SEQ ID NO: 102); and
  • the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY (SEQ ID NO: 103), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NO: 104), and a CDR-L3 sequence comprising the amino acid sequence of HQYLSSYT (SEQ ID NO: 105).
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 16
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 17.
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of VDPETGGT (SEQ ID NO: 297), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAFDY (SEQ ID NO: 301); and
  • the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSNNNKNY (SEQ ID NO: 302), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, 104), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75).
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 57
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 19 or 59.
  • the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 63
  • the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of VDPETGGT (SEQ ID NO: 297), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAFDY (SEQ ID NO: 301); and
  • the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSDNQKNY (SEQ ID NO: 306), a CDR-L2 sequence comprising the amino acid sequence of FAS (SEQ ID NO: 304), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75).
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 57
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 61.
  • the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 65
  • the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antigen binding protein or antigen-binding binding fragment thereof binds a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 133.
  • the antigen binding protein or antigen-binding fragment thereof binds a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 134.
  • the antigen binding protein or antigen-binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through L163 of SEQ ID NO: 133.
  • the antigen binding protein or antigen-binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through N170 of SEQ ID NO: 133.
  • the antigen binding protein or antigen-binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through D160 and G197 through L213 of SEQ ID NO: 133.
  • the antigen binding protein or antigen-binding binding fragment thereof is a chimeric or humanized antibody or antigen-binding binding fragment thereof.
  • the antigen binding protein or antigen-binding binding fragment thereof is a human antibody or antigen-binding binding fragment thereof.
  • the antigen binding protein or antigen-binding binding fragment thereof is a monoclonal antibody or antigen-binding binding fragment thereof.
  • the antigen binding protein or antigen-binding binding fragment thereof comprises one or more full-length antibody heavy chains comprising an Fc region.
  • the Fc region is a human IgG1 Fc region.
  • the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab), F(ab′)2, Fab′-SH, Fv, or scFv fragment.
  • the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab) fragment.
  • the antibody F(ab) fragment comprises SEQ ID NO: 56 and the first about 100 amino acids of SEQ ID NO: 54.
  • the antibody F(ab) fragment comprises SEQ ID NO: 57 and the first about 100 amino acids of SEQ ID NO: 54.
  • the antibody F(ab) fragment comprises SEQ ID NO: 58 and the first about 100 amino acids of SEQ ID NO: 54.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 141 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 142.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 143 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 144.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 145 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 146.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 147 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 148.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 149 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 150.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 151 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 152.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the antigen binding protein or antigen-binding binding fragment thereof comprises cross-reactivity to mouse and cynomolgus FGFR3.
  • the antigen binding or antigen-binding binding fragment thereof protein does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • the antigen binding protein or antigen-binding binding fragment thereof does not bind to each of FGFR1, FGFR2, and FGFR4.
  • the antigen binding protein or antigen-binding binding fragment thereof binds to each of FGFR1, FGFR2, and FGFR4 with an affinity of 100 ⁇ M or greater.
  • the antigen binding protein or antigen-binding binding fragment thereof binds human FGFR3 with an equilibrium dissociation constant (KD) of 10 nM or less.
  • the antigen binding protein or antigen-binding binding fragment thereof binds human FGFR3 with an off rate (Kd) of 10 ⁇ 4 or greater.
  • the antigen binding protein or antigen-binding binding fragment thereof inhibits ligand-induced FGFR3 dimerization with IC 50 of 5 ⁇ g/ml or less.
  • the antigen binding protein or antigen-binding binding fragment thereof inhibits FGFR3 receptor activation and downstream signaling with IC 50 of 5 ⁇ g/ml or less.
  • the antigen binding protein or antigen-binding binding fragment thereof inhibits the activity of an FGFR3 G380R mutant.
  • the antigen binding protein or antigen-binding fragment thereof is capable of penetrating a bone growth plate.
  • the antigen binding protein or antigen-binding fragment thereof is capable of decreasing binding of FGFR3 and its ligand in a bone growth plate.
  • the disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising the antigen binding protein or antigen-binding fragment thereof recited above, and a pharmaceutically acceptable carrier.
  • the disclosure provides an isolated nucleic acid molecule encoding the antigen binding protein or antigen-binding fragment thereof recited above.
  • the disclosure provides an expression vector comprising the nucleic acid molecule recited above.
  • the disclosure provides a host cell comprising the expression vector recited above.
  • the disclosure provides a method for treating a FGFR3-mediated disease or disorder in a subject, comprising administering to a subject in need thereof the antigen binding protein or antigen-binding fragment thereof recited above.
  • the FGFR3-mediated disease or disorder is achondroplasia.
  • the achondroplasia is FGFR3 G380R+ achondroplasia.
  • the subject suffering from achondroplasia comprises one or more symptoms selected from the group consisting of shortened proximal limbs, brachydactyly, large head with prominent forehead frontal bossing, small midface with a flattened nasal bridge, spinal kyphosis, spinal lordosis, varus, valgus, ear infections, sleep apnea, and hydrocephalus.
  • the FGFR3-mediated disease or disorder is cancer.
  • the cancer is bladder cancer melanoma, urothelial cancer, and endometrial cancer.
  • the disclosure provides a method for treating achondroplasia in a subject, comprising administering to a subject in need thereof an antigen-binding protein fragment that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • the disclosure provides a method for inhibiting one or both of FGFR3 activity and expression in a bone growth plate of a subject, comprising administering to a subject an antigen-binding protein fragment that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • the disclosure provides an antigen-binding protein or antigen-binding fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein the antigen binding protein binds a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 134.
  • FGFR3 fibroblast growth factor receptor 3
  • the antigen binding protein binds a region of human FGFR3 polypeptide comprising the amino acids D143 through L163 of SEQ ID NO: 133.
  • the antigen binding protein or antigen-binding binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through N170 of SEQ ID NO: 133.
  • the antigen binding protein or antigen-binding binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through D160 and G197 through L213 of SEQ ID NO: 133.
  • the disclosure provides an antigen-binding protein or antigen-binding fragment thereof with binding specificity to a fibroblast growth factor receptor 3 (FGFR3) epitope, comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein the antigen binding protein or antigen-binding binding fragment thereof competes for binding to FGFR3 with an antibody comprising VH/VL domain amino acid sequence pairs selected from the group consisting of: SEQ ID NO: 6/SEQ ID NO: 7, SEQ ID NO: 8/SEQ ID NO: 9, SEQ ID NO: 10/SEQ ID NO: 11, SEQ ID NO: 12/SEQ ID NO: 13, SEQ ID NO: 14/SEQ ID NO: 15, and SEQ ID NO: 16/SEQ ID NO: 17.
  • FGFR3 fibroblast growth factor receptor 3
  • the antigen binding protein or antigen-binding binding fragment thereof is a chimeric or humanized antibody or antigen-binding binding fragment thereof.
  • the antigen binding protein or antigen-binding binding fragment thereof is a human antibody or antigen-binding binding fragment thereof.
  • the antigen binding protein or antigen-binding binding fragment thereof is a monoclonal antibody or antigen-binding binding fragment thereof.
  • the antigen binding protein or antigen-binding binding fragment thereof comprises one or more full-length antibody heavy chains comprising an Fc region.
  • the Fc region is a human IgG1 Fc region.
  • the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab), F(ab′)2, Fab′-SH, Fv, or scFv fragment.
  • the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab) fragment.
  • the antibody F(ab) fragment comprises SEQ ID NO: 56 and the first about 100 amino acids of SEQ ID NO: 54.
  • the antibody F(ab) fragment comprises a heavy chain comprising SEQ ID NO: 57 and the first about 100 amino acids of SEQ ID NO: 54.
  • the antibody F(ab) fragment comprises a heavy chain comprising SEQ ID NO: 58 and the first about 100 amino acids of SEQ ID NO: 54.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 141, 164, 173, 182, 191, 200, 209, 218, 227, 236, 245, 254, 263, 272, or 281, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 142.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 143, 165, 174, 183, 192, 201, 210, 219, 228, 237, 246, 255, 264, 273, or 282, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 144.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 145, 166, 175, 184, 193, 202, 211, 220, 229, 238, 247, 256, 265, 274, or 283, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 146.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 147, 167, 176, 185, 194, 203, 212, 221, 230, 239, 248, 257, 266, 275, or 284, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 148.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 149, 168, 177, 186, 195, 204, 213, 222, 231, 240, 249, 258, 267, 276, or 285, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 150.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 151, 169, 178, 187, 196, 205, 214, 223, 232, 241, 250, 259, 268, 277, or 286, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 152.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the antigen binding protein or antigen-binding binding fragment thereof comprises has cross-reactivity to mouse and cynomolgus FGFR3.
  • the antigen binding or antigen-binding binding fragment thereof protein does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • the antigen binding protein or antigen-binding binding fragment thereof does not bind to each of FGFR1, FGFR2, and FGFR4.
  • the antigen binding protein or antigen-binding binding fragment thereof binds to each of FGFR1, FGFR2, and FGFR4 with an affinity equilibrium dissociation constant (KD) of 100 ⁇ M or greater.
  • KD affinity equilibrium dissociation constant
  • the antigen binding protein or antigen-binding binding fragment thereof binds human FGFR3 with an equilibrium dissociation constant (KD) of 10 nM or less.
  • the antigen binding protein or antigen-binding binding fragment thereof binds human FGFR3 with an off rate (Kd) of 10 ⁇ 4 or greater.
  • the antigen binding protein or antigen-binding binding fragment thereof inhibits ligand-induced FGFR3 dimerization with IC 50 of 5 ⁇ g/ml or less.
  • the antigen binding protein or antigen-binding binding fragment thereof inhibits FGFR3 receptor activation and downstream signaling with IC 50 of 5 ⁇ g/ml or less.
  • the antigen binding protein or antigen-binding binding fragment thereof inhibits the activity of an FGFR3 G380R mutant.
  • the antigen binding protein or antigen-binding binding fragment thereof is capable of penetrating a bone growth plate.
  • the antigen binding protein or antigen-binding binding fragment thereof is capable of decreasing the binding of FGFR3 with its ligand in a bone growth plate. In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is capable of decreasing the kinase activity of FGFR3 in a bone growth plate.
  • compositions comprising the antigen binding protein or antigen-binding fragment thereof as described herein.
  • pharmaceutical composition comprises a pharmaceutically acceptable carrier.
  • an isolated nucleic acid molecule encoding the antigen binding protein or antigen-binding fragment thereof as described herein.
  • an expression cassette comprising said nucleic acid molecule.
  • an expression vector comprising the isolated nucleic acid molecule.
  • a host cell comprising the expression vector, the expression cassette or the nucleic acid molecule.
  • a method for treating a FGFR3-mediated disease or disorder in a subject comprises administering to a subject in need thereof the antigen binding protein or antigen-binding fragment thereof as described herein.
  • the FGFR3-mediated disease or disorder is achondroplasia.
  • the achondroplasia is FGFR3 G380R+ achondroplasia.
  • the FGFR3-mediated disease or disorder is cancer.
  • the cancer is bladder cancer melanoma, urothelial cancer, and endometrial cancer.
  • the method comprises administering to a subject in need thereof an antigen-binding protein fragment that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • the method comprises administering to a subject an antigen-binding protein fragment that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • the subject is a child. In certain embodiments, the child is an infant. In certain embodiments, the infant is a newborn.
  • the method comprises administering to the subject an antigen-binding protein or an antigen-binding protein fragment thereof that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • FIG. 1 schematically depicts fibroblast growth factor receptor 3 (FGFR3) isoform IIIc.
  • FIG. 2 depicts heat maps generated with hydrogen deuterium exchange (HDX) mass spectrometry used to determine the epitopes on FGFR3 for select antibodies by measuring the amide hydrogen deuterium exchange on FGFR3.
  • HDX hydrogen deuterium exchange
  • FIG. 3 depicts fluorescent images from internalization assays to detect internalization of anti-FGFR3 antibodies in KMS-11 cells.
  • FIG. 4 graphically depicts the average amount of anti-FGFR3 antibody internalization relative to the total amount of antibody.
  • FIG. 5 A - FIG. 5 C graphically depict inhibition of FGFR3 dimerization by anti-FGFR3 antibody KC18 ( FIG. 5 A ), KE58 ( FIG. 5 B ), KE94 ( FIG. 5 C ). Inhibition was evaluated by a chemiluminescent assay in U2OS cells co-expressing fusion protein of ⁇ -galactosidase-prolink (PK) and FGFR3 (FGFR3-PK) and ⁇ -galactosidase-enzyme acceptor (EA) and FGFR3 (FGFR3-EA).
  • PK ⁇ -galactosidase-prolink
  • FGFR3-PK FGFR3
  • EA ⁇ -galactosidase-enzyme acceptor
  • FIG. 6 depicts an alignment of anti-FGFR3 antibodies KC18, KE63, and KE94.
  • FIG. 7 depicts an alignment of anti-FGFR3 antibody KC18_Hu18 with variants. Mutations of Hu18 residues are highlighted green or red.
  • FIG. 8 A - FIG. 8 C depict graphs demonstrating IC 50 values for the inhibition of Erk phosphorylation by humanized anti-FGFR3 antibodies Hu18 ( FIG. 8 A ), Hu44 ( FIG. 8 B ), and Hu46 ( FIG. 8 C ). Inhibition of Erk phosphorylation was determined by a homogenous time-resolved fluorescence (HTRF) assay.
  • HTRF time-resolved fluorescence
  • FIG. 9 A - FIG. 9 B graphically depict relative Erk phosphorylation inhibition by anti-FGFR3 antibodies KC18 ( FIG. 9 A ), KE63 ( FIG. 9 B ), and KE94 ( FIG. 9 B ) and their corresponding Fab fragments.
  • FIG. 10 A - FIG. 10 C graphically depict relative Erk phosphorylation inhibition by anti-FGFR3 antibody KC18 in different formats.
  • FIG. 10 A depicts inhibition effect of KC18 as a full-length antibody (KC18), a Fab fragment (Kc18 Fab), a one-armed, monovalent antibody (MetMab), and a PEGylated Fab fragment (PEG) in WT cells.
  • FIG. 10 B depicts inhibition effect of KC18 as a full-length antibody (IgG), a Fab fragment, a one-armed, monovalent antibody (MetMab), and a PEGylated Fab fragment (PEG) in Ach cells.
  • FIG. 10 A depicts inhibition effect of KC18 as a full-length antibody (KC18), a Fab fragment (Kc18 Fab), a one-armed, monovalent antibody (MetMab), and a PEGylated Fab fragment (PEG) in Ach cells.
  • IgG full-length antibody
  • FIG. 10 C depicts KC18 fab fragments with half-life extension moieties using a human albumin nanobody conjugate (KC18 Fab-HLE), with and without human serum albumin (HSA) or mouse serum albumin (MSA). Erk phosphorylation was measured in an HTRF assay and compared to an isotype control (Iso).
  • KC18 Fab-HLE human albumin nanobody conjugate
  • HSA human serum albumin
  • MSA mouse serum albumin
  • FIG. 11 graphically depicts inhibition of Erk phosphorylation by humanized anti-FGFR3 antibodies Hu18, Hu44, and Hu46. Inhibition of Erk phosphorylation was determined using an HTRF assay.
  • FIG. 12 A - FIG. 12 B graphically depict femur ( FIG. 12 A ) and tibia ( FIG. 12 B ) length in an achondroplasia mouse model (Ach), which is a transgenic mouse that overexpresses the mouse FGFR3 protein with the G380R mutation under the collagen II promoter.
  • Mice were administered the KC18 fab fragment subcutaneously from 3 days of age to 20 days of age.
  • FIG. 13 A - FIG. 13 B graphically depict vertebrae ( FIG. 13 A ) and skull ( FIG. 13 B ) length in the Ach mouse model.
  • NL nasal length
  • FL frontal length
  • PL parietal length.
  • FIG. 14 graphically depicts brain volume in the WT and Ach mouse model treated by saline or KC18 fab fragment.
  • FIG. 15 A graphically depicts Kyphosis Index in the WT and Ach mouse model treated by saline or KC18 fab fragment.
  • FIG. 15 B depicts the calculation of Kyphotic Index using a mouse model.
  • FIG. 16 A graphically depicts femur growth plate (GP) volume in Ach mouse model treated by vehicle or KC18 fab fragment.
  • FIG. 16 B depicts femur diameter in Ach mouse model treated by vehicle or KC18 fab fragment.
  • FIG. 17 graphically depicts increased secondary ossification center in tibia in Ach mouse model compared to those treated with vehicle.
  • Antigen-binding proteins or antigen-binding fragments thereof are provided. Methods of inhibiting one or more FGFR3 activities, and methods of treating FGFR3-mediated diseases and disorders are also provided.
  • FGFR3 refers to the FGFR3 protein encoded by the FGFR3 gene.
  • FGFR3 belongs to a family of fibroblast growth factor receptors that also includes FGFR1, FGFR2, and FGFR4.
  • FGFR3 is a single-pass membrane receptor tyrosine kinase with 3 Ig-like domains (D1, D2, and D3).
  • Ligand dependent receptor dimerization leads to tyrosine kinase activation and downstream signal transduction.
  • FGFR3 undergoes alternative splicing leading to several isoforms, including isoform IIIb and isoform IIIc.
  • IIIb and IIIc arise from alternative splicing of exons 8 and 9.
  • IIIb and IIIc have identical Ig1 (D1) and Ig2 (D2) domains, but vary in the Ig3 (D3) domain.
  • FGFR3 IIIc that is the major FGFR3 isoform in chondrocytes and mediates the anabolic effects of the FGFR3 ligand, FGF18, in articular cartilage.
  • the structure and function of FGFR3 is described in further detail in Olsen et al. (PNAS. 101(4): 935-940. 2004), incorporated herein by reference in its entirety for all purposes.
  • the human FGFR3 isoform IIIc amino acid sequence is recited below.
  • FGFR3 G380R Mutations in FGFR3 can lead to certain undesired conditions.
  • a G380R mutation in the transmembrane domain of FGFR3 is associated with 98% of all achondroplasia cases.
  • FGFR3 with a G380R mutation can be referred to as FGFR3 G380R , and the sequence of the human FGFR3 G380R isoform IIIc is recited below.
  • antibody or “antigen-binding protein” refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive with an antigen or epitope (e.g., a FGFR3 antigen or epitope), and includes both polyclonal and monoclonal antibodies, as well as functional antibody fragments thereof, including but not limited to fragment antigen-binding (Fab) fragments, F(ab′)2 fragments, Fab′ fragments, Fv fragments, recombinant IgG (rIgG) fragments, single chain variable fragments (scFv) and single domain antibodies (e.g., sdAb, sdFv, nanobody) fragments.
  • Fab fragment antigen-binding
  • rIgG recombinant IgG
  • scFv single chain variable fragments
  • single domain antibodies e.g., sdAb, sdFv, nanobody
  • antibody includes genetically engineered or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, meditope-enabled antibodies, heteroconjugate antibodies (e.g., bispecific antibodies, diabodies, triabodies, tetrabodies, tandem di-scFv, tandem tri-scFv) and the like. Unless otherwise stated, the term “antibody” should be understood to encompass functional antibody fragments thereof. As used herein, the term “functional antibody fragment” refers to an antibody fragment having at least 80%, at least 85%, at least 90%, or at least 95% affinity as the antibody of interest from which the fragment is derived from.
  • CDR complementarity determining region
  • CDR-H1, CDR-H2, CDR-H3 three CDRs in each heavy chain variable region
  • CDR-L1, CDR-L2, CDR-L3 three CDRs in each light chain variable region
  • FR Framework regions
  • FR-H1, FR-H2, FR-H3, and FR-H4 there are four FRs in each heavy chain variable region (FR-H1, FR-H2, FR-H3, and FR-H4), and four FRs in each light chain variable region (FR-L1, FR-L2, FR-L3, and FR-L4).
  • the boundaries of a given CDR or FR may vary depending on the scheme used for identification.
  • the Kabat scheme is based structural alignments
  • the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters, for example, “30a,” and deletions appearing in some antibodies. The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering.
  • the Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme.
  • a “CDR” or “complementary determining region,” or individual specified CDRs (e.g., “CDR-H1,” “CDR-H2,” “CDR-H3”), of a given antibody or region thereof, such as a variable region thereof, should be understood to encompass a (or the specific) complementary determining region as defined by any of the known schemes.
  • an “FR” or “framework region,” or individual specified FRs (e.g., “FR-H1,” “FR-H2”) of a given antibody or region thereof, such as a variable region thereof, should be understood to encompass a (or the specific) framework region as defined by any of the known schemes.
  • the scheme for identification of a particular CDR or FR is specified, such as the CDR as defined by the IMGT, Kabat, Chothia, AbM, or Contact method.
  • the particular amino acid sequence of a CDR or FR is given.
  • all particular CDR amino acid sequences mentioned in the disclosure are IMGT CDRs.
  • alternative CDRs defined by other schemes are also encompassed by the present disclosure, such as those determined by abYsis Key Annotation (Website: abysis.org/abysis/sequence_input/key_annotation/key_annotation.cgi).
  • the term “specifically binds,” “specifically binding,” “binding specificity” or “specifically recognized” refers that an antigen binding protein or antigen-binding fragment thereof that exhibits appreciable affinity for an antigen (e.g., an FGFR3 antigen) and does not exhibit significant cross reactivity to a target that is not an FGFR3 protein.
  • affinity refers to the strength of the interaction between an antigen binding protein or antigen-binding fragment thereof antigen binding site and the epitope to which it binds.
  • an antigen binding protein affinity may be reported as a dissociation constant (KD) in molarity (M).
  • the antigen binding protein or antigen-binding fragment thereof of the disclosure have KD values in the range of about 10 ⁇ 6 M to about 10 ⁇ 12 M (i.e., low micromolar to picomolar range), about 10 ⁇ 7 M to 10 ⁇ 11 M, about 10 ⁇ 8 M to about 10 ⁇ 10 M, about 10 ⁇ 9 M.
  • the antigen binding protein or antigen-binding fragment thereof has a binding affinity of about 10 ⁇ 6 M, 10 ⁇ 7 M, 10 ⁇ 8 M, 10 ⁇ 9 M, 10 ⁇ 10 M, 10 ⁇ 11 M, or 10 ⁇ 12 M.
  • the antigen binding protein or antigen-binding fragment thereof has a binding affinity of about 10 ⁇ 7 M to about 10 ⁇ 9 M (nanomolar range).
  • Specific binding can be determined according to any art-recognized means for determining such binding.
  • specific binding is determined by competitive binding assays (e.g. ELISA) or Biacore assays.
  • the assay is conducted at about 20° C., 25° C., 30° C., or 37° C.
  • the disclosure provides antigen binding proteins and antigen-binding fragments thereof with binding specificity to FGFR3.
  • Exemplary anti-FGFR3 antigen binding protein and antigen-binding fragment thereof CDRs are recited below in Table 1 and Table 4.
  • Exemplary anti-FGFR3 antigen binding protein and antigen-binding fragment thereof variable heavy (VH) and variable light (VL) domains are recited below in Table 3, Table 8, Table 9, and Table 13.
  • Exemplary anti-FGFR3 antigen binding protein full length heavy and light chains are recited below in Table 14.
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof comprise an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence, a CDR-H2 sequence, and a CDR-H3 sequence.
  • VH antibody heavy chain variable
  • the CDR-H1 sequence comprises the amino acid sequence of GX 1 TFTDX 2 E (SEQ ID NO: 157), wherein X 1 comprises Y or D and X 2 comprises F or Y; the CDR-H2 sequence comprises the amino acid sequence of IDPETGX 3 T (SEQ ID NO: 158), wherein X 3 comprises G or S; or CDR-H2 sequence comprising the amino acid sequence of INPNNGX 4 T (SEQ ID NO: 159), wherein X 4 comprises G or V; or CDR-H2 sequence comprising the amino acid sequence of VX 5 PETGGT (SEQ ID NO: 160), wherein X 5 comprises D or E; and the CDR-H3 sequence comprises the amino acid sequence of TRX 6 YX 7 GYX 8 X 9 X 10 X 11 DY (SEQ ID NO: 161), wherein X 6 comprises T or N, comprises D or E, X 8 comprises S or P, X 9 comprises Q, R, or Y, X 19 comprises T or A,
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof comprise an antibody light chain variable (VL) domain comprising a CDR-L1 sequence, a CDR-L2 sequence, and a CDR-L3 sequence.
  • VL antibody light chain variable
  • the CDR-L1 sequence comprises the amino acid sequence of QS X 12 LYS X 13 N X 14 KNY (SEQ ID NO: 162), wherein X 12 comprises L or V, X 13 comprises N, D, or S, and X 14 comprises Q or N;
  • the CDR-L2 sequence comprises the amino acid sequence of X 15 AS (SEQ ID NO: 163), wherein X 15 comprises W, Y, or F;
  • the CDR-L3 sequence comprises the amino acid sequence of QQYYSYRT (SEQ ID NO: 75), LQYDNLLWT (SEQ ID NO: 81), or HQYLSX 16 YT (SEQ ID NO: 290), wherein X 16 comprises P or S.
  • the disclosure provides an antigen-binding protein or fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein:
  • the antigen binding protein or fragment thereof comprises a VH domain and a VL domain, wherein:
  • the FGFR3 antigen binding proteins and antigen-binding fragments thereof comprise one VH domain and one VL domain recited in Table 3, 8, 9, or 13.
  • exemplary antigen-binding proteins or antigen-binding fragments thereof are provided:
  • the anti-FGFR3 antigen binding protein or fragment thereof comprises a pair of heavy chain and light chain of Table 1.1 above.
  • the anti-FGFR3 antigen binding protein or fragment thereof comprises a VH domain and a VL domain, wherein:
  • the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 63 or 65
  • the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67 or 69.
  • the VH domain of a variant is at least about 80%, at least at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90% identical, at least about 91% identical, at least about 92% identical, at least about 93% identical, at least about 94% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 28, SEQ ID NO: 29, SEQ
  • the amino acid sequence alignment for obtaining the identity can be any conventional amino acid sequence alignment tool, and the sequence alignment algorithms includes Needle-Wunsch algorithm, Smith-Waterman algorithm, or Karling & Altschul algorithm, but is not limited thereto; the amino acid sequence alignment tool includes BLAST (Basic Local Alignment Search Tool), BLAT (BLAST-like Alignment Tool), Grapped BLAST or FASTA, but is not limited thereto.
  • the variant has all of the identical heavy chain CDRs and light chain CDRs of the anti-FGFR3 antigen binding protein or fragment thereof as described herein, with modifications in the constant region on the heavy chain and/or the light chain.
  • the anti-FGFR3 antigen binding protein or fragment thereof comprises an antibody heavy chain at least about 80%, at least at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90% identical, at least about 91% identical, at least about 92% identical, at least about 93% identical, at least about 94% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 63 or 65, and an antibody light chain at least about 80%, at least at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90% identical, at least about 91% identical, at least about 92%
  • the anti-FGFR3 antigen binding protein or fragment thereof comprises a VH domain and a VL domain, wherein: (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of VDPETGGT (SEQ ID NO: 297), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAFDY (SEQ ID NO: 301); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSNNNKNY (SEQ ID NO: 302), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75).
  • the VH domain comprises a CDR-H1 sequence comprising the amino
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 57
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 19 or 59.
  • the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 63, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67. In certain embodiments, the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 65, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the anti-FGFR3 antigen binding protein or fragment thereof comprises a VH domain and a VL domain, wherein: (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of VDPETGGT (SEQ ID NO: 297), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAFDY (SEQ ID NO: 301); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSDNQKNY (SEQ ID NO: 306), a CDR-L2 sequence comprising the amino acid sequence of FAS (SEQ ID NO: 304), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75).
  • the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (S
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 57
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 61.
  • the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 65
  • the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure comprise one or more sequences with at least about 80%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any of the sequences of Table 1, Table 3, Table 4, Table 8, Table 13, or Table 14, or protein sequences encoded by the nucleic acid sequences in Table 9.
  • human framework regions for anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof are provided herein.
  • Non-limiting examples of human framework regions are provided below.
  • Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X) n1 IHWVRQAP X is any naturally occurring amino acid, and GQGLEWIGA(X) n2 AYNQKFQGRVTITADKSTSTAYMEL n1, n2, and n3 are numbers at least 3, and less SSLRSEDTAVYYC(X) n3 WGQGTLVTVSS than 50, each X can be the same or different SEQ ID NO: 318 amino acid as the amino acid next to it Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X) n1 IHWVRQAP GQGLEWIGA(X) n2 AYNQKFQGRVTITADKSTSTAYMEL SSLRSEDTAVYYC(X) n3 WGQGTLVTVSS SEQ ID NO: 319 Heavy chain QV
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments comprise three heavy chain CDRs that bind to FGFR3, such as the three heavy chain CDRs of mouse antibody KC18, KE35, KE42, KE58, KE63, or KE94, and a human heavy chain variable region framework.
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments further comprise three light chain CDRs that bind to FGFR3, such as the three light chain CDRs of mouse antibody KC18, KE35, KE42, KE58, KE63, or KE94, and a human light chain variable region framework.
  • the human heavy chain variable region framework comprises any one of SEQ ID NOs: 318 to 328.
  • the human light chain variable region framework comprises any one of SEQ ID NOs: 329 to 339.
  • the human heavy chain variable region framework comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more identity to any one of SEQ ID NOs: 318 to 328.
  • the human light chain variable region framework comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more identity to any one of SEQ ID NOs: 329 to 339.
  • such anti-FGFR3 antigen binding proteins and antigen-binding fragments bind human FGFR3 with an equilibrium dissociation constant (KD) of about 100 nM or less, about 90 nM or less, about 80 nM or less, about 70 nM or less, about 60 nM or less, about 50 nM or less, about 40 nM or less, about 30 nM or less, about 20 nM or less, about 10 nM or less, about 9 nM or less, about 8 nM or less, about 7 nM or less, about 6 nM or less, about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2.89 nM or less, about 2 nM or less, about 1.5 or less, about 1.4 or less, about 1.23 or less, about 1.2 or less, or about 1 nM or less, about 0.8 or less, or about 0.6 or less.
  • KD equilibrium dissociation constant
  • X nM or less therein includes the embodiment “less than X nM”. “Less” therein can mean e.g. to about 2.8 nM, to about 1.3 nM, to about 1.1 nM, to about 0.7 nM or to about 0.5 nM.
  • nM values are as obtained by a Surface Plasmon Resonance assay, such as the Biacore assay.
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure are chimeric or humanized antibodies.
  • the antigen binding protein is a humanized antibody.
  • the antigen binding protein is a monoclonal antibody.
  • the antigen binding protein comprises one or more full-length antibody heavy chains comprising an Fc region.
  • the Fc region is a human IgG1 Fc region. In certain embodiments, the Fc region is a human IgG4 Fc region.
  • the antibody Fc region comprises one or more mutations that reduces Fc effector function.
  • the one or more mutations reduces one or more of antibody dependent cellular cytotoxicity (ADCC), antibody dependent cellular phagocytosis (ADCP), or complement dependent cytotoxicity (CDC).
  • ADCC antibody dependent cellular cytotoxicity
  • ADCP antibody dependent cellular phagocytosis
  • CDC complement dependent cytotoxicity
  • the human IgG1 Fc region comprises a L234A and L235A mutation.
  • the human IgG4 Fc region comprises a F234A and L235A mutation.
  • the human IgG4 Fc region comprises one or more stabilizing mutations, including, but limited to, mutations in the IgG4 hinge that reduce or prevent the formation of disulfide bonds and in vivo fab arm exchange (FAE).
  • the human IgG4 Fc region comprises a S228P mutation.
  • the IgG4 hinge mutation is described in further detail in Angal et al. (Mol. Immunol. 1993; 30:105-108).
  • the human IgG4 Fc region comprises a S228P mutation and a L235A mutation.
  • the human IgG1 Fc region comprises one or more mutations that alters antibody glycosylation.
  • the human IgG1 Fc region comprises one or more of a S298N mutation, a T299A mutation, and a Y300S mutation. In certain embodiments, the human IgG1 Fc region comprises a S298N mutation, a T299A mutation, and a Y300S mutation.
  • the Fc region amino acid positions referred to herein are based on EU antibody numbering.
  • the anti-FGFR3 antigen binding protein fragments of the disclosure comprise or consists of an antibody F(ab), F(ab′)2, Fab′-SH, Fv, or scFv fragment.
  • the antigen binding protein fragment comprises an antibody F(ab) fragment.
  • the antibody F(ab) fragment can be modified with one or more serum half-life extending moieties.
  • the antibody F(ab) fragment is conjugated to an antigen binding protein with binding specificity to serum albumin.
  • the antigen binding protein with binding specificity to serum albumin is a nanobody.
  • the serum albumin is human serum albumin or mouse serum albumin.
  • the antibody F(ab) fragment comprises a heavy chain and a light chain.
  • the heavy chain of the F(ab) fragment comprises a heavy chain variable region disclosed herewith, and a light chain variable region disclosed herewith.
  • the heavy chain variable region comprises or consists of any one of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20, 21, 22, 23, 28, 29, 30, 31, 56, 57, 58, 106, 107, 108, 109, 110, 111, 115, 116, 117, 118, 119, 120, 121, or 112, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identity to any of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20, 21, 22, 23, 28, 29, 30, 31, 56, 57, 58, 106, 107, 108, 109, 110, 111, 115, 116, 117, 118, 119, 120, 121, or 112, or a sequence having
  • the light chain variable region comprises or consists of any one of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 24, 25, 26, 27, 32, 33, 34, 35, 59, 60, 61, 112, 113, 114, 123, 124, 125, 126, 127, 128, 129, 130, 131, or 132, or a or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identity to any of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 24, 25, 26, 27, 32, 33, 34, 35, 59, 60, 61, 112, 113, 114, 123, 124, 125, 126, 127, 128, 129, 130, 131, or 132.
  • the heavy chain of the F(ab) fragment comprises or consists of a heavy chain variable region disclosed herewith and a heavy chain constant region.
  • the heavy chain constant region is derived from a human IgG1 Fc region, a human IgG2 Fc region, a human IgG3 Fc region, a human IgG4 Fc region, or a combination thereof.
  • the heavy chain constant region is a fragment of a human IgG1 Fc region, a human IgG2 Fc region, a human IgG3 Fc region, a human IgG4 Fc region, or a combination thereof.
  • the heavy chain constant region comprises or consists of the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 5, 36, 37, 38, 39, 40, 41, 44, 45, 46, 7, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,
  • the light chain of the F(ab) fragment comprises or consists of a light chain variable region disclosed herewith, and a light chain constant region.
  • the light chain constant region is derived from a human kappa ( ⁇ ) chain, a human lambda ( ⁇ ) chain, or a combination thereof.
  • the light chain constant region comprises or consists of a part of IgG1 light constant region.
  • the part of the IgG1 light constant region comprises or consists of the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 5, 36, 37, 38, 39, 40, 41, 44, 45, 46, 7, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, or 107 amino acids of SEQ ID NO: 55.
  • the F(ab) fragment comprises one or more point mutations in the C-terminus to reduce anti-Fab antibody binding.
  • the antigen binding protein comprises cross-reactivity to one or both of mouse and cynomolgus FGFR3.
  • the cynomolgus FGFR3 is encoded by SEQ ID NO: 136:
  • the cynomolgus FGFR3 is the IIIc isoform, comprising SEQ ID NO: 138, or its mutated version comprising the G380R mutation (SEQ ID NO: 139):
  • the antigen binding protein comprises binding specificity for FGFR3 isoform IIIb and/or isoform IIIc.
  • the antigen binding protein specifically binds to FGFR3, and does not bind to one or more of FGFR1, FGFR2, and FGFR4, or does not have detectable binding to one or more of FGFR1, FGFR2, and FGFR4. In certain embodiments, the antigen binding protein does not bind to each of FGFR1, FGFR2, and FGFR4, or does not have detectable binding to each of FGFR1, FGFR2, and FGFR4. In certain embodiments, the antigen binding protein binds to each of FGFR1, FGFR2, and FGFR4 with an affinity of about 100 ⁇ M, 500 ⁇ M, 1000 ⁇ M, or greater. In certain embodiments, the antigen binding protein does not bind to one or more of FGFR1, FGFR2, and FGFR4 over a background measurement, as determined by a Biacore affinity analysis.
  • the antigen binding protein binds human FGFR3 with an equilibrium dissociation constant (KD) of about 100 nM or less, about 90 nM or less, about 80 nM or less, about 70 nM or less, about 60 nM or less, about 50 nM or less, about 40 nM or less, about 30 nM or less, about 20 nM or less, about 10 nM or less, about 9 nM or less, about 8 nM or less, about 7 nM or less, about 6 nM or less, about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2.89 nM or less, about 2 nM or less, about 1.5 or less, about 1.4 or less, about 1.23 or less, about 1.2 or less, or about 1 nM or less, about 0.8 or less, or about 0.6 or less.
  • KD equilibrium dissociation constant
  • X nM or less therein includes the embodiment “less than X nM”. “Less” therein can mean e.g. to about 2.8 nM, to about 1.3 nM, to about 1.1 nM, to about 0.7 nM or to about 0.5 nM.
  • the nM values are as obtained by a Surface Plasmon Resonance assay, such as the Biacore assay.
  • the Biacore assay is carried out at about 4° C., 10° C., 15° C., 20° C., 25° C., 30° C., or 37° C.
  • the antigen binding protein binds human FGFR3 with an off rate (Kd) of about 10 ⁇ 2 s ⁇ 1 or less, about 5 ⁇ 10 ⁇ 3 s ⁇ 1 or less, about 2 ⁇ 10 ⁇ 3 s ⁇ 1 or less, about 10 ⁇ 3 s ⁇ 1 or less, about 9 ⁇ 10 ⁇ 4 s ⁇ 1 or less, about 8 ⁇ 10 ⁇ 4 s ⁇ 1 or less, about 7 ⁇ 10 ⁇ 4 s ⁇ 1 or less, about 6 ⁇ 10 ⁇ 4 s ⁇ 1 or less, about 5 ⁇ 10 ⁇ 4 s ⁇ 1 or less, about 4 ⁇ 10 ⁇ 4 s ⁇ 1 or less, or about 3.5 ⁇ 10 ⁇ 4 s ⁇ 1 or less.
  • Kd off rate
  • Less therein can mean e.g. to about 3 ⁇ 10 ⁇ 4 s ⁇ 1 .
  • “About X” therein can mean e.g. “X ⁇ 10%”, “X ⁇ 5%”, “X ⁇ 4%”, “X ⁇ 4%”, “X ⁇ 3%”, “X ⁇ 2%”, “X ⁇ 1%” or “X ⁇ 0.5%”.
  • the antigen binding protein inhibits ligand-induced FGFR3 dimerization with IC 50 of about 5 ⁇ g/ml or less, about 4 ⁇ g/ml or less, about 3 ⁇ g/ml or less, about 2 ⁇ g/ml or less, about 1 ⁇ g/ml or less, about 0.9 ⁇ g/ml or less, about 0.8 ⁇ g/ml or less, about 0.7 ⁇ g/ml or less, about 0.6 ⁇ g/ml or less, about 0.5 ⁇ g/ml or less, about 0.4 ⁇ g/ml or less, or about 0.3 ⁇ g/ml or less.
  • “Less” therein can mean e.g.
  • nM values are as obtained by a Homogenous Time-Resolved Fluorescence (HTRF) assay at about 4° C., 10° C., 15° C., 20° C., 25° C., 30° C., or 37° C.
  • HTRF Homogenous Time-Resolved Fluorescence
  • the antigen binding protein inhibits FGFR3 receptor activation and downstream signaling with IC 50 of about 5 ⁇ g/ml or less, about 4 ⁇ g/ml or less, about 3 ⁇ g/ml or less, about 2 ⁇ g/ml or less, about 1 ⁇ g/ml or less, about 0.9 ⁇ g/ml or less, about 0.8 ⁇ g/ml or less, about 0.7 ⁇ g/ml or less, about 0.6 ⁇ g/ml or less, about 0.5 ⁇ g/ml or less, about 0.4 ⁇ g/ml or less, or about 0.3 ⁇ g/ml or less.
  • “Less” therein can mean e.g.
  • nM values are as obtained by a homogenous time-resolved fluorescence (HTRF) assay.
  • Inhibition of FGFR3 receptor activation and downstream signaling can be determined by any means known in the art. In certain embodiments, inhibition of FGFR3 receptor activation and downstream signaling is measured by determining Erk phosphorylation. A decrease in Erk phosphorylation indicates inhibition of FGFR3 activation. Erk phosphorylation can be determined using a homogenous time-resolved fluorescence (HTRF) assay. In certain embodiments, the assay is performed in chondrocytes. In certain embodiments, the assay is performed in mouse primary rib chondrocytes.
  • the antigen binding protein inhibits the activity of an FGFR3 G380R mutant. In certain embodiments, the antigen binding protein inhibits the activity of a human FGFR3 G380R mutant, a mouse FGFR3 G380R mutant, and/or a cynomolgus FGFR3 G380R mutant. In certain embodiments, the human FGFR3 G380R mutant is represented by the amino acid sequence set forth in SEQ ID NO: 133.
  • the antigen binding protein or fragment thereof is capable of penetrating a bone growth plate.
  • the antigen binding protein or fragment thereof is capable of decreasing the binding of FGFR3 with its ligand in a bone growth plate.
  • the disclosure provides an antigen-binding protein or fragment thereof with binding specificity to a fibroblast growth factor receptor 3 (FGFR3) epitope, comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein the antigen binding protein binds a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 134, recited below.
  • FGFR3 fibroblast growth factor receptor 3
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure bind a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 134, recited above.
  • the amino acid sequence recited above corresponds to the D2D3 region of FGFR3 isoform IIIc, specifically to amino acid D143 to E365 of FGFR3 isoform IIIc.
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure bind an epitope of human FGFR3 polypeptide comprising the N-terminus of the D2 region (amino acids D143 to L163) of SEQ ID NO: 133, shown above.
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure bind an epitope of human FGFR3 polypeptide comprising the N-terminus of the D2 region (amino acids D143 to N170) of SEQ ID NO: 133, shown above.
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure bind an epitope of human FGFR3 polypeptide comprising the N-terminus and middle of the D2 region (amino acids D143 to D160 and G197 to L213) of SEQ ID NO: 133, shown above.
  • the one or more epitopes of the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure are determined by hydrogen deuterium exchange (HDX) mass spectrometry.
  • HDX is performed by measuring the amide hydrogen deuterium exchange on FGFR3 over time.
  • HDX mass spectrometry is described in further detail in Pr ⁇ dzi ⁇ ska et al. (Amino Acids. 48: 2809-2820. 2016).
  • the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure compete with a reference binding protein for binding to the human FGFR3 polypeptide D2 region.
  • the disclosure provides an antigen-binding protein or fragment thereof with binding specificity to a fibroblast growth factor receptor 3 (FGFR3) epitope, comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein the antigen binding protein competes for binding to FGFR3 with an antibody comprising VH/VL domain amino acid sequence pairs selected from the group consisting of: SEQ ID NO: 6/SEQ ID NO: 7, SEQ ID NO: 8/SEQ ID NO: 9, SEQ ID NO: 10/SEQ ID NO: 11, SEQ ID NO: 12/SEQ ID NO: 13, SEQ ID NO: 14/SEQ ID NO: 15, and SEQ ID NO: 16/SEQ ID NO: 17.
  • FGFR3 fibroblast growth factor receptor 3
  • polynucleotides encoding the binding proteins e.g., antigen-binding proteins and antigen-binding fragments thereof.
  • Methods of making binding proteins comprising expressing these polynucleotides are also provided.
  • Polynucleotides encoding the binding proteins disclosed herein are typically inserted in an expression vector for introduction into host cells that may be used to produce the desired quantity of the binding proteins. Accordingly, in certain aspects, the disclosure provides expression vectors comprising polynucleotides disclosed herein and host cells comprising these vectors and polynucleotides.
  • vector or “expression vector” is used herein to mean vectors used in accordance with the present disclosure as a vehicle for introducing into and expressing a desired gene in a cell.
  • vectors may readily be selected from the group consisting of plasmids, phages, viruses and retroviruses.
  • vectors compatible with the disclosure will comprise a selection marker, appropriate restriction sites to facilitate cloning of the desired gene and the ability to enter and/or replicate in eukaryotic or prokaryotic cells.
  • one class of vector utilizes DNA elements which are derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (RSV, MMTV or MOMLV), or SV40 virus.
  • Others involve the use of polycistronic systems with internal ribosome binding sites.
  • cells which have integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow selection of transfected host cells. The marker may provide for prototrophy to an auxotrophic host, biocide resistance (e.g., antibiotics) or resistance to heavy metals such as copper.
  • the selectable marker gene can either be directly linked to the DNA sequences to be expressed, or introduced into the same cell by co-transformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include signal sequences, splice signals, as well as transcriptional promoters, enhancers, and termination signals.
  • the cloned variable region genes are inserted into an expression vector along with the heavy and light chain constant region genes (e.g., human constant region genes) synthesized as discussed above.
  • the binding proteins may be expressed using polycistronic constructs.
  • multiple gene products of interest such as heavy and light chains of antibodies may be produced from a single polycistronic construct.
  • IRES internal ribosome entry site
  • Compatible IRES sequences are disclosed in U.S. Pat. No. 6,193,980, which is incorporated by reference herein in its entirety for all purposes. Those skilled in the art will appreciate that such expression systems may be used to effectively produce the full range of polypeptides disclosed in the instant application.
  • the expression vector may be introduced into an appropriate host cell. That is, the host cells may be transformed.
  • Introduction of the plasmid into the host cell can be accomplished by various techniques well known to those of skill in the art. These include, but are not limited to, transfection (including electrophoresis and electroporation), protoplast fusion, calcium phosphate precipitation, cell fusion with enveloped DNA, microinjection, and infection with intact virus. See, Ridgway, A. A. G. “Mammalian Expression Vectors” Chapter 24.2, pp. 470-472 Vectors, Rodriguez and Denhardt, Eds. (Butterworths, Boston, Mass.
  • Plasmid introduction into the host can be by electroporation.
  • the transformed cells are grown under conditions appropriate to the production of the light chains and heavy chains, and assayed for heavy and/or light chain protein synthesis.
  • Exemplary assay techniques include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), or fluorescence-activated cell sorter analysis (FACS), immunohistochemistry and the like.
  • transformation shall be used in a broad sense to refer to the introduction of DNA into a recipient host cell that changes the genotype.
  • host cells refers to cells that have been transformed with vectors constructed using recombinant DNA techniques and encoding at least one heterologous gene.
  • the terms “cell” and “cell culture” are used interchangeably to denote the source of antibody unless it is clearly specified otherwise.
  • recovery of polypeptide from the “cells” may mean either from spun down whole cells, from supernatant of lysed cells culture, or from the cell culture containing both the medium and the suspended cells.
  • a host cell line used for antibody expression is of mammalian origin. Those skilled in the art can determine particular host cell lines which are best suited for the desired gene product to be expressed therein. Exemplary host cell lines include, but are not limited to, DG44 and DUXB11 (Chinese Hamster Ovary lines, DHFR minus), HELA (human cervical carcinoma), CV-1 (monkey kidney line), COS (a derivative of CV-1 with SV40 T antigen), R1610 (Chinese hamster fibroblast) BALBC/3T3 (mouse fibroblast), HEK (human kidney line), SP2/O (mouse myeloma), BFA-1c1BPT (bovine endothelial cells), RAJI (human lymphocyte), 293 (human kidney).
  • DG44 and DUXB11 Choinese Hamster Ovary lines, DHFR minus
  • HELA human cervical carcinoma
  • CV-1 monkey kidney line
  • COS a derivative of CV-1 with SV40
  • the cell line provides for altered glycosylation, e.g., afucosylation, of the antibody expressed therefrom (e.g., PER.C6® (Crucell) or FUT8-knock-out CHO cell lines (POTELLIGENT® cells) (Biowa, Princeton, N.J.)).
  • PER.C6® Crucell
  • FUT8-knock-out CHO cell lines POTELLIGENT® cells
  • NSO cells may be used.
  • CHO cells are particularly useful. Host cell lines are typically available from commercial services, e.g., the American Tissue Culture Collection, or from authors of published literature.
  • Genes encoding the binding proteins featured in the disclosure can also be expressed in non-mammalian cells such as bacteria or yeast or plant cells.
  • non-mammalian microorganisms such as bacteria can also be transformed, i.e., those capable of being grown in cultures or fermentation.
  • Bacteria which are susceptible to transformation, include members of the enterobacteriaceae, such as strains of Escherichia coli or Salmonella ; Bacillaceae, such as Bacillus subtilis ; Pneumococcus; Streptococcus , and Haemophilus influenzae .
  • the binding proteins can become part of inclusion bodies.
  • the binding proteins are then isolated, purified and assembled into functional molecules.
  • the binding proteins of the disclosure are expressed in a bacterial host cell.
  • the bacterial host cell is transformed with an expression vector comprising a nucleic acid molecule encoding a binding protein of the disclosure.
  • eukaryotic microbes may also be used. Saccharomyces cerevisiae , or common baker's yeast, is the most commonly used among eukaryotic microbes, although a number of other strains are commonly available.
  • Saccharomyces cerevisiae or common baker's yeast
  • the plasmid YRp7 for example (Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)), is commonly used.
  • This plasmid already contains the TRP1 gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC No.
  • binding proteins e.g., antigen-binding proteins and antigen-binding fragments thereof disclosed herein
  • the route of administration of the antigen binding proteins and antigen-binding fragments thereof of the current disclosure may be oral, parenteral, by inhalation or topical.
  • parenteral as used herein includes intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, rectal or vaginal administration. While all these forms of administration are clearly contemplated as being within the scope of the current disclosure, a form for administration would be a solution for injection, e.g. for intravenous or intraarterial injection or drip.
  • a suitable pharmaceutical composition for injection may comprise a buffer, a surfactant, optionally a stabilizer agent, etc.
  • the modified antibodies can be delivered directly to the site of the adverse cellular population thereby increasing the exposure of the diseased tissue to the therapeutic agent.
  • Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Other common parenteral vehicles include sodium phosphate solutions, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the composition must be sterile and should be fluid to the extent that syringability for injection exists. It should be stable under the conditions of manufacture and storage, and should also be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium. The proper fluidity can be maintained, for example, by the use of a coating, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Isotonic agents for example, sugars, polyalcohols, may also be included in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • sterile injectable solutions can be prepared by incorporating an active compound (e.g., a modified binding protein by itself or in combination with other active agents) in a required amount in an appropriate solvent with one or a combination of ingredients enumerated, followed by filtered sterilization.
  • an active compound e.g., a modified binding protein by itself or in combination with other active agents
  • dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and any required other ingredients.
  • methods of preparation typically include vacuum drying and freeze-drying, which yield a powder of an active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the preparations for injections are processed, filled into containers such as ampoules, bags, bottles, syringes or vials, and sealed under aseptic conditions according to methods known in the art. Further, the preparations may be packaged and sold in the form of a kit.
  • Effective doses of the compositions of the present disclosure, for the treatment of a disease or disorder vary depending upon many different factors, including means of administration, target site, physiological state of the subject, whether the subject is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic.
  • the patient is a human, but non-human mammals including transgenic mammals can also be treated. Treatment dosages may be titrated to optimize safety and efficacy.
  • Binding proteins described herein can be administered on multiple occasions. Intervals between single dosages can be weekly, monthly or yearly. Intervals can also be irregular as indicated by measuring levels of binding protein or antigen in the subject. Alternatively, binding proteins can be administered as a sustained release formulation, in which case less frequent administration is required.
  • dosage and frequency vary depending on the half-life of the antibody in the patient. In general, humanized antibodies show the longest half-life, followed by chimeric antibodies and non-human antibodies.
  • compositions containing the present binding protein are administered to a subject not already in the disease state to enhance the subject's resistance.
  • a prophylactic treatment is understood as a method of preventing or alleviating one or more symptoms of the disorder.
  • a prophylactic treatment is understood as a method of preventing the happening of cancer, or alleviating one or more symptoms of the cancer.
  • Such an amount is defined to be a “prophylactic effective dose.”
  • the precise amounts again depend upon the subject's state of health and general immunity.
  • a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, or until the patient shows partial or complete amelioration of disease symptoms. Thereafter, the patient can be administered a prophylactic regime.
  • Binding proteins described herein can optionally be administered in combination with other agents that are effective in treating the disorder or condition in need of treatment (e.g., prophylactic or therapeutic).
  • binding proteins may be administered as described immediately above, it must be emphasized that in other embodiments binding proteins may be administered to otherwise healthy subjects as a first line therapy. In such embodiments the binding proteins may be administered to subjects that have not, and are not, undergoing one or more other therapies, or subjects that have, or are undergoing one or more other therapies.
  • the administration of binding proteins, e.g. antibodies or fragments thereof, in conjunction or combination with an adjunct therapy means the sequential, simultaneous, coextensive, concurrent, concomitant, or contemporaneous administration or application of the therapy and the disclosed binding proteins.
  • the administration or application of the various components of the combined therapeutic regimen may be timed to enhance the overall effectiveness of the treatment.
  • binding proteins of the present disclosure may be administered in a pharmaceutically effective amount for the in vivo treatment of mammalian disorders.
  • compositions in accordance with the present disclosure typically include a pharmaceutically acceptable, non-toxic, sterile carrier such as physiological saline, buffers, preservatives and the like.
  • a pharmaceutically effective amount of the binding protein that, shall be held to mean an amount sufficient to achieve effective binding to an antigen and to achieve a benefit, e.g., to ameliorate symptoms of a disease or disorder.
  • the pharmaceutical compositions of the present disclosure may be administered in single or multiple doses to provide for a pharmaceutically effective amount of the antigen-binding protein or antigen-binding fragment thereof.
  • the antigen-binding protein or antigen-binding fragment thereof may be administered to a human or other animal in accordance with the methods of treatment herein in an amount sufficient to produce a therapeutic or prophylactic effect.
  • the binding proteins of the disclosure can be administered to such human or other animal in a conventional dosage form prepared by combining the binding protein with a conventional pharmaceutically acceptable carrier or diluent according to known techniques.
  • the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.
  • a cocktail comprising one or more species of binding proteins described in the current disclosure may prove to be particularly effective.
  • FGFR3-mediated disease or disorder refers to any disease or disorder that is the result of aberrant FGFR3 activity.
  • the disease or disorder is caused by FGFR3 over activity or over expression.
  • Non-limiting examples of FGFR3-mediated diseases or disorders include achondroplasia, hypochondroplasia, and cancer.
  • an “FGFR3 activity” refers to any signaling event associated with the dimerization of FGFR3 on the surface of a cell.
  • the FGFR3 activity can be one or both of an extracellular activity and an intracellular activity.
  • FGFR3 activities include, but are not limited to, FGFR3 dimerization, extracellular signal-regulated kinase (Erk) phosphorylation, mitogen-activated protein kinase kinase (MKK, MEK, or MAP2K) phosphorylation, FGFR3 cytoplasmic tyrosine kinase domain activity, and FGF ligand binding activity (e.g., FGF18 binding to FGFR3).
  • Erk extracellular signal-regulated kinase
  • MKK mitogen-activated protein kinase kinase
  • MEK mitogen-activated protein kinase kinase
  • MAP2K MAP2K
  • achondroplasia refers to a genetic disorder caused by mutations in the FGFR3 gene that make the resulting protein overactive.
  • the anti-FGFR3 antigen binding proteins or fragments thereof are useful for the reduction of one or more symptoms of achondroplasia.
  • Achondroplasia symptoms include, but are not limited to, shortening of the proximal limbs, brachydactyly (i.e., short fingers and toes with trident hands), large head with prominent forehead frontal bossing, small midface with a flattened nasal bridge, spinal kyphosis (convex curvature) or lordosis (concave curvature), varus (i.e., bowleg) or valgus (i.e., knock knee, ear infections (due to Eustachian tube blockages)), sleep apnea (central or obstructive), and hydrocephalus.
  • Achondroplasia may be diagnosed through the measurement of one or more of proximal limb length (e.g., femur and tibia length), finger and toe length, head circumference (e.g., skull length), and lumbar vertebrae length, although other anatomical measurements can be employed.
  • proximal limb length e.g., femur and tibia length
  • finger and toe length e.g., finger and toe length
  • head circumference e.g., skull length
  • lumbar vertebrae length e.g., lumbar vertebrae length
  • the disclosure provides a method for treating a FGFR3-mediated disease or disorder in a subject, comprising administering to a subject in need thereof the antigen binding protein or fragment thereof described herein.
  • the term “subject,” “patient,” or “individual” refers to a human or non-human animal.
  • the term “non-human animal” includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, cats, rabbits, ferrets, rodents such as mice, rats and guinea pigs, avian species (e.g., chickens), amphibians, and reptiles.
  • the subject is a mammal such as a non-human primate, sheep, dog, cat, rabbit, ferret or rodent.
  • the subject is a cynomolgus monkey.
  • the subject is a human.
  • the subject is a child.
  • the subject is an adolescent.
  • the FGFR3-mediated disease or disorder is achondroplasia.
  • the achondroplasia is FGFR3 G380R+ achondroplasia, meaning the subject to be treated contains the G380R mutation in its FGFR3 gene, either homozygous or heterozygous.
  • a subject diagnosed as having achondroplasia or risk of achondroplasia is treated with a binding protein disclosed herewith.
  • the treatment leads to one or more effects selected from the group consisting of increased bone length (e.g., femur length and/or tibia length), increased bone diameter (e.g., femur diameter), increased growth plate volume (e.g., femur growth plate volume), increased vertebrae length, increased skull length, increased bone volume, increased skull volume, corrected vertebral abnormalities (e.g., increased Kyphosis Index), and improved bone age (e.g., more developed secondary ossification center), as compared to a control subject not receiving the treatment that is of the same development stage.
  • increased bone length e.g., femur length and/or tibia length
  • increased bone diameter e.g., femur diameter
  • increased growth plate volume e.g., femur growth plate volume
  • corrected vertebral abnormalities e.g.
  • a method of improving one or more bone features in a subject comprises administrating a binding protein or an antigen-binding fragment thereof disclosed herewith to a subject in need.
  • the improved bone feature is selected from the group consisting of bone length (e.g., femur length or tibia length), bone diameter (e.g., femur diameter), growth plate volume, vertebrae length, skull length, bone volume, skull volume, Kyphosis Index, and improved bone age.
  • the FGFR3-mediated disease or disorder is cancer.
  • the cancer is selected from the group consisting of bladder cancer, melanoma, urothelial cancer, and endometrial cancer.
  • the disclosure provides a method for treating achondroplasia in a subject, comprising administering to a subject in need thereof an antigen binding protein or an antigen-binding fragment thereof with binding specificity to an FGFR3 epitope, wherein the antigen binding protein or the antigen binding fragment thereof does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • the disclosure provides a method for inhibiting one or both of FGFR3 activity and expression in a bone growth plate of a subject, comprising administering to a subject an antigen binding protein or an antigen binding fragment thereof with binding specificity to an FGFR3 epitope, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • an FGFR3 antibody as described herewith is used.
  • the disclosure provides therapeutic uses of its binding proteins or an antigen binding protein fragment thereof with binding specificity to an FGFR3 epitope, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4) corresponding to the methods of treatment disclosed above.
  • the disclosure provides a binding protein or the antigen binding protein fragment thereof as described herein for use in medicine.
  • it provides a binding protein, or an antigen binding protein fragment thereof as described herein for use as an FGFR3-activity inhibiting medicament.
  • it provides a binding protein, or an antigen binding protein fragment thereof as described herein for use in treating an FGFR3-mediated disorder. Examples of such disorders are given herein.
  • it provides a binding protein, or antigen binding protein fragment thereof as described herein for use in preventing one or more symptoms of achondroplasia, as exemplified above. In some embodiments, it provides a binding protein, or antigen binding protein fragment thereof as described herein for use in preventing cancer, as exemplified above.
  • a binding protein, or antigen binding protein fragment thereof as described herein for use in preventing cancer as exemplified above.
  • Embodiments described herein regarding methods of treatment, administration, subjects and all other aspects relevant to therapy and prevention also apply to these uses of binding proteins.
  • Anti-FGFR3 monoclonal antibodies were developed using 300.19 pre-B lymphoblast cells (ATCC, Manassas, VA) transformed with DNA encoding full-length human FGFR3 (see FIG. 1 , GenBank ID NP_000133.1, FGFR3 isoform IIIc) with the mutation G380R (SEQ ID NO: 133) which was expressed on the cell surface (FGFR3 G380R -300.19 cell).
  • the FGFR3 G380R open reading frame was subcloned into the pXL-MCS vector and transfected into 300.19 cells (Immunogen 1).
  • FGFR3 expression on FGFR3 G380R -300.19 cells was monitored and quantified by FACS analysis using the comparator antibody, GT184.6.1, described further in Yin et al. (Mol. Cancer Ther. 14(10): 2270-8. 2015).
  • Anti-FGFR1 (MAB765), anti-FGFR2 (MAB6843), anti-FGFR3 (MAB766), and anti-FGFR4 (MAB6852) antibodies were used as negative controls (R&D Systems, Minneapolis, MN).
  • the FGFR3 ECD protein was quantified using an enzyme-linked immunosorbent assay (ELISA) with the antibodies described further below.
  • the cells expressing FGFR3 were maintained at 37° C. under 5% CO 2 in RPMI (Gibco) supplemented with heat inactivated fetal bovine serum (FBS) (Hyclone).
  • FBS heat inactivated fetal bovine serum
  • Cells were prepared for injection by substituting the above culture medium with phosphate buffered (Ca—Mg free) saline (CMF-PBS) supplemented with 5 mM EDTA and harvesting the cells in that buffer.
  • the harvested cells were pelleted by centrifugation at 500 ⁇ g for 5 minutes, washed once by resuspending the pellet in CMF-PBS and centrifuging as before, counted and adjusted to the appropriate volume (such as 5 ⁇ 10 6 cells in 0.2 ml) for injection by resuspending the cell pellet in CMF-PBS.
  • the FGFR3 ECD protein was used to boost antibody titers in animals before sacrificing the mouse.
  • Cells were maintained in RPMI medium by seeding about 3-5 ⁇ 10 5 cells per ml in a T75 flask and grown for approximately 24-48 hours with selection antibiotic to eliminate the cells not carrying FGFR3 plasmid. Cell surface expression of FGFR3 on cells was verified by FACS analysis prior to use as an immunogen.
  • mice Six eight-week old female FGFR3 KO (C57BL/6 mFGFR3 ⁇ ) mice from the Jackson Laboratory (Bar Harbor, ME) were immunized with the FGFR3-transfected cells (Immunogen 1). Separately, wild-type Balb/c mice were immunized with the FGFR3 ECD protein described above (Immunogen 2). A group of mice were primed intraperitoneally on day 0 with FGFR3-expressing cells, FGFR3 G380R -300.19 cells, in PBS without adjuvants, administrated on days 14, 28, 42 and 56, followed by an intraperitoneal boost on day 77 with the FGFR3 ECD protein in PBS without adjuvants.
  • Each injection was administrated with approximately 5 ⁇ 10 6 cells in a volume of 200 ⁇ l and 50 ⁇ g protein in a volume of 100 ⁇ l PBS. Immunizations were performed in two-week intervals and the IgG titer was evaluated by ELISA with FGFR3 ECD protein to assess immune response.
  • mice were sacrificed for harvesting the spleen and placed in approximately 10 ml of pre-warmed serum-free DMEM (Hyclone) at 37° C. in a petri dish.
  • the splenocytes were teased out of the capsule using forceps and transferred to a 15-ml conical tube.
  • the cells were then washed three times with pre-warmed serum-free IMDM (Hyclone) and cells from multiple mice were pooled.
  • FO B lymphoblasts ATCC, Manassas, VA
  • HAT hypoxanthine/aminopterin/thymidine
  • IgG IgG non-secreting myeloma cell line.
  • FO B lymphoblasts Prior to the fusion, FO B lymphoblasts were maintained in IMDM medium supplemented with 10% FBS (37° C., 7% CO 2 ) ensuring that the cells were in logarithmic growth phase on the day of the fusion.
  • the fusion protocol was derived from Lerner (Yale J Biol Med, 1981, 54 (5) 387-402) and Gefter et al. (Somatic Cell Genet, 1977, 3 (2) 231-236).
  • the spleen cells and the logarithmic phase myeloma cells were washed three times with serum-free IMDM and counted.
  • 1-1.5 ⁇ 10 8 spleen cells were mixed with 2-3 ⁇ 10 7 myeloma cells in a 50-ml conical polypropylene tube and cells were washed once with serum-free IMDM.
  • the ratio of spleen cells to myeloma cells was 5:1.
  • the tubes were centrifuged at 500 ⁇ g for 10 minutes to pellet the cells.
  • the pellets were gently resuspended by tapping the bottom of the tubes.
  • the tubes were then placed in a beaker of 37° C. water. All subsequent fusion steps were carried out in the beaker of 37° C. water.
  • the pellet was resuspended in 200 ml of filtered complete hybridoma production media, IMDM (Hyclone) supplemented with 10% FBS (Hyclone), 1 ⁇ non-essential amino acid (Gibco), 1 mM sodium pyruvate (Gibco), 1 ⁇ pen-strep (Gibco) and 1 ⁇ HAT (Sigma).
  • IMDM Hyclone
  • FBS Hexe
  • Nibco 1 ⁇ non-essential amino acid
  • Gabco 1 mM sodium pyruvate
  • Gabco pen-strep
  • HAT 1 ⁇ HAT
  • a primary hybridoma screen was designed to select hybridoma clones producing antibodies which recognized native FGFR3 epitopes.
  • Antibody binding was detected by FACS using a fluorescently labeled goat anti-mouse secondary antibody.
  • Clones were considered positive if labeled supernatant samples were greater than 10-fold over background in the FACS analysis. Selected positive clones were transferred to 24-well flat bottom plates and expanded for a second screen to confirm selection.
  • a first campaign screened the scFv phage libraries against the hFGFR3 isoform IIIc dimer. 2,700 scFv antibodies were screened with only 13 antibodies identified as potential candidates.
  • a second campaign screened fab and scFv libraries against the hFGFR3 isoform IIIc dimer. 1,940 antibodies were screened with only 13 antibodies identified as potential candidates.
  • a third and fourth campaign screened fab and scFv libraries against the hFGFR3 isoform IIIc dimer, the hFGFR3 isoform IIIc his tagged monomer, and hFGFR3 isoform IIIc-expressing cells.
  • 9,770 antibodies were screened with only 36 antibodies identified as potential candidates.
  • a fifth campaign screened fab libraries against the hFGFR3 isoform IIIc monomer and mouse FGFR3 (mFGFR3) isoform IIIc monomer, and hFGFR3 isoform IIIc- and mFGFR3 isoform IIIc-expressing cells. 2,990 antibodies were screened with only 57 antibodies identified as potential candidates. Between the five screening campaigns, 17,400 antibodies were screened. Among those screened antibodies, only 48 were found to be cross-reactive between human, mouse, and cyno, and only 15 were found to block FGFR3 ligand binding.
  • FGFR family member proteins (human FGFR1 ⁇ IIIb, FGFR1 ⁇ IIIc, FGFR1 ⁇ IIIb, FGFR1 ⁇ Mc, FGFR2 ⁇ IIIc, FGFR2 ⁇ IIIb, FGFR3 IIIb, FGFR3 Mc, FGFR4; mouse FGFR3; and cynomolgus FGFR3 recombinant proteins) were purchased from R&D Systems (Minneapolis, MN) for identifying FGFR3 specific clones by ELISA.
  • cDNA encoding the following proteins were all subcloned into the pTT5 vector (Invitrogen): partial ECD and chimeric ECD proteins of FGFR3; human D2D3 (hD2D3) and D3 (hD3) of human FGFR3; mouse D2D3 (mD2D3) and D3 (mD3) of mouse FGFR3; cynomolgus D2D3 (cyD2D3) and D3 (cyD3) of cynomolgus FGFR3; and hD1-cyD2D3 and hD1-mD2D3 recombinant proteins.
  • Proteins were prepared by transient transfection using Lipofectamine 2000 (Invitrogen) in Expi293 cells (Invitrogen). Supernatants from the selected clones were incubated in 96-well plates coated with the recombinant FGFR proteins and detected with goat anti-mouse IgG horseradish peroxidase (Jackson Immunoresearch, West Grove, PA) followed by chemiluminescent detection.
  • a cell-based binding assay was used to characterize the anti-FGFR3 antibodies generated above.
  • Full-length human, mouse, and cynomolgus FGFR3 cDNAs were subcloned into different pcDNA 3.1 (Invitrogen) vectors and transfected into 300.19 cells (ATCC).
  • the cDNA of FGFR3 Ig domains D2D3 was subcloned into pcDNA 3.1 and transfected into CHO (D2D3-CHO) (ATCC) cells.
  • Full-length human FGFR3 G380R , mouse FGFR3, and cynomolgus FGFR3 G380R cDNAs were also subcloned into different pcDNA 3.1 vectors.
  • Stable cell lines expressing FGFR3 were generated by transfection of human FGFR3 G380R , mouse FGFR3, and cynomolgus FGFR3 G380R cDNA plasmid constructs into CHO (hFGFR3 G380R -CHO and cyFGFR3 G380R -CHO) and human embryonic kidney (HEK, mFGFR3-HEK) (ATCC) cells using the Lipofectamine 2000 kit (Invitrogen).
  • Cell lines were maintained in F-12K medium supplemented with 10% FBS for CHO cells and in DMEM supplemented with 10% FBS for HEK cells overnight, then cultured in the presence of geneticin (0.5 ml/ml) for 10-14 days. Isolated single colonies were picked and grown in separate wells until sufficient clonal cells were expanded.
  • Stable clones resistant to geneticin and expressing high copies of FGFR3 protein were identified by FACS assay using GT184.6.1.
  • the N-terminal ECD proteins of FGFR3 from human and mouse were produced with a terminal avidin tag and used in a forward format Biacore assay where proteins were immobilized on a Biacore chip and then the kinetics of antibody interaction with the proteins on the chip were determined.
  • the proteins were immobilized on a Biacore chip for approximately 10,000 response units (RU).
  • the antibodies were exposed to the chip for kinetic measurements, following the manufacturer's recommendations (GE Healthcare). Sensorgrams were fit to a 1:1 binding model and analyzed using double-reference subtraction by T200 Evaluation software (GE Healthcare). Affinities of the tested antibodies are shown in Table 2.
  • the isotype of each clone was determined using the IsoStrip Mouse Monoclonal Antibody Isotyping Kit (Roche Applied Science, Indianapolis, IN).
  • the heavy (VH) and light (VL) chain variable regions of clones were sequenced using 5′ RACE (Rapid Amplification of cDNA Ends) Kit (Clontech, Mountain View, CA) as per the manufacturer's instruction.
  • Total RNA was extracted from each hybridoma clone using the RNeasy Miniprep kit according to the manufacturer's instructions (Qiagen, Germantown, MD).
  • Full-length first strand cDNAs containing 5′ ends were generated by polymerase chain reaction (PCR) using 5′RACE kits (Clontech).
  • VH and VL genes were amplified by TA cloning kit (Invitrogen) with primers, 5′ primer (5′RACE kit, Clontech), and 3′ primer of IgG isotype specific heavy chain and 3′ primer of kappa light chain.
  • the amplified cDNAs were cloned into pCR2.1 vectors (Invitrogen) and transformed using a TOPO-TA cloning kit (Invitrogen) as per the manufacturer's instructions. Plasmids were isolated from 2 ml of an LB culture, inoculated from a single colony and grown overnight, using QIAprep spin miniprep kit (Qiagen) and sequenced using M13 Forward and M13 Reverse primers included in the TOPO-TA cloning kit (Invitrogen). The VH and VL gene sequences were analyzed using the IMGT V-Quest web server to identify and confirm variable region sequences. VH and VL sequences of each antibody are provided below in Table 3:
  • an FGF1 ligand blocking assay was conducted.
  • human FGFR3 cells FGFR3-300.19 and FGFR3 G380R -300.19, were pre-incubated with various concentration of anti-FGFR3 antibodies and isotype controls, prior to addition of human FGF1 ligand (R&D Systems).
  • Binding of hFGF1 to FGFR3 expressed on the cells was determined by FACS assay using biotinylated anti-FGF1 antibody followed by incubation with a streptavidin-fluorescent secondary antibody.
  • the anti-FGFR3 antibodies which bound to the EC domain including KC18, KE35, KE42, KE58, KE63, and KE94, all blocked binding of FGF1 to FGFR3 on these cells.
  • anti-FGFR3 antibodies were immobilized on a Biacore CM5 chip and ECD proteins of FGFR3 were injected.
  • Competition of second anti-FGFR3 antibodies (Ab2) bound to FGFR3 protein captured by immobilized anti-FGFR3 antibodies (Ab1) were determined.
  • the anti-FGFR3 antibodies were immobilized on a Biacore chip for approximately 100 response units (RU).
  • Flow cell 1 remained blank for reference subtraction on each chip.
  • the ECD FGFR3 protein and mouse anti-FGFR3 antibodies (Ab2) prepared in HBS-EP+ running buffer were injected for 3 minutes and 5 minutes at a flow rate of 50 ⁇ l/min, respectively.
  • the Ab1 surface was regenerated between cycles using 10 mM glycine-HCl (pH 2.0) at 50 ⁇ l/min for 1 minutes. Sensorgrams were fit to a 1:1 binding model and analyzed using double-reference subtraction by BiaEvaluation software (GE Healthcare). It was determined that anti-FGFR3 antibodies KC18, KE35, KE42, KE58, KE63, and KE94 competed for the same region on FGFR3 around the D2 domain.
  • Hydrogen deuterium exchange (HDX) mass spectrometry was also used to determine the epitopes on FGFR3 for these antibodies by measuring the amide hydrogen deuterium exchange on FGFR3.
  • HDX mass spectrometry measured amide hydrogen deuterium exchange over time and quenched at 0° C. and pH 2.5 along with protease digestion. Briefly, the antibody to be tested and antigen were mixed such that about 90% of the antibody is bound to the antigen at room temperature. Deuterium exchange was performed with a 10-fold dilution into D20 at neutral pH. Quenching was then performed by holding the reaction mixture for 1 minute at about 0 to 1° C. to reduce disulfide bonds. Protease digestion was performed with protease XIII and pepsin.
  • HDX mass spectrometry is described in further detail in Pr ⁇ dzi ⁇ ska et al. (Amino Acids. 48: 2809-2820. 2016).
  • the FGFR3 sequence used in the HDX assay is recited below, and corresponds to the D2D3 region, corresponding to D143 to E365 of FGFR3 Isoform IIIc:
  • FIG. 2 The results indicated that KE35 and KE58 bind to the N-terminus of the D2 region (D143 to L163); KE42 binds to N-terminus of the D2 region (D143 to N170); while KC18, KE94, and KE63 bind to N-terminus and middle of the D2 region (D143 to D160 and G197 to L213).
  • KMS-11 cells JCRB cell bank, Japan.
  • the KMS-11 cells were incubated with each antibody at a final concentration of 2 ⁇ g/ml for 30 minutes, 1, 2, 5, and 24 hours, then placed at 4° C. before washing the cells with PBS (Ca 2+ and Mg 2+ ).
  • PBS Ca 2+ and Mg 2+ .
  • a subset of samples was washed with glycine-HCl buffer (pH 4) and fixed with 4% paraformaldehyde (Sigma).
  • Another subset of samples was permeabilized with Triton X-100 (Sigma).
  • FGFR3 dimerization by anti-FGFR3 antibodies was evaluated by a chemiluminescent assay.
  • U2OS cells co-expressing a fusion protein of ⁇ -galactosidase-prolink (PK) and FGFR3 (FGFR3-PK) and ⁇ -galactosidase-enzyme acceptor (EA) and FGFR3 (FGFR3-EA) were developed by DiscoveRx (Fremont, CA).
  • ⁇ -galactosidase is in an inactive form and when dimerization occurs the prolink and enzyme acceptor come together and are cleaved by the now activated ⁇ -galactosidase.
  • the cells were pre-incubated with anti-FGFR3 antibodies at various concentrations before addition of FGF18 ligand to induce dimerization of FGFR3 proteins, then incubated at 37° C. overnight.
  • the substrate was added to the cells and chemiluminescent signal was measured by EnVision (PerkinElmer). Blocking of FGFR3 dimerization by anti-FGFR3 antibodies was observed ( FIG. 5 A - FIG. 5 C ).
  • Humanized variants of KC18, KE63 and KE94 clones were generated as follows: 1) Structural models of the Fv regions of these antibodies in complex with FGFR3 were generated by the Molecular Operating Environment (MOE) from the Chemical Computing Group using KC18-FGFR3 complex structure as template given their high sequence similarity with KC18 ( FIG. 6 ); 2) The VH and VL sequences were searched against the human germline sequence, and the most similar human germline Fv sequence and J region were identified. CDRs from KC18, KE63 and KE94 were then grafted onto the framework of the closest human germline genes; 3) Analysis was performed to identify amino acids that were likely to be important for the FGFR3 binding properties of the antibodies. Selected Vernier zone and key contact residues were mutated back to mouse residues after examination within the structural models; and 4) Potential liability sites were removed.
  • MOE Molecular Operating Environment
  • Heavy chain of KC18_Hrw1-3 and _HV1.69rw2-4, and light chain of KC18_Lrw1-3 were designed by the method described above. Further analysis to introduce back-mutations, stabilizing mutations and to eliminate other unwanted motifs, additional heavy and light chains of KC18 variants were identified KC18_VH1, VH1b-c, VH2-3, VH3b-c and VH4, and KC18_VL1, VL1b-d, VL2, VL3, VL3b, VL4, VL5 and VL6, respectively. Heavy chains KE63 VH1-6 and light chains KE63_VL1-4 were designed.
  • KE63_VH1 and KE63_VL1 humanized constructs were designed, then further modifications to the heavy and light chain were designed (KE63_VH2-6 and KE63_VL2-4) to introduce back-mutations, stabilizing mutations and to eliminate other unwanted motifs. Similar methods were also used to design KE94 humanized constructs KE94_VH1-6. Notably, KE63 and KE94 share the same set of VL designs, namely KE63_VL1-4 here. Tables 5, 6, and 7 indicate the strategy used to pair the heavy and light chain variants for KC18, KE63 and KE94, respectively, including the human and mouse germline identity percentage.
  • Amino acid sequences for the humanized variants of KC18, KE64 and KE94, without the constant regions, are depicted below in Table 8.
  • Nucleic acid sequences for the humanized variants of KC18, KE64 and KE94, without the constant regions, are depicted below in Table 9.
  • the heavy and light constant regions are indicated in SEQ ID NO: 54 and SEQ ID NO: 55, respectively.
  • Humanized antibodies KC18_Hu42 to KC18_49 were designed based on the sequence of KC_Hu18 to further remove liability sites, such as oxidation sites in FRWH3 and CDRH3, a deamidation site in CDRL1, and an oxidation site in CDRL2 (Table 11). At the end, two additional variants each for VH and VL were designed, which resulted in 8 more variants (KC18_Hu42-49) in addition to KC18_Hu18 (Table 12).
  • FIG. 7 A sequence alignment of Hu18 and the newly designed variants (Hu42-49) is shown in FIG. 7 . Mutations of Hu18 residues are underlined.
  • an anti-FGFR3 F(ab) fragment of the present application comprises a heavy chain of Table 15, and a light chain in Table 16.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 141, 164, 173, 182, 191, 200, 209, 218, 227, 236, 245, 254, 263, 272, or 281, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 142.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 143, 165, 174, 183, 192, 201, 210, 219, 228, 237, 246, 255, 264, 273, or 282, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 144.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 145, 166, 175, 184, 193, 202, 211, 220, 229, 238, 247, 256, 265, 274, or 283 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 146.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 147, 167, 176, 185, 194, 203, 212, 221, 230, 239, 248, 257, 266, 275, or 284, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 148.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 149, 168, 177, 186, 195, 204, 213, 222, 231, 240, 249, 258, 267, 276, or 285, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 150.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 151, 169, 178, 187, 196, 205, 214, 223, 232, 241, 250, 259, 268, 277, or 286, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 152.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289
  • the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • Antibodies were screened for binding and specificity to FGFR3. Activity was assessed using a Homogenous Time-Resolved Fluorescence (HTRF) assay to evaluate the level of inhibition on Erk phosphorylation using mouse primary rib chondrocytes. Briefly, primary mouse rib chondrocyte cells isolated from the achondroplasia mouse model were pretreated for 2 hours with anti-FGFR3 antibodies with a concentration ranging from 0.016 ⁇ g/ml to 100 ⁇ g/ml. Cells were then stimulated with FGF18 for 5 minutes. The reaction was then stopped, total Erk was measured using the HTRF assay, and Phospho-Erk (Thr202/Tyr204) was measured in a separate HTRF assay.
  • HTRF Homogenous Time-Resolved Fluorescence
  • the percent inhibition of Erk phosphorylation was measured by taking the ratio of Phospho-Erk over total Erk and multiplying by 100.
  • mouse antibodies KC18, KE63, and KE94 and their corresponding Fab fragments were tested in the HTRF assay, all of which inhibited Erk phosphorylation ( FIG. 9 A and FIG. 9 B ).
  • KC18 mouse antibody in various formats including full-length antibody (IgG), Fab, a one-armed, monovalent antibody (MetMab), and pegylated (PEG) Fab fragment were tested in the HTRF assay and compared to isotype control (Iso). Also, KC18 Fab with half-life extension using a human albumin nanobody (KC18 Fab-HLE) was tested, with and without human serum albumin (HSA) or mouse serum albumin (MSA).
  • the full-length KC18 mouse antibody has a heavy chain of SEQ ID NO: 291 (with mIgG2a Fc sequence), and a light chain of SEQ ID NO: 292.
  • the KC18 mouse Fab antibody has a heavy chain of SEQ ID NO: 293, and a light chain of SEQ ID NO: 294.
  • Humanized FGFR3 antibodies including Hu18, Hu44, and Hu46, were also tested in the HTRF assay, and found to inhibit Erk phosphorylation ( FIG. 11 ).
  • the IC 50 s of these humanized antibodies were determined, as well ( FIG. 8 A to FIG. 8 C , respectively).
  • achondroplasia mouse model (Ach) was used.
  • the achondroplasia mouse is a transgenic mouse that overexpresses the mouse FGFR3 protein having the G380R mutation under control of the collagen II promoter (Shazeeb et al., (2016) Sci Rep 8, 469).
  • the mice were genotyped at 1 day of age, and randomized to either a control (i.e., saline) group or an antibody dosed group.
  • Achondroplasia mice (G380R) received a daily dose subcutaneously (SC) from 3 days of age to 20 days of age. The mice were then euthanized, and bones were collected at 21 days of age for microCT analysis.
  • SC subcutaneously
  • Ach mice treated with KC18 Fab also had several improved bone parameters, including femur growth plate volume, and femur diameter ( FIG. 16 A and FIG. 16 B ).
  • Ach mice treated with KC18 Fab also had improved bone age as shown by more developed secondary ossification center in tibia ( FIG. 17 ) compared to those treated with vehicle.
  • achondroplasia is the most common form of dwarfism due to activating mutations in the FGFR3 gene.
  • FGFR3 protein is expressed in the growth plate and its function is to regulate proper growth.
  • the activating mutations lead to excessive inhibition of chondrocyte proliferation and differentiation which is the main cause for the short stature and other skeletal deformities.
  • the antibodies generated herein are specific to FGFR3 and inhibit FGFR3 activity.
  • the mechanism of action of the antibody is to inhibit ligand binding and prevent activation of the receptor.
  • the antibodies described herein can block ligand activation and subsequently inhibit downstream signaling measured by the decrease in Erk phosphorylation. This translates into inhibition of receptor activity.

Abstract

Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

Description

    RELATED APPLICATIONS
  • This application is a division of U.S. patent application Ser. No. 17/407,774, filed Aug. 20, 2021, which claims the benefit of priority of U.S. Provisional Application No. 63/068,575, filed Aug. 21, 2020, the contents of which are incorporated by reference in their entirety for all purposes.
    • SEQUENCE LISTING
  • The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Oct. 12, 2022, is named 734907 SA9-231DIV_ST26.xml, and is 572,730 bytes in size.
    • FIELD OF THE INVENTION
  • This disclosure relates to compositions of anti-fibroblast growth factor receptor 3 (anti-FGFR3) antigen-binding proteins or antigen-binding fragments thereof, such as antibodies and fragments thereof, and methods of using the same.
    • BACKGROUND
  • Fibroblast growth factor receptor 3 (FGFR3) is a protein involved, in part, in the negative regulation of bone development, being highly expressed in growth plate chondrocytes (Sarabipour et al. Biochim Biophys Acta. 1858(7 Pt A): 1436-1442. 2016). FGFR3 is a single-pass membrane receptor tyrosine kinase with 3 Ig-like domains (D1-D3). Binding of FGFR3 to an FGFR3-ligand, such as FGF18, triggers ligand-dependent receptor dimerization which leads to tyrosine kinase activation and downstream signal transduction. This signaling cascade regulates, among other things, chondrocyte proliferation and differentiation.
  • FGFR3 is a member of the fibroblast growth factor receptor family, which also includes FGFR1, FGFR2, and FGFR4. Each member of the receptor family is a single-pass membrane receptor tyrosine kinase and shares the feature of 3 Ig-like domains. Moreover, each member of the receptor family possesses a high degree of homology with the other members. Strategies to develop FGFR3-specific inhibitors have proven challenging for this reason. Nonetheless, it is important to develop FGFR3-specific inhibitors that do not cross-react with other fibroblast growth factor receptor family members to avoid unwanted side effects in the treatment of an FGFR3-mediate disease or disorder.
  • Accordingly, there is a need in the art to identify antigen-binding proteins or antigen-binding fragments thereof, that achieve effective inhibition of FGFR3 activity. Such antigen-binding proteins or antigen-binding fragments thereof may be useful in the treatment of FGFR3-mediated diseases and disorders.
    • SUMMARY
  • Disclosed herein are anti-FGFR3 antigen-binding proteins or antigen-binding fragments thereof, such as antibodies and antigen-binding fragments thereof. The antigen-binding proteins or antigen-binding fragments thereof, such as anti-FGFR3 antibodies and antigen-binding fragments thereof of the disclosure are suitable for treating FGFR3-mediated diseases and disorders.
  • In one aspect, the disclosure provides an antigen-binding protein or antigen-binding fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GX1TFTDX2E (SEQ ID NO: 157), wherein X1 comprises or consists of Y or D and X2 comprises or consists of F or Y; a CDR-H2 sequence comprising the amino acid sequence of IDPETGX3T (SEQ ID NO: 158), wherein X3 comprises or consists of G or S; or CDR-H2 sequence comprising the amino acid sequence of INPNNGX4T (SEQ ID NO: 159), wherein X4 comprises or consists of G or V; or CDR-H2 sequence comprising the amino acid sequence of VX5PETGGT (SEQ ID NO: 160), wherein X5 comprises or consists of D or E; a CDR-H3 sequence comprising the amino acid sequence of TRX6YX7GYX8X9X10X11DY (SEQ ID NO: 161), wherein X6 comprises or consists of T or N, X7 comprises D or E, X8 comprises or consists of S or P, X9 comprises or consists of Q, R, or Y, X10 comprises or consists of T or A, X11 comprises or consists of F or M; and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QS X12LYS X13N X14KNY (SEQ ID NO: 162), wherein X12 comprises or consists of L or V, X13 comprises or consists of N, D, or S, and X14 comprises or consists of Q or N; a CDR-L2 sequence comprising the amino acid sequence of X15AS (SEQ ID NO: 163), wherein X15 comprises or consists of W, Y, or F; a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75), LQYDNLLWT (SEQ ID NO: 81), or HQYLSX16YT (SEQ ID NO: 290) wherein X16 comprises or consists of P or S; (b) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82); a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83); a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGAMDY (SEQ ID NO: 78); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85); a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86); a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87); (c) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82); a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83); a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGSMDF (SEQ ID NO: 84); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85); a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86); a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87); (d) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTVTDYY (SEQ ID NO: 88); a CDR-H2 sequence comprising the amino acid sequence of INPNNGVT (SEQ ID NO: 89); a CDR-H3 sequence comprising the amino acid sequence of AREEDFDGFDY (SEQ ID NO: 90); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVSTG (SEQ ID NO: 91); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98 and 104); a CDR-L3 sequence comprising the amino acid sequence of QQHYSTPLT (SEQ ID NO: 93); (e) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFSDFE (SEQ ID NO: 94); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101); a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTX17DY (SEQ ID NO: 308), wherein X17 comprises M or F; and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSX18NQKNY (SEQ ID NO: 309), wherein X18 comprises S or D; a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98 and 104); a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105); or (f) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFTDFE (SEQ ID NO: 100); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101); a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTX17DY (SEQ ID NO: 308), wherein X17 comprises M or F; and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSX18NQKNY (SEQ ID NO: 309), wherein X18 comprises S or D; a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98 and 104); a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105).
  • In certain embodiments, (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), GDTFTDYE (SEQ ID NO: 295), or GYTFTDFE (SEQ ID NO: 296); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101), VDPETGGT (SEQ ID NO: 297), IDPETGST (SEQ ID NO: 298), or VEPETGGT (SEQ ID NO: 299); a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAMDY (SEQ ID NO: 72), TRTYEGYPYAMDY (SEQ ID NO: 300), or TRTYDGYPYAFDY (SEQ ID NO: 301); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLLYSNNQKNY (SEQ ID NO: 73), QSVLYSNNNKNY (SEQ ID NO: 302), or QSVLYSDNQKNY (SEQ ID NO: 306); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104), YAS (SEQ ID NO: 303), or FAS (SEQ ID NO: 304); a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75); (b) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82); a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83); a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGAMDY (SEQ ID NO: 78); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85); a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86); a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87); (c) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82); a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83); a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGSMDF (SEQ ID NO: 84); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85); a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86); a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87); (d) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTVTDYY (SEQ ID NO: 88); a CDR-H2 sequence comprising the amino acid sequence of INPNNGVT (SEQ ID NO: 89); a CDR-H3 sequence comprising the amino acid sequence of AREEDFDGFDY (SEQ ID NO: 90); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVSTG (SEQ ID NO: 91); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104); a CDR-L3 sequence comprising the amino acid sequence of QQHYSTPLT (SEQ ID NO: 93); (e) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFSDFE (SEQ ID NO: 94); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101); a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTMDY (SEQ ID NO: 96) or TRNYDGYSQTFDY (SEQ ID NO: 305); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY (SEQ ID NOs: 97 and 103) or QSVLYSDNQKNY (SEQ ID NO: 306); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104); a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105); or (f) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFTDFE (SEQ ID NO: 100); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101); a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSRTMDY (SEQ ID NO: 102) or TRNYDGYSRTFDY (SEQ ID NO: 307); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY(SEQ ID NOs: 97 and 103) or QSVLYSDNQKNY (SEQ ID NO: 306); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104); a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105).
  • In certain embodiments, (a) the VH domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 6, SEQ ID NO: 18, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 10, SEQ ID NO: 110, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 57, and SEQ ID NO: 58; and the VL domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 7, SEQ ID NO: 19, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 60, and SEQ ID NO: 61; (b) the VH domain comprises the amino acid sequence of SEQ ID NO: 8; and the VL domain comprises the amino acid sequence of SEQ ID NO: 9; (c) the VH domain comprises the amino acid sequence of SEQ ID NO: 10; and the VL domain comprises the amino acid sequence of SEQ ID NO: 11; (d) the VH domain comprises the amino acid sequence of SEQ ID NO: 12; and the VL domain comprises the amino acid sequence of SEQ ID NO: 13; (e) the VH domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 23; and the VL domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27; (f) the VH domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 16, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31; the VL domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 17, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
  • In certain embodiments, the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 63 or 65, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67 or 69.
  • In certain embodiments, the VH domain is at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, or SEQ ID NO: 122, and wherein the VL domain is at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, or SEQ ID NO: 132.
  • In certain embodiments, the antigen binding protein or fragment thereof of comprises an antibody heavy chain at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 63 or 65, and an antibody light chain at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 67 or 69.
  • In certain embodiments, (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NO: 71), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAMDY (SEQ ID NO: 72); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLLYSNNQKNY (SEQ ID NO: 73), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NO: 74), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75). In some embodiments thereof, the VH domain comprises the amino acid sequence of SEQ ID NO: 6, and the VL domain comprises the amino acid sequence of SEQ ID NO: 7.
  • In certain embodiments, (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NO: 76), a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NO: 77), and a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGAMDY (SEQ ID NO: 78); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NO: 79), a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NO: 80), and a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NO: 81).
  • In certain embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 8, and the VL domain comprises the amino acid sequence of SEQ ID NO: 9.
  • In certain embodiments, (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NO: 82), a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NO: 83), and a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGSMDF (SEQ ID NO: 84); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NO: 85), a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NO: 86), and a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NO: 87).
  • In certain embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 10, and the VL domain comprises the amino acid sequence of SEQ ID NO: 11.
  • In certain embodiments, (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTVTDYY (SEQ ID NO: 88), a CDR-H2 sequence comprising the amino acid sequence of INPNNGVT (SEQ ID NO: 89), and a CDR-H3 sequence comprising the amino acid sequence of AREEDFDGFDY (SEQ ID NO: 90); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVSTG (SEQ ID NO: 91), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NO: 92), and a CDR-L3 sequence comprising the amino acid sequence of QQHYSTPLT (SEQ ID NO: 93).
  • In certain embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 12, and the VL domain comprises the amino acid sequence of SEQ ID NO: 13.
  • In certain embodiments, (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFSDFE (SEQ ID NO: 94), a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NO: 95), and a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTMDY (SEQ ID NO: 96); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY (SEQ ID NO: 97), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NO: 98), and a CDR-L3 sequence comprising the amino acid sequence of HQYLSSYT (SEQ ID NO: 99).
  • In certain embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 14, and the VL domain comprises the amino acid sequence of SEQ ID NO: 15.
  • In certain embodiments, (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFTDFE (SEQ ID NO: 100), a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NO: 101), and a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSRTMDY (SEQ ID NO: 102); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY (SEQ ID NO: 103), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NO: 104), and a CDR-L3 sequence comprising the amino acid sequence of HQYLSSYT (SEQ ID NO: 105).
  • In certain embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 16, and the VL domain comprises the amino acid sequence of SEQ ID NO: 17.
  • In certain embodiments, (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of VDPETGGT (SEQ ID NO: 297), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAFDY (SEQ ID NO: 301); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSNNNKNY (SEQ ID NO: 302), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, 104), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75).
  • In certain embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 57, and the VL domain comprises the amino acid sequence of SEQ ID NO: 19 or 59.
  • In certain embodiments, the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 63, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of VDPETGGT (SEQ ID NO: 297), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAFDY (SEQ ID NO: 301); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSDNQKNY (SEQ ID NO: 306), a CDR-L2 sequence comprising the amino acid sequence of FAS (SEQ ID NO: 304), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75).
  • In certain embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 57, and the VL domain comprises the amino acid sequence of SEQ ID NO: 61.
  • In certain embodiments, the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 65, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof binds a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 133.
  • In certain embodiments, the antigen binding protein or antigen-binding fragment thereof binds a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 134.
  • In certain embodiments, the antigen binding protein or antigen-binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through L163 of SEQ ID NO: 133.
  • In certain embodiments, the antigen binding protein or antigen-binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through N170 of SEQ ID NO: 133.
  • In certain embodiments, the antigen binding protein or antigen-binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through D160 and G197 through L213 of SEQ ID NO: 133.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is a chimeric or humanized antibody or antigen-binding binding fragment thereof.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is a human antibody or antigen-binding binding fragment thereof.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is a monoclonal antibody or antigen-binding binding fragment thereof.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof comprises one or more full-length antibody heavy chains comprising an Fc region.
  • In certain embodiments, the Fc region is a human IgG1 Fc region.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab), F(ab′)2, Fab′-SH, Fv, or scFv fragment.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab) fragment.
  • In certain embodiments, the antibody F(ab) fragment comprises SEQ ID NO: 56 and the first about 100 amino acids of SEQ ID NO: 54.
  • In certain embodiments, the antibody F(ab) fragment comprises SEQ ID NO: 57 and the first about 100 amino acids of SEQ ID NO: 54.
  • In certain embodiments, the antibody F(ab) fragment comprises SEQ ID NO: 58 and the first about 100 amino acids of SEQ ID NO: 54.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 141 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 142.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 143 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 144.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 145 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 146.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 147 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 148.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 149 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 150.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 151 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 152.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof comprises cross-reactivity to mouse and cynomolgus FGFR3.
  • In certain embodiments, the antigen binding or antigen-binding binding fragment thereof protein does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof does not bind to each of FGFR1, FGFR2, and FGFR4.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof binds to each of FGFR1, FGFR2, and FGFR4 with an affinity of 100 μM or greater.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof binds human FGFR3 with an equilibrium dissociation constant (KD) of 10 nM or less.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof binds human FGFR3 with an off rate (Kd) of 10−4 or greater.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof inhibits ligand-induced FGFR3 dimerization with IC50 of 5 μg/ml or less.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof inhibits FGFR3 receptor activation and downstream signaling with IC50 of 5 μg/ml or less.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof inhibits the activity of an FGFR3G380R mutant.
  • In certain embodiments, the antigen binding protein or antigen-binding fragment thereof is capable of penetrating a bone growth plate.
  • In certain embodiments, the antigen binding protein or antigen-binding fragment thereof is capable of decreasing binding of FGFR3 and its ligand in a bone growth plate.
  • In another aspect, the disclosure provides a pharmaceutical composition comprising the antigen binding protein or antigen-binding fragment thereof recited above, and a pharmaceutically acceptable carrier.
  • In another aspect, the disclosure provides an isolated nucleic acid molecule encoding the antigen binding protein or antigen-binding fragment thereof recited above.
  • In another aspect, the disclosure provides an expression vector comprising the nucleic acid molecule recited above.
  • In another aspect, the disclosure provides a host cell comprising the expression vector recited above.
  • In another aspect, the disclosure provides a method for treating a FGFR3-mediated disease or disorder in a subject, comprising administering to a subject in need thereof the antigen binding protein or antigen-binding fragment thereof recited above.
  • In certain embodiments, the FGFR3-mediated disease or disorder is achondroplasia.
  • In certain embodiments, the achondroplasia is FGFR3G380R+ achondroplasia.
  • In certain embodiments, the subject suffering from achondroplasia comprises one or more symptoms selected from the group consisting of shortened proximal limbs, brachydactyly, large head with prominent forehead frontal bossing, small midface with a flattened nasal bridge, spinal kyphosis, spinal lordosis, varus, valgus, ear infections, sleep apnea, and hydrocephalus.
  • In certain embodiments, the FGFR3-mediated disease or disorder is cancer.
  • In certain embodiments, the cancer is bladder cancer melanoma, urothelial cancer, and endometrial cancer.
  • In one aspect, the disclosure provides a method for treating achondroplasia in a subject, comprising administering to a subject in need thereof an antigen-binding protein fragment that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • In one aspect, the disclosure provides a method for inhibiting one or both of FGFR3 activity and expression in a bone growth plate of a subject, comprising administering to a subject an antigen-binding protein fragment that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • In one aspect, the disclosure provides an antigen-binding protein or antigen-binding fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein the antigen binding protein binds a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 134.
  • In certain embodiments, the antigen binding protein binds a region of human FGFR3 polypeptide comprising the amino acids D143 through L163 of SEQ ID NO: 133.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through N170 of SEQ ID NO: 133.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof binds a region of human FGFR3 polypeptide comprising the amino acids D143 through D160 and G197 through L213 of SEQ ID NO: 133.
  • In one aspect, the disclosure provides an antigen-binding protein or antigen-binding fragment thereof with binding specificity to a fibroblast growth factor receptor 3 (FGFR3) epitope, comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein the antigen binding protein or antigen-binding binding fragment thereof competes for binding to FGFR3 with an antibody comprising VH/VL domain amino acid sequence pairs selected from the group consisting of: SEQ ID NO: 6/SEQ ID NO: 7, SEQ ID NO: 8/SEQ ID NO: 9, SEQ ID NO: 10/SEQ ID NO: 11, SEQ ID NO: 12/SEQ ID NO: 13, SEQ ID NO: 14/SEQ ID NO: 15, and SEQ ID NO: 16/SEQ ID NO: 17.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is a chimeric or humanized antibody or antigen-binding binding fragment thereof.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is a human antibody or antigen-binding binding fragment thereof.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is a monoclonal antibody or antigen-binding binding fragment thereof.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof comprises one or more full-length antibody heavy chains comprising an Fc region.
  • In certain embodiments, the Fc region is a human IgG1 Fc region.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab), F(ab′)2, Fab′-SH, Fv, or scFv fragment.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab) fragment.
  • In certain embodiments, the antibody F(ab) fragment comprises SEQ ID NO: 56 and the first about 100 amino acids of SEQ ID NO: 54.
  • In certain embodiments, the antibody F(ab) fragment comprises a heavy chain comprising SEQ ID NO: 57 and the first about 100 amino acids of SEQ ID NO: 54.
  • In certain embodiments, the antibody F(ab) fragment comprises a heavy chain comprising SEQ ID NO: 58 and the first about 100 amino acids of SEQ ID NO: 54.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 141, 164, 173, 182, 191, 200, 209, 218, 227, 236, 245, 254, 263, 272, or 281, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 142.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 143, 165, 174, 183, 192, 201, 210, 219, 228, 237, 246, 255, 264, 273, or 282, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 144.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 145, 166, 175, 184, 193, 202, 211, 220, 229, 238, 247, 256, 265, 274, or 283, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 146.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 147, 167, 176, 185, 194, 203, 212, 221, 230, 239, 248, 257, 266, 275, or 284, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 148.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 149, 168, 177, 186, 195, 204, 213, 222, 231, 240, 249, 258, 267, 276, or 285, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 150.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 151, 169, 178, 187, 196, 205, 214, 223, 232, 241, 250, 259, 268, 277, or 286, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 152.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof comprises has cross-reactivity to mouse and cynomolgus FGFR3.
  • In certain embodiments, the antigen binding or antigen-binding binding fragment thereof protein does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof does not bind to each of FGFR1, FGFR2, and FGFR4.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof binds to each of FGFR1, FGFR2, and FGFR4 with an affinity equilibrium dissociation constant (KD) of 100 μM or greater.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof binds human FGFR3 with an equilibrium dissociation constant (KD) of 10 nM or less.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof binds human FGFR3 with an off rate (Kd) of 10−4 or greater.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof inhibits ligand-induced FGFR3 dimerization with IC50 of 5 μg/ml or less.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof inhibits FGFR3 receptor activation and downstream signaling with IC50 of 5 μg/ml or less.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof inhibits the activity of an FGFR3G380R mutant.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is capable of penetrating a bone growth plate.
  • In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is capable of decreasing the binding of FGFR3 with its ligand in a bone growth plate. In certain embodiments, the antigen binding protein or antigen-binding binding fragment thereof is capable of decreasing the kinase activity of FGFR3 in a bone growth plate.
  • Also provided is a pharmaceutical composition comprising the antigen binding protein or antigen-binding fragment thereof as described herein. In certain embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
  • Also provided is an isolated nucleic acid molecule encoding the antigen binding protein or antigen-binding fragment thereof as described herein. Also provided is an expression cassette comprising said nucleic acid molecule. Also provided is an expression vector comprising the isolated nucleic acid molecule. Further provided is a host cell comprising the expression vector, the expression cassette or the nucleic acid molecule.
  • Further provided is a method for treating a FGFR3-mediated disease or disorder in a subject. In certain embodiments, the method comprises administering to a subject in need thereof the antigen binding protein or antigen-binding fragment thereof as described herein. In certain embodiments, the FGFR3-mediated disease or disorder is achondroplasia. In certain embodiments, the achondroplasia is FGFR3G380R+ achondroplasia.
  • In certain embodiments, the FGFR3-mediated disease or disorder is cancer.
  • In certain embodiments, the cancer is bladder cancer melanoma, urothelial cancer, and endometrial cancer.
  • Also provided is a method for treating achondroplasia in a subject. In certain embodiments, the method comprises administering to a subject in need thereof an antigen-binding protein fragment that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • Also provided is a method for inhibiting one or both of FGFR3 activity and expression in a bone growth plate of a subject. In certain embodiments, the method comprises administering to a subject an antigen-binding protein fragment that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • In certain embodiments, the subject is a child. In certain embodiments, the child is an infant. In certain embodiments, the infant is a newborn.
  • Also provided is a method for preventing or alleviating one or more symptoms of achondroplasia in a subject. In certain embodiments, the method comprises administering to the subject an antigen-binding protein or an antigen-binding protein fragment thereof that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • The foregoing and other features and advantages of the present disclosure will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided to the Office upon request and payment of the necessary fee.
  • FIG. 1 schematically depicts fibroblast growth factor receptor 3 (FGFR3) isoform IIIc.
  • FIG. 2 depicts heat maps generated with hydrogen deuterium exchange (HDX) mass spectrometry used to determine the epitopes on FGFR3 for select antibodies by measuring the amide hydrogen deuterium exchange on FGFR3.
  • FIG. 3 depicts fluorescent images from internalization assays to detect internalization of anti-FGFR3 antibodies in KMS-11 cells.
  • FIG. 4 graphically depicts the average amount of anti-FGFR3 antibody internalization relative to the total amount of antibody.
  • FIG. 5A-FIG. 5C graphically depict inhibition of FGFR3 dimerization by anti-FGFR3 antibody KC18 (FIG. 5A), KE58 (FIG. 5B), KE94 (FIG. 5C). Inhibition was evaluated by a chemiluminescent assay in U2OS cells co-expressing fusion protein of β-galactosidase-prolink (PK) and FGFR3 (FGFR3-PK) and β-galactosidase-enzyme acceptor (EA) and FGFR3 (FGFR3-EA).
  • FIG. 6 depicts an alignment of anti-FGFR3 antibodies KC18, KE63, and KE94.
  • FIG. 7 depicts an alignment of anti-FGFR3 antibody KC18_Hu18 with variants. Mutations of Hu18 residues are highlighted green or red.
  • FIG. 8A-FIG. 8C depict graphs demonstrating IC50 values for the inhibition of Erk phosphorylation by humanized anti-FGFR3 antibodies Hu18 (FIG. 8A), Hu44 (FIG. 8B), and Hu46 (FIG. 8C). Inhibition of Erk phosphorylation was determined by a homogenous time-resolved fluorescence (HTRF) assay.
  • FIG. 9A-FIG. 9B graphically depict relative Erk phosphorylation inhibition by anti-FGFR3 antibodies KC18 (FIG. 9A), KE63 (FIG. 9B), and KE94 (FIG. 9B) and their corresponding Fab fragments.
  • FIG. 10A-FIG. 10C graphically depict relative Erk phosphorylation inhibition by anti-FGFR3 antibody KC18 in different formats. FIG. 10A depicts inhibition effect of KC18 as a full-length antibody (KC18), a Fab fragment (Kc18 Fab), a one-armed, monovalent antibody (MetMab), and a PEGylated Fab fragment (PEG) in WT cells. FIG. 10B depicts inhibition effect of KC18 as a full-length antibody (IgG), a Fab fragment, a one-armed, monovalent antibody (MetMab), and a PEGylated Fab fragment (PEG) in Ach cells. FIG. 10C depicts KC18 fab fragments with half-life extension moieties using a human albumin nanobody conjugate (KC18 Fab-HLE), with and without human serum albumin (HSA) or mouse serum albumin (MSA). Erk phosphorylation was measured in an HTRF assay and compared to an isotype control (Iso).
  • FIG. 11 graphically depicts inhibition of Erk phosphorylation by humanized anti-FGFR3 antibodies Hu18, Hu44, and Hu46. Inhibition of Erk phosphorylation was determined using an HTRF assay.
  • FIG. 12A-FIG. 12B graphically depict femur (FIG. 12A) and tibia (FIG. 12B) length in an achondroplasia mouse model (Ach), which is a transgenic mouse that overexpresses the mouse FGFR3 protein with the G380R mutation under the collagen II promoter. Mice were administered the KC18 fab fragment subcutaneously from 3 days of age to 20 days of age.
  • FIG. 13A-FIG. 13B graphically depict vertebrae (FIG. 13A) and skull (FIG. 13B) length in the Ach mouse model. For skull measurements, NL=nasal length; FL=frontal length; and PL=parietal length.
  • FIG. 14 graphically depicts brain volume in the WT and Ach mouse model treated by saline or KC18 fab fragment.
  • FIG. 15A graphically depicts Kyphosis Index in the WT and Ach mouse model treated by saline or KC18 fab fragment. FIG. 15B depicts the calculation of Kyphotic Index using a mouse model.
  • FIG. 16A graphically depicts femur growth plate (GP) volume in Ach mouse model treated by vehicle or KC18 fab fragment. FIG. 16B depicts femur diameter in Ach mouse model treated by vehicle or KC18 fab fragment.
  • FIG. 17 graphically depicts increased secondary ossification center in tibia in Ach mouse model compared to those treated with vehicle.
    •  DETAILED DESCRIPTION
  • Antigen-binding proteins or antigen-binding fragments thereof are provided. Methods of inhibiting one or more FGFR3 activities, and methods of treating FGFR3-mediated diseases and disorders are also provided.
  • Generally, nomenclature used in connection with cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques provided herein are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclature used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
  • Unless otherwise defined herein, scientific and technical terms used herein have the meanings that are commonly understood by those of ordinary skill in the art. In the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The use of “or” means “and/or” unless stated otherwise. The use of the term “including,” as well as other forms, such as “includes” and “included,” is not limiting.
  • So that the disclosure may be more readily understood, certain terms are first defined.
    • Fibroblast Growth Factor Receptor 3 (FGFR3)
  • As used herein, the term “FGFR3” or “fibroblast growth factor receptor 3” or “CD333” refers to the FGFR3 protein encoded by the FGFR3 gene. FGFR3 belongs to a family of fibroblast growth factor receptors that also includes FGFR1, FGFR2, and FGFR4. Like the other fibroblast growth factor receptor family members, FGFR3 is a single-pass membrane receptor tyrosine kinase with 3 Ig-like domains (D1, D2, and D3). Ligand dependent receptor dimerization leads to tyrosine kinase activation and downstream signal transduction. FGFR3 undergoes alternative splicing leading to several isoforms, including isoform IIIb and isoform IIIc. IIIb and IIIc arise from alternative splicing of exons 8 and 9. IIIb and IIIc have identical Ig1 (D1) and Ig2 (D2) domains, but vary in the Ig3 (D3) domain. It is FGFR3 IIIc that is the major FGFR3 isoform in chondrocytes and mediates the anabolic effects of the FGFR3 ligand, FGF18, in articular cartilage. The structure and function of FGFR3 is described in further detail in Olsen et al. (PNAS. 101(4): 935-940. 2004), incorporated herein by reference in its entirety for all purposes.
  • The human FGFR3 isoform IIIc amino acid sequence is recited below.
  • (SEQ ID NO: 135)
    MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLV
    FGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNAS
    HEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGDDEDGEDEAEDTGVDTGA
    PYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGREFRGEHR
    IGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSP
    HRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP
    DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHH
    SAWLVVLPAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRS
    PPKKGLGSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPT
    LANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAA
    KPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGP
    LYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ
    VARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKK
    TTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPV
    EELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDR
    VLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPS
    SGGSRT
  • Mutations in FGFR3 can lead to certain undesired conditions. A G380R mutation in the transmembrane domain of FGFR3 is associated with 98% of all achondroplasia cases. FGFR3 with a G380R mutation can be referred to as FGFR3G380R, and the sequence of the human FGFR3G380R isoform IIIc is recited below.
  • (SEQ ID NO: 133)
    MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLV
    FGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNAS
    HEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGDDEDGEDEAEDTGVDTGA
    PYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGREFRGEHR
    IGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSP
    HRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP
    DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHH
    SAWLVVLPAEEELVEADEAGSVYAGILSY R VGFFLFILVVAAVTLCRLRS
    PPKKGLGSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPT
    LANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAA
    KPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGP
    LYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ
    VARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKK
    TTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPV
    EELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDR
    VLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPS
    SGGSRT
    • Antigen-Binding Proteins
  • As used herein, the term “antibody” or “antigen-binding protein” refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive with an antigen or epitope (e.g., a FGFR3 antigen or epitope), and includes both polyclonal and monoclonal antibodies, as well as functional antibody fragments thereof, including but not limited to fragment antigen-binding (Fab) fragments, F(ab′)2 fragments, Fab′ fragments, Fv fragments, recombinant IgG (rIgG) fragments, single chain variable fragments (scFv) and single domain antibodies (e.g., sdAb, sdFv, nanobody) fragments. The term “antibody” includes genetically engineered or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, meditope-enabled antibodies, heteroconjugate antibodies (e.g., bispecific antibodies, diabodies, triabodies, tetrabodies, tandem di-scFv, tandem tri-scFv) and the like. Unless otherwise stated, the term “antibody” should be understood to encompass functional antibody fragments thereof. As used herein, the term “functional antibody fragment” refers to an antibody fragment having at least 80%, at least 85%, at least 90%, or at least 95% affinity as the antibody of interest from which the fragment is derived from.
  • As used herein, the term “complementarity determining region” or “CDR” refers to sequences of amino acids within antibody variable regions, which confer antigen specificity and binding affinity. In general, there are three CDRs in each heavy chain variable region (CDR-H1, CDR-H2, CDR-H3) and three CDRs in each light chain variable region (CDR-L1, CDR-L2, CDR-L3). “Framework regions” or “FR” are known in the art to refer to the non-CDR portions of the variable regions of the heavy and light chains. In general, there are four FRs in each heavy chain variable region (FR-H1, FR-H2, FR-H3, and FR-H4), and four FRs in each light chain variable region (FR-L1, FR-L2, FR-L3, and FR-L4).
  • The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 (“Chothia” numbering scheme), MacCallum et al., J. Mol. Biol. 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262, 732-745. (“Contact” numbering scheme), Lefranc M P et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 January; 27(1):55-77 (“IMGT” numbering scheme), and Honegger A and Pluckthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun. 8; 309(3):657-70, (AHo numbering scheme).
  • The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based structural alignments, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters, for example, “30a,” and deletions appearing in some antibodies. The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering. The Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme.
  • A “CDR” or “complementary determining region,” or individual specified CDRs (e.g., “CDR-H1,” “CDR-H2,” “CDR-H3”), of a given antibody or region thereof, such as a variable region thereof, should be understood to encompass a (or the specific) complementary determining region as defined by any of the known schemes. Likewise, an “FR” or “framework region,” or individual specified FRs (e.g., “FR-H1,” “FR-H2”) of a given antibody or region thereof, such as a variable region thereof, should be understood to encompass a (or the specific) framework region as defined by any of the known schemes. In some instances, the scheme for identification of a particular CDR or FR is specified, such as the CDR as defined by the IMGT, Kabat, Chothia, AbM, or Contact method. In other cases, the particular amino acid sequence of a CDR or FR is given. Unless otherwise specified, all particular CDR amino acid sequences mentioned in the disclosure are IMGT CDRs. However, alternative CDRs defined by other schemes are also encompassed by the present disclosure, such as those determined by abYsis Key Annotation (Website: abysis.org/abysis/sequence_input/key_annotation/key_annotation.cgi).
  • As used herein, the term “specifically binds,” “specifically binding,” “binding specificity” or “specifically recognized” refers that an antigen binding protein or antigen-binding fragment thereof that exhibits appreciable affinity for an antigen (e.g., an FGFR3 antigen) and does not exhibit significant cross reactivity to a target that is not an FGFR3 protein. As used herein, the term “affinity” refers to the strength of the interaction between an antigen binding protein or antigen-binding fragment thereof antigen binding site and the epitope to which it binds. As readily understood by those skilled in the art, an antigen binding protein affinity may be reported as a dissociation constant (KD) in molarity (M). The antigen binding protein or antigen-binding fragment thereof of the disclosure have KD values in the range of about 10−6 M to about 10−12 M (i.e., low micromolar to picomolar range), about 10−7 M to 10−11 M, about 10−8 M to about 10−10 M, about 10−9 M. In certain embodiments, the antigen binding protein or antigen-binding fragment thereof has a binding affinity of about 10−6 M, 10−7 M, 10−8 M, 10−9 M, 10−10 M, 10−11 M, or 10−12 M. In certain embodiments, the antigen binding protein or antigen-binding fragment thereof has a binding affinity of about 10−7 M to about 10−9 M (nanomolar range).
  • Specific binding can be determined according to any art-recognized means for determining such binding. In some embodiments, specific binding is determined by competitive binding assays (e.g. ELISA) or Biacore assays. In certain embodiments, the assay is conducted at about 20° C., 25° C., 30° C., or 37° C.
    • Anti-FGFR3 Antigen-Binding Proteins
  • In one aspect, the disclosure provides antigen binding proteins and antigen-binding fragments thereof with binding specificity to FGFR3.
  • Exemplary anti-FGFR3 antigen binding protein and antigen-binding fragment thereof CDRs are recited below in Table 1 and Table 4. Exemplary anti-FGFR3 antigen binding protein and antigen-binding fragment thereof variable heavy (VH) and variable light (VL) domains are recited below in Table 3, Table 8, Table 9, and Table 13. Exemplary anti-FGFR3 antigen binding protein full length heavy and light chains are recited below in Table 14.
  • TABLE 1
    Antibody Heavy chain and Light chain CDR regions
    HEAVY Chain
    VH Chain ID HCDR1-IMGT HCDR2-IMGT HCDR3-IMGT
    KC18_VH GDTFTDFE IDPETGGT TRTYDGYPYAMDY
    (SEQ ID NO: 70) (SEQ ID NO: 71) (SEQ ID NO: 72)
    KE35_VH GYTFTDYN INPNNGGT ARERDYDGAMDY
    (SEQ ID NO: 76) (SEQ ID NO: 77) (SEQ ID NO: 78)
    KE42_VH GYTFTDYN INPNNGGT ARERDYDGSMDF
    (SEQ ID NO: 82) (SEQ ID NO: 83) (SEQ ID NO: 84)
    KE58_VH GYTVTDYY INPNNGVT AREEDFDGFDY
    (SEQ ID NO: 88) (SEQ ID NO: 89) (SEQ ID NO: 90)
    KE63_VH GSTFSDEE IDPETGGT TRNYDGYSQTMDY
    (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96)
    KE94_VH GSTFTDEE IDPETGGT TRNYDGYSRTMDY
    (SEQ ID NO: 100) (SEQ ID NO: 101) (SEQ ID NO: 102)
    KC18 Hu18 VH GDTFTDFE VDPETGGT TRTYDGYPYAFDY
    (SEQ ID NO: 70) (SEQ ID NO: 297) (SEQ ID NO: 301)
    KC18Hrw1 GDTFTDFE IDPETGST TRTYDGYPYAMDY
    (SEQ ID NO: 70) (SEQ ID NO: 298) (SEQ ID NO: 72)
    KC18Hrw2 GDTFTDYE IDPETGST TRTYDGYPYAMDY
    (SEQ ID NO: 295) (SEQ ID NO: 298) (SEQ ID NO: 72)
    KC18Hrw3 GDTFTDYE IDPETGST TRTYDGYPYAMDY
    (SEQ ID NO: 295) (SEQ ID NO: 298) (SEQ ID NO: 72)
    KC18HV1-69rw2 GDTFTDFE VDPETGGT TRTYDGYPYAMDY
    (SEQ ID NO: 70) (SEQ ID NO: 297) (SEQ ID NO: 72)
    KC18HV1-69rw3 GDTFTDFE VDPETGGT TRTYEGYPYAMDY
    (SEQ ID NO: 70) (SEQ ID NO: 297) (SEQ ID NO: 300)
    KC18HV1-69rw4 GDTFTDFE VDPETGGT TRTYDGYPYAFDY
    (SEQ ID NO: 70) (SEQ ID NO: 297) (SEQ ID NO: 301)
    KC18_CL_VH1 GDTFTDFE IDPETGGT ARTYDGYPYAMDY
    (SEQ ID NO: 70) (SEQ ID NO: 95) (SEQ ID NO: 310)
    KC18_CL_VH1b GYTFTDFE VDPETGGT ARTYDGYPYAMDY
    (SEQ ID NO: 296) (SEQ ID NO: 297) (SEQ ID NO: 310)
    KC18_CL_VH1c GYTFTDFE VEPETGGT ARTYDGYPYAMDV
    (SEQ ID NO: 296) (SEQ ID NO: 299) (SEQ ID NO: 311)
    KC18_CL_VH2 GDTFTDFE IDPETGGT TRTYDGYPYAMDY
    (SEQ ID NO: 70) (SEQ ID NO: 95) (SEQ ID NO: 72)
    KC18_CL_VH3 GDTFTDFE IDPESGGT ARTYDGYPYAMDY
    (SEQ ID NO: 70) (SEQ ID NO: 312) (SEQ ID NO: 310)
    KC18_CL_VH3b GYTFTDFE IDPESGGT ARTYDGYPYAMDY
    (SEQ ID NO: 296) (SEQ ID NO: 312) (SEQ ID NO: 310)
    KC18_CL_VH3c GYTFTDFE IEPESGGT ARTYDGYPYAMDV
    (SEQ ID NO: 296) (SEQ ID NO: 313) (SEQ ID NO: 311)
    KC18_CL_VH4 GDTFTDFE IDPETGGT TRTYDGYPYAMDY
    (SEQ ID NO: 70) (SEQ ID NO: 95) (SEQ ID NO: 72)
    KC18_VH_6 GDTFTDFE VDPETGGT TRTYDGYPYAFDY
    (SEQ ID NO: 70) (SEQ ID NO: 297) (SEQ ID NO: 301)
    KC18_VH_15 GDTFTDFE VDPETGGT TRTYDGYPYAFDY
    (SEQ ID NO: 70) (SEQ ID NO: 297) (SEQ ID NO: 301)
    KC18_VH_16 GDTFTDFE VDPETGGT TRTYDGYPYAFDY
    (SEQ ID NO: 70) (SEQ ID NO: 297) (SEQ ID NO: 301)
    KE63 Hu01 VH GSTFSDEE IDPETGGT TRNYDGYSQTFDY
    (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 305)
    KE63 Hu02 VH GSTFSDEE IDPETGGT TRNYDGYSQTFDY
    (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 305)
    KE63 Hu03 VH GSTFSDEE IDPETGGT TRNYDGYSQTFDY
    (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 305)
    KE63 Hu04 VH GSTFSDEE IDPETGGT TRNYDGYSQTFDY
    (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 305)
    KE94 Hu01 VH GSTFTDEE IDPETGGT TRNYDGYSRTFDY
    (SEQ ID NO: 100) (SEQ ID NO: 101) (SEQ ID NO: 307)
    KE94 Hu02 VH GSTFTDEE IDPETGGT TRNYDGYSRTFDY
    (SEQ ID NO: 100) (SEQ ID NO: 101) (SEQ ID NO: 307)
    KE94 Hu03 VH GSTFTDEE IDPETGGT TRNYDGYSRTFDY
    (SEQ ID NO: 100) (SEQ ID NO: 101) (SEQ ID NO: 307)
    KE94 Hu04 VH GSTFTDEE IDPETGGT TRNYDGYSRTFDY
    (SEQ ID NO: 100) (SEQ ID NO: 101) (SEQ ID NO: 307)
    LIGHT Chain
    VL Chain ID LCDR1-IMGT LCDR2-IMGT LCDR3-IMGT
    KC18_VL QSLLYSNNQKNY WAS QQYYSYRT
    (SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KE35_VL QDINKF YTS LQYDNLLWT
    (SEQ ID NO: 79) (SEQ ID NO: 80) (SEQ ID NO: 81)
    KE42_VL QDINKF YTS LQYDNLLWT
    (SEQ ID NO: 85) (SEQ ID NO: 86) (SEQ ID NO: 87)
    KE58_VL QDVSTG WAS QQHYSTPLT
    (SEQ ID NO: 91) (SEQ ID NO: 92) (SEQ ID NO: 93)
    KE63_VL QSVLYSSNQKNY WAS HQYLSSYT
    (SEQ ID NO: 97) (SEQ ID NO: 98) (SEQ ID NO: 99)
    KE94_VL QSVLYSSNQKNY WAS HQYLSSYT
    (SEQ ID NO: 103) (SEQ ID NO: 104) (SEQ ID NO: 105)
    KC18 Hu18 VL QSVLYSNNNKNY WAS QQYYSYRT
    (SEQ ID NO: 302) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18Lrw1 QSLLYSNNQKNY WAS QQYYSYRT
    (SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18Lrw2 QSVLYSSNNKNY WAS QQYYSYRT
    (SEQ ID NO: X) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18Lrw3 QSVLYSNNNKNY WAS QQYYSYRT
    (SEQ ID NO: 302) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18_CL_VL1 QSVLYSSNQKNY WAS QQYYSYRT
    (SEQ ID NO: 97) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18_CL_VL1b QSVLYSNNQKNY WAS QQYYSYRT
    (SEQ ID NO: 315) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18_CL_VL1c QSVLYSSNQKNY WAS QQYYSYRT
    (SEQ ID NO: 97) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18_CL_VL1d QSVLYSSNQKNY YAS QQYYSYRT
    (SEQ ID NO: 97) (SEQ ID NO: 303) (SEQ ID NO: 75)
    KC18_CL_VL2 QSLLYSNNQKNY WAS QQYYSYRT
    (SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18_CL_VL3 QSLLHSNNQKNY WGS QQYYSYRT
    (SEQ ID NO: 317) (SEQ ID NO: 316) (SEQ ID NO: 75)
    KC18_CL_VL3b QSLLYSNNQKNY WGS QQYYSYRT
    (SEQ ID NO: 73) (SEQ ID NO: 316) (SEQ ID NO: 75)
    KC18_CL_VL4 QSLLYSNNQKNY WGS QQYYSYRT
    (SEQ ID NO: 73) (SEQ ID NO: 316) (SEQ ID NO: 75)
    KC18_CL_VL5 QGISYSNNQKNY WAS QQYYSYRT
    (SEQ ID NO: X) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18_CL_VL6 QSLLYSNNQKNY WAS QQYYSYRT
    (SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18_VL_3 QSVLYSNNNKNY WAS QQYYSYRT
    (SEQ ID NO: 302) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KC18_VL_14 QSVLYSDNQKNY YAS QQYYSYRT
    (SEQ ID NO: 306) (SEQ ID NO: 303) (SEQ ID NO: 75)
    KC18_VL_15 QSVLYSDNQKNY FAS QQYYSYRT
    (SEQ ID NO: 306) (SEQ ID NO: 304) (SEQ ID NO: 75)
    KE63 Hu01 VL QSVLYSSNQKNY WAS HQYLSSYT
    (SEQ ID NO: 97) (SEQ ID NO: 98) (SEQ ID NO: 99)
    KE63 Hu02 VL QSVLYSSNQKNY WAS HQYLSPYT
    (SEQ ID NO: 97) (SEQ ID NO: 98) (SEQ ID NO: 314)
    KE63 Hu03 VL QSVLYSDNQKNY YAS HQYLSPYT
    (SEQ ID NO: 306) (SEQ ID NO: 303) (SEQ ID NO: 314)
    KE63 Hu04 VL QSVLYSDNQKNY FAS HQYLSPYT
    (SEQ ID NO: 306) (SEQ ID NO: 304) (SEQ ID NO: 314)
    KE94 Hu01 VL QSVLYSSNQKNY WAS HQYLSSYT
    (SEQ ID NO: 97) (SEQ ID NO: 104) (SEQ ID NO: 105)
    KE94 Hu02 VL QSVLYSSNQKNY WAS HQYLSPYT
    (SEQ ID NO: 97) (SEQ ID NO: 104) (SEQ ID NO: 314)
    KE94 Hu03 VL QSVLYSDNQKNY YAS HQYLSPYT
    (SEQ ID NO: 306) (SEQ ID NO: 303) (SEQ ID NO: 314)
    KE94 Hu04 VL QSVLYSDNQKNY FAS HQYLSPYT
    (SEQ ID NO: 306) (SEQ ID NO: 304) (SEQ ID NO: 314)
  • In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof comprise an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence, a CDR-H2 sequence, and a CDR-H3 sequence. The CDR-H1 sequence comprises the amino acid sequence of GX1TFTDX2E (SEQ ID NO: 157), wherein X1 comprises Y or D and X2 comprises F or Y; the CDR-H2 sequence comprises the amino acid sequence of IDPETGX3T (SEQ ID NO: 158), wherein X3 comprises G or S; or CDR-H2 sequence comprising the amino acid sequence of INPNNGX4T (SEQ ID NO: 159), wherein X4 comprises G or V; or CDR-H2 sequence comprising the amino acid sequence of VX5PETGGT (SEQ ID NO: 160), wherein X5 comprises D or E; and the CDR-H3 sequence comprises the amino acid sequence of TRX6YX7GYX8X9X10X11DY (SEQ ID NO: 161), wherein X6 comprises T or N, comprises D or E, X8 comprises S or P, X9 comprises Q, R, or Y, X19 comprises T or A, X11 comprises F or M.
  • In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof comprise an antibody light chain variable (VL) domain comprising a CDR-L1 sequence, a CDR-L2 sequence, and a CDR-L3 sequence. The CDR-L1 sequence comprises the amino acid sequence of QS X12LYS X13N X14KNY (SEQ ID NO: 162), wherein X12 comprises L or V, X13 comprises N, D, or S, and X14 comprises Q or N; the CDR-L2 sequence comprises the amino acid sequence of X15AS (SEQ ID NO: 163), wherein X15 comprises W, Y, or F; and the CDR-L3 sequence comprises the amino acid sequence of QQYYSYRT (SEQ ID NO: 75), LQYDNLLWT (SEQ ID NO: 81), or HQYLSX16YT (SEQ ID NO: 290), wherein X16 comprises P or S.
  • In one aspect, the disclosure provides an antigen-binding protein or fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein:
      • (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GX1TFTDX2E (SEQ ID NO: 157), wherein X1 comprises Y or D and X2 comprises F or Y; a CDR-H2 sequence comprising the amino acid sequence of IDPETGX3T (SEQ ID NO: 158), wherein X3 comprises G or S; or CDR-H2 sequence comprising the amino acid sequence of INPNNGX4T (SEQ ID NO: 159), wherein X4 comprises G or V; or CDR-H2 sequence comprising the amino acid sequence of VX5PETGGT (SEQ ID NO: 160), wherein X5 comprises D or E; a CDR-H3 sequence comprising the amino acid sequence of TRX6YX7GYX8X9X10X11DY (SEQ ID NO: 161), wherein X6 comprises T or N, X7 comprises D or E, X8 comprises S or P, X9 comprises Q, R, or Y, X10 comprises T or A, X11 comprises F or M; and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QS X12LYS X13N X14KNY (SEQ ID NO: 162), wherein X12 comprises L or V, X13 comprises N, D, or S, and X14 comprises Q or N; a CDR-L2 sequence comprising the amino acid sequence of X15AS (SEQ ID NO: 163), wherein X15 comprises W, Y, or F; a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75), LQYDNLLWT (SEQ ID NO: 81), or HQYLSX16YT (SEQ ID NO: 290) wherein X16 comprises P or S;
      • (b) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82); a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83); a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGAMDY (SEQ ID NO: 78); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85); a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86); a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
      • (c) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82); a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83); a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGSMDF (SEQ ID NO: 84); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85); a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86); a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
      • (d) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTVTDYY (SEQ ID NO: 88); a CDR-H2 sequence comprising the amino acid sequence of INPNNGVT (SEQ ID NO: 89); a CDR-H3 sequence comprising the amino acid sequence of AREEDFDGFDY (SEQ ID NO: 90); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVSTG (SEQ ID NO: 91); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104); a CDR-L3 sequence comprising the amino acid sequence of QQHYSTPLT (SEQ ID NO: 93);
      • (e) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFSDFE (SEQ ID NO: 94); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101); a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTX17DY (SEQ ID NO: 308), wherein X17 comprises M or F; and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSX18NQKNY (SEQ ID NO: 309), wherein X18 comprises S or D; a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104); a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105); or
      • (f) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFTDFE (SEQ ID NO: 100); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101); a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTX17DY (SEQ ID NO: 308), wherein X17 comprises M or F; and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSX18NQKNY (SEQ ID NO: 309), wherein X18 comprises S or D; a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104); a CDR-L3 sequence comprising the amino acid sequence of HQYLSSYT (SEQ ID NOs: 99 and 105).
  • In certain embodiments, the antigen binding protein or fragment thereof comprises a VH domain and a VL domain, wherein:
      • (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), GDTFTDYE (SEQ ID NO: 295), or GYTFTDFE (SEQ ID NO: 296); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101), VDPETGGT (SEQ ID NO: 297), IDPETGST (SEQ ID NO: 298), or VEPETGGT (SEQ ID NO: 299); a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAMDY (SEQ ID NO: 72), TRTYEGYPYAMDY (SEQ ID NO: 300), or TRTYDGYPYAFDY (SEQ ID NO: 301); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLLYSNNQKNY (SEQ ID NO: 73), QSVLYSNNNKNY (SEQ ID NO: 302), or QSVLYSDNQKNY (SEQ ID NO: 306); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104), YAS (SEQ ID NO: 303), or FAS (SEQ ID NO: 304); a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75);
      • (b) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82); a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83); a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGAMDY (SEQ ID NO: 78); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85); a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86); a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
      • (c) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82); a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83); a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGSMDF (SEQ ID NO: 84); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85); a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86); a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
      • (d) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTVTDYY (SEQ ID NO: 88); a CDR-H2 sequence comprising the amino acid sequence of INPNNGVT (SEQ ID NO: 89); a CDR-H3 sequence comprising the amino acid sequence of AREEDFDGFDY (SEQ ID NO: 90); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVSTG (SEQ ID NO: 91); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, 104); a CDR-L3 sequence comprising the amino acid sequence of QQHYSTPLT (SEQ ID NO: 93);
      • (e) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFSDFE (SEQ ID NO: 94); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101); a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTMDY (SEQ ID NO: 96) or TRNYDGYSQTFDY (SEQ ID NO: 305); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY(SEQ ID NOs: 97 and 103) or QSVLYSDNQKNY (SEQ ID NO: 306); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104); a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105); or
      • (f) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GSTFTDFE (SEQ ID NO: 100); a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101); a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSRTMDY (SEQ ID NO: 102) or TRNYDGYSRTFDY (SEQ ID NO: 307); and the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY(SEQ ID NOs: 97 and 103) or QSVLYSDNQKNY (SEQ ID NO: 306); a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, 104); a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105).
  • In certain embodiments, the FGFR3 antigen binding proteins and antigen-binding fragments thereof comprise one VH domain and one VL domain recited in Table 3, 8, 9, or 13. In certain embodiments, exemplary antigen-binding proteins or antigen-binding fragments thereof are provided:
  • TABLE 1.1
    Heavy chains and light chains of exemplary
    antigen-binding proteins or antigen-binding fragments
    No. Heavy Chain Light Chain
    1 SEQ ID NO: 6 SEQ ID NO: 7
    2 SEQ ID NO: 6 SEQ ID NO: 9
    3 SEQ ID NO: 6 SEQ ID NO: 11
    4 SEQ ID NO: 6 SEQ ID NO: 13
    5 SEQ ID NO: 6 SEQ ID NO: 15
    6 SEQ ID NO: 6 SEQ ID NO: 17
    7 SEQ ID NO: 8 SEQ ID NO: 7
    8 SEQ ID NO: 8 SEQ ID NO: 9
    9 SEQ ID NO: 8 SEQ ID NO: 11
    10 SEQ ID NO: 8 SEQ ID NO: 13
    11 SEQ ID NO: 8 SEQ ID NO: 15
    12 SEQ ID NO: 8 SEQ ID NO: 17
    13 SEQ ID NO: 10 SEQ ID NO: 7
    14 SEQ ID NO: 10 SEQ ID NO: 9
    15 SEQ ID NO: 10 SEQ ID NO: 11
    16 SEQ ID NO: 10 SEQ ID NO: 13
    17 SEQ ID NO: 10 SEQ ID NO: 15
    18 SEQ ID NO: 10 SEQ ID NO: 17
    19 SEQ ID NO: 12 SEQ ID NO: 7
    20 SEQ ID NO: 12 SEQ ID NO: 9
    21 SEQ ID NO: 12 SEQ ID NO: 11
    22 SEQ ID NO: 12 SEQ ID NO: 13
    23 SEQ ID NO: 12 SEQ ID NO: 15
    24 SEQ ID NO: 12 SEQ ID NO: 17
    25 SEQ ID NO: 14 SEQ ID NO: 7
    26 SEQ ID NO: 14 SEQ ID NO: 9
    27 SEQ ID NO: 14 SEQ ID NO: 11
    28 SEQ ID NO: 14 SEQ ID NO: 13
    29 SEQ ID NO: 14 SEQ ID NO: 15
    30 SEQ ID NO: 14 SEQ ID NO: 17
    31 SEQ ID NO: 18 SEQ ID NO: 19
    32 SEQ ID NO: 18 SEQ ID NO: 24
    33 SEQ ID NO: 18 SEQ ID NO: 25
    34 SEQ ID NO: 18 SEQ ID NO: 26
    35 SEQ ID NO: 18 SEQ ID NO: 27
    36 SEQ ID NO: 18 SEQ ID NO: 32
    37 SEQ ID NO: 18 SEQ ID NO: 33
    38 SEQ ID NO: 18 SEQ ID NO: 34
    39 SEQ ID NO: 18 SEQ ID NO: 35
    40 SEQ ID NO: 18 SEQ ID NO: 59
    41 SEQ ID NO: 18 SEQ ID NO: 60
    42 SEQ ID NO: 18 SEQ ID NO: 61
    43 SEQ ID NO: 18 SEQ ID NO: 67
    44 SEQ ID NO: 18 SEQ ID NO: 69
    45 SEQ ID NO: 18 SEQ ID NO: 112
    46 SEQ ID NO: 18 SEQ ID NO: 113
    47 SEQ ID NO: 18 SEQ ID NO: 114
    48 SEQ ID NO: 18 SEQ ID NO: 123
    49 SEQ ID NO: 18 SEQ ID NO: 124
    50 SEQ ID NO: 18 SEQ ID NO: 125
    51 SEQ ID NO: 18 SEQ ID NO: 126
    52 SEQ ID NO: 18 SEQ ID NO: 127
    53 SEQ ID NO: 18 SEQ ID NO: 128
    54 SEQ ID NO: 18 SEQ ID NO: 129
    55 SEQ ID NO: 18 SEQ ID NO: 130
    56 SEQ ID NO: 18 SEQ ID NO: 131
    57 SEQ ID NO: 18 SEQ ID NO: 132
    58 SEQ ID NO: 20 SEQ ID NO: 19
    59 SEQ ID NO: 20 SEQ ID NO: 24
    60 SEQ ID NO: 20 SEQ ID NO: 25
    61 SEQ ID NO: 20 SEQ ID NO: 26
    62 SEQ ID NO: 20 SEQ ID NO: 27
    63 SEQ ID NO: 20 SEQ ID NO: 32
    64 SEQ ID NO: 20 SEQ ID NO: 33
    65 SEQ ID NO: 20 SEQ ID NO: 34
    66 SEQ ID NO: 20 SEQ ID NO: 35
    67 SEQ ID NO: 20 SEQ ID NO: 59
    68 SEQ ID NO: 20 SEQ ID NO: 60
    69 SEQ ID NO: 20 SEQ ID NO: 61
    70 SEQ ID NO: 20 SEQ ID NO: 67
    71 SEQ ID NO: 20 SEQ ID NO: 69
    72 SEQ ID NO: 20 SEQ ID NO: 112
    73 SEQ ID NO: 20 SEQ ID NO: 113
    74 SEQ ID NO: 20 SEQ ID NO: 114
    75 SEQ ID NO: 20 SEQ ID NO: 123
    76 SEQ ID NO: 20 SEQ ID NO: 124
    77 SEQ ID NO: 20 SEQ ID NO: 125
    78 SEQ ID NO: 20 SEQ ID NO: 126
    79 SEQ ID NO: 20 SEQ ID NO: 127
    80 SEQ ID NO: 20 SEQ ID NO: 128
    81 SEQ ID NO: 20 SEQ ID NO: 129
    82 SEQ ID NO: 20 SEQ ID NO: 130
    83 SEQ ID NO: 20 SEQ ID NO: 131
    84 SEQ ID NO: 20 SEQ ID NO: 132
    85 SEQ ID NO: 21 SEQ ID NO: 19
    86 SEQ ID NO: 21 SEQ ID NO: 24
    87 SEQ ID NO: 21 SEQ ID NO: 25
    88 SEQ ID NO: 21 SEQ ID NO: 26
    89 SEQ ID NO: 21 SEQ ID NO: 27
    90 SEQ ID NO: 21 SEQ ID NO: 32
    91 SEQ ID NO: 21 SEQ ID NO: 33
    92 SEQ ID NO: 21 SEQ ID NO: 34
    93 SEQ ID NO: 21 SEQ ID NO: 35
    94 SEQ ID NO: 21 SEQ ID NO: 59
    95 SEQ ID NO: 21 SEQ ID NO: 60
    96 SEQ ID NO: 21 SEQ ID NO: 61
    97 SEQ ID NO: 21 SEQ ID NO: 67
    98 SEQ ID NO: 21 SEQ ID NO: 69
    99 SEQ ID NO: 21 SEQ ID NO: 112
    100 SEQ ID NO: 21 SEQ ID NO: 113
    101 SEQ ID NO: 21 SEQ ID NO: 114
    102 SEQ ID NO: 21 SEQ ID NO: 123
    103 SEQ ID NO: 21 SEQ ID NO: 124
    104 SEQ ID NO: 21 SEQ ID NO: 125
    105 SEQ ID NO: 21 SEQ ID NO: 126
    106 SEQ ID NO: 21 SEQ ID NO: 127
    107 SEQ ID NO: 21 SEQ ID NO: 128
    108 SEQ ID NO: 21 SEQ ID NO: 129
    109 SEQ ID NO: 21 SEQ ID NO: 130
    110 SEQ ID NO: 21 SEQ ID NO: 131
    111 SEQ ID NO: 21 SEQ ID NO: 132
    112 SEQ ID NO: 22 SEQ ID NO: 19
    113 SEQ ID NO: 22 SEQ ID NO: 24
    114 SEQ ID NO: 22 SEQ ID NO: 25
    115 SEQ ID NO: 22 SEQ ID NO: 26
    116 SEQ ID NO: 22 SEQ ID NO: 27
    117 SEQ ID NO: 22 SEQ ID NO: 32
    118 SEQ ID NO: 22 SEQ ID NO: 33
    119 SEQ ID NO: 22 SEQ ID NO: 34
    120 SEQ ID NO: 22 SEQ ID NO: 35
    121 SEQ ID NO: 22 SEQ ID NO: 59
    122 SEQ ID NO: 22 SEQ ID NO: 60
    123 SEQ ID NO: 22 SEQ ID NO: 61
    124 SEQ ID NO: 22 SEQ ID NO: 67
    125 SEQ ID NO: 22 SEQ ID NO: 69
    126 SEQ ID NO: 22 SEQ ID NO: 112
    127 SEQ ID NO: 22 SEQ ID NO: 113
    128 SEQ ID NO: 22 SEQ ID NO: 114
    129 SEQ ID NO: 22 SEQ ID NO: 123
    130 SEQ ID NO: 22 SEQ ID NO: 124
    131 SEQ ID NO: 22 SEQ ID NO: 125
    132 SEQ ID NO: 22 SEQ ID NO: 126
    133 SEQ ID NO: 22 SEQ ID NO: 127
    134 SEQ ID NO: 22 SEQ ID NO: 128
    135 SEQ ID NO: 22 SEQ ID NO: 129
    136 SEQ ID NO: 22 SEQ ID NO: 130
    137 SEQ ID NO: 22 SEQ ID NO: 131
    138 SEQ ID NO: 22 SEQ ID NO: 132
    139 SEQ ID NO: 23 SEQ ID NO: 19
    140 SEQ ID NO: 23 SEQ ID NO: 24
    141 SEQ ID NO: 23 SEQ ID NO: 25
    142 SEQ ID NO: 23 SEQ ID NO: 26
    143 SEQ ID NO: 23 SEQ ID NO: 27
    144 SEQ ID NO: 23 SEQ ID NO: 32
    145 SEQ ID NO: 23 SEQ ID NO: 33
    146 SEQ ID NO: 23 SEQ ID NO: 34
    147 SEQ ID NO: 23 SEQ ID NO: 35
    148 SEQ ID NO: 23 SEQ ID NO: 59
    149 SEQ ID NO: 23 SEQ ID NO: 60
    150 SEQ ID NO: 23 SEQ ID NO: 61
    151 SEQ ID NO: 23 SEQ ID NO: 67
    152 SEQ ID NO: 23 SEQ ID NO: 69
    153 SEQ ID NO: 23 SEQ ID NO: 112
    154 SEQ ID NO: 23 SEQ ID NO: 113
    155 SEQ ID NO: 23 SEQ ID NO: 114
    156 SEQ ID NO: 23 SEQ ID NO: 123
    157 SEQ ID NO: 23 SEQ ID NO: 124
    158 SEQ ID NO: 23 SEQ ID NO: 125
    159 SEQ ID NO: 23 SEQ ID NO: 126
    160 SEQ ID NO: 23 SEQ ID NO: 127
    161 SEQ ID NO: 23 SEQ ID NO: 128
    162 SEQ ID NO: 23 SEQ ID NO: 129
    163 SEQ ID NO: 23 SEQ ID NO: 130
    164 SEQ ID NO: 23 SEQ ID NO: 131
    165 SEQ ID NO: 23 SEQ ID NO: 132
    166 SEQ ID NO: 28 SEQ ID NO: 19
    167 SEQ ID NO: 28 SEQ ID NO: 24
    168 SEQ ID NO: 28 SEQ ID NO: 25
    169 SEQ ID NO: 28 SEQ ID NO: 26
    170 SEQ ID NO: 28 SEQ ID NO: 27
    171 SEQ ID NO: 28 SEQ ID NO: 32
    172 SEQ ID NO: 28 SEQ ID NO: 33
    173 SEQ ID NO: 28 SEQ ID NO: 34
    174 SEQ ID NO: 28 SEQ ID NO: 35
    175 SEQ ID NO: 28 SEQ ID NO: 59
    176 SEQ ID NO: 28 SEQ ID NO: 60
    177 SEQ ID NO: 28 SEQ ID NO: 61
    178 SEQ ID NO: 28 SEQ ID NO: 67
    179 SEQ ID NO: 28 SEQ ID NO: 69
    180 SEQ ID NO: 28 SEQ ID NO: 112
    181 SEQ ID NO: 28 SEQ ID NO: 113
    182 SEQ ID NO: 28 SEQ ID NO: 114
    183 SEQ ID NO: 28 SEQ ID NO: 123
    184 SEQ ID NO: 28 SEQ ID NO: 124
    185 SEQ ID NO: 28 SEQ ID NO: 125
    186 SEQ ID NO: 28 SEQ ID NO: 126
    187 SEQ ID NO: 28 SEQ ID NO: 127
    188 SEQ ID NO: 28 SEQ ID NO: 128
    189 SEQ ID NO: 28 SEQ ID NO: 129
    190 SEQ ID NO: 28 SEQ ID NO: 130
    191 SEQ ID NO: 28 SEQ ID NO: 131
    192 SEQ ID NO: 28 SEQ ID NO: 132
    193 SEQ ID NO: 29 SEQ ID NO: 19
    194 SEQ ID NO: 29 SEQ ID NO: 24
    195 SEQ ID NO: 29 SEQ ID NO: 25
    196 SEQ ID NO: 29 SEQ ID NO: 26
    197 SEQ ID NO: 29 SEQ ID NO: 27
    198 SEQ ID NO: 29 SEQ ID NO: 32
    199 SEQ ID NO: 29 SEQ ID NO: 33
    200 SEQ ID NO: 29 SEQ ID NO: 34
    201 SEQ ID NO: 29 SEQ ID NO: 35
    202 SEQ ID NO: 29 SEQ ID NO: 59
    203 SEQ ID NO: 29 SEQ ID NO: 60
    204 SEQ ID NO: 29 SEQ ID NO: 61
    205 SEQ ID NO: 29 SEQ ID NO: 67
    206 SEQ ID NO: 29 SEQ ID NO: 69
    207 SEQ ID NO: 29 SEQ ID NO: 112
    208 SEQ ID NO: 29 SEQ ID NO: 113
    209 SEQ ID NO: 29 SEQ ID NO: 114
    210 SEQ ID NO: 29 SEQ ID NO: 123
    211 SEQ ID NO: 29 SEQ ID NO: 124
    212 SEQ ID NO: 29 SEQ ID NO: 125
    213 SEQ ID NO: 29 SEQ ID NO: 126
    214 SEQ ID NO: 29 SEQ ID NO: 127
    215 SEQ ID NO: 29 SEQ ID NO: 128
    216 SEQ ID NO: 29 SEQ ID NO: 129
    217 SEQ ID NO: 29 SEQ ID NO: 130
    218 SEQ ID NO: 29 SEQ ID NO: 131
    219 SEQ ID NO: 29 SEQ ID NO: 132
    220 SEQ ID NO: 30 SEQ ID NO: 19
    221 SEQ ID NO: 30 SEQ ID NO: 24
    222 SEQ ID NO: 30 SEQ ID NO: 25
    223 SEQ ID NO: 30 SEQ ID NO: 26
    224 SEQ ID NO: 30 SEQ ID NO: 27
    225 SEQ ID NO: 30 SEQ ID NO: 32
    226 SEQ ID NO: 30 SEQ ID NO: 33
    227 SEQ ID NO: 30 SEQ ID NO: 34
    228 SEQ ID NO: 30 SEQ ID NO: 35
    229 SEQ ID NO: 30 SEQ ID NO: 59
    230 SEQ ID NO: 30 SEQ ID NO: 60
    231 SEQ ID NO: 30 SEQ ID NO: 61
    232 SEQ ID NO: 30 SEQ ID NO: 67
    233 SEQ ID NO: 30 SEQ ID NO: 69
    234 SEQ ID NO: 30 SEQ ID NO: 112
    235 SEQ ID NO: 30 SEQ ID NO: 113
    236 SEQ ID NO: 30 SEQ ID NO: 114
    237 SEQ ID NO: 30 SEQ ID NO: 123
    238 SEQ ID NO: 30 SEQ ID NO: 124
    239 SEQ ID NO: 30 SEQ ID NO: 125
    240 SEQ ID NO: 30 SEQ ID NO: 126
    241 SEQ ID NO: 30 SEQ ID NO: 127
    242 SEQ ID NO: 30 SEQ ID NO: 128
    243 SEQ ID NO: 30 SEQ ID NO: 129
    244 SEQ ID NO: 30 SEQ ID NO: 130
    245 SEQ ID NO: 30 SEQ ID NO: 131
    246 SEQ ID NO: 30 SEQ ID NO: 132
    247 SEQ ID NO: 31 SEQ ID NO: 19
    248 SEQ ID NO: 31 SEQ ID NO: 24
    249 SEQ ID NO: 31 SEQ ID NO: 25
    250 SEQ ID NO: 31 SEQ ID NO: 26
    251 SEQ ID NO: 31 SEQ ID NO: 27
    252 SEQ ID NO: 31 SEQ ID NO: 32
    253 SEQ ID NO: 31 SEQ ID NO: 33
    254 SEQ ID NO: 31 SEQ ID NO: 34
    255 SEQ ID NO: 31 SEQ ID NO: 35
    256 SEQ ID NO: 31 SEQ ID NO: 59
    257 SEQ ID NO: 31 SEQ ID NO: 60
    258 SEQ ID NO: 31 SEQ ID NO: 61
    259 SEQ ID NO: 31 SEQ ID NO: 67
    260 SEQ ID NO: 31 SEQ ID NO: 69
    261 SEQ ID NO: 31 SEQ ID NO: 112
    262 SEQ ID NO: 31 SEQ ID NO: 113
    263 SEQ ID NO: 31 SEQ ID NO: 114
    264 SEQ ID NO: 31 SEQ ID NO: 123
    265 SEQ ID NO: 31 SEQ ID NO: 124
    266 SEQ ID NO: 31 SEQ ID NO: 125
    267 SEQ ID NO: 31 SEQ ID NO: 126
    268 SEQ ID NO: 31 SEQ ID NO: 127
    269 SEQ ID NO: 31 SEQ ID NO: 128
    270 SEQ ID NO: 31 SEQ ID NO: 129
    271 SEQ ID NO: 31 SEQ ID NO: 130
    272 SEQ ID NO: 31 SEQ ID NO: 131
    273 SEQ ID NO: 31 SEQ ID NO: 132
    274 SEQ ID NO: 56 SEQ ID NO: 19
    275 SEQ ID NO: 56 SEQ ID NO: 24
    276 SEQ ID NO: 56 SEQ ID NO: 25
    277 SEQ ID NO: 56 SEQ ID NO: 26
    278 SEQ ID NO: 56 SEQ ID NO: 27
    279 SEQ ID NO: 56 SEQ ID NO: 32
    280 SEQ ID NO: 56 SEQ ID NO: 33
    281 SEQ ID NO: 56 SEQ ID NO: 34
    282 SEQ ID NO: 56 SEQ ID NO: 35
    283 SEQ ID NO: 56 SEQ ID NO: 59
    284 SEQ ID NO: 56 SEQ ID NO: 60
    285 SEQ ID NO: 56 SEQ ID NO: 61
    286 SEQ ID NO: 56 SEQ ID NO: 67
    287 SEQ ID NO: 56 SEQ ID NO: 69
    288 SEQ ID NO: 56 SEQ ID NO: 112
    289 SEQ ID NO: 56 SEQ ID NO: 113
    290 SEQ ID NO: 56 SEQ ID NO: 114
    291 SEQ ID NO: 56 SEQ ID NO: 123
    292 SEQ ID NO: 56 SEQ ID NO: 124
    293 SEQ ID NO: 56 SEQ ID NO: 125
    294 SEQ ID NO: 56 SEQ ID NO: 126
    295 SEQ ID NO: 56 SEQ ID NO: 127
    296 SEQ ID NO: 56 SEQ ID NO: 128
    297 SEQ ID NO: 56 SEQ ID NO: 129
    298 SEQ ID NO: 56 SEQ ID NO: 130
    299 SEQ ID NO: 56 SEQ ID NO: 131
    300 SEQ ID NO: 56 SEQ ID NO: 132
    301 SEQ ID NO: 57 SEQ ID NO: 19
    302 SEQ ID NO: 57 SEQ ID NO: 24
    303 SEQ ID NO: 57 SEQ ID NO: 25
    304 SEQ ID NO: 57 SEQ ID NO: 26
    305 SEQ ID NO: 57 SEQ ID NO: 27
    306 SEQ ID NO: 57 SEQ ID NO: 32
    307 SEQ ID NO: 57 SEQ ID NO: 33
    308 SEQ ID NO: 57 SEQ ID NO: 34
    309 SEQ ID NO: 57 SEQ ID NO: 35
    310 SEQ ID NO: 57 SEQ ID NO: 59
    311 SEQ ID NO: 57 SEQ ID NO: 60
    312 SEQ ID NO: 57 SEQ ID NO: 61
    313 SEQ ID NO: 57 SEQ ID NO: 67
    314 SEQ ID NO: 57 SEQ ID NO: 69
    315 SEQ ID NO: 57 SEQ ID NO: 112
    316 SEQ ID NO: 57 SEQ ID NO: 113
    317 SEQ ID NO: 57 SEQ ID NO: 114
    318 SEQ ID NO: 57 SEQ ID NO: 123
    319 SEQ ID NO: 57 SEQ ID NO: 124
    320 SEQ ID NO: 57 SEQ ID NO: 125
    321 SEQ ID NO: 57 SEQ ID NO: 126
    322 SEQ ID NO: 57 SEQ ID NO: 127
    323 SEQ ID NO: 57 SEQ ID NO: 128
    324 SEQ ID NO: 57 SEQ ID NO: 129
    325 SEQ ID NO: 57 SEQ ID NO: 130
    326 SEQ ID NO: 57 SEQ ID NO: 131
    327 SEQ ID NO: 57 SEQ ID NO: 132
    328 SEQ ID NO: 58 SEQ ID NO: 19
    329 SEQ ID NO: 58 SEQ ID NO: 24
    330 SEQ ID NO: 58 SEQ ID NO: 25
    331 SEQ ID NO: 58 SEQ ID NO: 26
    332 SEQ ID NO: 58 SEQ ID NO: 27
    333 SEQ ID NO: 58 SEQ ID NO: 32
    334 SEQ ID NO: 58 SEQ ID NO: 33
    335 SEQ ID NO: 58 SEQ ID NO: 34
    336 SEQ ID NO: 58 SEQ ID NO: 35
    337 SEQ ID NO: 58 SEQ ID NO: 59
    338 SEQ ID NO: 58 SEQ ID NO: 60
    339 SEQ ID NO: 58 SEQ ID NO: 61
    340 SEQ ID NO: 58 SEQ ID NO: 67
    341 SEQ ID NO: 58 SEQ ID NO: 69
    342 SEQ ID NO: 58 SEQ ID NO: 112
    343 SEQ ID NO: 58 SEQ ID NO: 113
    344 SEQ ID NO: 58 SEQ ID NO: 114
    345 SEQ ID NO: 58 SEQ ID NO: 123
    346 SEQ ID NO: 58 SEQ ID NO: 124
    347 SEQ ID NO: 58 SEQ ID NO: 125
    348 SEQ ID NO: 58 SEQ ID NO: 126
    349 SEQ ID NO: 58 SEQ ID NO: 127
    350 SEQ ID NO: 58 SEQ ID NO: 128
    351 SEQ ID NO: 58 SEQ ID NO: 129
    352 SEQ ID NO: 58 SEQ ID NO: 130
    353 SEQ ID NO: 58 SEQ ID NO: 131
    354 SEQ ID NO: 58 SEQ ID NO: 132
    355 SEQ ID NO: 63 SEQ ID NO: 19
    356 SEQ ID NO: 63 SEQ ID NO: 24
    357 SEQ ID NO: 63 SEQ ID NO: 25
    358 SEQ ID NO: 63 SEQ ID NO: 26
    359 SEQ ID NO: 63 SEQ ID NO: 27
    360 SEQ ID NO: 63 SEQ ID NO: 32
    361 SEQ ID NO: 63 SEQ ID NO: 33
    362 SEQ ID NO: 63 SEQ ID NO: 34
    363 SEQ ID NO: 63 SEQ ID NO: 35
    364 SEQ ID NO: 63 SEQ ID NO: 59
    365 SEQ ID NO: 63 SEQ ID NO: 60
    366 SEQ ID NO: 63 SEQ ID NO: 61
    367 SEQ ID NO: 63 SEQ ID NO: 67
    368 SEQ ID NO: 63 SEQ ID NO: 69
    369 SEQ ID NO: 63 SEQ ID NO: 112
    370 SEQ ID NO: 63 SEQ ID NO: 113
    371 SEQ ID NO: 63 SEQ ID NO: 114
    372 SEQ ID NO: 63 SEQ ID NO: 123
    373 SEQ ID NO: 63 SEQ ID NO: 124
    374 SEQ ID NO: 63 SEQ ID NO: 125
    375 SEQ ID NO: 63 SEQ ID NO: 126
    376 SEQ ID NO: 63 SEQ ID NO: 127
    377 SEQ ID NO: 63 SEQ ID NO: 128
    378 SEQ ID NO: 63 SEQ ID NO: 129
    379 SEQ ID NO: 63 SEQ ID NO: 130
    380 SEQ ID NO: 63 SEQ ID NO: 131
    381 SEQ ID NO: 63 SEQ ID NO: 132
    382 SEQ ID NO: 65 SEQ ID NO: 19
    383 SEQ ID NO: 65 SEQ ID NO: 24
    384 SEQ ID NO: 65 SEQ ID NO: 25
    385 SEQ ID NO: 65 SEQ ID NO: 26
    386 SEQ ID NO: 65 SEQ ID NO: 27
    387 SEQ ID NO: 65 SEQ ID NO: 32
    388 SEQ ID NO: 65 SEQ ID NO: 33
    389 SEQ ID NO: 65 SEQ ID NO: 34
    390 SEQ ID NO: 65 SEQ ID NO: 35
    391 SEQ ID NO: 65 SEQ ID NO: 59
    392 SEQ ID NO: 65 SEQ ID NO: 60
    393 SEQ ID NO: 65 SEQ ID NO: 61
    394 SEQ ID NO: 65 SEQ ID NO: 67
    395 SEQ ID NO: 65 SEQ ID NO: 69
    396 SEQ ID NO: 65 SEQ ID NO: 112
    397 SEQ ID NO: 65 SEQ ID NO: 113
    398 SEQ ID NO: 65 SEQ ID NO: 114
    399 SEQ ID NO: 65 SEQ ID NO: 123
    400 SEQ ID NO: 65 SEQ ID NO: 124
    401 SEQ ID NO: 65 SEQ ID NO: 125
    402 SEQ ID NO: 65 SEQ ID NO: 126
    403 SEQ ID NO: 65 SEQ ID NO: 127
    404 SEQ ID NO: 65 SEQ ID NO: 128
    405 SEQ ID NO: 65 SEQ ID NO: 129
    406 SEQ ID NO: 65 SEQ ID NO: 130
    407 SEQ ID NO: 65 SEQ ID NO: 131
    408 SEQ ID NO: 65 SEQ ID NO: 132
    409 SEQ ID NO: 106 SEQ ID NO: 19
    410 SEQ ID NO: 106 SEQ ID NO: 24
    411 SEQ ID NO: 106 SEQ ID NO: 25
    412 SEQ ID NO: 106 SEQ ID NO: 26
    413 SEQ ID NO: 106 SEQ ID NO: 27
    414 SEQ ID NO: 106 SEQ ID NO: 32
    415 SEQ ID NO: 106 SEQ ID NO: 33
    416 SEQ ID NO: 106 SEQ ID NO: 34
    417 SEQ ID NO: 106 SEQ ID NO: 35
    418 SEQ ID NO: 106 SEQ ID NO: 59
    419 SEQ ID NO: 106 SEQ ID NO: 60
    420 SEQ ID NO: 106 SEQ ID NO: 61
    421 SEQ ID NO: 106 SEQ ID NO: 67
    422 SEQ ID NO: 106 SEQ ID NO: 69
    423 SEQ ID NO: 106 SEQ ID NO: 112
    424 SEQ ID NO: 106 SEQ ID NO: 113
    425 SEQ ID NO: 106 SEQ ID NO: 114
    426 SEQ ID NO: 106 SEQ ID NO: 123
    427 SEQ ID NO: 106 SEQ ID NO: 124
    428 SEQ ID NO: 106 SEQ ID NO: 125
    429 SEQ ID NO: 106 SEQ ID NO: 126
    430 SEQ ID NO: 106 SEQ ID NO: 127
    431 SEQ ID NO: 106 SEQ ID NO: 128
    432 SEQ ID NO: 106 SEQ ID NO: 129
    433 SEQ ID NO: 106 SEQ ID NO: 130
    434 SEQ ID NO: 106 SEQ ID NO: 131
    435 SEQ ID NO: 106 SEQ ID NO: 132
    436 SEQ ID NO: 107 SEQ ID NO: 19
    437 SEQ ID NO: 107 SEQ ID NO: 24
    438 SEQ ID NO: 107 SEQ ID NO: 25
    439 SEQ ID NO: 107 SEQ ID NO: 26
    440 SEQ ID NO: 107 SEQ ID NO: 27
    441 SEQ ID NO: 107 SEQ ID NO: 32
    442 SEQ ID NO: 107 SEQ ID NO: 33
    443 SEQ ID NO: 107 SEQ ID NO: 34
    444 SEQ ID NO: 107 SEQ ID NO: 35
    445 SEQ ID NO: 107 SEQ ID NO: 59
    446 SEQ ID NO: 107 SEQ ID NO: 60
    447 SEQ ID NO: 107 SEQ ID NO: 61
    448 SEQ ID NO: 107 SEQ ID NO: 67
    449 SEQ ID NO: 107 SEQ ID NO: 69
    450 SEQ ID NO: 107 SEQ ID NO: 112
    451 SEQ ID NO: 107 SEQ ID NO: 113
    452 SEQ ID NO: 107 SEQ ID NO: 114
    453 SEQ ID NO: 107 SEQ ID NO: 123
    454 SEQ ID NO: 107 SEQ ID NO: 124
    455 SEQ ID NO: 107 SEQ ID NO: 125
    456 SEQ ID NO: 107 SEQ ID NO: 126
    457 SEQ ID NO: 107 SEQ ID NO: 127
    458 SEQ ID NO: 107 SEQ ID NO: 128
    459 SEQ ID NO: 107 SEQ ID NO: 129
    460 SEQ ID NO: 107 SEQ ID NO: 130
    461 SEQ ID NO: 107 SEQ ID NO: 131
    462 SEQ ID NO: 107 SEQ ID NO: 132
    463 SEQ ID NO: 108 SEQ ID NO: 19
    464 SEQ ID NO: 108 SEQ ID NO: 24
    465 SEQ ID NO: 108 SEQ ID NO: 25
    466 SEQ ID NO: 108 SEQ ID NO: 26
    467 SEQ ID NO: 108 SEQ ID NO: 27
    468 SEQ ID NO: 108 SEQ ID NO: 32
    469 SEQ ID NO: 108 SEQ ID NO: 33
    470 SEQ ID NO: 108 SEQ ID NO: 34
    471 SEQ ID NO: 108 SEQ ID NO: 35
    472 SEQ ID NO: 108 SEQ ID NO: 59
    473 SEQ ID NO: 108 SEQ ID NO: 60
    474 SEQ ID NO: 108 SEQ ID NO: 61
    475 SEQ ID NO: 108 SEQ ID NO: 67
    476 SEQ ID NO: 108 SEQ ID NO: 69
    477 SEQ ID NO: 108 SEQ ID NO: 112
    478 SEQ ID NO: 108 SEQ ID NO: 113
    479 SEQ ID NO: 108 SEQ ID NO: 114
    480 SEQ ID NO: 108 SEQ ID NO: 123
    481 SEQ ID NO: 108 SEQ ID NO: 124
    482 SEQ ID NO: 108 SEQ ID NO: 125
    483 SEQ ID NO: 108 SEQ ID NO: 126
    484 SEQ ID NO: 108 SEQ ID NO: 127
    485 SEQ ID NO: 108 SEQ ID NO: 128
    486 SEQ ID NO: 108 SEQ ID NO: 129
    487 SEQ ID NO: 108 SEQ ID NO: 130
    488 SEQ ID NO: 108 SEQ ID NO: 131
    489 SEQ ID NO: 108 SEQ ID NO: 132
    490 SEQ ID NO: 109 SEQ ID NO: 19
    491 SEQ ID NO: 109 SEQ ID NO: 24
    492 SEQ ID NO: 109 SEQ ID NO: 25
    493 SEQ ID NO: 109 SEQ ID NO: 26
    494 SEQ ID NO: 109 SEQ ID NO: 27
    495 SEQ ID NO: 109 SEQ ID NO: 32
    496 SEQ ID NO: 109 SEQ ID NO: 33
    497 SEQ ID NO: 109 SEQ ID NO: 34
    498 SEQ ID NO: 109 SEQ ID NO: 35
    499 SEQ ID NO: 109 SEQ ID NO: 59
    500 SEQ ID NO: 109 SEQ ID NO: 60
    501 SEQ ID NO: 109 SEQ ID NO: 61
    502 SEQ ID NO: 109 SEQ ID NO: 67
    503 SEQ ID NO: 109 SEQ ID NO: 69
    504 SEQ ID NO: 109 SEQ ID NO: 112
    505 SEQ ID NO: 109 SEQ ID NO: 113
    506 SEQ ID NO: 109 SEQ ID NO: 114
    507 SEQ ID NO: 109 SEQ ID NO: 123
    508 SEQ ID NO: 109 SEQ ID NO: 124
    509 SEQ ID NO: 109 SEQ ID NO: 125
    510 SEQ ID NO: 109 SEQ ID NO: 126
    511 SEQ ID NO: 109 SEQ ID NO: 127
    512 SEQ ID NO: 109 SEQ ID NO: 128
    513 SEQ ID NO: 109 SEQ ID NO: 129
    514 SEQ ID NO: 109 SEQ ID NO: 130
    515 SEQ ID NO: 109 SEQ ID NO: 131
    516 SEQ ID NO: 109 SEQ ID NO: 132
    517 SEQ ID NO: 110 SEQ ID NO: 19
    518 SEQ ID NO: 110 SEQ ID NO: 24
    519 SEQ ID NO: 110 SEQ ID NO: 25
    520 SEQ ID NO: 110 SEQ ID NO: 26
    521 SEQ ID NO: 110 SEQ ID NO: 27
    522 SEQ ID NO: 110 SEQ ID NO: 32
    523 SEQ ID NO: 110 SEQ ID NO: 33
    524 SEQ ID NO: 110 SEQ ID NO: 34
    525 SEQ ID NO: 110 SEQ ID NO: 35
    526 SEQ ID NO: 110 SEQ ID NO: 59
    527 SEQ ID NO: 110 SEQ ID NO: 60
    528 SEQ ID NO: 110 SEQ ID NO: 61
    529 SEQ ID NO: 110 SEQ ID NO: 67
    530 SEQ ID NO: 110 SEQ ID NO: 69
    531 SEQ ID NO: 110 SEQ ID NO: 112
    532 SEQ ID NO: 110 SEQ ID NO: 113
    533 SEQ ID NO: 110 SEQ ID NO: 114
    534 SEQ ID NO: 110 SEQ ID NO: 123
    535 SEQ ID NO: 110 SEQ ID NO: 124
    536 SEQ ID NO: 110 SEQ ID NO: 125
    537 SEQ ID NO: 110 SEQ ID NO: 126
    538 SEQ ID NO: 110 SEQ ID NO: 127
    539 SEQ ID NO: 110 SEQ ID NO: 128
    540 SEQ ID NO: 110 SEQ ID NO: 129
    541 SEQ ID NO: 110 SEQ ID NO: 130
    542 SEQ ID NO: 110 SEQ ID NO: 131
    543 SEQ ID NO: 111 SEQ ID NO: 132
    544 SEQ ID NO: 111 SEQ ID NO: 19
    545 SEQ ID NO: 111 SEQ ID NO: 24
    546 SEQ ID NO: 111 SEQ ID NO: 25
    547 SEQ ID NO: 111 SEQ ID NO: 26
    548 SEQ ID NO: 111 SEQ ID NO: 27
    549 SEQ ID NO: 111 SEQ ID NO: 32
    550 SEQ ID NO: 111 SEQ ID NO: 33
    551 SEQ ID NO: 111 SEQ ID NO: 34
    552 SEQ ID NO: 111 SEQ ID NO: 35
    553 SEQ ID NO: 111 SEQ ID NO: 59
    554 SEQ ID NO: 111 SEQ ID NO: 60
    555 SEQ ID NO: 111 SEQ ID NO: 61
    556 SEQ ID NO: 111 SEQ ID NO: 67
    557 SEQ ID NO: 111 SEQ ID NO: 69
    558 SEQ ID NO: 111 SEQ ID NO: 112
    559 SEQ ID NO: 111 SEQ ID NO: 113
    560 SEQ ID NO: 111 SEQ ID NO: 114
    561 SEQ ID NO: 111 SEQ ID NO: 123
    562 SEQ ID NO: 111 SEQ ID NO: 124
    563 SEQ ID NO: 111 SEQ ID NO: 125
    564 SEQ ID NO: 111 SEQ ID NO: 126
    565 SEQ ID NO: 111 SEQ ID NO: 127
    566 SEQ ID NO: 111 SEQ ID NO: 128
    567 SEQ ID NO: 111 SEQ ID NO: 129
    568 SEQ ID NO: 111 SEQ ID NO: 130
    569 SEQ ID NO: 111 SEQ ID NO: 131
    570 SEQ ID NO: 111 SEQ ID NO: 132
    571 SEQ ID NO: 115 SEQ ID NO: 19
    572 SEQ ID NO: 115 SEQ ID NO: 24
    573 SEQ ID NO: 115 SEQ ID NO: 25
    574 SEQ ID NO: 115 SEQ ID NO: 26
    575 SEQ ID NO: 115 SEQ ID NO: 27
    576 SEQ ID NO: 115 SEQ ID NO: 32
    577 SEQ ID NO: 115 SEQ ID NO: 33
    578 SEQ ID NO: 115 SEQ ID NO: 34
    579 SEQ ID NO: 115 SEQ ID NO: 35
    580 SEQ ID NO: 115 SEQ ID NO: 59
    581 SEQ ID NO: 115 SEQ ID NO: 60
    582 SEQ ID NO: 115 SEQ ID NO: 61
    583 SEQ ID NO: 115 SEQ ID NO: 67
    584 SEQ ID NO: 115 SEQ ID NO: 69
    585 SEQ ID NO: 115 SEQ ID NO: 112
    586 SEQ ID NO: 115 SEQ ID NO: 113
    587 SEQ ID NO: 115 SEQ ID NO: 114
    588 SEQ ID NO: 115 SEQ ID NO: 123
    589 SEQ ID NO: 115 SEQ ID NO: 124
    590 SEQ ID NO: 115 SEQ ID NO: 125
    591 SEQ ID NO: 115 SEQ ID NO: 126
    592 SEQ ID NO: 115 SEQ ID NO: 127
    593 SEQ ID NO: 115 SEQ ID NO: 128
    594 SEQ ID NO: 115 SEQ ID NO: 129
    595 SEQ ID NO: 115 SEQ ID NO: 130
    596 SEQ ID NO: 115 SEQ ID NO: 131
    597 SEQ ID NO: 115 SEQ ID NO: 132
    598 SEQ ID NO: 116 SEQ ID NO: 19
    599 SEQ ID NO: 116 SEQ ID NO: 24
    600 SEQ ID NO: 116 SEQ ID NO: 25
    601 SEQ ID NO: 116 SEQ ID NO: 26
    602 SEQ ID NO: 116 SEQ ID NO: 27
    603 SEQ ID NO: 116 SEQ ID NO: 32
    604 SEQ ID NO: 116 SEQ ID NO: 33
    605 SEQ ID NO: 116 SEQ ID NO: 34
    606 SEQ ID NO: 116 SEQ ID NO: 35
    607 SEQ ID NO: 116 SEQ ID NO: 59
    608 SEQ ID NO: 116 SEQ ID NO: 60
    609 SEQ ID NO: 116 SEQ ID NO: 61
    610 SEQ ID NO: 116 SEQ ID NO: 67
    611 SEQ ID NO: 116 SEQ ID NO: 69
    612 SEQ ID NO: 116 SEQ ID NO: 112
    613 SEQ ID NO: 116 SEQ ID NO: 113
    614 SEQ ID NO: 116 SEQ ID NO: 114
    615 SEQ ID NO: 116 SEQ ID NO: 123
    616 SEQ ID NO: 116 SEQ ID NO: 124
    617 SEQ ID NO: 116 SEQ ID NO: 125
    618 SEQ ID NO: 116 SEQ ID NO: 126
    619 SEQ ID NO: 116 SEQ ID NO: 127
    620 SEQ ID NO: 116 SEQ ID NO: 128
    621 SEQ ID NO: 116 SEQ ID NO: 129
    622 SEQ ID NO: 116 SEQ ID NO: 130
    623 SEQ ID NO: 116 SEQ ID NO: 131
    624 SEQ ID NO: 116 SEQ ID NO: 132
    625 SEQ ID NO: 117 SEQ ID NO: 19
    626 SEQ ID NO: 117 SEQ ID NO: 24
    627 SEQ ID NO: 117 SEQ ID NO: 25
    628 SEQ ID NO: 117 SEQ ID NO: 26
    629 SEQ ID NO: 117 SEQ ID NO: 27
    630 SEQ ID NO: 117 SEQ ID NO: 32
    631 SEQ ID NO: 117 SEQ ID NO: 33
    632 SEQ ID NO: 117 SEQ ID NO: 34
    633 SEQ ID NO: 117 SEQ ID NO: 35
    634 SEQ ID NO: 117 SEQ ID NO: 59
    635 SEQ ID NO: 117 SEQ ID NO: 60
    636 SEQ ID NO: 117 SEQ ID NO: 61
    637 SEQ ID NO: 117 SEQ ID NO: 67
    638 SEQ ID NO: 117 SEQ ID NO: 69
    639 SEQ ID NO: 117 SEQ ID NO: 112
    640 SEQ ID NO: 117 SEQ ID NO: 113
    641 SEQ ID NO: 117 SEQ ID NO: 114
    642 SEQ ID NO: 117 SEQ ID NO: 123
    643 SEQ ID NO: 117 SEQ ID NO: 124
    644 SEQ ID NO: 117 SEQ ID NO: 125
    645 SEQ ID NO: 117 SEQ ID NO: 126
    646 SEQ ID NO: 117 SEQ ID NO: 127
    647 SEQ ID NO: 117 SEQ ID NO: 128
    648 SEQ ID NO: 117 SEQ ID NO: 129
    649 SEQ ID NO: 117 SEQ ID NO: 130
    650 SEQ ID NO: 117 SEQ ID NO: 131
    651 SEQ ID NO: 117 SEQ ID NO: 132
    652 SEQ ID NO: 118 SEQ ID NO: 19
    653 SEQ ID NO: 118 SEQ ID NO: 24
    654 SEQ ID NO: 118 SEQ ID NO: 25
    655 SEQ ID NO: 118 SEQ ID NO: 26
    656 SEQ ID NO: 118 SEQ ID NO: 27
    657 SEQ ID NO: 118 SEQ ID NO: 32
    658 SEQ ID NO: 118 SEQ ID NO: 33
    659 SEQ ID NO: 118 SEQ ID NO: 34
    660 SEQ ID NO: 118 SEQ ID NO: 35
    661 SEQ ID NO: 118 SEQ ID NO: 59
    662 SEQ ID NO: 118 SEQ ID NO: 60
    663 SEQ ID NO: 118 SEQ ID NO: 61
    664 SEQ ID NO: 118 SEQ ID NO: 67
    665 SEQ ID NO: 118 SEQ ID NO: 69
    666 SEQ ID NO: 118 SEQ ID NO: 112
    667 SEQ ID NO: 118 SEQ ID NO: 113
    668 SEQ ID NO: 118 SEQ ID NO: 114
    669 SEQ ID NO: 118 SEQ ID NO: 123
    670 SEQ ID NO: 118 SEQ ID NO: 124
    671 SEQ ID NO: 118 SEQ ID NO: 125
    672 SEQ ID NO: 118 SEQ ID NO: 126
    673 SEQ ID NO: 118 SEQ ID NO: 127
    674 SEQ ID NO: 118 SEQ ID NO: 128
    675 SEQ ID NO: 118 SEQ ID NO: 129
    676 SEQ ID NO: 118 SEQ ID NO: 130
    677 SEQ ID NO: 118 SEQ ID NO: 131
    678 SEQ ID NO: 118 SEQ ID NO: 132
    679 SEQ ID NO: 119 SEQ ID NO: 19
    680 SEQ ID NO: 119 SEQ ID NO: 24
    681 SEQ ID NO: 119 SEQ ID NO: 25
    682 SEQ ID NO: 119 SEQ ID NO: 26
    683 SEQ ID NO: 119 SEQ ID NO: 27
    684 SEQ ID NO: 119 SEQ ID NO: 32
    685 SEQ ID NO: 119 SEQ ID NO: 33
    686 SEQ ID NO: 119 SEQ ID NO: 34
    687 SEQ ID NO: 119 SEQ ID NO: 35
    688 SEQ ID NO: 119 SEQ ID NO: 59
    689 SEQ ID NO: 119 SEQ ID NO: 60
    690 SEQ ID NO: 119 SEQ ID NO: 61
    691 SEQ ID NO: 119 SEQ ID NO: 67
    692 SEQ ID NO: 119 SEQ ID NO: 69
    693 SEQ ID NO: 119 SEQ ID NO: 112
    694 SEQ ID NO: 119 SEQ ID NO: 113
    695 SEQ ID NO: 119 SEQ ID NO: 114
    696 SEQ ID NO: 119 SEQ ID NO: 123
    697 SEQ ID NO: 119 SEQ ID NO: 124
    698 SEQ ID NO: 119 SEQ ID NO: 125
    699 SEQ ID NO: 119 SEQ ID NO: 126
    700 SEQ ID NO: 119 SEQ ID NO: 127
    701 SEQ ID NO: 119 SEQ ID NO: 128
    702 SEQ ID NO: 119 SEQ ID NO: 129
    703 SEQ ID NO: 119 SEQ ID NO: 130
    704 SEQ ID NO: 119 SEQ ID NO: 131
    705 SEQ ID NO: 119 SEQ ID NO: 132
    706 SEQ ID NO: 120 SEQ ID NO: 19
    707 SEQ ID NO: 120 SEQ ID NO: 24
    708 SEQ ID NO: 120 SEQ ID NO: 25
    709 SEQ ID NO: 120 SEQ ID NO: 26
    710 SEQ ID NO: 120 SEQ ID NO: 27
    711 SEQ ID NO: 120 SEQ ID NO: 32
    712 SEQ ID NO: 120 SEQ ID NO: 33
    713 SEQ ID NO: 120 SEQ ID NO: 34
    714 SEQ ID NO: 120 SEQ ID NO: 35
    715 SEQ ID NO: 120 SEQ ID NO: 59
    716 SEQ ID NO: 120 SEQ ID NO: 60
    717 SEQ ID NO: 120 SEQ ID NO: 61
    718 SEQ ID NO: 120 SEQ ID NO: 67
    719 SEQ ID NO: 120 SEQ ID NO: 69
    720 SEQ ID NO: 120 SEQ ID NO: 112
    721 SEQ ID NO: 120 SEQ ID NO: 113
    722 SEQ ID NO: 120 SEQ ID NO: 114
    723 SEQ ID NO: 120 SEQ ID NO: 123
    724 SEQ ID NO: 120 SEQ ID NO: 124
    725 SEQ ID NO: 120 SEQ ID NO: 125
    726 SEQ ID NO: 120 SEQ ID NO: 126
    727 SEQ ID NO: 120 SEQ ID NO: 127
    728 SEQ ID NO: 120 SEQ ID NO: 128
    729 SEQ ID NO: 120 SEQ ID NO: 129
    730 SEQ ID NO: 120 SEQ ID NO: 130
    731 SEQ ID NO: 120 SEQ ID NO: 131
    732 SEQ ID NO: 120 SEQ ID NO: 132
    733 SEQ ID NO: 121 SEQ ID NO: 19
    734 SEQ ID NO: 121 SEQ ID NO: 24
    735 SEQ ID NO: 121 SEQ ID NO: 25
    736 SEQ ID NO: 121 SEQ ID NO: 26
    737 SEQ ID NO: 121 SEQ ID NO: 27
    738 SEQ ID NO: 121 SEQ ID NO: 32
    739 SEQ ID NO: 121 SEQ ID NO: 33
    740 SEQ ID NO: 121 SEQ ID NO: 34
    741 SEQ ID NO: 121 SEQ ID NO: 35
    742 SEQ ID NO: 121 SEQ ID NO: 59
    743 SEQ ID NO: 121 SEQ ID NO: 60
    744 SEQ ID NO: 121 SEQ ID NO: 61
    745 SEQ ID NO: 121 SEQ ID NO: 67
    746 SEQ ID NO: 121 SEQ ID NO: 69
    747 SEQ ID NO: 121 SEQ ID NO: 112
    748 SEQ ID NO: 121 SEQ ID NO: 113
    749 SEQ ID NO: 121 SEQ ID NO: 114
    750 SEQ ID NO: 121 SEQ ID NO: 123
    751 SEQ ID NO: 121 SEQ ID NO: 124
    752 SEQ ID NO: 121 SEQ ID NO: 125
    753 SEQ ID NO: 121 SEQ ID NO: 126
    754 SEQ ID NO: 121 SEQ ID NO: 127
    755 SEQ ID NO: 121 SEQ ID NO: 128
    756 SEQ ID NO: 121 SEQ ID NO: 129
    757 SEQ ID NO: 121 SEQ ID NO: 130
    758 SEQ ID NO: 121 SEQ ID NO: 131
    759 SEQ ID NO: 121 SEQ ID NO: 132
    760 SEQ ID NO: 122 SEQ ID NO: 19
    761 SEQ ID NO: 122 SEQ ID NO: 24
    762 SEQ ID NO: 122 SEQ ID NO: 25
    763 SEQ ID NO: 122 SEQ ID NO: 26
    764 SEQ ID NO: 122 SEQ ID NO: 27
    765 SEQ ID NO: 122 SEQ ID NO: 32
    766 SEQ ID NO: 122 SEQ ID NO: 33
    767 SEQ ID NO: 122 SEQ ID NO: 34
    768 SEQ ID NO: 122 SEQ ID NO: 35
    769 SEQ ID NO: 122 SEQ ID NO: 59
    770 SEQ ID NO: 122 SEQ ID NO: 60
    771 SEQ ID NO: 122 SEQ ID NO: 61
    772 SEQ ID NO: 122 SEQ ID NO: 67
    773 SEQ ID NO: 122 SEQ ID NO: 69
    774 SEQ ID NO: 122 SEQ ID NO: 112
    775 SEQ ID NO: 122 SEQ ID NO: 113
    776 SEQ ID NO: 122 SEQ ID NO: 114
    777 SEQ ID NO: 122 SEQ ID NO: 123
    778 SEQ ID NO: 122 SEQ ID NO: 124
    779 SEQ ID NO: 122 SEQ ID NO: 125
    780 SEQ ID NO: 122 SEQ ID NO: 126
    781 SEQ ID NO: 122 SEQ ID NO: 127
    782 SEQ ID NO: 122 SEQ ID NO: 128
    783 SEQ ID NO: 122 SEQ ID NO: 129
    784 SEQ ID NO: 122 SEQ ID NO: 130
    785 SEQ ID NO: 122 SEQ ID NO: 131
    786 SEQ ID NO: 122 SEQ ID NO: 132
    787 SEQ ID NO: 141 SEQ ID NO: 142
    788 SEQ ID NO: 143 SEQ ID NO: 142
    789 SEQ ID NO: 145 SEQ ID NO: 142
    790 SEQ ID NO: 147 SEQ ID NO: 142
    791 SEQ ID NO: 149 SEQ ID NO: 142
    792 SEQ ID NO: 151 SEQ ID NO: 142
    793 SEQ ID NO: 153 SEQ ID NO: 142
    794 SEQ ID NO: 155 SEQ ID NO: 142
    795 SEQ ID NO: 156 SEQ ID NO: 142
    796 SEQ ID NO: 164 SEQ ID NO: 142
    797 SEQ ID NO: 165 SEQ ID NO: 142
    798 SEQ ID NO: 166 SEQ ID NO: 142
    799 SEQ ID NO: 167 SEQ ID NO: 142
    800 SEQ ID NO: 168 SEQ ID NO: 142
    801 SEQ ID NO: 169 SEQ ID NO: 142
    802 SEQ ID NO: 170 SEQ ID NO: 142
    803 SEQ ID NO: 171 SEQ ID NO: 142
    804 SEQ ID NO: 172 SEQ ID NO: 142
    805 SEQ ID NO: 173 SEQ ID NO: 142
    806 SEQ ID NO: 174 SEQ ID NO: 142
    807 SEQ ID NO: 175 SEQ ID NO: 142
    808 SEQ ID NO: 176 SEQ ID NO: 142
    809 SEQ ID NO: 177 SEQ ID NO: 142
    810 SEQ ID NO: 178 SEQ ID NO: 142
    811 SEQ ID NO: 179 SEQ ID NO: 142
    812 SEQ ID NO: 180 SEQ ID NO: 142
    813 SEQ ID NO: 181 SEQ ID NO: 142
    814 SEQ ID NO: 182 SEQ ID NO: 142
    815 SEQ ID NO: 183 SEQ ID NO: 142
    816 SEQ ID NO: 184 SEQ ID NO: 142
    817 SEQ ID NO: 185 SEQ ID NO: 142
    818 SEQ ID NO: 186 SEQ ID NO: 142
    819 SEQ ID NO: 187 SEQ ID NO: 142
    820 SEQ ID NO: 188 SEQ ID NO: 142
    821 SEQ ID NO: 189 SEQ ID NO: 142
    822 SEQ ID NO: 190 SEQ ID NO: 142
    823 SEQ ID NO: 191 SEQ ID NO: 142
    824 SEQ ID NO: 192 SEQ ID NO: 142
    825 SEQ ID NO: 193 SEQ ID NO: 142
    826 SEQ ID NO: 194 SEQ ID NO: 142
    827 SEQ ID NO: 195 SEQ ID NO: 142
    828 SEQ ID NO: 196 SEQ ID NO: 142
    829 SEQ ID NO: 197 SEQ ID NO: 142
    830 SEQ ID NO: 198 SEQ ID NO: 142
    831 SEQ ID NO: 199 SEQ ID NO: 142
    832 SEQ ID NO: 200 SEQ ID NO: 142
    833 SEQ ID NO: 201 SEQ ID NO: 142
    834 SEQ ID NO: 202 SEQ ID NO: 142
    835 SEQ ID NO: 203 SEQ ID NO: 142
    836 SEQ ID NO: 204 SEQ ID NO: 142
    837 SEQ ID NO: 205 SEQ ID NO: 142
    838 SEQ ID NO: 206 SEQ ID NO: 142
    839 SEQ ID NO: 207 SEQ ID NO: 142
    840 SEQ ID NO: 208 SEQ ID NO: 142
    841 SEQ ID NO: 209 SEQ ID NO: 142
    842 SEQ ID NO: 210 SEQ ID NO: 142
    843 SEQ ID NO: 211 SEQ ID NO: 142
    844 SEQ ID NO: 212 SEQ ID NO: 142
    845 SEQ ID NO: 213 SEQ ID NO: 142
    846 SEQ ID NO: 214 SEQ ID NO: 142
    847 SEQ ID NO: 215 SEQ ID NO: 142
    848 SEQ ID NO: 216 SEQ ID NO: 142
    849 SEQ ID NO: 217 SEQ ID NO: 142
    850 SEQ ID NO: 218 SEQ ID NO: 142
    851 SEQ ID NO: 219 SEQ ID NO: 142
    852 SEQ ID NO: 220 SEQ ID NO: 142
    853 SEQ ID NO: 221 SEQ ID NO: 142
    854 SEQ ID NO: 222 SEQ ID NO: 142
    855 SEQ ID NO: 223 SEQ ID NO: 142
    856 SEQ ID NO: 224 SEQ ID NO: 142
    857 SEQ ID NO: 225 SEQ ID NO: 142
    858 SEQ ID NO: 226 SEQ ID NO: 142
    859 SEQ ID NO: 227 SEQ ID NO: 142
    860 SEQ ID NO: 228 SEQ ID NO: 142
    861 SEQ ID NO: 229 SEQ ID NO: 142
    862 SEQ ID NO: 230 SEQ ID NO: 142
    863 SEQ ID NO: 231 SEQ ID NO: 142
    864 SEQ ID NO: 232 SEQ ID NO: 142
    865 SEQ ID NO: 233 SEQ ID NO: 142
    866 SEQ ID NO: 234 SEQ ID NO: 142
    867 SEQ ID NO: 235 SEQ ID NO: 142
    868 SEQ ID NO: 236 SEQ ID NO: 142
    869 SEQ ID NO: 237 SEQ ID NO: 142
    870 SEQ ID NO: 238 SEQ ID NO: 142
    871 SEQ ID NO: 239 SEQ ID NO: 142
    872 SEQ ID NO: 240 SEQ ID NO: 142
    873 SEQ ID NO: 241 SEQ ID NO: 142
    874 SEQ ID NO: 242 SEQ ID NO: 142
    875 SEQ ID NO: 243 SEQ ID NO: 142
    876 SEQ ID NO: 244 SEQ ID NO: 142
    877 SEQ ID NO: 245 SEQ ID NO: 142
    878 SEQ ID NO: 246 SEQ ID NO: 142
    879 SEQ ID NO: 247 SEQ ID NO: 142
    880 SEQ ID NO: 248 SEQ ID NO: 142
    881 SEQ ID NO: 249 SEQ ID NO: 142
    882 SEQ ID NO: 250 SEQ ID NO: 142
    883 SEQ ID NO: 251 SEQ ID NO: 142
    884 SEQ ID NO: 252 SEQ ID NO: 142
    885 SEQ ID NO: 253 SEQ ID NO: 142
    886 SEQ ID NO: 254 SEQ ID NO: 142
    887 SEQ ID NO: 255 SEQ ID NO: 142
    888 SEQ ID NO: 256 SEQ ID NO: 142
    889 SEQ ID NO: 257 SEQ ID NO: 142
    890 SEQ ID NO: 258 SEQ ID NO: 142
    891 SEQ ID NO: 259 SEQ ID NO: 142
    892 SEQ ID NO: 260 SEQ ID NO: 142
    893 SEQ ID NO: 261 SEQ ID NO: 142
    894 SEQ ID NO: 262 SEQ ID NO: 142
    895 SEQ ID NO: 263 SEQ ID NO: 142
    896 SEQ ID NO: 264 SEQ ID NO: 142
    897 SEQ ID NO: 265 SEQ ID NO: 142
    898 SEQ ID NO: 266 SEQ ID NO: 142
    899 SEQ ID NO: 267 SEQ ID NO: 142
    900 SEQ ID NO: 268 SEQ ID NO: 142
    901 SEQ ID NO: 269 SEQ ID NO: 142
    902 SEQ ID NO: 270 SEQ ID NO: 142
    903 SEQ ID NO: 271 SEQ ID NO: 142
    904 SEQ ID NO: 272 SEQ ID NO: 142
    905 SEQ ID NO: 273 SEQ ID NO: 142
    906 SEQ ID NO: 274 SEQ ID NO: 142
    907 SEQ ID NO: 275 SEQ ID NO: 142
    908 SEQ ID NO: 276 SEQ ID NO: 142
    909 SEQ ID NO: 277 SEQ ID NO: 142
    910 SEQ ID NO: 278 SEQ ID NO: 142
    911 SEQ ID NO: 279 SEQ ID NO: 142
    912 SEQ ID NO: 280 SEQ ID NO: 142
    913 SEQ ID NO: 281 SEQ ID NO: 142
    914 SEQ ID NO: 282 SEQ ID NO: 142
    915 SEQ ID NO: 283 SEQ ID NO: 142
    916 SEQ ID NO: 284 SEQ ID NO: 142
    917 SEQ ID NO: 285 SEQ ID NO: 142
    918 SEQ ID NO: 286 SEQ ID NO: 142
    919 SEQ ID NO: 287 SEQ ID NO: 142
    920 SEQ ID NO: 288 SEQ ID NO: 142
    921 SEQ ID NO: 289 SEQ ID NO: 142
    922 SEQ ID NO: 141 SEQ ID NO: 144
    923 SEQ ID NO: 143 SEQ ID NO: 144
    924 SEQ ID NO: 145 SEQ ID NO: 144
    925 SEQ ID NO: 147 SEQ ID NO: 144
    926 SEQ ID NO: 149 SEQ ID NO: 144
    927 SEQ ID NO: 151 SEQ ID NO: 144
    928 SEQ ID NO: 153 SEQ ID NO: 144
    929 SEQ ID NO: 155 SEQ ID NO: 144
    930 SEQ ID NO: 156 SEQ ID NO: 144
    931 SEQ ID NO: 164 SEQ ID NO: 144
    932 SEQ ID NO: 165 SEQ ID NO: 144
    933 SEQ ID NO: 166 SEQ ID NO: 144
    934 SEQ ID NO: 167 SEQ ID NO: 144
    935 SEQ ID NO: 168 SEQ ID NO: 144
    936 SEQ ID NO: 169 SEQ ID NO: 144
    937 SEQ ID NO: 170 SEQ ID NO: 144
    938 SEQ ID NO: 171 SEQ ID NO: 144
    939 SEQ ID NO: 172 SEQ ID NO: 144
    940 SEQ ID NO: 173 SEQ ID NO: 144
    941 SEQ ID NO: 174 SEQ ID NO: 144
    942 SEQ ID NO: 175 SEQ ID NO: 144
    943 SEQ ID NO: 176 SEQ ID NO: 144
    944 SEQ ID NO: 177 SEQ ID NO: 144
    945 SEQ ID NO: 178 SEQ ID NO: 144
    946 SEQ ID NO: 179 SEQ ID NO: 144
    947 SEQ ID NO: 180 SEQ ID NO: 144
    948 SEQ ID NO: 181 SEQ ID NO: 144
    949 SEQ ID NO: 182 SEQ ID NO: 144
    950 SEQ ID NO: 183 SEQ ID NO: 144
    951 SEQ ID NO: 184 SEQ ID NO: 144
    952 SEQ ID NO: 185 SEQ ID NO: 144
    953 SEQ ID NO: 186 SEQ ID NO: 144
    954 SEQ ID NO: 187 SEQ ID NO: 144
    955 SEQ ID NO: 188 SEQ ID NO: 144
    956 SEQ ID NO: 189 SEQ ID NO: 144
    957 SEQ ID NO: 190 SEQ ID NO: 144
    958 SEQ ID NO: 191 SEQ ID NO: 144
    959 SEQ ID NO: 192 SEQ ID NO: 144
    960 SEQ ID NO: 193 SEQ ID NO: 144
    961 SEQ ID NO: 194 SEQ ID NO: 144
    962 SEQ ID NO: 195 SEQ ID NO: 144
    963 SEQ ID NO: 196 SEQ ID NO: 144
    964 SEQ ID NO: 197 SEQ ID NO: 144
    965 SEQ ID NO: 198 SEQ ID NO: 144
    966 SEQ ID NO: 199 SEQ ID NO: 144
    967 SEQ ID NO: 200 SEQ ID NO: 144
    968 SEQ ID NO: 201 SEQ ID NO: 144
    969 SEQ ID NO: 202 SEQ ID NO: 144
    970 SEQ ID NO: 203 SEQ ID NO: 144
    971 SEQ ID NO: 204 SEQ ID NO: 144
    972 SEQ ID NO: 205 SEQ ID NO: 144
    973 SEQ ID NO: 206 SEQ ID NO: 144
    974 SEQ ID NO: 207 SEQ ID NO: 144
    975 SEQ ID NO: 208 SEQ ID NO: 144
    976 SEQ ID NO: 209 SEQ ID NO: 144
    977 SEQ ID NO: 210 SEQ ID NO: 144
    978 SEQ ID NO: 211 SEQ ID NO: 144
    979 SEQ ID NO: 212 SEQ ID NO: 144
    980 SEQ ID NO: 213 SEQ ID NO: 144
    981 SEQ ID NO: 214 SEQ ID NO: 144
    982 SEQ ID NO: 215 SEQ ID NO: 144
    983 SEQ ID NO: 216 SEQ ID NO: 144
    984 SEQ ID NO: 217 SEQ ID NO: 144
    985 SEQ ID NO: 218 SEQ ID NO: 144
    986 SEQ ID NO: 219 SEQ ID NO: 144
    987 SEQ ID NO: 220 SEQ ID NO: 144
    988 SEQ ID NO: 221 SEQ ID NO: 144
    989 SEQ ID NO: 222 SEQ ID NO: 144
    990 SEQ ID NO: 223 SEQ ID NO: 144
    991 SEQ ID NO: 224 SEQ ID NO: 144
    992 SEQ ID NO: 225 SEQ ID NO: 144
    993 SEQ ID NO: 226 SEQ ID NO: 144
    994 SEQ ID NO: 227 SEQ ID NO: 144
    995 SEQ ID NO: 228 SEQ ID NO: 144
    996 SEQ ID NO: 229 SEQ ID NO: 144
    997 SEQ ID NO: 230 SEQ ID NO: 144
    998 SEQ ID NO: 231 SEQ ID NO: 144
    999 SEQ ID NO: 232 SEQ ID NO: 144
    1000 SEQ ID NO: 233 SEQ ID NO: 144
    1001 SEQ ID NO: 234 SEQ ID NO: 144
    1002 SEQ ID NO: 235 SEQ ID NO: 144
    1003 SEQ ID NO: 236 SEQ ID NO: 144
    1004 SEQ ID NO: 237 SEQ ID NO: 144
    1005 SEQ ID NO: 238 SEQ ID NO: 144
    1006 SEQ ID NO: 239 SEQ ID NO: 144
    1007 SEQ ID NO: 240 SEQ ID NO: 144
    1008 SEQ ID NO: 241 SEQ ID NO: 144
    1009 SEQ ID NO: 242 SEQ ID NO: 144
    1010 SEQ ID NO: 243 SEQ ID NO: 144
    1011 SEQ ID NO: 244 SEQ ID NO: 144
    1012 SEQ ID NO: 245 SEQ ID NO: 144
    1013 SEQ ID NO: 246 SEQ ID NO: 144
    1014 SEQ ID NO: 247 SEQ ID NO: 144
    1015 SEQ ID NO: 248 SEQ ID NO: 144
    1016 SEQ ID NO: 249 SEQ ID NO: 144
    1017 SEQ ID NO: 250 SEQ ID NO: 144
    1018 SEQ ID NO: 251 SEQ ID NO: 144
    1019 SEQ ID NO: 252 SEQ ID NO: 144
    1020 SEQ ID NO: 253 SEQ ID NO: 144
    1021 SEQ ID NO: 254 SEQ ID NO: 144
    1022 SEQ ID NO: 255 SEQ ID NO: 144
    1023 SEQ ID NO: 256 SEQ ID NO: 144
    1024 SEQ ID NO: 257 SEQ ID NO: 144
    1025 SEQ ID NO: 258 SEQ ID NO: 144
    1026 SEQ ID NO: 259 SEQ ID NO: 144
    1027 SEQ ID NO: 260 SEQ ID NO: 144
    1028 SEQ ID NO: 261 SEQ ID NO: 144
    1029 SEQ ID NO: 262 SEQ ID NO: 144
    1030 SEQ ID NO: 263 SEQ ID NO: 144
    1031 SEQ ID NO: 264 SEQ ID NO: 144
    1032 SEQ ID NO: 265 SEQ ID NO: 144
    1033 SEQ ID NO: 266 SEQ ID NO: 144
    1034 SEQ ID NO: 267 SEQ ID NO: 144
    1035 SEQ ID NO: 268 SEQ ID NO: 144
    1036 SEQ ID NO: 269 SEQ ID NO: 144
    1037 SEQ ID NO: 270 SEQ ID NO: 144
    1038 SEQ ID NO: 271 SEQ ID NO: 144
    1039 SEQ ID NO: 272 SEQ ID NO: 144
    1040 SEQ ID NO: 273 SEQ ID NO: 144
    1041 SEQ ID NO: 274 SEQ ID NO: 144
    1042 SEQ ID NO: 275 SEQ ID NO: 144
    1043 SEQ ID NO: 276 SEQ ID NO: 144
    1044 SEQ ID NO: 277 SEQ ID NO: 144
    1045 SEQ ID NO: 278 SEQ ID NO: 144
    1046 SEQ ID NO: 279 SEQ ID NO: 144
    1047 SEQ ID NO: 280 SEQ ID NO: 144
    1048 SEQ ID NO: 281 SEQ ID NO: 144
    1049 SEQ ID NO: 282 SEQ ID NO: 144
    1050 SEQ ID NO: 283 SEQ ID NO: 144
    1051 SEQ ID NO: 284 SEQ ID NO: 144
    1052 SEQ ID NO: 285 SEQ ID NO: 144
    1053 SEQ ID NO: 286 SEQ ID NO: 144
    1054 SEQ ID NO: 287 SEQ ID NO: 144
    1055 SEQ ID NO: 288 SEQ ID NO: 144
    1056 SEQ ID NO: 289 SEQ ID NO: 144
    1057 SEQ ID NO: 141 SEQ ID NO: 146
    1058 SEQ ID NO: 143 SEQ ID NO: 146
    1059 SEQ ID NO: 145 SEQ ID NO: 146
    1060 SEQ ID NO: 147 SEQ ID NO: 146
    1061 SEQ ID NO: 149 SEQ ID NO: 146
    1062 SEQ ID NO: 151 SEQ ID NO: 146
    1063 SEQ ID NO: 153 SEQ ID NO: 146
    1064 SEQ ID NO: 155 SEQ ID NO: 146
    1065 SEQ ID NO: 156 SEQ ID NO: 146
    1066 SEQ ID NO: 164 SEQ ID NO: 146
    1067 SEQ ID NO: 165 SEQ ID NO: 146
    1068 SEQ ID NO: 166 SEQ ID NO: 146
    1069 SEQ ID NO: 167 SEQ ID NO: 146
    1070 SEQ ID NO: 168 SEQ ID NO: 146
    1071 SEQ ID NO: 169 SEQ ID NO: 146
    1072 SEQ ID NO: 170 SEQ ID NO: 146
    1073 SEQ ID NO: 171 SEQ ID NO: 146
    1074 SEQ ID NO: 172 SEQ ID NO: 146
    1075 SEQ ID NO: 173 SEQ ID NO: 146
    1076 SEQ ID NO: 174 SEQ ID NO: 146
    1077 SEQ ID NO: 175 SEQ ID NO: 146
    1078 SEQ ID NO: 176 SEQ ID NO: 146
    1079 SEQ ID NO: 177 SEQ ID NO: 146
    1080 SEQ ID NO: 178 SEQ ID NO: 146
    1081 SEQ ID NO: 179 SEQ ID NO: 146
    1082 SEQ ID NO: 180 SEQ ID NO: 146
    1083 SEQ ID NO: 181 SEQ ID NO: 146
    1084 SEQ ID NO: 182 SEQ ID NO: 146
    1085 SEQ ID NO: 183 SEQ ID NO: 146
    1086 SEQ ID NO: 184 SEQ ID NO: 146
    1087 SEQ ID NO: 185 SEQ ID NO: 146
    1088 SEQ ID NO: 186 SEQ ID NO: 146
    1089 SEQ ID NO: 187 SEQ ID NO: 146
    1090 SEQ ID NO: 188 SEQ ID NO: 146
    1091 SEQ ID NO: 189 SEQ ID NO: 146
    1092 SEQ ID NO: 190 SEQ ID NO: 146
    1093 SEQ ID NO: 191 SEQ ID NO: 146
    1094 SEQ ID NO: 192 SEQ ID NO: 146
    1095 SEQ ID NO: 193 SEQ ID NO: 146
    1096 SEQ ID NO: 194 SEQ ID NO: 146
    1097 SEQ ID NO: 195 SEQ ID NO: 146
    1098 SEQ ID NO: 196 SEQ ID NO: 146
    1099 SEQ ID NO: 197 SEQ ID NO: 146
    1100 SEQ ID NO: 198 SEQ ID NO: 146
    1101 SEQ ID NO: 199 SEQ ID NO: 146
    1102 SEQ ID NO: 200 SEQ ID NO: 146
    1103 SEQ ID NO: 201 SEQ ID NO: 146
    1104 SEQ ID NO: 202 SEQ ID NO: 146
    1105 SEQ ID NO: 203 SEQ ID NO: 146
    1106 SEQ ID NO: 204 SEQ ID NO: 146
    1107 SEQ ID NO: 205 SEQ ID NO: 146
    1108 SEQ ID NO: 206 SEQ ID NO: 146
    1109 SEQ ID NO: 207 SEQ ID NO: 146
    1110 SEQ ID NO: 208 SEQ ID NO: 146
    1111 SEQ ID NO: 209 SEQ ID NO: 146
    1112 SEQ ID NO: 210 SEQ ID NO: 146
    1113 SEQ ID NO: 211 SEQ ID NO: 146
    1114 SEQ ID NO: 212 SEQ ID NO: 146
    1115 SEQ ID NO: 213 SEQ ID NO: 146
    1116 SEQ ID NO: 214 SEQ ID NO: 146
    1117 SEQ ID NO: 215 SEQ ID NO: 146
    1118 SEQ ID NO: 216 SEQ ID NO: 146
    1119 SEQ ID NO: 217 SEQ ID NO: 146
    1120 SEQ ID NO: 218 SEQ ID NO: 146
    1121 SEQ ID NO: 219 SEQ ID NO: 146
    1122 SEQ ID NO: 220 SEQ ID NO: 146
    1123 SEQ ID NO: 221 SEQ ID NO: 146
    1124 SEQ ID NO: 222 SEQ ID NO: 146
    1125 SEQ ID NO: 223 SEQ ID NO: 146
    1126 SEQ ID NO: 224 SEQ ID NO: 146
    1127 SEQ ID NO: 225 SEQ ID NO: 146
    1128 SEQ ID NO: 226 SEQ ID NO: 146
    1129 SEQ ID NO: 227 SEQ ID NO: 146
    1130 SEQ ID NO: 228 SEQ ID NO: 146
    1131 SEQ ID NO: 229 SEQ ID NO: 146
    1132 SEQ ID NO: 230 SEQ ID NO: 146
    1133 SEQ ID NO: 231 SEQ ID NO: 146
    1134 SEQ ID NO: 232 SEQ ID NO: 146
    1135 SEQ ID NO: 233 SEQ ID NO: 146
    1136 SEQ ID NO: 234 SEQ ID NO: 146
    1137 SEQ ID NO: 235 SEQ ID NO: 146
    1138 SEQ ID NO: 236 SEQ ID NO: 146
    1139 SEQ ID NO: 237 SEQ ID NO: 146
    1140 SEQ ID NO: 238 SEQ ID NO: 146
    1141 SEQ ID NO: 239 SEQ ID NO: 146
    1142 SEQ ID NO: 240 SEQ ID NO: 146
    1143 SEQ ID NO: 241 SEQ ID NO: 146
    1144 SEQ ID NO: 242 SEQ ID NO: 146
    1145 SEQ ID NO: 243 SEQ ID NO: 146
    1146 SEQ ID NO: 244 SEQ ID NO: 146
    1147 SEQ ID NO: 245 SEQ ID NO: 146
    1148 SEQ ID NO: 246 SEQ ID NO: 146
    1149 SEQ ID NO: 247 SEQ ID NO: 146
    1150 SEQ ID NO: 248 SEQ ID NO: 146
    1151 SEQ ID NO: 249 SEQ ID NO: 146
    1152 SEQ ID NO: 250 SEQ ID NO: 146
    1153 SEQ ID NO: 251 SEQ ID NO: 146
    1154 SEQ ID NO: 252 SEQ ID NO: 146
    1155 SEQ ID NO: 253 SEQ ID NO: 146
    1156 SEQ ID NO: 254 SEQ ID NO: 146
    1157 SEQ ID NO: 255 SEQ ID NO: 146
    1158 SEQ ID NO: 256 SEQ ID NO: 146
    1159 SEQ ID NO: 257 SEQ ID NO: 146
    1160 SEQ ID NO: 258 SEQ ID NO: 146
    1161 SEQ ID NO: 259 SEQ ID NO: 146
    1162 SEQ ID NO: 260 SEQ ID NO: 146
    1163 SEQ ID NO: 261 SEQ ID NO: 146
    1164 SEQ ID NO: 262 SEQ ID NO: 146
    1165 SEQ ID NO: 263 SEQ ID NO: 146
    1166 SEQ ID NO: 264 SEQ ID NO: 146
    1167 SEQ ID NO: 265 SEQ ID NO: 146
    1168 SEQ ID NO: 266 SEQ ID NO: 146
    1169 SEQ ID NO: 267 SEQ ID NO: 146
    1170 SEQ ID NO: 268 SEQ ID NO: 146
    1171 SEQ ID NO: 269 SEQ ID NO: 146
    1172 SEQ ID NO: 270 SEQ ID NO: 146
    1173 SEQ ID NO: 271 SEQ ID NO: 146
    1174 SEQ ID NO: 272 SEQ ID NO: 146
    1175 SEQ ID NO: 273 SEQ ID NO: 146
    1176 SEQ ID NO: 274 SEQ ID NO: 146
    1177 SEQ ID NO: 275 SEQ ID NO: 146
    1178 SEQ ID NO: 276 SEQ ID NO: 146
    1179 SEQ ID NO: 277 SEQ ID NO: 146
    1180 SEQ ID NO: 278 SEQ ID NO: 146
    1181 SEQ ID NO: 279 SEQ ID NO: 146
    1182 SEQ ID NO: 280 SEQ ID NO: 146
    1183 SEQ ID NO: 281 SEQ ID NO: 146
    1184 SEQ ID NO: 282 SEQ ID NO: 146
    1185 SEQ ID NO: 283 SEQ ID NO: 146
    1186 SEQ ID NO: 284 SEQ ID NO: 146
    1187 SEQ ID NO: 285 SEQ ID NO: 146
    1188 SEQ ID NO: 286 SEQ ID NO: 146
    1189 SEQ ID NO: 287 SEQ ID NO: 146
    1190 SEQ ID NO: 288 SEQ ID NO: 146
    1191 SEQ ID NO: 289 SEQ ID NO: 146
    1192 SEQ ID NO: 141 SEQ ID NO: 148
    1193 SEQ ID NO: 143 SEQ ID NO: 148
    1194 SEQ ID NO: 145 SEQ ID NO: 148
    1195 SEQ ID NO: 147 SEQ ID NO: 148
    1196 SEQ ID NO: 149 SEQ ID NO: 148
    1197 SEQ ID NO: 151 SEQ ID NO: 148
    1198 SEQ ID NO: 153 SEQ ID NO: 148
    1199 SEQ ID NO: 155 SEQ ID NO: 148
    1200 SEQ ID NO: 156 SEQ ID NO: 148
    1201 SEQ ID NO: 164 SEQ ID NO: 148
    1202 SEQ ID NO: 165 SEQ ID NO: 148
    1203 SEQ ID NO: 166 SEQ ID NO: 148
    1204 SEQ ID NO: 167 SEQ ID NO: 148
    1205 SEQ ID NO: 168 SEQ ID NO: 148
    1206 SEQ ID NO: 169 SEQ ID NO: 148
    1207 SEQ ID NO: 170 SEQ ID NO: 148
    1208 SEQ ID NO: 171 SEQ ID NO: 148
    1209 SEQ ID NO: 172 SEQ ID NO: 148
    1210 SEQ ID NO: 173 SEQ ID NO: 148
    1211 SEQ ID NO: 174 SEQ ID NO: 148
    1212 SEQ ID NO: 175 SEQ ID NO: 148
    1213 SEQ ID NO: 176 SEQ ID NO: 148
    1214 SEQ ID NO: 177 SEQ ID NO: 148
    1215 SEQ ID NO: 178 SEQ ID NO: 148
    1216 SEQ ID NO: 179 SEQ ID NO: 148
    1217 SEQ ID NO: 180 SEQ ID NO: 148
    1218 SEQ ID NO: 181 SEQ ID NO: 148
    1219 SEQ ID NO: 182 SEQ ID NO: 148
    1220 SEQ ID NO: 183 SEQ ID NO: 148
    1221 SEQ ID NO: 184 SEQ ID NO: 148
    1222 SEQ ID NO: 185 SEQ ID NO: 148
    1223 SEQ ID NO: 186 SEQ ID NO: 148
    1224 SEQ ID NO: 187 SEQ ID NO: 148
    1225 SEQ ID NO: 188 SEQ ID NO: 148
    1226 SEQ ID NO: 189 SEQ ID NO: 148
    1227 SEQ ID NO: 190 SEQ ID NO: 148
    1228 SEQ ID NO: 191 SEQ ID NO: 148
    1229 SEQ ID NO: 192 SEQ ID NO: 148
    1230 SEQ ID NO: 193 SEQ ID NO: 148
    1231 SEQ ID NO: 194 SEQ ID NO: 148
    1232 SEQ ID NO: 195 SEQ ID NO: 148
    1233 SEQ ID NO: 196 SEQ ID NO: 148
    1234 SEQ ID NO: 197 SEQ ID NO: 148
    1235 SEQ ID NO: 198 SEQ ID NO: 148
    1236 SEQ ID NO: 199 SEQ ID NO: 148
    1237 SEQ ID NO: 200 SEQ ID NO: 148
    1238 SEQ ID NO: 201 SEQ ID NO: 148
    1239 SEQ ID NO: 202 SEQ ID NO: 148
    1240 SEQ ID NO: 203 SEQ ID NO: 148
    1241 SEQ ID NO: 204 SEQ ID NO: 148
    1242 SEQ ID NO: 205 SEQ ID NO: 148
    1243 SEQ ID NO: 206 SEQ ID NO: 148
    1244 SEQ ID NO: 207 SEQ ID NO: 148
    1245 SEQ ID NO: 208 SEQ ID NO: 148
    1246 SEQ ID NO: 209 SEQ ID NO: 148
    1247 SEQ ID NO: 210 SEQ ID NO: 148
    1248 SEQ ID NO: 211 SEQ ID NO: 148
    1249 SEQ ID NO: 212 SEQ ID NO: 148
    1250 SEQ ID NO: 213 SEQ ID NO: 148
    1251 SEQ ID NO: 214 SEQ ID NO: 148
    1252 SEQ ID NO: 215 SEQ ID NO: 148
    1253 SEQ ID NO: 216 SEQ ID NO: 148
    1254 SEQ ID NO: 217 SEQ ID NO: 148
    1255 SEQ ID NO: 218 SEQ ID NO: 148
    1256 SEQ ID NO: 219 SEQ ID NO: 148
    1257 SEQ ID NO: 220 SEQ ID NO: 148
    1258 SEQ ID NO: 221 SEQ ID NO: 148
    1259 SEQ ID NO: 222 SEQ ID NO: 148
    1260 SEQ ID NO: 223 SEQ ID NO: 148
    1261 SEQ ID NO: 224 SEQ ID NO: 148
    1262 SEQ ID NO: 225 SEQ ID NO: 148
    1263 SEQ ID NO: 226 SEQ ID NO: 148
    1264 SEQ ID NO: 227 SEQ ID NO: 148
    1265 SEQ ID NO: 228 SEQ ID NO: 148
    1266 SEQ ID NO: 229 SEQ ID NO: 148
    1267 SEQ ID NO: 230 SEQ ID NO: 148
    1268 SEQ ID NO: 231 SEQ ID NO: 148
    1269 SEQ ID NO: 232 SEQ ID NO: 148
    1270 SEQ ID NO: 233 SEQ ID NO: 148
    1271 SEQ ID NO: 234 SEQ ID NO: 148
    1272 SEQ ID NO: 235 SEQ ID NO: 148
    1273 SEQ ID NO: 236 SEQ ID NO: 148
    1274 SEQ ID NO: 237 SEQ ID NO: 148
    1275 SEQ ID NO: 238 SEQ ID NO: 148
    1276 SEQ ID NO: 239 SEQ ID NO: 148
    1277 SEQ ID NO: 240 SEQ ID NO: 148
    1278 SEQ ID NO: 241 SEQ ID NO: 148
    1279 SEQ ID NO: 242 SEQ ID NO: 148
    1280 SEQ ID NO: 243 SEQ ID NO: 148
    1281 SEQ ID NO: 244 SEQ ID NO: 148
    1282 SEQ ID NO: 245 SEQ ID NO: 148
    1283 SEQ ID NO: 246 SEQ ID NO: 148
    1284 SEQ ID NO: 247 SEQ ID NO: 148
    1285 SEQ ID NO: 248 SEQ ID NO: 148
    1286 SEQ ID NO: 249 SEQ ID NO: 148
    1287 SEQ ID NO: 250 SEQ ID NO: 148
    1288 SEQ ID NO: 251 SEQ ID NO: 148
    1289 SEQ ID NO: 252 SEQ ID NO: 148
    1290 SEQ ID NO: 253 SEQ ID NO: 148
    1291 SEQ ID NO: 254 SEQ ID NO: 148
    1292 SEQ ID NO: 255 SEQ ID NO: 148
    1293 SEQ ID NO: 256 SEQ ID NO: 148
    1294 SEQ ID NO: 257 SEQ ID NO: 148
    1295 SEQ ID NO: 258 SEQ ID NO: 148
    1296 SEQ ID NO: 259 SEQ ID NO: 148
    1297 SEQ ID NO: 260 SEQ ID NO: 148
    1298 SEQ ID NO: 261 SEQ ID NO: 148
    1299 SEQ ID NO: 262 SEQ ID NO: 148
    1300 SEQ ID NO: 263 SEQ ID NO: 148
    1301 SEQ ID NO: 264 SEQ ID NO: 148
    1302 SEQ ID NO: 265 SEQ ID NO: 148
    1303 SEQ ID NO: 266 SEQ ID NO: 148
    1304 SEQ ID NO: 267 SEQ ID NO: 148
    1305 SEQ ID NO: 268 SEQ ID NO: 148
    1306 SEQ ID NO: 269 SEQ ID NO: 148
    1307 SEQ ID NO: 270 SEQ ID NO: 148
    1308 SEQ ID NO: 271 SEQ ID NO: 148
    1309 SEQ ID NO: 272 SEQ ID NO: 148
    1310 SEQ ID NO: 273 SEQ ID NO: 148
    1311 SEQ ID NO: 274 SEQ ID NO: 148
    1312 SEQ ID NO: 275 SEQ ID NO: 148
    1313 SEQ ID NO: 276 SEQ ID NO: 148
    1314 SEQ ID NO: 277 SEQ ID NO: 148
    1315 SEQ ID NO: 278 SEQ ID NO: 148
    1316 SEQ ID NO: 279 SEQ ID NO: 148
    1317 SEQ ID NO: 280 SEQ ID NO: 148
    1318 SEQ ID NO: 281 SEQ ID NO: 148
    1319 SEQ ID NO: 282 SEQ ID NO: 148
    1320 SEQ ID NO: 283 SEQ ID NO: 148
    1321 SEQ ID NO: 284 SEQ ID NO: 148
    1322 SEQ ID NO: 285 SEQ ID NO: 148
    1323 SEQ ID NO: 286 SEQ ID NO: 148
    1324 SEQ ID NO: 287 SEQ ID NO: 148
    1325 SEQ ID NO: 288 SEQ ID NO: 148
    1326 SEQ ID NO: 289 SEQ ID NO: 148
    1327 SEQ ID NO: 141 SEQ ID NO: 150
    1328 SEQ ID NO: 143 SEQ ID NO: 150
    1329 SEQ ID NO: 145 SEQ ID NO: 150
    1330 SEQ ID NO: 147 SEQ ID NO: 150
    1331 SEQ ID NO: 149 SEQ ID NO: 150
    1332 SEQ ID NO: 151 SEQ ID NO: 150
    1333 SEQ ID NO: 153 SEQ ID NO: 150
    1334 SEQ ID NO: 155 SEQ ID NO: 150
    1335 SEQ ID NO: 156 SEQ ID NO: 150
    1336 SEQ ID NO: 164 SEQ ID NO: 150
    1337 SEQ ID NO: 165 SEQ ID NO: 150
    1338 SEQ ID NO: 166 SEQ ID NO: 150
    1339 SEQ ID NO: 167 SEQ ID NO: 150
    1340 SEQ ID NO: 168 SEQ ID NO: 150
    1341 SEQ ID NO: 169 SEQ ID NO: 150
    1342 SEQ ID NO: 170 SEQ ID NO: 150
    1343 SEQ ID NO: 171 SEQ ID NO: 150
    1344 SEQ ID NO: 172 SEQ ID NO: 150
    1345 SEQ ID NO: 173 SEQ ID NO: 150
    1346 SEQ ID NO: 174 SEQ ID NO: 150
    1347 SEQ ID NO: 175 SEQ ID NO: 150
    1348 SEQ ID NO: 176 SEQ ID NO: 150
    1349 SEQ ID NO: 177 SEQ ID NO: 150
    1350 SEQ ID NO: 178 SEQ ID NO: 150
    1351 SEQ ID NO: 179 SEQ ID NO: 150
    1352 SEQ ID NO: 180 SEQ ID NO: 150
    1353 SEQ ID NO: 181 SEQ ID NO: 150
    1354 SEQ ID NO: 182 SEQ ID NO: 150
    1355 SEQ ID NO: 183 SEQ ID NO: 150
    1356 SEQ ID NO: 184 SEQ ID NO: 150
    1357 SEQ ID NO: 185 SEQ ID NO: 150
    1358 SEQ ID NO: 186 SEQ ID NO: 150
    1359 SEQ ID NO: 187 SEQ ID NO: 150
    1360 SEQ ID NO: 188 SEQ ID NO: 150
    1361 SEQ ID NO: 189 SEQ ID NO: 150
    1362 SEQ ID NO: 190 SEQ ID NO: 150
    1363 SEQ ID NO: 191 SEQ ID NO: 150
    1364 SEQ ID NO: 192 SEQ ID NO: 150
    1365 SEQ ID NO: 193 SEQ ID NO: 150
    1366 SEQ ID NO: 194 SEQ ID NO: 150
    1367 SEQ ID NO: 195 SEQ ID NO: 150
    1368 SEQ ID NO: 196 SEQ ID NO: 150
    1369 SEQ ID NO: 197 SEQ ID NO: 150
    1370 SEQ ID NO: 198 SEQ ID NO: 150
    1371 SEQ ID NO: 199 SEQ ID NO: 150
    1372 SEQ ID NO: 200 SEQ ID NO: 150
    1373 SEQ ID NO: 201 SEQ ID NO: 150
    1374 SEQ ID NO: 202 SEQ ID NO: 150
    1375 SEQ ID NO: 203 SEQ ID NO: 150
    1376 SEQ ID NO: 204 SEQ ID NO: 150
    1377 SEQ ID NO: 205 SEQ ID NO: 150
    1378 SEQ ID NO: 206 SEQ ID NO: 150
    1379 SEQ ID NO: 207 SEQ ID NO: 150
    1380 SEQ ID NO: 208 SEQ ID NO: 150
    1381 SEQ ID NO: 209 SEQ ID NO: 150
    1382 SEQ ID NO: 210 SEQ ID NO: 150
    1383 SEQ ID NO: 211 SEQ ID NO: 150
    1384 SEQ ID NO: 212 SEQ ID NO: 150
    1385 SEQ ID NO: 213 SEQ ID NO: 150
    1386 SEQ ID NO: 214 SEQ ID NO: 150
    1387 SEQ ID NO: 215 SEQ ID NO: 150
    1388 SEQ ID NO: 216 SEQ ID NO: 150
    1389 SEQ ID NO: 217 SEQ ID NO: 150
    1390 SEQ ID NO: 218 SEQ ID NO: 150
    1391 SEQ ID NO: 219 SEQ ID NO: 150
    1392 SEQ ID NO: 220 SEQ ID NO: 150
    1393 SEQ ID NO: 221 SEQ ID NO: 150
    1394 SEQ ID NO: 222 SEQ ID NO: 150
    1395 SEQ ID NO: 223 SEQ ID NO: 150
    1396 SEQ ID NO: 224 SEQ ID NO: 150
    1397 SEQ ID NO: 225 SEQ ID NO: 150
    1398 SEQ ID NO: 226 SEQ ID NO: 150
    1399 SEQ ID NO: 227 SEQ ID NO: 150
    1400 SEQ ID NO: 228 SEQ ID NO: 150
    1401 SEQ ID NO: 229 SEQ ID NO: 150
    1402 SEQ ID NO: 230 SEQ ID NO: 150
    1403 SEQ ID NO: 231 SEQ ID NO: 150
    1404 SEQ ID NO: 232 SEQ ID NO: 150
    1405 SEQ ID NO: 233 SEQ ID NO: 150
    1406 SEQ ID NO: 234 SEQ ID NO: 150
    1407 SEQ ID NO: 235 SEQ ID NO: 150
    1408 SEQ ID NO: 236 SEQ ID NO: 150
    1409 SEQ ID NO: 237 SEQ ID NO: 150
    1410 SEQ ID NO: 238 SEQ ID NO: 150
    1411 SEQ ID NO: 239 SEQ ID NO: 150
    1412 SEQ ID NO: 240 SEQ ID NO: 150
    1413 SEQ ID NO: 241 SEQ ID NO: 150
    1414 SEQ ID NO: 242 SEQ ID NO: 150
    1415 SEQ ID NO: 243 SEQ ID NO: 150
    1416 SEQ ID NO: 244 SEQ ID NO: 150
    1417 SEQ ID NO: 245 SEQ ID NO: 150
    1418 SEQ ID NO: 246 SEQ ID NO: 150
    1419 SEQ ID NO: 247 SEQ ID NO: 150
    1420 SEQ ID NO: 248 SEQ ID NO: 150
    1421 SEQ ID NO: 249 SEQ ID NO: 150
    1422 SEQ ID NO: 250 SEQ ID NO: 150
    1423 SEQ ID NO: 251 SEQ ID NO: 150
    1424 SEQ ID NO: 252 SEQ ID NO: 150
    1425 SEQ ID NO: 253 SEQ ID NO: 150
    1426 SEQ ID NO: 254 SEQ ID NO: 150
    1427 SEQ ID NO: 255 SEQ ID NO: 150
    1428 SEQ ID NO: 256 SEQ ID NO: 150
    1429 SEQ ID NO: 257 SEQ ID NO: 150
    1430 SEQ ID NO: 258 SEQ ID NO: 150
    1431 SEQ ID NO: 259 SEQ ID NO: 150
    1432 SEQ ID NO: 260 SEQ ID NO: 150
    1433 SEQ ID NO: 261 SEQ ID NO: 150
    1434 SEQ ID NO: 262 SEQ ID NO: 150
    1435 SEQ ID NO: 263 SEQ ID NO: 150
    1436 SEQ ID NO: 264 SEQ ID NO: 150
    1437 SEQ ID NO: 265 SEQ ID NO: 150
    1438 SEQ ID NO: 266 SEQ ID NO: 150
    1439 SEQ ID NO: 267 SEQ ID NO: 150
    1440 SEQ ID NO: 268 SEQ ID NO: 150
    1441 SEQ ID NO: 269 SEQ ID NO: 150
    1442 SEQ ID NO: 270 SEQ ID NO: 150
    1443 SEQ ID NO: 271 SEQ ID NO: 150
    1444 SEQ ID NO: 272 SEQ ID NO: 150
    1445 SEQ ID NO: 273 SEQ ID NO: 150
    1446 SEQ ID NO: 274 SEQ ID NO: 150
    1447 SEQ ID NO: 275 SEQ ID NO: 150
    1448 SEQ ID NO: 276 SEQ ID NO: 150
    1449 SEQ ID NO: 277 SEQ ID NO: 150
    1450 SEQ ID NO: 278 SEQ ID NO: 150
    1451 SEQ ID NO: 279 SEQ ID NO: 150
    1452 SEQ ID NO: 280 SEQ ID NO: 150
    1453 SEQ ID NO: 281 SEQ ID NO: 150
    1454 SEQ ID NO: 282 SEQ ID NO: 150
    1455 SEQ ID NO: 283 SEQ ID NO: 150
    1456 SEQ ID NO: 284 SEQ ID NO: 150
    1457 SEQ ID NO: 285 SEQ ID NO: 150
    1458 SEQ ID NO: 286 SEQ ID NO: 150
    1459 SEQ ID NO: 287 SEQ ID NO: 150
    1460 SEQ ID NO: 288 SEQ ID NO: 150
    1461 SEQ ID NO: 289 SEQ ID NO: 150
    1462 SEQ ID NO: 141 SEQ ID NO: 152
    1463 SEQ ID NO: 143 SEQ ID NO: 152
    1464 SEQ ID NO: 145 SEQ ID NO: 152
    1465 SEQ ID NO: 147 SEQ ID NO: 152
    1466 SEQ ID NO: 149 SEQ ID NO: 152
    1467 SEQ ID NO: 151 SEQ ID NO: 152
    1468 SEQ ID NO: 153 SEQ ID NO: 152
    1469 SEQ ID NO: 155 SEQ ID NO: 152
    1470 SEQ ID NO: 156 SEQ ID NO: 152
    1471 SEQ ID NO: 164 SEQ ID NO: 152
    1472 SEQ ID NO: 165 SEQ ID NO: 152
    1473 SEQ ID NO: 166 SEQ ID NO: 152
    1474 SEQ ID NO: 167 SEQ ID NO: 152
    1475 SEQ ID NO: 168 SEQ ID NO: 152
    1476 SEQ ID NO: 169 SEQ ID NO: 152
    1477 SEQ ID NO: 170 SEQ ID NO: 152
    1478 SEQ ID NO: 171 SEQ ID NO: 152
    1479 SEQ ID NO: 172 SEQ ID NO: 152
    1480 SEQ ID NO: 173 SEQ ID NO: 152
    1481 SEQ ID NO: 174 SEQ ID NO: 152
    1482 SEQ ID NO: 175 SEQ ID NO: 152
    1483 SEQ ID NO: 176 SEQ ID NO: 152
    1484 SEQ ID NO: 177 SEQ ID NO: 152
    1485 SEQ ID NO: 178 SEQ ID NO: 152
    1486 SEQ ID NO: 179 SEQ ID NO: 152
    1487 SEQ ID NO: 180 SEQ ID NO: 152
    1488 SEQ ID NO: 181 SEQ ID NO: 152
    1489 SEQ ID NO: 182 SEQ ID NO: 152
    1490 SEQ ID NO: 183 SEQ ID NO: 152
    1491 SEQ ID NO: 184 SEQ ID NO: 152
    1492 SEQ ID NO: 185 SEQ ID NO: 152
    1493 SEQ ID NO: 186 SEQ ID NO: 152
    1494 SEQ ID NO: 187 SEQ ID NO: 152
    1495 SEQ ID NO: 188 SEQ ID NO: 152
    1496 SEQ ID NO: 189 SEQ ID NO: 152
    1497 SEQ ID NO: 190 SEQ ID NO: 152
    1498 SEQ ID NO: 191 SEQ ID NO: 152
    1499 SEQ ID NO: 192 SEQ ID NO: 152
    1500 SEQ ID NO: 193 SEQ ID NO: 152
    1501 SEQ ID NO: 194 SEQ ID NO: 152
    1502 SEQ ID NO: 195 SEQ ID NO: 152
    1503 SEQ ID NO: 196 SEQ ID NO: 152
    1504 SEQ ID NO: 197 SEQ ID NO: 152
    1505 SEQ ID NO: 198 SEQ ID NO: 152
    1506 SEQ ID NO: 199 SEQ ID NO: 152
    1507 SEQ ID NO: 200 SEQ ID NO: 152
    1508 SEQ ID NO: 201 SEQ ID NO: 152
    1509 SEQ ID NO: 202 SEQ ID NO: 152
    1510 SEQ ID NO: 203 SEQ ID NO: 152
    1511 SEQ ID NO: 204 SEQ ID NO: 152
    1512 SEQ ID NO: 205 SEQ ID NO: 152
    1513 SEQ ID NO: 206 SEQ ID NO: 152
    1514 SEQ ID NO: 207 SEQ ID NO: 152
    1515 SEQ ID NO: 208 SEQ ID NO: 152
    1516 SEQ ID NO: 209 SEQ ID NO: 152
    1517 SEQ ID NO: 210 SEQ ID NO: 152
    1518 SEQ ID NO: 211 SEQ ID NO: 152
    1519 SEQ ID NO: 212 SEQ ID NO: 152
    1520 SEQ ID NO: 213 SEQ ID NO: 152
    1521 SEQ ID NO: 214 SEQ ID NO: 152
    1522 SEQ ID NO: 215 SEQ ID NO: 152
    1523 SEQ ID NO: 216 SEQ ID NO: 152
    1524 SEQ ID NO: 217 SEQ ID NO: 152
    1525 SEQ ID NO: 218 SEQ ID NO: 152
    1526 SEQ ID NO: 219 SEQ ID NO: 152
    1527 SEQ ID NO: 220 SEQ ID NO: 152
    1528 SEQ ID NO: 221 SEQ ID NO: 152
    1529 SEQ ID NO: 222 SEQ ID NO: 152
    1530 SEQ ID NO: 223 SEQ ID NO: 152
    1531 SEQ ID NO: 224 SEQ ID NO: 152
    1532 SEQ ID NO: 225 SEQ ID NO: 152
    1533 SEQ ID NO: 226 SEQ ID NO: 152
    1534 SEQ ID NO: 227 SEQ ID NO: 152
    1535 SEQ ID NO: 228 SEQ ID NO: 152
    1536 SEQ ID NO: 229 SEQ ID NO: 152
    1537 SEQ ID NO: 230 SEQ ID NO: 152
    1538 SEQ ID NO: 231 SEQ ID NO: 152
    1539 SEQ ID NO: 232 SEQ ID NO: 152
    1540 SEQ ID NO: 233 SEQ ID NO: 152
    1541 SEQ ID NO: 234 SEQ ID NO: 152
    1542 SEQ ID NO: 235 SEQ ID NO: 152
    1543 SEQ ID NO: 236 SEQ ID NO: 152
    1544 SEQ ID NO: 237 SEQ ID NO: 152
    1545 SEQ ID NO: 238 SEQ ID NO: 152
    1546 SEQ ID NO: 239 SEQ ID NO: 152
    1547 SEQ ID NO: 240 SEQ ID NO: 152
    1548 SEQ ID NO: 241 SEQ ID NO: 152
    1549 SEQ ID NO: 242 SEQ ID NO: 152
    1550 SEQ ID NO: 243 SEQ ID NO: 152
    1551 SEQ ID NO: 244 SEQ ID NO: 152
    1552 SEQ ID NO: 245 SEQ ID NO: 152
    1553 SEQ ID NO: 246 SEQ ID NO: 152
    1554 SEQ ID NO: 247 SEQ ID NO: 152
    1555 SEQ ID NO: 248 SEQ ID NO: 152
    1556 SEQ ID NO: 249 SEQ ID NO: 152
    1557 SEQ ID NO: 250 SEQ ID NO: 152
    1558 SEQ ID NO: 251 SEQ ID NO: 152
    1559 SEQ ID NO: 252 SEQ ID NO: 152
    1560 SEQ ID NO: 253 SEQ ID NO: 152
    1561 SEQ ID NO: 254 SEQ ID NO: 152
    1562 SEQ ID NO: 255 SEQ ID NO: 152
    1563 SEQ ID NO: 256 SEQ ID NO: 152
    1564 SEQ ID NO: 257 SEQ ID NO: 152
    1565 SEQ ID NO: 258 SEQ ID NO: 152
    1566 SEQ ID NO: 259 SEQ ID NO: 152
    1567 SEQ ID NO: 260 SEQ ID NO: 152
    1568 SEQ ID NO: 261 SEQ ID NO: 152
    1569 SEQ ID NO: 262 SEQ ID NO: 152
    1570 SEQ ID NO: 263 SEQ ID NO: 152
    1571 SEQ ID NO: 264 SEQ ID NO: 152
    1572 SEQ ID NO: 265 SEQ ID NO: 152
    1573 SEQ ID NO: 266 SEQ ID NO: 152
    1574 SEQ ID NO: 267 SEQ ID NO: 152
    1575 SEQ ID NO: 268 SEQ ID NO: 152
    1576 SEQ ID NO: 269 SEQ ID NO: 152
    1577 SEQ ID NO: 270 SEQ ID NO: 152
    1578 SEQ ID NO: 271 SEQ ID NO: 152
    1579 SEQ ID NO: 272 SEQ ID NO: 152
    1580 SEQ ID NO: 273 SEQ ID NO: 152
    1581 SEQ ID NO: 274 SEQ ID NO: 152
    1582 SEQ ID NO: 275 SEQ ID NO: 152
    1583 SEQ ID NO: 276 SEQ ID NO: 152
    1584 SEQ ID NO: 277 SEQ ID NO: 152
    1585 SEQ ID NO: 278 SEQ ID NO: 152
    1586 SEQ ID NO: 279 SEQ ID NO: 152
    1587 SEQ ID NO: 280 SEQ ID NO: 152
    1588 SEQ ID NO: 281 SEQ ID NO: 152
    1589 SEQ ID NO: 282 SEQ ID NO: 152
    1590 SEQ ID NO: 283 SEQ ID NO: 152
    1591 SEQ ID NO: 284 SEQ ID NO: 152
    1592 SEQ ID NO: 285 SEQ ID NO: 152
    1593 SEQ ID NO: 286 SEQ ID NO: 152
    1594 SEQ ID NO: 287 SEQ ID NO: 152
    1595 SEQ ID NO: 288 SEQ ID NO: 152
    1596 SEQ ID NO: 289 SEQ ID NO: 152
    1597 SEQ ID NO: 141 SEQ ID NO: 154
    1598 SEQ ID NO: 143 SEQ ID NO: 154
    1599 SEQ ID NO: 145 SEQ ID NO: 154
    1600 SEQ ID NO: 147 SEQ ID NO: 154
    1601 SEQ ID NO: 149 SEQ ID NO: 154
    1602 SEQ ID NO: 151 SEQ ID NO: 154
    1603 SEQ ID NO: 153 SEQ ID NO: 154
    1604 SEQ ID NO: 155 SEQ ID NO: 154
    1605 SEQ ID NO: 156 SEQ ID NO: 154
    1606 SEQ ID NO: 164 SEQ ID NO: 154
    1607 SEQ ID NO: 165 SEQ ID NO: 154
    1608 SEQ ID NO: 166 SEQ ID NO: 154
    1609 SEQ ID NO: 167 SEQ ID NO: 154
    1610 SEQ ID NO: 168 SEQ ID NO: 154
    1611 SEQ ID NO: 169 SEQ ID NO: 154
    1612 SEQ ID NO: 170 SEQ ID NO: 154
    1613 SEQ ID NO: 171 SEQ ID NO: 154
    1614 SEQ ID NO: 172 SEQ ID NO: 154
    1615 SEQ ID NO: 173 SEQ ID NO: 154
    1616 SEQ ID NO: 174 SEQ ID NO: 154
    1617 SEQ ID NO: 175 SEQ ID NO: 154
    1618 SEQ ID NO: 176 SEQ ID NO: 154
    1619 SEQ ID NO: 177 SEQ ID NO: 154
    1620 SEQ ID NO: 178 SEQ ID NO: 154
    1621 SEQ ID NO: 179 SEQ ID NO: 154
    1622 SEQ ID NO: 180 SEQ ID NO: 154
    1623 SEQ ID NO: 181 SEQ ID NO: 154
    1624 SEQ ID NO: 182 SEQ ID NO: 154
    1625 SEQ ID NO: 183 SEQ ID NO: 154
    1626 SEQ ID NO: 184 SEQ ID NO: 154
    1627 SEQ ID NO: 185 SEQ ID NO: 154
    1628 SEQ ID NO: 186 SEQ ID NO: 154
    1629 SEQ ID NO: 187 SEQ ID NO: 154
    1630 SEQ ID NO: 188 SEQ ID NO: 154
    1631 SEQ ID NO: 189 SEQ ID NO: 154
    1632 SEQ ID NO: 190 SEQ ID NO: 154
    1633 SEQ ID NO: 191 SEQ ID NO: 154
    1634 SEQ ID NO: 192 SEQ ID NO: 154
    1635 SEQ ID NO: 193 SEQ ID NO: 154
    1636 SEQ ID NO: 194 SEQ ID NO: 154
    1637 SEQ ID NO: 195 SEQ ID NO: 154
    1638 SEQ ID NO: 196 SEQ ID NO: 154
    1639 SEQ ID NO: 197 SEQ ID NO: 154
    1640 SEQ ID NO: 198 SEQ ID NO: 154
    1641 SEQ ID NO: 199 SEQ ID NO: 154
    1642 SEQ ID NO: 200 SEQ ID NO: 154
    1643 SEQ ID NO: 201 SEQ ID NO: 154
    1644 SEQ ID NO: 202 SEQ ID NO: 154
    1645 SEQ ID NO: 203 SEQ ID NO: 154
    1646 SEQ ID NO: 204 SEQ ID NO: 154
    1647 SEQ ID NO: 205 SEQ ID NO: 154
    1648 SEQ ID NO: 206 SEQ ID NO: 154
    1649 SEQ ID NO: 207 SEQ ID NO: 154
    1650 SEQ ID NO: 208 SEQ ID NO: 154
    1651 SEQ ID NO: 209 SEQ ID NO: 154
    1652 SEQ ID NO: 210 SEQ ID NO: 154
    1653 SEQ ID NO: 211 SEQ ID NO: 154
    1654 SEQ ID NO: 212 SEQ ID NO: 154
    1655 SEQ ID NO: 213 SEQ ID NO: 154
    1656 SEQ ID NO: 214 SEQ ID NO: 154
    1657 SEQ ID NO: 215 SEQ ID NO: 154
    1658 SEQ ID NO: 216 SEQ ID NO: 154
    1659 SEQ ID NO: 217 SEQ ID NO: 154
    1660 SEQ ID NO: 218 SEQ ID NO: 154
    1661 SEQ ID NO: 219 SEQ ID NO: 154
    1662 SEQ ID NO: 220 SEQ ID NO: 154
    1663 SEQ ID NO: 221 SEQ ID NO: 154
    1664 SEQ ID NO: 222 SEQ ID NO: 154
    1665 SEQ ID NO: 223 SEQ ID NO: 154
    1666 SEQ ID NO: 224 SEQ ID NO: 154
    1667 SEQ ID NO: 225 SEQ ID NO: 154
    1668 SEQ ID NO: 226 SEQ ID NO: 154
    1669 SEQ ID NO: 227 SEQ ID NO: 154
    1670 SEQ ID NO: 228 SEQ ID NO: 154
    1671 SEQ ID NO: 229 SEQ ID NO: 154
    1672 SEQ ID NO: 230 SEQ ID NO: 154
    1673 SEQ ID NO: 231 SEQ ID NO: 154
    1674 SEQ ID NO: 232 SEQ ID NO: 154
    1675 SEQ ID NO: 233 SEQ ID NO: 154
    1676 SEQ ID NO: 234 SEQ ID NO: 154
    1677 SEQ ID NO: 235 SEQ ID NO: 154
    1678 SEQ ID NO: 236 SEQ ID NO: 154
    1679 SEQ ID NO: 237 SEQ ID NO: 154
    1680 SEQ ID NO: 238 SEQ ID NO: 154
    1681 SEQ ID NO: 239 SEQ ID NO: 154
    1682 SEQ ID NO: 240 SEQ ID NO: 154
    1683 SEQ ID NO: 241 SEQ ID NO: 154
    1684 SEQ ID NO: 242 SEQ ID NO: 154
    1685 SEQ ID NO: 243 SEQ ID NO: 154
    1686 SEQ ID NO: 244 SEQ ID NO: 154
    1687 SEQ ID NO: 245 SEQ ID NO: 154
    1688 SEQ ID NO: 246 SEQ ID NO: 154
    1689 SEQ ID NO: 247 SEQ ID NO: 154
    1690 SEQ ID NO: 248 SEQ ID NO: 154
    1691 SEQ ID NO: 249 SEQ ID NO: 154
    1692 SEQ ID NO: 250 SEQ ID NO: 154
    1693 SEQ ID NO: 251 SEQ ID NO: 154
    1694 SEQ ID NO: 252 SEQ ID NO: 154
    1695 SEQ ID NO: 253 SEQ ID NO: 154
    1696 SEQ ID NO: 254 SEQ ID NO: 154
    1697 SEQ ID NO: 255 SEQ ID NO: 154
    1698 SEQ ID NO: 256 SEQ ID NO: 154
    1699 SEQ ID NO: 257 SEQ ID NO: 154
    1700 SEQ ID NO: 258 SEQ ID NO: 154
    1701 SEQ ID NO: 259 SEQ ID NO: 154
    1702 SEQ ID NO: 260 SEQ ID NO: 154
    1703 SEQ ID NO: 261 SEQ ID NO: 154
    1704 SEQ ID NO: 262 SEQ ID NO: 154
    1705 SEQ ID NO: 263 SEQ ID NO: 154
    1706 SEQ ID NO: 264 SEQ ID NO: 154
    1707 SEQ ID NO: 265 SEQ ID NO: 154
    1708 SEQ ID NO: 266 SEQ ID NO: 154
    1709 SEQ ID NO: 267 SEQ ID NO: 154
    1710 SEQ ID NO: 268 SEQ ID NO: 154
    1711 SEQ ID NO: 269 SEQ ID NO: 154
    1712 SEQ ID NO: 270 SEQ ID NO: 154
    1713 SEQ ID NO: 271 SEQ ID NO: 154
    1714 SEQ ID NO: 272 SEQ ID NO: 154
    1715 SEQ ID NO: 273 SEQ ID NO: 154
    1716 SEQ ID NO: 274 SEQ ID NO: 154
    1717 SEQ ID NO: 275 SEQ ID NO: 154
    1718 SEQ ID NO: 276 SEQ ID NO: 154
    1719 SEQ ID NO: 277 SEQ ID NO: 154
    1720 SEQ ID NO: 278 SEQ ID NO: 154
    1721 SEQ ID NO: 279 SEQ ID NO: 154
    1722 SEQ ID NO: 280 SEQ ID NO: 154
    1723 SEQ ID NO: 281 SEQ ID NO: 154
    1724 SEQ ID NO: 282 SEQ ID NO: 154
    1725 SEQ ID NO: 283 SEQ ID NO: 154
    1726 SEQ ID NO: 284 SEQ ID NO: 154
    1727 SEQ ID NO: 285 SEQ ID NO: 154
    1728 SEQ ID NO: 286 SEQ ID NO: 154
    1729 SEQ ID NO: 287 SEQ ID NO: 154
    1730 SEQ ID NO: 288 SEQ ID NO: 154
    1731 SEQ ID NO: 289 SEQ ID NO: 154
  • In certain embodiments, the anti-FGFR3 antigen binding protein or fragment thereof comprises a pair of heavy chain and light chain of Table 1.1 above.
  • In certain embodiments, the anti-FGFR3 antigen binding protein or fragment thereof comprises a VH domain and a VL domain, wherein:
      • (a) the VH domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 6, SEQ ID NO: 18, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, and SEQ ID NO: 122; and the VL domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 7, SEQ ID NO: 19, SEQ ID NO: 60, SEQ ID NO: 61 SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, and SEQ ID NO: 132;
      • (b) the VH domain comprises the amino acid sequence of SEQ ID NO: 8; and the VL domain comprises the amino acid sequence of SEQ ID NO: 9;
      • (c) the VH domain comprises the amino acid sequence of SEQ ID NO: 10; and the VL domain comprises the amino acid sequence of SEQ ID NO: 11;
      • (d) the VH domain comprises the amino acid sequence of SEQ ID NO: 12; and the VL domain comprises the amino acid sequence of SEQ ID NO: 13;
      • (e) the VH domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 23; and the VL domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27;
      • (f) the VH domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 16, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31; the VL domain comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 17, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
  • In certain embodiments, the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 63 or 65, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67 or 69.
  • Variants of the anti-FGFR3 antigen binding protein or fragment thereof as described herein are also provided. In certain embodiments, the VH domain of a variant is at least about 80%, at least at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90% identical, at least about 91% identical, at least about 92% identical, at least about 93% identical, at least about 94% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, or SEQ ID NO: 122, and the VL domain of the variant is at least about 80%, at least at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90% identical, at least about 91% identical, at least about 92% identical, at least about 93% identical, at least about 94% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, or SEQ ID NO: 132. The amino acid sequence alignment for obtaining the identity can be any conventional amino acid sequence alignment tool, and the sequence alignment algorithms includes Needle-Wunsch algorithm, Smith-Waterman algorithm, or Karling & Altschul algorithm, but is not limited thereto; the amino acid sequence alignment tool includes BLAST (Basic Local Alignment Search Tool), BLAT (BLAST-like Alignment Tool), Grapped BLAST or FASTA, but is not limited thereto. In certain embodiments, the variant has all of the identical heavy chain CDRs and light chain CDRs of the anti-FGFR3 antigen binding protein or fragment thereof as described herein, with modifications in the constant region on the heavy chain and/or the light chain.
  • In certain embodiments, the anti-FGFR3 antigen binding protein or fragment thereof comprises an antibody heavy chain at least about 80%, at least at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90% identical, at least about 91% identical, at least about 92% identical, at least about 93% identical, at least about 94% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 63 or 65, and an antibody light chain at least about 80%, at least at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90% identical, at least about 91% identical, at least about 92% identical, at least about 93% identical, at least about 94% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 67 or 69.
  • In certain embodiments, the anti-FGFR3 antigen binding protein or fragment thereof comprises a VH domain and a VL domain, wherein: (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of VDPETGGT (SEQ ID NO: 297), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAFDY (SEQ ID NO: 301); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSNNNKNY (SEQ ID NO: 302), a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75).
  • In certain embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 57, and the VL domain comprises the amino acid sequence of SEQ ID NO: 19 or 59.
  • In certain embodiments, the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 63, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67. In certain embodiments, the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 65, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In certain embodiments, the anti-FGFR3 antigen binding protein or fragment thereof comprises a VH domain and a VL domain, wherein: (a) the VH domain comprises a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), a CDR-H2 sequence comprising the amino acid sequence of VDPETGGT (SEQ ID NO: 297), and a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAFDY (SEQ ID NO: 301); and (b) the VL domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVLYSDNQKNY (SEQ ID NO: 306), a CDR-L2 sequence comprising the amino acid sequence of FAS (SEQ ID NO: 304), and a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75).
  • In certain embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 57, and the VL domain comprises the amino acid sequence of SEQ ID NO: 61.
  • In certain embodiments, the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 65, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure comprise one or more sequences with at least about 80%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any of the sequences of Table 1, Table 3, Table 4, Table 8, Table 13, or Table 14, or protein sequences encoded by the nucleic acid sequences in Table 9.
  • Also provided herein are human framework regions for anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof. Non-limiting examples of human framework regions are provided below.
  • TABLE 1.2
    Human Framework regions of anti-FGFR3 antigen binding
    proteins and antigen-binding fragments thereof
    Framework
    type Sequence Note
    Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X)n1IHWVRQAP X is any naturally occurring amino acid, and
    GQGLEWIGA(X)n2AYNQKFQGRVTITADKSTSTAYMEL n1, n2, and n3 are numbers at least 3, and less
    SSLRSEDTAVYYC(X)n3WGQGTLVTVSS than 50, each X can be the same or different
    SEQ ID NO: 318 amino acid as the amino acid next to it
    Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X)n1IHWVRQAP
    GQGLEWIGA(X)n2AYNQKFQGRVTITADKSTSTAYMEL
    SSLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 319
    Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X)n1IHWVRQAP
    GQGLEWIGA(X)n2AYNQKFQGRVTITADKSTSTAYMEL
    SSLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 320
    Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X)n1IHWVRQAP
    GQGLEWIGA(X)n2AYNQKFQGRVTITADKSTSTAYMEL
    SSLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 321
    Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X)n1IHWVRQAP
    GQGLEWIGG(X)n2AYNQKFQGRVTITADRSTSTAYMEL
    SSLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 322
    Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X)n1IHWVRQAP
    GQGLEWIGG(X)n2AYNQKFQGRVTITADRSTSTAYMEL
    SSLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 323
    Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X)n1IHWVRQAP
    GQGLEWIGG(X)n2AYNQKFQGRVTITADRSTSTAYMEL
    SSLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 324
    Heavy chain QVQLVQSGAEVKKPGASVKVSCKAS(X)n1IHWVRQAP
    GQGLEWIGG(X)n2AYNQKFQGRVTITADRSTSTAYMEL
    SSLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 325
    Heavy chain EVQLVQSGAEVKKPGATVKLSCKAS(X)n1IHWVQQAPG
    KGLEWIGD(X)n2AYAEKFQGRATLTADRSTDTAYMELS
    SLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 326
    Heavy chain EVQLVQSGAEVKKPGATVKLSCKAS(X)n1IHWVQQAPG
    KGLEWIGD(X)n2AYAEKFQGRATLTADRSTDTAYLELS
    SLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 327
    Heavy chain EVQLVQSGAEVKKPGATVKLSCKAS(X)n1IHWVQQAPG
    KGLEWIGD(X)n2AYAEKFQGRATLTADRSTDTAYLELS
    SLRSEDTAVYYC(X)n3WGQGTLVTVSS
    SEQ ID NO: 328
    Light chain DIVMTQSPDSLAVSLGERVTINCKSS(X)n1ILAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSLQAE
    DVAVYYC(X)n3FGQGTKLEIK
    SEQ ID NO: 329
    Light chain DIVMTQSPDSLAVSLGERVTINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSLQAE
    DVAVYYC(X)n3FGQGTKLEIK
    SEQ ID NO: 330
    Light chain DIVMTQSPDSLAVSLGERVTINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSLQAE
    DVAVYYC(X)n3FGQGTKLEIK
    SEQ ID NO: 331
    Light chain DIVMTQSPDSLAVSLGERVTINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSLQAE
    DVAVYYC(X)n3FGQGTKLEIK
    SEQ ID NO: 332
    Light chain DIVMTQSPDSLAVSLGERVTINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSLQAE
    DVAVYYC(X)n3FGQGTKLEIK
    SEQ ID NO: 333
    Light chain DIVMTQSPDSLAVSLGERVTINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSLQAE
    DVAVYYC(X)n3FGQGTKLEIK
    SEQ ID NO: 334
    Light chain DIVMTQSPDSLAVSLGERVTINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSLQAE
    DVAVYYC(X)n3FGQGTKLEIK
    SEQ ID NO: 335
    Light chain DIVMTQSPDSLAVSLGERVTINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSLQAE
    DVAVYYC(X)n3FGQGTKLEIK
    SEQ ID NO: 336
    Light chain DIVMTQSPDSLAVSLGERATINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSVQA
    EDVAVYYC(X)n3FGGGTKVEIK
    SEQ ID NO: 337
    Light chain DIVMTQSPDSLAVSLGERATINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSVQA
    EDVAVYYC(X)n3FGGGTKVEIK
    SEQ ID NO: 338
    Light chain DIVMTQSPDSLAVSLGERVTINCKSS(X)n1LAWYQQKPG
    QSPKLLIY(X)n2TRESGVPDRFSGSGSGTDFTLTISSVQA
    EDVAVYYC(X)n3FGGGTKLEIK
    SEQ ID NO: 339
  • In some embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments comprise three heavy chain CDRs that bind to FGFR3, such as the three heavy chain CDRs of mouse antibody KC18, KE35, KE42, KE58, KE63, or KE94, and a human heavy chain variable region framework. In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments further comprise three light chain CDRs that bind to FGFR3, such as the three light chain CDRs of mouse antibody KC18, KE35, KE42, KE58, KE63, or KE94, and a human light chain variable region framework. In certain embodiments, the human heavy chain variable region framework comprises any one of SEQ ID NOs: 318 to 328. In certain embodiments, the human light chain variable region framework comprises any one of SEQ ID NOs: 329 to 339. In certain embodiments, the human heavy chain variable region framework comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more identity to any one of SEQ ID NOs: 318 to 328. In certain embodiments, the human light chain variable region framework comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more identity to any one of SEQ ID NOs: 329 to 339. In certain embodiments, such anti-FGFR3 antigen binding proteins and antigen-binding fragments bind human FGFR3 with an equilibrium dissociation constant (KD) of about 100 nM or less, about 90 nM or less, about 80 nM or less, about 70 nM or less, about 60 nM or less, about 50 nM or less, about 40 nM or less, about 30 nM or less, about 20 nM or less, about 10 nM or less, about 9 nM or less, about 8 nM or less, about 7 nM or less, about 6 nM or less, about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2.89 nM or less, about 2 nM or less, about 1.5 or less, about 1.4 or less, about 1.23 or less, about 1.2 or less, or about 1 nM or less, about 0.8 or less, or about 0.6 or less. “X nM or less” therein includes the embodiment “less than X nM”. “Less” therein can mean e.g. to about 2.8 nM, to about 1.3 nM, to about 1.1 nM, to about 0.7 nM or to about 0.5 nM. These lower limits can be used to form ranges with any of the aforementioned upper limits, such as about 3 nM or <3 nM to about 2.8 nM, about 1.5 nM or <1.5 nM to about 1.3 nM, about 1.3 nM or <1.3 nM to about 1.1 nM, about 0.9 nM or <0.9 nM to about 0.7 nM, or about 0.7 nM or <0.7 nM to about 0.5 nM. “About X” therein can mean e.g. “X±5%”, “X±4%”, “X±4%”, “X±3%”, “X±2%”, “X±1%” or “X±0.5%”. In certain embodiments, the nM values are as obtained by a Surface Plasmon Resonance assay, such as the Biacore assay.
  • In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure are chimeric or humanized antibodies. In certain embodiments, the antigen binding protein is a humanized antibody.
  • In certain embodiments, the antigen binding protein is a monoclonal antibody.
  • In certain embodiments, the antigen binding protein comprises one or more full-length antibody heavy chains comprising an Fc region. In certain embodiments, the Fc region is a human IgG1 Fc region. In certain embodiments, the Fc region is a human IgG4 Fc region.
  • In certain embodiments, the antibody Fc region comprises one or more mutations that reduces Fc effector function. In certain embodiments, the one or more mutations reduces one or more of antibody dependent cellular cytotoxicity (ADCC), antibody dependent cellular phagocytosis (ADCP), or complement dependent cytotoxicity (CDC). In certain embodiments, the human IgG1 Fc region comprises a L234A and L235A mutation. In certain embodiments, the human IgG4 Fc region comprises a F234A and L235A mutation. These IgG1 and IgG4 mutations are also known as the “LALA” and “FALA” mutations, respectively, and are described in further detail in Xu et al. (Cell Immunol. 2000; 200:16-26). In certain embodiments, the human IgG4 Fc region comprises one or more stabilizing mutations, including, but limited to, mutations in the IgG4 hinge that reduce or prevent the formation of disulfide bonds and in vivo fab arm exchange (FAE). In certain embodiments, the human IgG4 Fc region comprises a S228P mutation. The IgG4 hinge mutation is described in further detail in Angal et al. (Mol. Immunol. 1993; 30:105-108). In certain embodiments, the human IgG4 Fc region comprises a S228P mutation and a L235A mutation. In certain embodiments, the human IgG1 Fc region comprises one or more mutations that alters antibody glycosylation. In certain embodiments, the human IgG1 Fc region comprises one or more of a S298N mutation, a T299A mutation, and a Y300S mutation. In certain embodiments, the human IgG1 Fc region comprises a S298N mutation, a T299A mutation, and a Y300S mutation. The Fc region amino acid positions referred to herein are based on EU antibody numbering.
  • In certain embodiments, the anti-FGFR3 antigen binding protein fragments of the disclosure comprise or consists of an antibody F(ab), F(ab′)2, Fab′-SH, Fv, or scFv fragment. In certain embodiments, the antigen binding protein fragment comprises an antibody F(ab) fragment.
  • The antibody F(ab) fragment can be modified with one or more serum half-life extending moieties. In certain embodiments, the antibody F(ab) fragment is conjugated to an antigen binding protein with binding specificity to serum albumin. In certain embodiments, the antigen binding protein with binding specificity to serum albumin is a nanobody. In certain embodiments, the serum albumin is human serum albumin or mouse serum albumin.
  • In certain embodiments, the antibody F(ab) fragment comprises a heavy chain and a light chain. In certain embodiments, the heavy chain of the F(ab) fragment comprises a heavy chain variable region disclosed herewith, and a light chain variable region disclosed herewith. In certain embodiments, the heavy chain variable region comprises or consists of any one of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20, 21, 22, 23, 28, 29, 30, 31, 56, 57, 58, 106, 107, 108, 109, 110, 111, 115, 116, 117, 118, 119, 120, 121, or 112, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identity to any of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20, 21, 22, 23, 28, 29, 30, 31, 56, 57, 58, 106, 107, 108, 109, 110, 111, 115, 116, 117, 118, 119, 120, 121, or 112. In certain embodiments, the light chain variable region comprises or consists of any one of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 24, 25, 26, 27, 32, 33, 34, 35, 59, 60, 61, 112, 113, 114, 123, 124, 125, 126, 127, 128, 129, 130, 131, or 132, or a or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identity to any of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 24, 25, 26, 27, 32, 33, 34, 35, 59, 60, 61, 112, 113, 114, 123, 124, 125, 126, 127, 128, 129, 130, 131, or 132.
  • In certain embodiments, the heavy chain of the F(ab) fragment comprises or consists of a heavy chain variable region disclosed herewith and a heavy chain constant region. In certain embodiments, the heavy chain constant region is derived from a human IgG1 Fc region, a human IgG2 Fc region, a human IgG3 Fc region, a human IgG4 Fc region, or a combination thereof. In certain embodiments, the heavy chain constant region is a fragment of a human IgG1 Fc region, a human IgG2 Fc region, a human IgG3 Fc region, a human IgG4 Fc region, or a combination thereof. In certain embodiments, the heavy chain constant region comprises or consists of the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 5, 36, 37, 38, 39, 40, 41, 44, 45, 46, 7, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224,225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, or 300 amino acids of a human IgG Fc region, such as the human IgG1 Fc region (SEQ ID NO: 54).
  • In certain embodiments, the light chain of the F(ab) fragment comprises or consists of a light chain variable region disclosed herewith, and a light chain constant region. In certain embodiments, the light chain constant region is derived from a human kappa (κ) chain, a human lambda (λ) chain, or a combination thereof. In certain embodiments, the light chain constant region comprises or consists of a part of IgG1 light constant region. In certain embodiments, the part of the IgG1 light constant region comprises or consists of the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 5, 36, 37, 38, 39, 40, 41, 44, 45, 46, 7, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, or 107 amino acids of SEQ ID NO: 55.
  • In certain embodiments, the F(ab) fragment comprises one or more point mutations in the C-terminus to reduce anti-Fab antibody binding.
  • In certain embodiments, the antigen binding protein comprises cross-reactivity to one or both of mouse and cynomolgus FGFR3. In certain embodiments, the cynomolgus FGFR3 is encoded by SEQ ID NO: 136:
  • (SEQ ID NO: 136)
    ATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCAGTGGCCATCGT
    GGCCGGCGCCTCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGGGGC
    GAGTGGCAGAAGTGTCCGGCCCGGAGCCCAGCCAGCAGGAGCAGTTGGTC
    TTCGGCAGCGGGGACGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGG
    TCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCGCAGGGCTGGTGCCCT
    CGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCC
    CACGAGGACTCTGGGGCCTACAGCTGCCGGCAGCGGCTCACACAGCTCGT
    ACTGTGCCACTTCAGTGTGCGGGTGACAGATGCTCCATCCTCGGGAGATG
    ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCC
    CCTTACTGGACTCGGCCCGAGCGGATGGACAAGAAGCTGCTGGCTGTGCC
    GGCCGCCAACACCGTCCGCTTCCGCTGCCCGGCTGCCGGCAACCCCACTC
    CCTCCATCTCCTGGCTGAAGAATGGCAAGGAGTTCCGCGGCGAGCACCGC
    ATTGGCGGCATCAAGCTTCGGCACCAGCAGTGGAGCCTGGTCATGGAAAG
    CGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTGGTGGAGAACAAGT
    TTGGCAGCATCCGGCAGACATACACGCTGGACGTGCTGGAGCGCTCCCCG
    CACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCT
    GGGCAGCGATGTGGAGTTTCACTGCAAGGTGTACAGTGATGCGCAGCCCC
    ACATCCAGTGGCTCAAGCACGTGGAGGTGAATGGCAGCAAGGTGGGCCCC
    GACGGCACACCCTACGTCACCGTGCTCAAGACGGCGGGCGCTAATACCAC
    CGACAAGGAGCTAGAGGTTCTGTCCTTGCACAACGTCACCTTTGAGGACG
    CCGGGGAGTACACCTGCCTGGCGGGCAATTCTATTGGGTTTTCCCATCAC
    TCTGCGTGGCTCGTGGTGCTGCCAGCTGAGGAGGAGCTGGTGGAGGCTGA
    CGAGGCGGGCAGTGTGTACGCAGGCATCCTCAGCTACGGGGTGGGCTTCT
    TCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTGCGCAGC
    ACCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTT
    CCCACTCAAGCGACAGGTGTCCCTGGAGTCCAACGCGTCCATGAGCTCCA
    ACACACCGCTGGTGCGCATCGCAAGGCTGTCCTCAGGGGAGGGTCCCACA
    CTGGCCAATGTCTCCGAGCTTGAGCTGCCTGCTGACCCCAAATGGGAGCT
    GTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCTTGGGGAGGGCTGCTTTG
    GCCAGGTGGTCATGGCGGAGGCTATCGGCATTGACAAGGACCGGGCCGCC
    AAGCCTGTCACCGTAGCCGTGAAGATGCTGAAAGATGATGCCACTGACAA
    GGACCTGTCAGACCTGGTGTCTGAGATGGAGATGATGAAGATGATTGGGA
    AACACAAGAACATTATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCC
    CTGTACGTGCTGGTGGAGTACGCGGCCAAGGGCAACCTGAGGGAGTTTCT
    GCGGGCGCGGCGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGC
    CGCCTGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCCTGTGCCTACCAG
    GTGGCCCGAGGCATGGAGTACCTCGCCTCCCAGAAGTGCATCCACAGGGA
    CCTGGCTGCTCGAAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCG
    CAGACTTCGGGCTGGCCCGCGACGTGCACAACCTTGACTACTACAAGAAG
    ACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGCCCTGTT
    TGACCGAGTCTACACCCACCAGAGTGACGTCTGGTCCTTTGGGGTCCTGC
    TCTGGGAGATCTTCACGCTGGGGGGCTCTCCGTACCCCGGCATCCCTGTG
    GAGGAGCTCTTCAAGCTGCTGAAGGAGGGTCACCGGATGGACAAGCCGGC
    CAACTGCACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCTG
    CGCCCTCCCAGAGGCCCACCTTCAAGCAGCTGGTGGAGGACCTGGACCGT
    GTCCTCACTGTGACGTCCACCGACGAGTACCTGGACCTGTCAGCGCCCTT
    CGAGCAGTACTCCCCCGGCGGCCAGGACACCCCGAGCTCCAGCTCCTCAG
    GGGATGACTCCGTGTTTGCCCACGACCTGCTGCCCCCGGCCCCACCCAGC
    AGTGGGGGCTCGCGGACGTGA
  • In certain embodiments, the cynomolgus FGFR3 is the IIIc isoform, comprising SEQ ID NO: 138, or its mutated version comprising the G380R mutation (SEQ ID NO: 139):
  • (SEQ ID NO: 138)
    MGAPACALALCVAVAIVAGASSESLGTEQRVVGRVAEVSGPEPSQQEQLV
    FGSGDAVELSCPPPGGGPMGPTVWVKDGAGLVPSERVLVGPQRLQVLNAS
    HEDSGAYSCRQRLTQLVLCHFSVRVTDAPSSGDDEDGEDEAEDTGVDTGA
    PYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGKEFRGEHR
    IGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSP
    HRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP
    DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHH
    SAWLVVLPAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRS
    TPKKGLGSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPT
    LANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAA
    KPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGP
    LYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ
    VARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKK
    TTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPV
    EELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDR
    VLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPS
    SGGSRT
    (SEQ ID NO: 139)
    MGAPACALALCVAVAIVAGASSESLGTEQRVVGRVAEVSGPEPSQQEQLV
    FGSGDAVELSCPPPGGGPMGPTVWVKDGAGLVPSERVLVGPQRLQVLNAS
    HEDSGAYSCRQRLTQLVLCHFSVRVTDAPSSGDDEDGEDEAEDTGVDTGA
    PYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGKEFRGEHR
    IGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSP
    HRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP
    DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHH
    SAWLVVLPAEEELVEADEAGSVYAGILSY R VGFFLFILVVAAVTLCRLRS
    TPKKGLGSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPT
    LANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAA
    KPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGP
    LYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ
    VARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKK
    TTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPV
    EELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDR
    VLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPS
    SGGSRT
  • In certain embodiments, the antigen binding protein comprises binding specificity for FGFR3 isoform IIIb and/or isoform IIIc.
  • In certain embodiments, the antigen binding protein specifically binds to FGFR3, and does not bind to one or more of FGFR1, FGFR2, and FGFR4, or does not have detectable binding to one or more of FGFR1, FGFR2, and FGFR4. In certain embodiments, the antigen binding protein does not bind to each of FGFR1, FGFR2, and FGFR4, or does not have detectable binding to each of FGFR1, FGFR2, and FGFR4. In certain embodiments, the antigen binding protein binds to each of FGFR1, FGFR2, and FGFR4 with an affinity of about 100 μM, 500 μM, 1000 μM, or greater. In certain embodiments, the antigen binding protein does not bind to one or more of FGFR1, FGFR2, and FGFR4 over a background measurement, as determined by a Biacore affinity analysis.
  • In certain embodiments, the antigen binding protein binds human FGFR3 with an equilibrium dissociation constant (KD) of about 100 nM or less, about 90 nM or less, about 80 nM or less, about 70 nM or less, about 60 nM or less, about 50 nM or less, about 40 nM or less, about 30 nM or less, about 20 nM or less, about 10 nM or less, about 9 nM or less, about 8 nM or less, about 7 nM or less, about 6 nM or less, about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2.89 nM or less, about 2 nM or less, about 1.5 or less, about 1.4 or less, about 1.23 or less, about 1.2 or less, or about 1 nM or less, about 0.8 or less, or about 0.6 or less. “X nM or less” therein includes the embodiment “less than X nM”. “Less” therein can mean e.g. to about 2.8 nM, to about 1.3 nM, to about 1.1 nM, to about 0.7 nM or to about 0.5 nM. These lower limits can be used to form ranges with any of the aforementioned upper limits, such as about 3 nM or <3 nM to about 2.8 nM, about 1.5 nM or <1.5 nM to about 1.3 nM, about 1.3 nM or <1.3 nM to about 1.1 nM, about 0.9 nM or <0.9 nM to about 0.7 nM, or about 0.7 nM or <0.7 nM to about 0.5 nM. “About X” therein can mean e.g. “X±5%”, “X±4%”, “X±4%”, “X±3%”, “X±2%”, “X±1%” or “X±0.5%”. In certain embodiments, the nM values are as obtained by a Surface Plasmon Resonance assay, such as the Biacore assay. In certain embodiments, the Biacore assay is carried out at about 4° C., 10° C., 15° C., 20° C., 25° C., 30° C., or 37° C.
  • In certain embodiments, the antigen binding protein binds human FGFR3 with an off rate (Kd) of about 10−2 s−1 or less, about 5×10−3 s−1 or less, about 2×10−3 s−1 or less, about 10−3 s−1 or less, about 9×10−4 s−1 or less, about 8×10−4 s−1 or less, about 7×10−4 s−1 or less, about 6×10−4 s−1 or less, about 5×10−4 s−1 or less, about 4×10−4 s−1 or less, or about 3.5×10−4 s−1 or less. “Less” therein can mean e.g. to about 3×10−4 s−1. “About X” therein can mean e.g. “X±10%”, “X±5%”, “X±4%”, “X±4%”, “X±3%”, “X±2%”, “X±1%” or “X±0.5%”.
  • In certain embodiments, the antigen binding protein inhibits ligand-induced FGFR3 dimerization with IC50 of about 5 μg/ml or less, about 4 μg/ml or less, about 3 μg/ml or less, about 2 μg/ml or less, about 1 μg/ml or less, about 0.9 μg/ml or less, about 0.8 μg/ml or less, about 0.7 μg/ml or less, about 0.6 μg/ml or less, about 0.5 μg/ml or less, about 0.4 μg/ml or less, or about 0.3 μg/ml or less. “Less” therein can mean e.g. to about 0.25 μg/ml (or less, e.g. to about 0.2 μg/ml or about 0.1 μg/ml). “About X” therein can mean e.g. “X±10%”, “X±5%”, “X±4%”, “X±4%”, “X±3%”, “X±2%”, “X±1%” or “X±0.5%”. In certain embodiments, the nM values are as obtained by a Homogenous Time-Resolved Fluorescence (HTRF) assay at about 4° C., 10° C., 15° C., 20° C., 25° C., 30° C., or 37° C.
  • In certain embodiments, the antigen binding protein inhibits FGFR3 receptor activation and downstream signaling with IC50 of about 5 μg/ml or less, about 4 μg/ml or less, about 3 μg/ml or less, about 2 μg/ml or less, about 1 μg/ml or less, about 0.9 μg/ml or less, about 0.8 μg/ml or less, about 0.7 μg/ml or less, about 0.6 μg/ml or less, about 0.5 μg/ml or less, about 0.4 μg/ml or less, or about 0.3 μg/ml or less. “Less” therein can mean e.g. to about 0.25 μg/ml (or less, e.g. to about 0.2 μg/ml or about 0.1 μg/ml). About X” therein can mean e.g. “X±10%”, “X±5%”, “X±4%”, “X±4%”, “X±3%”, “X±2%”, “X±1%” or “X±0.5%”. %”. In certain embodiments, the nM values are as obtained by a homogenous time-resolved fluorescence (HTRF) assay.
  • Inhibition of FGFR3 receptor activation and downstream signaling can be determined by any means known in the art. In certain embodiments, inhibition of FGFR3 receptor activation and downstream signaling is measured by determining Erk phosphorylation. A decrease in Erk phosphorylation indicates inhibition of FGFR3 activation. Erk phosphorylation can be determined using a homogenous time-resolved fluorescence (HTRF) assay. In certain embodiments, the assay is performed in chondrocytes. In certain embodiments, the assay is performed in mouse primary rib chondrocytes.
  • In certain embodiments, the antigen binding protein inhibits the activity of an FGFR3G380R mutant. In certain embodiments, the antigen binding protein inhibits the activity of a human FGFR3G380R mutant, a mouse FGFR3G380R mutant, and/or a cynomolgus FGFR3G380R mutant. In certain embodiments, the human FGFR3G380R mutant is represented by the amino acid sequence set forth in SEQ ID NO: 133.
  • In certain embodiments, the antigen binding protein or fragment thereof is capable of penetrating a bone growth plate.
  • In certain embodiments, the antigen binding protein or fragment thereof is capable of decreasing the binding of FGFR3 with its ligand in a bone growth plate.
    • Anti-FGFR3 Antigen-Binding Protein Epitopes
  • In one aspect, the disclosure provides an antigen-binding protein or fragment thereof with binding specificity to a fibroblast growth factor receptor 3 (FGFR3) epitope, comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein the antigen binding protein binds a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 134, recited below.
  • (SEQ ID NO: 134)
    DTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNG
    REFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYT
    LDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVE
    VNGSKVGPDGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAG
    NSIGFSHHSAWLVVLPAEEELVE
  • In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure bind a human FGFR3 polypeptide comprising the amino acid sequence of SEQ ID NO: 134, recited above. The amino acid sequence recited above corresponds to the D2D3 region of FGFR3 isoform IIIc, specifically to amino acid D143 to E365 of FGFR3 isoform IIIc.
  • In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure bind an epitope of human FGFR3 polypeptide comprising the N-terminus of the D2 region (amino acids D143 to L163) of SEQ ID NO: 133, shown above.
  • In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure bind an epitope of human FGFR3 polypeptide comprising the N-terminus of the D2 region (amino acids D143 to N170) of SEQ ID NO: 133, shown above.
  • In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure bind an epitope of human FGFR3 polypeptide comprising the N-terminus and middle of the D2 region (amino acids D143 to D160 and G197 to L213) of SEQ ID NO: 133, shown above.
  • In certain embodiments, the one or more epitopes of the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure are determined by hydrogen deuterium exchange (HDX) mass spectrometry. HDX is performed by measuring the amide hydrogen deuterium exchange on FGFR3 over time. HDX mass spectrometry is described in further detail in Prądzińska et al. (Amino Acids. 48: 2809-2820. 2016).
  • In certain embodiments, the anti-FGFR3 antigen binding proteins and antigen-binding fragments thereof of the disclosure compete with a reference binding protein for binding to the human FGFR3 polypeptide D2 region.
  • In one aspect, the disclosure provides an antigen-binding protein or fragment thereof with binding specificity to a fibroblast growth factor receptor 3 (FGFR3) epitope, comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein the antigen binding protein competes for binding to FGFR3 with an antibody comprising VH/VL domain amino acid sequence pairs selected from the group consisting of: SEQ ID NO: 6/SEQ ID NO: 7, SEQ ID NO: 8/SEQ ID NO: 9, SEQ ID NO: 10/SEQ ID NO: 11, SEQ ID NO: 12/SEQ ID NO: 13, SEQ ID NO: 14/SEQ ID NO: 15, and SEQ ID NO: 16/SEQ ID NO: 17.
    • Expression of Antigen-Binding Proteins
  • In one aspect, polynucleotides encoding the binding proteins (e.g., antigen-binding proteins and antigen-binding fragments thereof) disclosed herein are provided. Methods of making binding proteins comprising expressing these polynucleotides are also provided.
  • Polynucleotides encoding the binding proteins disclosed herein are typically inserted in an expression vector for introduction into host cells that may be used to produce the desired quantity of the binding proteins. Accordingly, in certain aspects, the disclosure provides expression vectors comprising polynucleotides disclosed herein and host cells comprising these vectors and polynucleotides.
  • The term “vector” or “expression vector” is used herein to mean vectors used in accordance with the present disclosure as a vehicle for introducing into and expressing a desired gene in a cell. As known to those skilled in the art, such vectors may readily be selected from the group consisting of plasmids, phages, viruses and retroviruses. In general, vectors compatible with the disclosure will comprise a selection marker, appropriate restriction sites to facilitate cloning of the desired gene and the ability to enter and/or replicate in eukaryotic or prokaryotic cells.
  • Numerous expression vector systems may be employed for the purposes of this disclosure. For example, one class of vector utilizes DNA elements which are derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (RSV, MMTV or MOMLV), or SV40 virus. Others involve the use of polycistronic systems with internal ribosome binding sites. Additionally, cells which have integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow selection of transfected host cells. The marker may provide for prototrophy to an auxotrophic host, biocide resistance (e.g., antibiotics) or resistance to heavy metals such as copper. The selectable marker gene can either be directly linked to the DNA sequences to be expressed, or introduced into the same cell by co-transformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include signal sequences, splice signals, as well as transcriptional promoters, enhancers, and termination signals. In some embodiments, the cloned variable region genes are inserted into an expression vector along with the heavy and light chain constant region genes (e.g., human constant region genes) synthesized as discussed above.
  • In other embodiments, the binding proteins may be expressed using polycistronic constructs. In such expression systems, multiple gene products of interest such as heavy and light chains of antibodies may be produced from a single polycistronic construct. These systems advantageously use an internal ribosome entry site (IRES) to provide relatively high levels of polypeptides in eukaryotic host cells. Compatible IRES sequences are disclosed in U.S. Pat. No. 6,193,980, which is incorporated by reference herein in its entirety for all purposes. Those skilled in the art will appreciate that such expression systems may be used to effectively produce the full range of polypeptides disclosed in the instant application.
  • More generally, once a vector or DNA sequence encoding a binding protein, e.g. an antibody or fragment thereof, has been prepared, the expression vector may be introduced into an appropriate host cell. That is, the host cells may be transformed. Introduction of the plasmid into the host cell can be accomplished by various techniques well known to those of skill in the art. These include, but are not limited to, transfection (including electrophoresis and electroporation), protoplast fusion, calcium phosphate precipitation, cell fusion with enveloped DNA, microinjection, and infection with intact virus. See, Ridgway, A. A. G. “Mammalian Expression Vectors” Chapter 24.2, pp. 470-472 Vectors, Rodriguez and Denhardt, Eds. (Butterworths, Boston, Mass. 1988). Plasmid introduction into the host can be by electroporation. The transformed cells are grown under conditions appropriate to the production of the light chains and heavy chains, and assayed for heavy and/or light chain protein synthesis. Exemplary assay techniques include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), or fluorescence-activated cell sorter analysis (FACS), immunohistochemistry and the like.
  • As used herein, the term “transformation” shall be used in a broad sense to refer to the introduction of DNA into a recipient host cell that changes the genotype.
  • Along those same lines, “host cells” refers to cells that have been transformed with vectors constructed using recombinant DNA techniques and encoding at least one heterologous gene. In descriptions of processes for isolation of polypeptides from recombinant hosts, the terms “cell” and “cell culture” are used interchangeably to denote the source of antibody unless it is clearly specified otherwise. In other words, recovery of polypeptide from the “cells” may mean either from spun down whole cells, from supernatant of lysed cells culture, or from the cell culture containing both the medium and the suspended cells.
  • In one embodiment, a host cell line used for antibody expression is of mammalian origin. Those skilled in the art can determine particular host cell lines which are best suited for the desired gene product to be expressed therein. Exemplary host cell lines include, but are not limited to, DG44 and DUXB11 (Chinese Hamster Ovary lines, DHFR minus), HELA (human cervical carcinoma), CV-1 (monkey kidney line), COS (a derivative of CV-1 with SV40 T antigen), R1610 (Chinese hamster fibroblast) BALBC/3T3 (mouse fibroblast), HEK (human kidney line), SP2/O (mouse myeloma), BFA-1c1BPT (bovine endothelial cells), RAJI (human lymphocyte), 293 (human kidney). In one embodiment, the cell line provides for altered glycosylation, e.g., afucosylation, of the antibody expressed therefrom (e.g., PER.C6® (Crucell) or FUT8-knock-out CHO cell lines (POTELLIGENT® cells) (Biowa, Princeton, N.J.)). In one embodiment, NSO cells may be used. CHO cells are particularly useful. Host cell lines are typically available from commercial services, e.g., the American Tissue Culture Collection, or from authors of published literature.
  • In vitro production allows scale-up to give large amounts of the desired polypeptides. Techniques for mammalian cell cultivation under tissue culture conditions are known in the art and include homogeneous suspension culture, e.g., in an airlift reactor or in a continuous stirrer reactor, or immobilized or entrapped cell culture, e.g., in hollow fibers, microcapsules, on agarose microbeads or ceramic cartridges. If necessary and/or desired, the solutions of polypeptides can be purified by the customary chromatography methods, for example gel filtration, ion-exchange chromatography, chromatography over DEAE-cellulose and/or (immuno-) affinity chromatography.
  • Genes encoding the binding proteins featured in the disclosure can also be expressed in non-mammalian cells such as bacteria or yeast or plant cells. In this regard, it will be appreciated that various unicellular non-mammalian microorganisms such as bacteria can also be transformed, i.e., those capable of being grown in cultures or fermentation. Bacteria, which are susceptible to transformation, include members of the enterobacteriaceae, such as strains of Escherichia coli or Salmonella; Bacillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus, and Haemophilus influenzae. It will further be appreciated that, when expressed in bacteria, the binding proteins can become part of inclusion bodies. In some embodiments, the binding proteins are then isolated, purified and assembled into functional molecules. In some embodiments, the binding proteins of the disclosure are expressed in a bacterial host cell. In some embodiments, the bacterial host cell is transformed with an expression vector comprising a nucleic acid molecule encoding a binding protein of the disclosure.
  • In addition to prokaryotes, eukaryotic microbes may also be used. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among eukaryotic microbes, although a number of other strains are commonly available. For expression in Saccharomyces, the plasmid YRp7, for example (Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)), is commonly used. This plasmid already contains the TRP1 gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC No. 44076 or PEP4-1 (Jones, Genetics, 85:12 (1977)). The presence of the trpl lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.
    • Methods of Preparing/Administering Binding Proteins
  • Methods of preparing and administering binding proteins (e.g., antigen-binding proteins and antigen-binding fragments thereof disclosed herein) to a subject are also provided. The route of administration of the antigen binding proteins and antigen-binding fragments thereof of the current disclosure may be oral, parenteral, by inhalation or topical. The term parenteral as used herein includes intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, rectal or vaginal administration. While all these forms of administration are clearly contemplated as being within the scope of the current disclosure, a form for administration would be a solution for injection, e.g. for intravenous or intraarterial injection or drip. Usually, a suitable pharmaceutical composition for injection may comprise a buffer, a surfactant, optionally a stabilizer agent, etc. However, in other methods compatible with the teachings herein, the modified antibodies can be delivered directly to the site of the adverse cellular population thereby increasing the exposure of the diseased tissue to the therapeutic agent.
  • Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Other common parenteral vehicles include sodium phosphate solutions, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like. Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In such cases, the composition must be sterile and should be fluid to the extent that syringability for injection exists. It should be stable under the conditions of manufacture and storage, and should also be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium. The proper fluidity can be maintained, for example, by the use of a coating, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents. Isotonic agents, for example, sugars, polyalcohols, may also be included in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • In any case, sterile injectable solutions can be prepared by incorporating an active compound (e.g., a modified binding protein by itself or in combination with other active agents) in a required amount in an appropriate solvent with one or a combination of ingredients enumerated, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and any required other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation typically include vacuum drying and freeze-drying, which yield a powder of an active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The preparations for injections are processed, filled into containers such as ampoules, bags, bottles, syringes or vials, and sealed under aseptic conditions according to methods known in the art. Further, the preparations may be packaged and sold in the form of a kit.
  • Effective doses of the compositions of the present disclosure, for the treatment of a disease or disorder vary depending upon many different factors, including means of administration, target site, physiological state of the subject, whether the subject is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Usually, the patient is a human, but non-human mammals including transgenic mammals can also be treated. Treatment dosages may be titrated to optimize safety and efficacy.
  • Binding proteins described herein can be administered on multiple occasions. Intervals between single dosages can be weekly, monthly or yearly. Intervals can also be irregular as indicated by measuring levels of binding protein or antigen in the subject. Alternatively, binding proteins can be administered as a sustained release formulation, in which case less frequent administration is required. For antibodies, dosage and frequency vary depending on the half-life of the antibody in the patient. In general, humanized antibodies show the longest half-life, followed by chimeric antibodies and non-human antibodies.
  • The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, compositions containing the present binding protein are administered to a subject not already in the disease state to enhance the subject's resistance. In terms of achondroplasia, a prophylactic treatment is understood as a method of preventing or alleviating one or more symptoms of the disorder. In terms of cancer, a prophylactic treatment is understood as a method of preventing the happening of cancer, or alleviating one or more symptoms of the cancer. Such an amount is defined to be a “prophylactic effective dose.” In this use, the precise amounts again depend upon the subject's state of health and general immunity. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, or until the patient shows partial or complete amelioration of disease symptoms. Thereafter, the patient can be administered a prophylactic regime.
  • Binding proteins described herein can optionally be administered in combination with other agents that are effective in treating the disorder or condition in need of treatment (e.g., prophylactic or therapeutic).
  • While the binding proteins may be administered as described immediately above, it must be emphasized that in other embodiments binding proteins may be administered to otherwise healthy subjects as a first line therapy. In such embodiments the binding proteins may be administered to subjects that have not, and are not, undergoing one or more other therapies, or subjects that have, or are undergoing one or more other therapies. As used herein, the administration of binding proteins, e.g. antibodies or fragments thereof, in conjunction or combination with an adjunct therapy means the sequential, simultaneous, coextensive, concurrent, concomitant, or contemporaneous administration or application of the therapy and the disclosed binding proteins. The administration or application of the various components of the combined therapeutic regimen may be timed to enhance the overall effectiveness of the treatment.
  • As previously discussed, the binding proteins of the present disclosure may be administered in a pharmaceutically effective amount for the in vivo treatment of mammalian disorders.
  • Pharmaceutical compositions in accordance with the present disclosure typically include a pharmaceutically acceptable, non-toxic, sterile carrier such as physiological saline, buffers, preservatives and the like. For the purposes of the instant application, a pharmaceutically effective amount of the binding protein that, shall be held to mean an amount sufficient to achieve effective binding to an antigen and to achieve a benefit, e.g., to ameliorate symptoms of a disease or disorder. Of course, the pharmaceutical compositions of the present disclosure may be administered in single or multiple doses to provide for a pharmaceutically effective amount of the antigen-binding protein or antigen-binding fragment thereof.
  • In keeping with the scope of the present disclosure, the antigen-binding protein or antigen-binding fragment thereof may be administered to a human or other animal in accordance with the methods of treatment herein in an amount sufficient to produce a therapeutic or prophylactic effect. The binding proteins of the disclosure can be administered to such human or other animal in a conventional dosage form prepared by combining the binding protein with a conventional pharmaceutically acceptable carrier or diluent according to known techniques. The form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. In some embodiments, a cocktail comprising one or more species of binding proteins described in the current disclosure may prove to be particularly effective.
    • Methods of Treatment and Inhibition of FGFR3 Activity
  • The anti-FGFR3 antigen binding proteins or fragments thereof are useful for the treatment of FGFR3-mediated diseases or disorders. As used herein, the term “FGFR3-mediated disease or disorder” refers to any disease or disorder that is the result of aberrant FGFR3 activity. In certain embodiments, the disease or disorder is caused by FGFR3 over activity or over expression. Non-limiting examples of FGFR3-mediated diseases or disorders include achondroplasia, hypochondroplasia, and cancer.
  • The anti-FGFR3 antigen binding proteins or fragments thereof are useful for the reduction of FGFR3 activity. As used herein, an “FGFR3 activity” refers to any signaling event associated with the dimerization of FGFR3 on the surface of a cell. The FGFR3 activity can be one or both of an extracellular activity and an intracellular activity. FGFR3 activities include, but are not limited to, FGFR3 dimerization, extracellular signal-regulated kinase (Erk) phosphorylation, mitogen-activated protein kinase kinase (MKK, MEK, or MAP2K) phosphorylation, FGFR3 cytoplasmic tyrosine kinase domain activity, and FGF ligand binding activity (e.g., FGF18 binding to FGFR3).
  • As used herein, the term “achondroplasia” refers to a genetic disorder caused by mutations in the FGFR3 gene that make the resulting protein overactive. The anti-FGFR3 antigen binding proteins or fragments thereof are useful for the reduction of one or more symptoms of achondroplasia. Achondroplasia symptoms include, but are not limited to, shortening of the proximal limbs, brachydactyly (i.e., short fingers and toes with trident hands), large head with prominent forehead frontal bossing, small midface with a flattened nasal bridge, spinal kyphosis (convex curvature) or lordosis (concave curvature), varus (i.e., bowleg) or valgus (i.e., knock knee, ear infections (due to Eustachian tube blockages)), sleep apnea (central or obstructive), and hydrocephalus. Achondroplasia may be diagnosed through the measurement of one or more of proximal limb length (e.g., femur and tibia length), finger and toe length, head circumference (e.g., skull length), and lumbar vertebrae length, although other anatomical measurements can be employed. Achondroplasia may be diagnosed through genetic testing to detect one or more mutations in the FGFR3 gene.
  • In one aspect, the disclosure provides a method for treating a FGFR3-mediated disease or disorder in a subject, comprising administering to a subject in need thereof the antigen binding protein or fragment thereof described herein.
  • As used herein, the term “subject,” “patient,” or “individual” refers to a human or non-human animal. The term “non-human animal” includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, cats, rabbits, ferrets, rodents such as mice, rats and guinea pigs, avian species (e.g., chickens), amphibians, and reptiles. In certain embodiments, the subject is a mammal such as a non-human primate, sheep, dog, cat, rabbit, ferret or rodent. In certain embodiments, the subject is a cynomolgus monkey. In certain embodiments, the subject is a human. In certain embodiments, the subject is a child. In certain embodiments, the subject is an adolescent.
  • In certain embodiments, the FGFR3-mediated disease or disorder is achondroplasia. In certain embodiments, the achondroplasia is FGFR3G380R+ achondroplasia, meaning the subject to be treated contains the G380R mutation in its FGFR3 gene, either homozygous or heterozygous.
  • In certain embodiments, a subject diagnosed as having achondroplasia or risk of achondroplasia is treated with a binding protein disclosed herewith. In certain embodiments, the treatment leads to one or more effects selected from the group consisting of increased bone length (e.g., femur length and/or tibia length), increased bone diameter (e.g., femur diameter), increased growth plate volume (e.g., femur growth plate volume), increased vertebrae length, increased skull length, increased bone volume, increased skull volume, corrected vertebral abnormalities (e.g., increased Kyphosis Index), and improved bone age (e.g., more developed secondary ossification center), as compared to a control subject not receiving the treatment that is of the same development stage.
  • Accordingly, a method of improving one or more bone features in a subject is also provided. In certain embodiments, the method comprises administrating a binding protein or an antigen-binding fragment thereof disclosed herewith to a subject in need. In certain embodiments, the improved bone feature is selected from the group consisting of bone length (e.g., femur length or tibia length), bone diameter (e.g., femur diameter), growth plate volume, vertebrae length, skull length, bone volume, skull volume, Kyphosis Index, and improved bone age.
  • In certain embodiments, the FGFR3-mediated disease or disorder is cancer. In certain embodiments, the cancer is selected from the group consisting of bladder cancer, melanoma, urothelial cancer, and endometrial cancer.
  • In another aspect, the disclosure provides a method for treating achondroplasia in a subject, comprising administering to a subject in need thereof an antigen binding protein or an antigen-binding fragment thereof with binding specificity to an FGFR3 epitope, wherein the antigen binding protein or the antigen binding fragment thereof does not bind to one or more of FGFR1, FGFR2, and FGFR4.
  • In another aspect, the disclosure provides a method for inhibiting one or both of FGFR3 activity and expression in a bone growth plate of a subject, comprising administering to a subject an antigen binding protein or an antigen binding fragment thereof with binding specificity to an FGFR3 epitope, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4. In certain embodiments, an FGFR3 antibody as described herewith is used.
    • Therapeutic and Prophylactic Uses
  • The disclosure provides therapeutic uses of its binding proteins or an antigen binding protein fragment thereof with binding specificity to an FGFR3 epitope, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4) corresponding to the methods of treatment disclosed above. For instance, the disclosure provides a binding protein or the antigen binding protein fragment thereof as described herein for use in medicine. In some embodiments, it provides a binding protein, or an antigen binding protein fragment thereof as described herein for use as an FGFR3-activity inhibiting medicament. In some embodiments, it provides a binding protein, or an antigen binding protein fragment thereof as described herein for use in treating an FGFR3-mediated disorder. Examples of such disorders are given herein. In some embodiments, it provides a binding protein, or antigen binding protein fragment thereof as described herein for use in preventing one or more symptoms of achondroplasia, as exemplified above. In some embodiments, it provides a binding protein, or antigen binding protein fragment thereof as described herein for use in preventing cancer, as exemplified above. Embodiments described herein regarding methods of treatment, administration, subjects and all other aspects relevant to therapy and prevention also apply to these uses of binding proteins.
  • It will be readily apparent to those skilled in the art that other suitable modifications and adaptations of the methods described herein may be made using suitable equivalents without departing from the scope of the embodiments disclosed herein. Having now described certain embodiments in detail, the same will be more clearly understood by reference to the following example, which is included for purposes of illustration only and is not intended to be limiting.
    • EXAMPLE Example 1—Generation of Anti-FGFR3 Antibodies
  • Generation of Immunogen
  • Anti-FGFR3 monoclonal antibodies were developed using 300.19 pre-B lymphoblast cells (ATCC, Manassas, VA) transformed with DNA encoding full-length human FGFR3 (see FIG. 1 , GenBank ID NP_000133.1, FGFR3 isoform IIIc) with the mutation G380R (SEQ ID NO: 133) which was expressed on the cell surface (FGFR3G380R-300.19 cell). The FGFR3G380R open reading frame was subcloned into the pXL-MCS vector and transfected into 300.19 cells (Immunogen 1). Separately, DNA encoding the human FGFR3 extra cellular domain (ECD) protein (Immunogen 2) was subcloned into the pTT5 vector (Invitrogen), and was prepared using Expi293 cells (Invitrogen). FGFR3 extra cellular domain (ECD) protein (Immunogen 2):
  • (SEQ ID NO: 140)
    GGLNDIFEAQKIEWHEHHHHHHEDQVDPRLIDGKIQPEPESLGTEQRVVG
    RAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVP
    SERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGD
    DEDGEDEAEDTGVDTGAPYVVTRPERMDKKLLAVPAANTVRFRCPAAGNP
    TPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVEN
    KFGSIRQTYTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQ
    PHIQWLKHVEVNGSKVGPDGTPYVTVLKTAGANTTDKELEVLSLHNVTFE
    DAGEYTCLAGNSIGFSHHSAWLVVLPAEEELVEADEAGSAS
  • FGFR3 expression on FGFR3G380R-300.19 cells was monitored and quantified by FACS analysis using the comparator antibody, GT184.6.1, described further in Yin et al. (Mol. Cancer Ther. 14(10): 2270-8. 2015). Anti-FGFR1 (MAB765), anti-FGFR2 (MAB6843), anti-FGFR3 (MAB766), and anti-FGFR4 (MAB6852) antibodies were used as negative controls (R&D Systems, Minneapolis, MN). The FGFR3 ECD protein was quantified using an enzyme-linked immunosorbent assay (ELISA) with the antibodies described further below.
  • The cells expressing FGFR3 were maintained at 37° C. under 5% CO2 in RPMI (Gibco) supplemented with heat inactivated fetal bovine serum (FBS) (Hyclone). Cells were prepared for injection by substituting the above culture medium with phosphate buffered (Ca—Mg free) saline (CMF-PBS) supplemented with 5 mM EDTA and harvesting the cells in that buffer. The harvested cells were pelleted by centrifugation at 500×g for 5 minutes, washed once by resuspending the pellet in CMF-PBS and centrifuging as before, counted and adjusted to the appropriate volume (such as 5×106 cells in 0.2 ml) for injection by resuspending the cell pellet in CMF-PBS. The FGFR3 ECD protein was used to boost antibody titers in animals before sacrificing the mouse.
  • Cells were maintained in RPMI medium by seeding about 3-5×105 cells per ml in a T75 flask and grown for approximately 24-48 hours with selection antibiotic to eliminate the cells not carrying FGFR3 plasmid. Cell surface expression of FGFR3 on cells was verified by FACS analysis prior to use as an immunogen.
  • Generation of Anti-FGFR3 Antibodies—Hybridoma Strategy
  • Six eight-week old female FGFR3 KO (C57BL/6mFGFR3−) mice from the Jackson Laboratory (Bar Harbor, ME) were immunized with the FGFR3-transfected cells (Immunogen 1). Separately, wild-type Balb/c mice were immunized with the FGFR3 ECD protein described above (Immunogen 2). A group of mice were primed intraperitoneally on day 0 with FGFR3-expressing cells, FGFR3G380R-300.19 cells, in PBS without adjuvants, administrated on days 14, 28, 42 and 56, followed by an intraperitoneal boost on day 77 with the FGFR3 ECD protein in PBS without adjuvants. Each injection was administrated with approximately 5×106 cells in a volume of 200 μl and 50 μg protein in a volume of 100 μl PBS. Immunizations were performed in two-week intervals and the IgG titer was evaluated by ELISA with FGFR3 ECD protein to assess immune response.
  • The mice were sacrificed for harvesting the spleen and placed in approximately 10 ml of pre-warmed serum-free DMEM (Hyclone) at 37° C. in a petri dish. The splenocytes were teased out of the capsule using forceps and transferred to a 15-ml conical tube. The cells were then washed three times with pre-warmed serum-free IMDM (Hyclone) and cells from multiple mice were pooled.
  • The fusion partner cell, FO B lymphoblasts (ATCC, Manassas, VA), for the immunized spleen cells was established with a hypoxanthine/aminopterin/thymidine (HAT)-sensitive and IgG non-secreting myeloma cell line. Prior to the fusion, FO B lymphoblasts were maintained in IMDM medium supplemented with 10% FBS (37° C., 7% CO2) ensuring that the cells were in logarithmic growth phase on the day of the fusion.
  • The fusion protocol was derived from Lerner (Yale J Biol Med, 1981, 54 (5) 387-402) and Gefter et al. (Somatic Cell Genet, 1977, 3 (2) 231-236). Before the fusion, the spleen cells and the logarithmic phase myeloma cells were washed three times with serum-free IMDM and counted. For each fusion, 1-1.5×108 spleen cells were mixed with 2-3×107 myeloma cells in a 50-ml conical polypropylene tube and cells were washed once with serum-free IMDM. The ratio of spleen cells to myeloma cells was 5:1. The tubes were centrifuged at 500×g for 10 minutes to pellet the cells. After aspiration of the supernatant, the pellets were gently resuspended by tapping the bottom of the tubes. The tubes were then placed in a beaker of 37° C. water. All subsequent fusion steps were carried out in the beaker of 37° C. water.
  • Next, 1 ml of polyethylene glycol 1500 (PEG) (Roche Applied Science, Indianapolis, IN) preheated to 37 C was slowly added to the cell pellet over the course of about 1 minute, while gently rocking the tube. The cells were incubated in the PEG for one minute followed by addition of 1 ml serum-free IMDM added dropwise to the pellet over the course of 30 seconds, and then 9 ml of serum-free IMDM were added to the pellet for one minute. The tube was then centrifuged at 500×g for 10 minutes at room temperature, and the supernatant was aspirated. The pellet was resuspended in 200 ml of filtered complete hybridoma production media, IMDM (Hyclone) supplemented with 10% FBS (Hyclone), 1× non-essential amino acid (Gibco), 1 mM sodium pyruvate (Gibco), 1× pen-strep (Gibco) and 1× HAT (Sigma). The resuspended cells were then seeded in ten 96-well flat-bottom microtiter plates, in a volume of about 200 μl/well. The plates were kept in an incubator at 37° C., 7% CO2.
  • A primary hybridoma screen was designed to select hybridoma clones producing antibodies which recognized native FGFR3 epitopes. Supernatants from wells growing clones, typically on days 10-14 post-fusion, were incubated with Chinese hamster ovary (CHO) cells stably expressing FGFR3 (FGFR3-CHO). Antibody binding was detected by FACS using a fluorescently labeled goat anti-mouse secondary antibody. Clones were considered positive if labeled supernatant samples were greater than 10-fold over background in the FACS analysis. Selected positive clones were transferred to 24-well flat bottom plates and expanded for a second screen to confirm selection. Supernatants from 24-well plates were incubated with hFGFR3G380R-300.19 cells and detected by a fluorescently labeled goat anti-mouse secondary antibody. More than 4,000 hybridomas were generated and screened by FACS assay described above. Only 25 clones were confirmed specific to FGFR3. Positive clones were expanded for purified antibody production, VH and VL gene sequencing and cryo-preservation.
  • Generation of Anti-FGFR3 Antibodies—Phage-Display Strategy
  • Three scFv phage libraries and two fab fragment phage libraries were screened, with 5 separate screening campaigns performed. A first campaign screened the scFv phage libraries against the hFGFR3 isoform IIIc dimer. 2,700 scFv antibodies were screened with only 13 antibodies identified as potential candidates. A second campaign screened fab and scFv libraries against the hFGFR3 isoform IIIc dimer. 1,940 antibodies were screened with only 13 antibodies identified as potential candidates. A third and fourth campaign screened fab and scFv libraries against the hFGFR3 isoform IIIc dimer, the hFGFR3 isoform IIIc his tagged monomer, and hFGFR3 isoform IIIc-expressing cells. 9,770 antibodies were screened with only 36 antibodies identified as potential candidates. A fifth campaign screened fab libraries against the hFGFR3 isoform IIIc monomer and mouse FGFR3 (mFGFR3) isoform IIIc monomer, and hFGFR3 isoform IIIc- and mFGFR3 isoform IIIc-expressing cells. 2,990 antibodies were screened with only 57 antibodies identified as potential candidates. Between the five screening campaigns, 17,400 antibodies were screened. Among those screened antibodies, only 48 were found to be cross-reactive between human, mouse, and cyno, and only 15 were found to block FGFR3 ligand binding.
  • FGFR family member proteins (human FGFR1α IIIb, FGFR1α IIIc, FGFR1β IIIb, FGFR1β Mc, FGFR2α IIIc, FGFR2β IIIb, FGFR3 IIIb, FGFR3 Mc, FGFR4; mouse FGFR3; and cynomolgus FGFR3 recombinant proteins) were purchased from R&D Systems (Minneapolis, MN) for identifying FGFR3 specific clones by ELISA. cDNA encoding the following proteins were all subcloned into the pTT5 vector (Invitrogen): partial ECD and chimeric ECD proteins of FGFR3; human D2D3 (hD2D3) and D3 (hD3) of human FGFR3; mouse D2D3 (mD2D3) and D3 (mD3) of mouse FGFR3; cynomolgus D2D3 (cyD2D3) and D3 (cyD3) of cynomolgus FGFR3; and hD1-cyD2D3 and hD1-mD2D3 recombinant proteins. Proteins were prepared by transient transfection using Lipofectamine 2000 (Invitrogen) in Expi293 cells (Invitrogen). Supernatants from the selected clones were incubated in 96-well plates coated with the recombinant FGFR proteins and detected with goat anti-mouse IgG horseradish peroxidase (Jackson Immunoresearch, West Grove, PA) followed by chemiluminescent detection.
  • Cell Based-Binding Assays for Anti-FGFR3 Antibodies
  • A cell-based binding assay was used to characterize the anti-FGFR3 antibodies generated above. Full-length human, mouse, and cynomolgus FGFR3 cDNAs were subcloned into different pcDNA 3.1 (Invitrogen) vectors and transfected into 300.19 cells (ATCC). The cDNA of FGFR3 Ig domains D2D3 was subcloned into pcDNA 3.1 and transfected into CHO (D2D3-CHO) (ATCC) cells. Full-length human FGFR3G380R, mouse FGFR3, and cynomolgus FGFR3G380R cDNAs were also subcloned into different pcDNA 3.1 vectors. Stable cell lines expressing FGFR3 were generated by transfection of human FGFR3G380R, mouse FGFR3, and cynomolgus FGFR3G380R cDNA plasmid constructs into CHO (hFGFR3G380R-CHO and cyFGFR3G380R-CHO) and human embryonic kidney (HEK, mFGFR3-HEK) (ATCC) cells using the Lipofectamine 2000 kit (Invitrogen). Cell lines were maintained in F-12K medium supplemented with 10% FBS for CHO cells and in DMEM supplemented with 10% FBS for HEK cells overnight, then cultured in the presence of geneticin (0.5 ml/ml) for 10-14 days. Isolated single colonies were picked and grown in separate wells until sufficient clonal cells were expanded. Stable clones resistant to geneticin and expressing high copies of FGFR3 protein were identified by FACS assay using GT184.6.1.
  • Cell-based antibody binding to wild-type FGFR3, mutant FGFR3, and D2D3 FGFR3 expressed on CHO and HEK cells was accessed by FACS analysis. Cells were incubated with anti-FGFR3 antibodies in 1% bovine serum albumin in PBS (BPBS). After three washes, the cells were incubated with a fluorescent-conjugated secondary antibody (Invitrogen).
  • The results indicated that several antibodies bind specifically to FGFR3 expressed on the cells. For example, clones KC18, KE35, KE42, KE58, KE63, and KE94, with mouse and human isotype controls as negative controls and GT184.6.1 as a positive control, were tested for binding to CHO, HEK and 300.19 cells transfected to express wild-type FGFR3, mutant FGFR3, and the ECD domain of FGFR3. All antibodies bound to the cells as described above, with similar binding profiles and titration kinetics. The negative control antibodies exhibited only background reactivities. The binding of anti-FGFR3 antibodies to mouse primary rib chondrocytes was also observed by FACS analysis.
  • The binding specificities of antibodies KC18, KE35, KE42, KE58, KE63, and KE94 were also tested using GT184.6.1 as positive control. Unlike GT184.6.1, which bound to both hFGFR2 and hFGFR3, KC18, KE35, KE42, KE58, KE63, and KE94 only bound to hFGFR3, indicating high FGFR3 specificities.
  • Biacore Affinity Analysis
  • The N-terminal ECD proteins of FGFR3 from human and mouse were produced with a terminal avidin tag and used in a forward format Biacore assay where proteins were immobilized on a Biacore chip and then the kinetics of antibody interaction with the proteins on the chip were determined. The proteins were immobilized on a Biacore chip for approximately 10,000 response units (RU). Then the antibodies were exposed to the chip for kinetic measurements, following the manufacturer's recommendations (GE Healthcare). Sensorgrams were fit to a 1:1 binding model and analyzed using double-reference subtraction by T200 Evaluation software (GE Healthcare). Affinities of the tested antibodies are shown in Table 2.
  • TABLE 2
    anti-FGFR3 antibodies binding specificities and affinities
    FGFR3 Selectivity Reactivity
    antibodies FGFR1 FGRF2 FGFR3 FGFR4 hFGFR3IIIc hFGFR3IIIb mFGFR3 cynoFGFR3
    KC18 − − + − +++ +++ +++ +++
    KE35 − − + − +++ +++ +++ +++
    KE42 − − + − +++ +++ +++ +++
    KE58 − − + − +++ +++ +++ +++
    KE63 − − + − +++ +++ +++ +++
    KE94 − − + − +++ +++ +++ +++
    Control mAb: − + + − ++ ++ +++ +++
    GT184
    Affinity (hFGFR3) Affinity (mFGFR3)
    FGFR3 Ka Kd KD KD
    antibodies (M−1s−1) (s−1) (nM) Ka Kd (nM)
    KC18 7.92E+05 3.47E−04 1.4 1.74E+05 1.10E−03 6.30
    KE35 4.14E+05 1.20E−03 2.89 5.71E+5  1.08E−03 1.89
    KE42 4.60E+05 5.67E−04 1.23 7.39E+5  6.00E−04 0.81
    KE58 1.15E+06 1.43E−03 1.2 1.67E+05 9.18E−04 5.50
    KE63 8.87E+05 7.45E−04 0.8 4.36E+05 2.91E−03 6.70
    KE94 9.40E+05 5.95E−04 0.6 7.05E+05 1.48E−03 2.10
    Control mAb: 4.23E+05 1.20E−03 2.8 4.15E+05 1.52E−03 3.7
    GT184
  • Sequence Analysis of Anti-FGFR3 Monoclonal Antibodies
  • Prior to sequence analyses, the isotype of each clone was determined using the IsoStrip Mouse Monoclonal Antibody Isotyping Kit (Roche Applied Science, Indianapolis, IN). The heavy (VH) and light (VL) chain variable regions of clones were sequenced using 5′ RACE (Rapid Amplification of cDNA Ends) Kit (Clontech, Mountain View, CA) as per the manufacturer's instruction. Total RNA was extracted from each hybridoma clone using the RNeasy Miniprep kit according to the manufacturer's instructions (Qiagen, Germantown, MD). Full-length first strand cDNAs containing 5′ ends were generated by polymerase chain reaction (PCR) using 5′RACE kits (Clontech). The VH and VL genes were amplified by TA cloning kit (Invitrogen) with primers, 5′ primer (5′RACE kit, Clontech), and 3′ primer of IgG isotype specific heavy chain and 3′ primer of kappa light chain.
  • IgG1 3′ Primer:
    (SEQ ID NO: 1)
    5′-TATGCAAGGCTTACAACCACA-3′
    IgG2b
     3′ Primer:
    (SEQ ID NO: 2)
    5′-GTTAGGAGCTGGGCATTTGTGACACTCC-3′
    IgG2c
     3′ Primer:
    (SEQ ID NO: 3)
    5′-GTTAGGTGCTGGGCATTTGCATGGAGGACAGGG-3′
    IgG3
     3′ Primer:
    (SEQ ID NO: 4)
    5′-GTTTGGTGGGCATGAAGAACCCGGGG-3′
    Kappa light chain 3′Primer:
    (SEQ ID NO: 5)
    5′-CTCATTCCTGTTGAAGCTCTTGAC-3′
  • The amplified cDNAs were cloned into pCR2.1 vectors (Invitrogen) and transformed using a TOPO-TA cloning kit (Invitrogen) as per the manufacturer's instructions. Plasmids were isolated from 2 ml of an LB culture, inoculated from a single colony and grown overnight, using QIAprep spin miniprep kit (Qiagen) and sequenced using M13 Forward and M13 Reverse primers included in the TOPO-TA cloning kit (Invitrogen). The VH and VL gene sequences were analyzed using the IMGT V-Quest web server to identify and confirm variable region sequences. VH and VL sequences of each antibody are provided below in Table 3:
  • TABLE 3
    Antibody VH and VL amino acid sequences
    Antibody ID Sequence
    KC18 VH QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGDI
    DPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTYDG
    YPYAMDYWGQGTSVTVSS (SEQ ID NO: 6)
    KC18 VL DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSNNQKNYLAWYQQKPGQSPK
    LLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYRTF
    GGGTKLEIK (SEQ ID NO: 7)
    KE35 VH EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWIGY
    INPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCARERD
    YDGAMDYWGQGTSVTVSS (SEQ ID NO: 8)
    KE35 VL DIQMTQSPSSLSASLGGKVTITCKASQDINKFIAWYQHKPGKGPRLLIHYTST
    LQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLLWTFGGGTKLEIK
    (SEQ ID NO: 9)
    KE42 VH EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWIG
    YINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCARER
    DYDGSMDFWGQGTSVTVSS (SEQ ID NO: 10)
    KE42 VL DIQMTQSPSSLSASLGGKVTITCKASQDINKFIAWYQHKPGKGPRLLIHYTST
    LQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYFCLQYDNLLWTFGGGTKLEIK
    (SEQ ID NO: 11)
    KE58 VH EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIGD
    INPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAREED
    FDGFDYWGQGTTLTVSS (SEQ ID NO: 12)
    KE58 VL DIVMTQSHKFMSTSVGDRVSITCKASQDVSTGVAWYQQKPGQSPQLLIYWA
    STRHTGVPDRFTGSGSGTDYILTIRSVQAEDLALYYCQQHYSTPLTFGAGTK
    LELK (SEQ ID NO: 13)
    KE63 VH QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGGID
    PETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNYDGY
    SQTMDYWGQGTSVTVSS (SEQ ID NO: 14)
    KE63 VL NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLYSSNQKNYLAWYQQKPGQSP
    KLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCHQYLSSYT
    FGGGTKLEMK (SEQ ID NO: 15)
    KE94 VH QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGAID
    PETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNYDGY
    SRTMDYWGQGTSVTVSS (SEQ ID NO: 16)
    KE94 VL NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLYSSNQKNYLAWYQQKPGQSP
    KLLIYWASTRESGVPDRFTGSGSGTDFSLSISSVQTEDLAVYYCHQYLSSYTF
    GGGTRLEMK (SEQ ID NO: 17)
  • The CDR regions for the VH and VL sequences recited above are provided below in Table 4:
  • TABLE 4
    Antibody Heavy chain and Light chain CDR regions
    HEAVY Chain
    VH Chain ID HCDR1-IMGT HCDR2-IMGT HCDR3-IMGT
    KC18_VH GDTFTDFE IDPETGGT TRTYDGYPYAMDY
    (SEQ ID NO: 70) (SEQ ID NO: 71) (SEQ ID NO: 72)
    KE35_VH GYTFTDYN INPNNGGT ARERDYDGAMDY
    (SEQ ID NO: 76) (SEQ ID NO: 77) (SEQ ID NO: 78)
    KE42_VH GYTFTDYN INPNNGGT ARERDYDGSMDF
    (SEQ ID NO: 82) (SEQ ID NO: 83) (SEQ ID NO: 84)
    KE58_VH GYTVTDYY INPNNGVT AREEDFDGFDY
    (SEQ ID NO: 88) (SEQ ID NO: 89) (SEQ ID NO: 90)
    KE63_VH GSTFSDEE IDPETGGT TRNYDGYSQTMDY
    (SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96)
    KE94_VH GSTFTDFE IDPETGGT TRNYDGYSRTMDY
    (SEQ ID NO: 100) (SEQ ID NO: 101) (SEQ ID NO: 102)
    LIGHT Chain
    VL Chain ID LCDR1-IMGT LCDR2-IMGT LCDR3-IMGT
    KC18_VL QSLLYSNNQKNY WAS QQYYSYRT
    (SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: 75)
    KE35_VL QDINKF YTS LQYDNLLWT
    (SEQ ID NO: 79) (SEQ ID NO: 80) (SEQ ID NO: 81)
    KE42_VL QDINKF YTS LQYDNLLWT
    (SEQ ID NO: 85) (SEQ ID NO: 86) (SEQ ID NO: 87)
    KE58_VL QDVSTG WAS QQHYSTPLT
    (SEQ ID NO: 91) (SEQ ID NO: 92) (SEQ ID NO: 93)
    KE63_VL QSVLYSSNQKNY WAS HQYLSSYT
    (SEQ ID NO: 97) (SEQ ID NO: 98) (SEQ ID NO: 99)
    KE94_VL QSVLYSSNQKNY WAS HQYLSSYT
    (SEQ ID NO: 103) (SEQ ID NO: 104) (SEQ ID NO: 105)
  • Inhibition of FGF1 Ligand Binding by Anti-FGFR3 Antibodies
  • To test if the isolated antibodies could inhibit the binding between FGF1 ligand and FGFR3, an FGF1 ligand blocking assay was conducted. For the FGFR1 ligand blocking assay, human FGFR3 cells, FGFR3-300.19 and FGFR3G380R-300.19, were pre-incubated with various concentration of anti-FGFR3 antibodies and isotype controls, prior to addition of human FGF1 ligand (R&D Systems). Binding of hFGF1 to FGFR3 expressed on the cells was determined by FACS assay using biotinylated anti-FGF1 antibody followed by incubation with a streptavidin-fluorescent secondary antibody. The anti-FGFR3 antibodies which bound to the EC domain, including KC18, KE35, KE42, KE58, KE63, and KE94, all blocked binding of FGF1 to FGFR3 on these cells.
  • An ELISA-based blocking assay using human and mouse FGF1 ligand was conducted. Each well of 96-well plates was coated with either human or mouse FGFR3 proteins to capture both/either anti-hFGFR3 antibody and/or FGF1 ligand, then incubated with various concentrations of anti-FGFR3 antibody and isotype controls, prior to addition of human FGF1 ligand. Binding of FGF1 ligand was determined by addition of a substrate to induce a quantifiable chemiluminescence reaction. Inhibition of FGF1 binding to human FGFR3 and mouse FGFR3 proteins by the anti-FGFR3 antibodies was detected by ELISA, respectively.
  • Epitope Binning of Anti-FGFR3 Antibodies
  • Using a Biacore T100 (GE Healthcare, Piscataway, NJ), anti-FGFR3 antibodies were immobilized on a Biacore CM5 chip and ECD proteins of FGFR3 were injected. Competition of second anti-FGFR3 antibodies (Ab2) bound to FGFR3 protein captured by immobilized anti-FGFR3 antibodies (Ab1) were determined. The anti-FGFR3 antibodies were immobilized on a Biacore chip for approximately 100 response units (RU). Flow cell 1 remained blank for reference subtraction on each chip. The ECD FGFR3 protein and mouse anti-FGFR3 antibodies (Ab2) prepared in HBS-EP+ running buffer were injected for 3 minutes and 5 minutes at a flow rate of 50 μl/min, respectively. The Ab1 surface was regenerated between cycles using 10 mM glycine-HCl (pH 2.0) at 50 μl/min for 1 minutes. Sensorgrams were fit to a 1:1 binding model and analyzed using double-reference subtraction by BiaEvaluation software (GE Healthcare). It was determined that anti-FGFR3 antibodies KC18, KE35, KE42, KE58, KE63, and KE94 competed for the same region on FGFR3 around the D2 domain.
  • Hydrogen deuterium exchange (HDX) mass spectrometry was also used to determine the epitopes on FGFR3 for these antibodies by measuring the amide hydrogen deuterium exchange on FGFR3. HDX mass spectrometry measured amide hydrogen deuterium exchange over time and quenched at 0° C. and pH 2.5 along with protease digestion. Briefly, the antibody to be tested and antigen were mixed such that about 90% of the antibody is bound to the antigen at room temperature. Deuterium exchange was performed with a 10-fold dilution into D20 at neutral pH. Quenching was then performed by holding the reaction mixture for 1 minute at about 0 to 1° C. to reduce disulfide bonds. Protease digestion was performed with protease XIII and pepsin. HDX mass spectrometry is described in further detail in Prądzińska et al. (Amino Acids. 48: 2809-2820. 2016). The FGFR3 sequence used in the HDX assay is recited below, and corresponds to the D2D3 region, corresponding to D143 to E365 of FGFR3 Isoform IIIc:
  • (SEQ ID NO: 134)
    DTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNG
    REFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYT
    LDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVE
    VNGSKVGPDGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAG
    NSIGFSHHSAWLVVLPAEEELVE
  • The results (FIG. 2 ) indicated that KE35 and KE58 bind to the N-terminus of the D2 region (D143 to L163); KE42 binds to N-terminus of the D2 region (D143 to N170); while KC18, KE94, and KE63 bind to N-terminus and middle of the D2 region (D143 to D160 and G197 to L213).
  • Internalization Assay
  • Internalization of anti-FGFR3 antibodies was evaluated in KMS-11 cells (JCRB cell bank, Japan). The KMS-11 cells were incubated with each antibody at a final concentration of 2 μg/ml for 30 minutes, 1, 2, 5, and 24 hours, then placed at 4° C. before washing the cells with PBS (Ca2+ and Mg2+). A subset of samples was washed with glycine-HCl buffer (pH 4) and fixed with 4% paraformaldehyde (Sigma). Another subset of samples was permeabilized with Triton X-100 (Sigma). The cells with immunofluorescence staining buffer, containing dye and fluorescent conjugated secondary antibody, were imaged by a PerkinElmer Opera high-throughput automated microscope and analyzed using the PerkinElmer Columbus image management system (PerkinElmer, Hopkinton, MA). Internalization of anti-FGFR3 antibodies was observed in KMS-11 cells treated with glycine-HCl and Triton X-100. The cell surface staining of each antibody was detected in a subset without treatment of glycine-HCl and Triton X-100 (FIG. 3 ). The ratio of the fluorescence signal for internalized antibody (+pH3/+TX100) to total antibody (−pH3/+TX100) then allows comparison of the degree of internalization for different antibodies (FIG. 4 ). The results indicate that the anti-FGFR3 antibodies were effectively internalized into the KMS-11 cells.
  • Dimerization of FGFR3 Assay
  • Inhibition of FGFR3 dimerization by anti-FGFR3 antibodies was evaluated by a chemiluminescent assay. U2OS cells co-expressing a fusion protein of β-galactosidase-prolink (PK) and FGFR3 (FGFR3-PK) and β-galactosidase-enzyme acceptor (EA) and FGFR3 (FGFR3-EA) were developed by DiscoveRx (Fremont, CA). β-galactosidase is in an inactive form and when dimerization occurs the prolink and enzyme acceptor come together and are cleaved by the now activated β-galactosidase. The cells were pre-incubated with anti-FGFR3 antibodies at various concentrations before addition of FGF18 ligand to induce dimerization of FGFR3 proteins, then incubated at 37° C. overnight. The substrate was added to the cells and chemiluminescent signal was measured by EnVision (PerkinElmer). Blocking of FGFR3 dimerization by anti-FGFR3 antibodies was observed (FIG. 5A-FIG. 5C).
  • Humanization
  • Humanized variants of KC18, KE63 and KE94 clones were generated as follows: 1) Structural models of the Fv regions of these antibodies in complex with FGFR3 were generated by the Molecular Operating Environment (MOE) from the Chemical Computing Group using KC18-FGFR3 complex structure as template given their high sequence similarity with KC18 (FIG. 6 ); 2) The VH and VL sequences were searched against the human germline sequence, and the most similar human germline Fv sequence and J region were identified. CDRs from KC18, KE63 and KE94 were then grafted onto the framework of the closest human germline genes; 3) Analysis was performed to identify amino acids that were likely to be important for the FGFR3 binding properties of the antibodies. Selected Vernier zone and key contact residues were mutated back to mouse residues after examination within the structural models; and 4) Potential liability sites were removed.
  • Heavy chain of KC18_Hrw1-3 and _HV1.69rw2-4, and light chain of KC18_Lrw1-3 were designed by the method described above. Further analysis to introduce back-mutations, stabilizing mutations and to eliminate other unwanted motifs, additional heavy and light chains of KC18 variants were identified KC18_VH1, VH1b-c, VH2-3, VH3b-c and VH4, and KC18_VL1, VL1b-d, VL2, VL3, VL3b, VL4, VL5 and VL6, respectively. Heavy chains KE63 VH1-6 and light chains KE63_VL1-4 were designed. Particularly, initial KE63 (KE63_VH1 and KE63_VL1) humanized constructs were designed, then further modifications to the heavy and light chain were designed (KE63_VH2-6 and KE63_VL2-4) to introduce back-mutations, stabilizing mutations and to eliminate other unwanted motifs. Similar methods were also used to design KE94 humanized constructs KE94_VH1-6. Notably, KE63 and KE94 share the same set of VL designs, namely KE63_VL1-4 here. Tables 5, 6, and 7 indicate the strategy used to pair the heavy and light chain variants for KC18, KE63 and KE94, respectively, including the human and mouse germline identity percentage.
  • TABLE 5
    Human and mouse germline identity percentage of the designed KC18 variants
    KC18 Lrw1 Lrw2 Lrw3 VL1 VL1d VL1c
    Human 93.07% 96.04% 95.05% 95.05% 93.07% 94.06%
    Mouse 88.12% 87.13% 86.14% 88.12% 88.12% 89.11%
    Hrw1 83.67% 74.49% KC18_Hu1 KC18_Hu7  KC18_Hu13
    Hrw2 84.73% 75.51% KC18_Hu2 KC18_Hu8  KC18_Hu14
    Hrw3 84.69% 75.51% KC18_Hu3 KC18_Hu9  KC18_Hu15
    HV1.69rw2 83.67% 72.45% KC18_Hu4 KC18_Hu10 KC18_Hu16
    HV1.69rw3 83.67% 72.45% KC18_Hu5 KC18 Hu11 KC18_Hu17
    HV1.69rw4 83.67% 72.45% KC18_Hu6 KC18_Hu12 KC18_Hu18
    VH1 80.61% 75.51% KC18_Hu19 KC18_Hu23
    VH1b 84.69% 73.47%
    VH1c 82.65% 73.47% KC18_Hu38
    VH2 77.55% 78.57%
    VH3 84.69% 73.47% KC18_Hu20 KC18_Hu24
    VH3b 85.71% 74.49%
    VH3c 84.69% 74.49% KC18_Hu39
    VH4 78.57% 79.59%
    KC18 VL1b VL2 VL3 VL3b VL4 VL5 VL6
    Human 94.06% 90.10% 86.14% 85.15% 81.19% 81.19% 81.19%
    Mouse 87.13% 91.09% 79.21% 80.20% 86.14% 81.19% 85.15%
    Hrw1 83.67% 74.49%
    Hrw2 84.73% 75.51%
    Hrw3 84.69% 75.51%
    HV1.69rw2 83.67% 72.45%
    HV1.69rw3 83.67% 72.45%
    HV1.69rw4 83.67% 72.45%
    VH1 80.61% 75.51% KC18_Hu29
    VH1b 84.69% 73.47% KC18_Hu40 KC18_Hu31 KC18_Hu35
    VH1c 82.65% 73.47%
    VH2 77.55% 78.57% KC18_Hu27 KC18_Hu35 KC18_Hu37
    VH3 84.69% 73.47% KC18_Hu30
    VH3b 85.71% 74.49% KC18_Hu41 KC18_Hu32
    VH3c 84.69% 74.49%
    VH4 78.57% 79.59% KC18_Hu28 KC18_Hu34
  • TABLE 6
    Human and mouse germline identity percentage of the designed KE63 variants
    KE63 KE63_VL1 KE63_VL2 KE63_VL3 KE63_VL4
    Human 93.07% 93.07% 91.09% 91.09%
    Mouse 90.00% 89.00% 87.00% 87.00%
    KE63_VH1 83.67% 74.49% KE63_Hu1 KE63_Hu2 KE63_Hu3 KE63_Hu4
    KE63_VH2 86.73% 73.47% KE63_Hu5 KE63_Hu6 KE63_Hu7 KE63_Hu8
    KE63_VH3 85.71% 74.49% KE63_Hu9 KE63_Hu10 KE63_Hu11 KE63_Hu12
    KE63_VH4 86.73% 73.47% KE63_Hu13 KE63_Hu14 KE63_Hu15 KE63_Hu16
    KE63_VH5 82.65% 73.47% KE63_Hu17 KE63_Hu18 KE63_Hu19 KE63_Hu20
    KE63_VH6 81.63% 72.45% KE63_Hu21 KE63_Hu22 KE63_Hu23 KE63_Hu24
  • TABLE 7
    Human and mouse germline identity percentage of the designed KE94 variants
    KE94 KE94_VL1 KE94_VL2 KE94_VL3 KE94_VL4
    Human 93.07% 93.07% 91.09% 91.09%
    Mouse 90.00% 89.00% 87.00% 87.00%
    KE94_VH1 82.65% 77.55% KE94_Hu1 KE94_Hu2 KE94_Hu3 KE94_Hu4
    KE94_VH2 85.71% 76.53% KE94_Hu5 KE94_Hu6 KE94_Hu7 KE94_Hu8
    KE94_VH3 84.69% 77.55% KE94_Hu9 KE94_Hu10 KE94_Hu11 KE94_Hu12
    KE94_VH4 83.67% 78.57% KE94_Hu13 KE94_Hu14 KE94_Hu15 KE94_Hu16
    KE94_VH5 82.65% 77.55% KE94_Hu17 KE94_Hu18 KE94_Hu19 KE94_Hu20
    KE94_VH6 81.63% 76.53% KE94_Hu21 KE94_Hu22 KE94_Hu23 KE94_Hu24
  • Amino acid sequences for the humanized variants of KC18, KE64 and KE94, without the constant regions, are depicted below in Table 8. Nucleic acid sequences for the humanized variants of KC18, KE64 and KE94, without the constant regions, are depicted below in Table 9. The heavy and light constant regions are indicated in SEQ ID NO: 54 and SEQ ID NO: 55, respectively.
  • TABLE 8
    Amino acid sequences of humanized variants of KC18, KE64
    and KE94
    Antibody ID Sequence
    KC18 Hu18 VH EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGL
    EWIGDVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDT
    AVYYCTRTYDGYPYAFDYWGQGTLVTVSS (SEQ ID NO: 18)
    KC18 Hu18 VL DIVMTQSPDSLAVSLGERATINCKSSQSVLYSNNNKNYLAWYQQKP
    GQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
    CQQYYSYRTFGGGTKVEIK (SEQ ID NO: 19)
    KE63 Hu01 VH QVQLVQSGAEVKKPGASVKVSCKASGSTFSDFEIHWVRQAPGQGL
    EWIGGIDPETGGTAYNQKFQGRVTITADRSTSTAYMELSSLRSEDTA
    VYYCTRNYDGYSQTFDYWGQGTLVTVSS (SEQ ID NO: 20)
    KE63 Hu02 VH QVQLVQSGAEVKKPGASVKVSCKASGSTFSDFEIHWVRQAPGQGL
    EWIGGIDPETGGTAYNQKFQGRVTITADRSTSTAYMELSSLRSEDTA
    VYYCTRNYDGYSQTFDYWGQGTLVTVSS (SEQ ID NO: 21)
    KE63 Hu03 VH QVQLVQSGAEVKKPGASVKVSCKASGSTFSDFEIHWVRQAPGQGL
    EWIGGIDPETGGTAYNQKFQGRVTITADRSTSTAYMELSSLRSEDTA
    VYYCTRNYDGYSQTFDYWGQGTLVTVSS (SEQ ID NO: 22)
    KE63 Hu04 VH QVQLVQSGAEVKKPGASVKVSCKASGSTFSDFEIHWVRQAPGQGL
    EWIGGIDPETGGTAYNQKFQGRVTITADRSTSTAYMELSSLRSEDTA
    VYYCTRNYDGYSQTFDYWGQGTLVTVSS (SEQ ID NO: 23)
    KE63 Hu01 VL DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSSNQKNYLAWYQQKP
    GQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYY
    CHQYLSSYTFGQGTKLEIK (SEQ ID NO: 24)
    KE63 Hu02 VL DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSSNQKNYLAWYQQKP
    GQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYY
    CHQYLSPYTFGQGTKLEIK (SEQ ID NO: 25)
    KE63 Hu03 VL DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSDNQKNYLAWYQQKP
    GQSPKLLIYYASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYY
    CHQYLSPYTFGQGTKLEIK (SEQ ID NO: 26)
    KE63 Hu04 VL DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSDNQKNYLAWYQQKP
    GQSPKLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC
    HQYLSPYTFGQGTKLEIK (SEQ ID NO: 27)
    KE94 Hu01 VH QVQLVQSGAEVKKPGASVKVSCKASGSTFTDFEIHWVRQAPGQGL
    EWIGAIDPETGGTAYNQKFQGRVTITADKSTSTAYMELSSLRSEDTA
    VYYCTRNYDGYSRTFDYWGQGTLVTVSS (SEQ ID NO: 28)
    KE94 Hu02 VH QVQLVQSGAEVKKPGASVKVSCKASGSTFTDFEIHWVRQAPGQGL
    EWIGAIDPETGGTAYNQKFQGRVTITADKSTSTAYMELSSLRSEDTA
    VYYCTRNYDGYSRTFDYWGQGTLVTVSS (SEQ ID NO: 29)
    KE94 Hu03 VH QVQLVQSGAEVKKPGASVKVSCKASGSTFTDFEIHWVRQAPGQGL
    EWIGAIDPETGGTAYNQKFQGRVTITADKSTSTAYMELSSLRSEDTA
    VYYCTRNYDGYSRTFDYWGQGTLVTVSS (SEQ ID NO: 30)
    KE94 Hu04 VH QVQLVQSGAEVKKPGASVKVSCKASGSTFTDFEIHWVRQAPGQGL
    EWIGAIDPETGGTAYNQKFQGRVTITADKSTSTAYMELSSLRSEDTA
    VYYCTRNYDGYSR1FDYWGQGTLVTVSS (SEQ ID NO: 31)
    KE94 Hu01 VL DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSSNQKNYLAWYQQKP
    GQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYY
    CHQYLSSYTFGQGTKLEIK (SEQ ID NO: 32)
    KE94 Hu02 VL DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSSNQKNYLAWYQQKP
    GQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYY
    CHQYLSPYTFGQGTKLEIK (SEQ ID NO: 33)
    KE94 Hu03 VL DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSDNQKNYLAWYQQKP
    GQSPKLLIYYASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYY
    CHQYLSPYTFGQGTKLEIK (SEQ ID NO: 34)
    KE94 Hu04 VL DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSDNQKNYLAWYQQKP
    GQSPKLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC
    HQYLSPYTFGQGTKLEIK (SEQ ID NO: 35)
    IgG1 Constant Heavy ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL
    TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK
    VDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP
    EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
    VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
    VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
    TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
    KSLSLSPG (SEQ ID NO: 54)
    IgG1 Constant Light RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA
    LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
    GLSSPVTKSFNRGEC (SEQ ID NO: 55)
    KC18Hrw1 QVQLVQSGAEVKKPGASVKVSCKASGDTFTDFEIHWVRQAPGQGL
    EWIGDIDPETGSTSYAQKFQGRATLTADRSTSTAYMELSSLRSEDTA
    VYYCTRTYDGYPYAMDYWGQGTLVTVSS (SEQ ID NO: 106)
    KC18Hrw2 QVQLVQSGAEVKKPGASVKVSCKASGDTFTDYEIHWVRQAPGQGL
    EWIGDIDPETGSTSYAQKFQGRATLTADRSTSTAYMELSSLRSEDTA
    VYYCTRTYDGYPYAMDYWGQGTLVTVSS (SEQ ID NO: 107)
    KC18Hrw3 QVQLVQSGAEVKKPGASVKVSCKASGDTFTDYEIHWVRQAPGQGL
    EWIGDIDPETGSTSYAQKFQGRATLTADRSTSTAYMELSSLRSEDTA
    VYYCTRTYDGYPYAMDYWGQGTSVTVSS (SEQ ID NO: 108)
    KC18HV1-69rw2 EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGL
    EWIGDVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDT
    AVYYCTRTYDGYPYAMDYWGQGTLVTVSS (SEQ ID NO: 109)
    KC18HV1-69rw3 EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGL
    EWIGDVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDT
    AVYYCTRTYEGYPYAMDYWGQGTLVTVSS (SEQ ID NO: 110)
    KC18HV1-69rw4 EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGL
    EWIGDVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDT
    AVYYCTRTYDGYPYAFDYWGQGTLVTVSS (SEQ ID NO: 111)
    KC18Lrw1 DIVMTQSPDSLAVSLGERATINCKSSQSLLYSNNQKNYLAWYQQKP
    GQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
    CQQYYSYRTFGGGTKVEIK (SEQ ID NO: 112)
    KC18Lrw2 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKP
    GQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
    CQQYYSYRTFGGGTKVEIK (SEQ ID NO: 113)
    KC18Lrw3 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSNNNKNYLAWYQQKP
    GQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
    CQQYYSYRTFGGGTKVEIK (SEQ ID NO: 114)
    KC18_CL_VH1 QVQLVQSGAEVVKPGATVKISCKASGDTFTDFEIHWVQQAPGKGL
    EWIGDIDPETGGTAYNEKFQGRATLTADRSTSTAYMELSSLRSEDT
    AVYYCARTYDGYPYAMDYWGQGTTVTVSS (SEQ ID NO: 115)
    KC18_CL_VH1b QVQLVQSGAEVVKPGATVKISCKASGYTFTDFEIHWVQQAPGKGL
    EWIGDVDPETGGTAYAEKFQGRATITADRSTSTAYMELSSLRSEDT
    AVYYCARTYDGYPYAMDYWGQGTTVTVSS (SEQ ID NO: 116)
    KC18_CL_VH1c QVQLVQSGAEVVKPGATVKISCKASGYTFTDFEIHWVQQAPGKGL
    EWIGDVEPETGGTAYAEKFQGRATITADRSTSTAYMELSSLRSEDA
    AVYYCARTYDGYPYAMDVWGQGTTVTVSS (SEQ ID NO: 117)
    KC18_CL_VH2 QVQLVQSGAEVVKPGATVKLSCKASGDTFTDFEIHWVKQAPGKGL
    EWIGDIDPETGGTAYNEKFQGRATLTADRSTSTAYMELSSLRSEDT
    AVYYCTRTYDGYPYAMDYWGQGTTVTVSS (SEQ ID NO: 118)
    KC18_CL_VH3 QVQLVQSGAEVVKPGASVKVSCKASGDTFTDFEIHWVKQAPGQGL
    EWIGDIDPESGGTAYNQKFQGRVTMTADRSISTAYMELSRLRSDDT
    AVYYCARTYDGYPYAMDYWGQGTTVTVSS (SEQ ID NO: 119)
    KC18_CL_VH3b QVQLVQSGAEVVKPGASVKVSCKASGYTFTDFEIHWVKQAPGQGL
    EWIGDIDPESGGTAYNQKFQGRVTMTADRSISTAYMELSRLRSDDT
    AVYYCARTYDGYPYAMDYWGQGTTVTVSS (SEQ ID NO: 120)
    KC18_CL_VH3c QVQLVQSGAEVVKPGASVKVSCKASGYTFTDFEIHWVKQAPGQGL
    EWIGDIEPESGGTAYNQKFQGRVTMTADRSISTAYMELSRLRSDDA
    AVYYCARTYDGYPYAMDVWGQGTTVTVSS (SEQ ID NO: 121)
    KC18_CL_VH4 QVQLVQSGAEVVKPGASVKLSCKASGDTFTDFEIHWVKQAPGQGL
    EWIGDIDPETGGTAYNQKFQGRATLTADRSSSTAYMELSRLRSDDT
    AVYYCTRTYDGYPYAMDYWGQGTTVTVSS (SEQ ID NO: 122)
    KC18_CL_VL1 DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSSNQKNYLAWYQQKP
    GQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
    CQQYYSYRTFGGGTKLEIK (SEQ ID NO: 123)
    KC18_CL_VL1b DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSNNQKNYLAWYQQKP
    GQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
    CQQYYSYRTFGGGTKLEIK (SEQ ID NO: 124)
    KC18_CL_VL1c DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSSNQKNYLAWYQQKP
    GQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
    CQQYYSYRTFGGGTKLEIK (SEQ ID NO: 125)
    KC18_CL_VL1d DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSSNQKNYLAWYQQKP
    GQSPKLLIYYASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
    CQQYYSYRTFGGGTKLEIK (SEQ ID NO: 126)
    KC18_CL_VL2 DIVMTQSPSSLAVSLGERVTMNCKSSQSLLYSNNQKNYLAWYQQK
    PGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVY
    YCQQYYSYRTFGGGTKLEIK (SEQ ID NO: 127)
    KC18_CL_VL3 DIVMTQSPLSLPVTVGEPVSISCRSSQSLLHSNNQKNYLAWYLQKPG
    QSPQLLIYWGSTRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC
    QQYYSYRTFGGGTKLEIK (SEQ ID NO: 128)
    KC18_CL_VL3b DIVMTQSPLSLPVTVGEPVSISCRSSQSLLYSNNQKNYLAWYLQKPG
    QSPQLLIYWGSTRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC
    QQYYSYRTFGGGTKLEIK (SEQ ID NO: 129)
    KC18_CL_VL4 DIVMTQSPLSLAVTVGEKVSISCRSSQSLLYSNNQKNYLAWYQQKP
    GQSPKLLIYWGSTRESGVPDRFSGSGSGTDFTLTISRVEAEDVGVYY
    CQQYYSYRTFGGGTKLEIK (SEQ ID NO: 130)
    KC18_CL_VL5 DIQMTQSPSSLSVSVGDRVTMTCRASQGISYSNNQKNYLAWYQQK
    PGKSPKLLIYWASTRQSGVPSRFSGSGSGTDFTLTISSVQAEDVAVY
    YCQQYYSYRTFGGGTKLEIK (SEQ ID NO: 131)
    KC18_CL_VL6 DIQMTQSPSSLSVSVGDRVTMTCRSSQSLLYSNNQKNYLAWYQQK
    PGKSPKLLIYWASTRQSGVPSRFSGSGSGTDFTLTISSVQAEDVAVY
    YCQQYYSYRTFGGGTKLEIK (SEQ ID NO: 132)
  • TABLE 9
    Nucleic acid sequences of humanized variants of KC18,
    KE64 and KE94 (HC: heavy chain; LC: light chain)
    Antibody ID Sequence
    KC18 Hu18 HC GAGGTACAACTTGTCCAGTCAGGTGCGGAGGTTAAAAAACCGGG
    GGCCACAGTTAAACTGAGCTGCAAGGCTAGCGGTGATACTTTTA
    CCGATTTTGAGATACACTGGGTTCAGCAGGCTCCGGGGAAAGGG
    CTTGAATGGATTGGTGATGTTGACCCCGAAACGGGCGGAACCGC
    GTATGCAGAGAAGTTTCAAGGTAGGGCAACGCTCACTGCGGACA
    GAAGCACAGACACGGCATACATGGAGCTTAGTTCTCTCCGCTCT
    GAGGATACCGCTGTTTATTATTGTACTAGAACCTATGATGGATAT
    CCATACGCATTCGATTATTGGGGGCAAGGGACTCTTGTCACAGT
    CAGCTCCGCTTCAACCAAGGGACCTTCTGTCTTTCCTCTGGCCCC
    TTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCACTCGGGTGCC
    TTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTGGAATT
    CAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGTGCTTC
    AGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGTGCCGT
    CCTCTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAATCATA
    AGCCTTCTAATACCAAGGTGGACAAGAAGGTGGAACCCAAATCA
    TGTGACAAGACCCACACCTGTCCGCCCTGTCCGGCACCCGAACT
    GCTGGGTGGCCCTTCCGTGTTCCTTTTCCCTCCAAAGCCGAAGGA
    CACTCTTATGATTTCTCGCACTCCCGAAGTGACTTGCGTCGTGGT
    GGATGTGTCCCATGAGGATCCAGAGGTCAAGTTCAACTGGTACG
    TGGACGGTGTGGAAGTCCACAACGCCAAGACTAAGCCGAGAGA
    GGAACAGTACAATTCAACCTATCGGGTGGTGAGCGTCCTGACCG
    TGCTGCACCAGGACTGGCTTAACGGAAAGGAGTACAAGTGCAA
    AGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGACCATTA
    GCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATACCCTT
    CCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCACTCAC
    TTGTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCGAATG
    GGAGTCCAATGGTCAGCCAGAGAACAACTACAAAACCACCCCTC
    CCGTGCTGGACAGCGACGGGTCTTTCTTTCTCTACTCAAAGCTGA
    CCGTGGATAAGTCTCGCTGGCAGCAAGGGAATGTGTTTTCCTGTT
    CAGTGATGCATGAGGCCCTTCATAATCATTACACCCAAAAGTCA
    CTGAGCCTGTCTCCCGGA (SEQ ID NO: 36)
    KC18 Hu18 LC GACATAGTGATGACTCAATCCCCAGATTCACTCGCCGTATCACTC
    GGAGAAAGAGCCACAATTAATTGTAAGAGTAGTCAGTCAGTCCT
    TTACTCTAATAACAACAAAAATTACCTGGCCTGGTACCAACAGA
    AACCAGGTCAATCTCCTAAACTGCTTATCTACTGGGCTAGTACCC
    GAGAATCAGGAGTTCCCGATAGGTTTTCTGGGTCTGGGAGCGGC
    ACCGACTTCACACTCACAATCTCTAGCGTACAGGCTGAAGATGT
    AGCGGTGTATTACTGCCAACAGTATTATTCATACAGGACCTTCG
    GTGGTGGCACCAAAGTAGAAATCAAACGCACTGTGGCAGCCCCT
    TCTGTGTTTATCTTCCCACCCTCCGACGAGCAGCTCAAGTCCGGT
    ACCGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCCAAGAGAG
    GCCAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCGGTA
    ATTCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCAC
    CTACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACGA
    AAAGCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTTT
    CTAGCCCTGTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ ID
    NO: 37)
    KE63 Hu01 HC CAGGTACAGTTGGTACAGTCAGGAGCGGAGGTTAAAAAACCAG
    GGGCGTCTGTGAAAGTCTCATGTAAAGCGAGCGGAAGCACGTTT
    AGCGATTTCGAGATTCACTGGGTGAGACAAGCACCCGGTCAGGG
    CCTGGAATGGATTGGAGGGATCGACCCGGAAACAGGGGGTACA
    GCATATAACCAAAAGTTTCAGGGACGGGTCACTATAACGGCTGA
    CAGGAGCACGTCAACTGCGTATATGGAATTGTCCAGTTTGAGGT
    CAGAAGATACGGCAGTCTACTACTGCACAAGAAATTATGATGGA
    TACTCTCAAACGTTTGATTATTGGGGTCAGGGGACCCTGGTAAC
    AGTCAGCTCAGCTTCAACCAAGGGACCTTCTGTCTTTCCTCTGGC
    CCCTTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCACTCGGGT
    GCCTTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTGG
    AATTCAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGT
    GCTTCAGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGT
    GCCGTCCTCTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAA
    TCATAAGCCTTCTAATACCAAGGTGGACAAGAAGGTGGAACCCA
    AATCATGTGACAAGACCCACACCTGTCCGCCCTGTCCGGCACCC
    GAACTGCTGGGTGGCCCTTCCGTGTTCCTTTTCCCTCCAAAGCCG
    AAGGACACTCTTATGATTTCTCGCACTCCCGAAGTGACTTGCGTC
    GTGGTGGATGTGTCCCATGAGGATCCAGAGGTCAAGTTCAACTG
    GTACGTGGACGGTGTGGAAGTCCACAACGCCAAGACTAAGCCG
    AGAGAGGAACAGTACAATTCAACCTATCGGGTGGTGAGCGTCCT
    GACCGTGCTGCACCAGGACTGGCTTAACGGAAAGGAGTACAAGT
    GCAAAGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGACC
    ATTAGCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATAC
    CCTTCCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCAC
    TCACTTGTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCG
    AATGGGAGTCCAATGGTCAGCCAGAGAACAACTACAAAACCAC
    CCCTCCCGTGCTGGACAGCGACGGGTCTTTCTTTCTCTACTCAAA
    GCTGACCGTGGATAAGTCTCGCTGGCAGCAAGGGAATGTGTTTT
    CCTGTTCAGTGATGCATGAGGCCCTTCATAATCATTACACCCAAA
    AGTCACTGAGCCTGTCTCCCGGA (SEQ ID NO: 38)
    KE63 Hu02 HC CAGGTACAGTTGGTACAGTCAGGAGCGGAGGTTAAAAAACCAG
    GGGCGTCTGTGAAAGTCTCATGTAAAGCGAGCGGAAGCACGTTT
    AGCGATTTCGAGATTCACTGGGTGAGACAAGCACCCGGTCAGGG
    CCTGGAATGGATTGGAGGGATCGACCCGGAAACAGGGGGTACA
    GCATATAACCAAAAGTTTCAGGGACGGGTCACTATAACGGCTGA
    CAGGAGCACGTCAACTGCGTATATGGAATTGTCCAGTTTGAGGT
    CAGAAGATACGGCAGTCTACTACTGCACAAGAAATTATGATGGA
    TACTCTCAAACGTTTGATTATTGGGGTCAGGGGACCCTGGTAAC
    AGTCAGCTCAGCTTCAACCAAGGGACCTTCTGTCTTTCCTCTGGC
    CCCTTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCACTCGGGT
    GCCTTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTGG
    AATTCAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGT
    GCTTCAGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGT
    GCCGTCCTCTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAA
    TCATAAGCCTTCTAATACCAAGGTGGACAAGAAGGTGGAACCCA
    AATCATGTGACAAGACCCACACCTGTCCGCCCTGTCCGGCACCC
    GAACTGCTGGGTGGCCCTTCCGTGTTCCTTTTCCCTCCAAAGCCG
    AAGGACACTCTTATGATTTCTCGCACTCCCGAAGTGACTTGCGTC
    GTGGTGGATGTGTCCCATGAGGATCCAGAGGTCAAGTTCAACTG
    GTACGTGGACGGTGTGGAAGTCCACAACGCCAAGACTAAGCCG
    AGAGAGGAACAGTACAATTCAACCTATCGGGTGGTGAGCGTCCT
    GACCGTGCTGCACCAGGACTGGCTTAACGGAAAGGAGTACAAGT
    GCAAAGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGACC
    ATTAGCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATAC
    CCTTCCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCAC
    TCACTTGTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCG
    AATGGGAGTCCAATGGTCAGCCAGAGAACAACTACAAAACCAC
    CCCTCCCGTGCTGGACAGCGACGGGTCTTTCTTTCTCTACTCAAA
    GCTGACCGTGGATAAGTCTCGCTGGCAGCAAGGGAATGTGTTTT
    CCTGTTCAGTGATGCATGAGGCCCTTCATAATCATTACACCCAAA
    AGTCACTGAGCCTGTCTCCCGGA (SEQ ID NO: 39)
    KE63 Hu03 HC CAGGTACAGTTGGTACAGTCAGGAGCGGAGGTTAAAAAACCAG
    GGGCGTCTGTGAAAGTCTCATGTAAAGCGAGCGGAAGCACGTTT
    AGCGATTTCGAGATTCACTGGGTGAGACAAGCACCCGGTCAGGG
    CCTGGAATGGATTGGAGGGATCGACCCGGAAACAGGGGGTACA
    GCATATAACCAAAAGTTTCAGGGACGGGTCACTATAACGGCTGA
    CAGGAGCACGTCAACTGCGTATATGGAATTGTCCAGTTTGAGGT
    CAGAAGATACGGCAGTCTACTACTGCACAAGAAATTATGATGGA
    TACTCTCAAACGTTTGATTATTGGGGTCAGGGGACCCTGGTAAC
    AGTCAGCTCAGCTTCAACCAAGGGACCTTCTGTCTTTCCTCTGGC
    CCCTTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCACTCGGGT
    GCCTTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTGG
    AATTCAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGT
    GCTTCAGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGT
    GCCGTCCTCTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAA
    TCATAAGCCTTCTAATACCAAGGTGGACAAGAAGGTGGAACCCA
    AATCATGTGACAAGACCCACACCTGTCCGCCCTGTCCGGCACCC
    GAACTGCTGGGTGGCCCTTCCGTGTTCCTTTTCCCTCCAAAGCCG
    AAGGACACTCTTATGATTTCTCGCACTCCCGAAGTGACTTGCGTC
    GTGGTGGATGTGTCCCATGAGGATCCAGAGGTCAAGTTCAACTG
    GTACGTGGACGGTGTGGAAGTCCACAACGCCAAGACTAAGCCG
    AGAGAGGAACAGTACAATTCAACCTATCGGGTGGTGAGCGTCCT
    GACCGTGCTGCACCAGGACTGGCTTAACGGAAAGGAGTACAAGT
    GCAAAGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGACC
    ATTAGCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATAC
    CCTTCCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCAC
    TCACTTGTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCG
    AATGGGAGTCCAATGGTCAGCCAGAGAACAACTACAAAACCAC
    CCCTCCCGTGCTGGACAGCGACGGGTCTTTCTTTCTCTACTCAAA
    GCTGACCGTGGATAAGTCTCGCTGGCAGCAAGGGAATGTGTTTT
    CCTGTTCAGTGATGCATGAGGCCCTTCATAATCATTACACCCAAA
    AGTCACTGAGCCTGTCTCCCGGA (SEQ ID NO: 40)
    KE63 Hu04 HC CAGGTACAGTTGGTACAGTCAGGAGCGGAGGTTAAAAAACCAG
    GGGCGTCTGTGAAAGTCTCATGTAAAGCGAGCGGAAGCACGTTT
    AGCGATTTCGAGATTCACTGGGTGAGACAAGCACCCGGTCAGGG
    CCTGGAATGGATTGGAGGGATCGACCCGGAAACAGGGGGTACA
    GCATATAACCAAAAGTTTCAGGGACGGGTCACTATAACGGCTGA
    CAGGAGCACGTCAACTGCGTATATGGAATTGTCCAGTTTGAGGT
    CAGAAGATACGGCAGTCTACTACTGCACAAGAAATTATGATGGA
    TACTCTCAAACGTTTGATTATTGGGGTCAGGGGACCCTGGTAAC
    AGTCAGCTCAGCTTCAACCAAGGGACCTTCTGTCTTTCCTCTGGC
    CCCTTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCACTCGGGT
    GCCTTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTGG
    AATTCAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGT
    GCTTCAGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGT
    GCCGTCCTCTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAA
    TCATAAGCCTTCTAATACCAAGGTGGACAAGAAGGTGGAACCCA
    AATCATGTGACAAGACCCACACCTGTCCGCCCTGTCCGGCACCC
    GAACTGCTGGGTGGCCCTTCCGTGTTCCTTTTCCCTCCAAAGCCG
    AAGGACACTCTTATGATTTCTCGCACTCCCGAAGTGACTTGCGTC
    GTGGTGGATGTGTCCCATGAGGATCCAGAGGTCAAGTTCAACTG
    GTACGTGGACGGTGTGGAAGTCCACAACGCCAAGACTAAGCCG
    AGAGAGGAACAGTACAATTCAACCTATCGGGTGGTGAGCGTCCT
    GACCGTGCTGCACCAGGACTGGCTTAACGGAAAGGAGTACAAGT
    GCAAAGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGACC
    ATTAGCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATAC
    CCTTCCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCAC
    TCACTTGTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCG
    AATGGGAGTCCAATGGTCAGCCAGAGAACAACTACAAAACCAC
    CCCTCCCGTGCTGGACAGCGACGGGTCTTTCTTTCTCTACTCAAA
    GCTGACCGTGGATAAGTCTCGCTGGCAGCAAGGGAATGTGTTTT
    CCTGTTCAGTGATGCATGAGGCCCTTCATAATCATTACACCCAAA
    AGTCACTGAGCCTGTCTCCCGGA (SEQ ID NO: 41)
    KE63 Hu01 LC GATATAGTTATGACACAGAGCCCTGACTCTCTGGCTGTGAGTTTG
    GGCGAGCGAGTAACCATTAATTGTAAGAGTTCTCAATCCGTCCT
    CTACTCAAGCAACCAGAAAAATTACCTCGCGTGGTACCAGCAAA
    AACCAGGACAGAGCCCCAAACTCTTGATCTATTGGGCGTCCACC
    CGAGAGAGTGGCGTGCCAGATCGGTTTTCAGGTTCTGGATCTGG
    TACCGACTTCACCCTTACAATCTCAAGCCTGCAAGCAGAGGATG
    TCGCAGTTTATTATTGCCATCAGTACCTGAGCAGCTACACATTCG
    GACAAGGAACGAAACTGGAAATCAAACGCACTGTGGCAGCCCC
    TTCTGTGTTTATCTTCCCACCCTCCGACGAGCAGCTCAAGTCCGG
    TACCGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCCAAGAGA
    GGCCAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCGGT
    AATTCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCA
    CCTACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACG
    AAAAGCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTT
    TCTAGCCCTGTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ
    ID NO: 42)
    KE63 Hu02 LC GACATAGTAATGACCCAAAGTCCAGATTCTTTGGCCGTATCTTTG
    GGTGAGCGCGTTACCATCAACTGTAAGTCTTCCCAGTCTGTGTTG
    TACTCATCTAATCAAAAAAACTACCTCGCTTGGTACCAGCAGAA
    GCCAGGTCAAAGCCCGAAACTGCTTATTTATTGGGCGTCTACGC
    GAGAGTCTGGGGTCCCCGATCGGTTTTCAGGGTCAGGCTCTGGC
    ACTGATTTTACTCTGACTATTTCATCCCTCCAAGCCGAAGACGTG
    GCAGTGTATTACTGCCACCAGTATTTGAGCCCTTACACGTTTGGG
    CAGGGGACTAAACTTGAAATCAAGCGCACTGTGGCAGCCCCTTC
    TGTGTTTATCTTCCCACCCTCCGACGAGCAGCTCAAGTCCGGTAC
    CGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCCAAGAGAGGC
    CAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCGGTAAT
    TCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCACCT
    ACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACGAA
    AAGCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTTTC
    TAGCCCTGTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ ID
    NO: 43)
    KE63 Hu03 LC GATATTGTGATGACTCAGTCACCTGACAGTCTGGCGGTTTCTTTG
    GGCGAAAGAGTGACTATAAATTGCAAAAGCAGCCAGTCAGTTCT
    CTATTCCGACAATCAAAAGAACTATCTCGCATGGTATCAGCAGA
    AGCCAGGGCAATCCCCAAAATTGCTTATATACTATGCATCAACG
    CGCGAAAGCGGTGTACCCGATCGGTTTTCAGGAAGTGGCAGTGG
    GACCGACTTTACGCTGACAATCTCTTCCCTTCAAGCGGAGGATGT
    CGCGGTTTATTATTGTCATCAGTATCTGAGTCCTTACACCTTTGG
    TCAAGGGACGAAGTTGGAGATCAAACGCACTGTGGCAGCCCCTT
    CTGTGTTTATCTTCCCACCCTCCGACGAGCAGCTCAAGTCCGGTA
    CCGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCCAAGAGAGG
    CCAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCGGTAA
    TTCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCACCT
    ACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACGAA
    AAGCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTTTC
    TAGCCCTGTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ ID
    NO: 44)
    KE63 Hu04 LC GACATCGTAATGACCCAGTCCCCCGATAGTCTGGCTGTGTCTTTG
    GGCGAGAGGGTAACGATAAACTGTAAATCAAGTCAGTCAGTGCT
    TTACTCAGATAACCAGAAGAACTATCTTGCGTGGTATCAGCAAA
    AGCCCGGACAGTCTCCAAAACTTCTTATATATTTCGCTTCTACCA
    GAGAATCAGGTGTACCAGACCGCTTTTCTGGAAGCGGCTCTGGT
    ACTGACTTTACCCTGACAATTAGTAGCTTGCAAGCTGAAGATGTT
    GCGGTATATTATTGTCACCAATACTTGAGTCCCTATACTTTTGGC
    CAAGGGACAAAACTGGAAATAAAGCGCACTGTGGCAGCCCCTTC
    TGTGTTTATCTTCCCACCCTCCGACGAGCAGCTCAAGTCCGGTAC
    CGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCCAAGAGAGGC
    CAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCGGTAAT
    TCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCACCT
    ACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACGAA
    AAGCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTTTC
    TAGCCCTGTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ ID
    NO: 45)
    KE94 Hu01 HC CAGGTTCAGCTGGTACAATCTGGCGCGGAAGTCAAAAAGCCAGG
    CGCAAGTGTTAAAGTGTCTTGCAAGGCTTCAGGATCTACCTTTAC
    AGATTTTGAAATCCACTGGGTAAGACAAGCACCTGGCCAGGGGC
    TGGAATGGATTGGTGCCATAGACCCTGAGACGGGAGGAACCGC
    ATATAACCAGAAATTCCAAGGTCGAGTGACTATTACTGCGGACA
    AGTCAACATCAACTGCCTATATGGAGCTGTCTTCTTTGAGGTCAG
    AGGATACAGCAGTTTACTACTGCACTAGAAATTACGATGGTTAT
    TCACGGACCTTCGATTATTGGGGTCAAGGCACTCTGGTGACCGT
    GAGTTCCGCTTCAACCAAGGGACCTTCTGTCTTTCCTCTGGCCCC
    TTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCACTCGGGTGCC
    TTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTGGAATT
    CAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGTGCTTC
    AGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGTGCCGT
    CCTCTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAATCATA
    AGCCTTCTAATACCAAGGTGGACAAGAAGGTGGAACCCAAATCA
    TGTGACAAGACCCACACCTGTCCGCCCTGTCCGGCACCCGAACT
    GCTGGGTGGCCCTTCCGTGTTCCTTTTCCCTCCAAAGCCGAAGGA
    CACTCTTATGATTTCTCGCACTCCCGAAGTGACTTGCGTCGTGGT
    GGATGTGTCCCATGAGGATCCAGAGGTCAAGTTCAACTGGTACG
    TGGACGGTGTGGAAGTCCACAACGCCAAGACTAAGCCGAGAGA
    GGAACAGTACAATTCAACCTATCGGGTGGTGAGCGTCCTGACCG
    TGCTGCACCAGGACTGGCTTAACGGAAAGGAGTACAAGTGCAA
    AGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGACCATTA
    GCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATACCCTT
    CCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCACTCAC
    TTGTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCGAATG
    GGAGTCCAATGGTCAGCCAGAGAACAACTACAAAACCACCCCTC
    CCGTGCTGGACAGCGACGGGTCTTTCTTTCTCTACTCAAAGCTGA
    CCGTGGATAAGTCTCGCTGGCAGCAAGGGAATGTGTTTTCCTGTT
    CAGTGATGCATGAGGCCCTTCATAATCATTACACCCAAAAGTCA
    CTGAGCCTGTCTCCCGGA (SEQ ID NO: 46)
    KE94 Hu02 HC CAGGTTCAGCTGGTACAATCTGGCGCGGAAGTCAAAAAGCCAGG
    CGCAAGTGTTAAAGTGTCTTGCAAGGCTTCAGGATCTACCTTTAC
    AGATTTTGAAATCCACTGGGTAAGACAAGCACCTGGCCAGGGGC
    TGGAATGGATTGGTGCCATAGACCCTGAGACGGGAGGAACCGC
    ATATAACCAGAAATTCCAAGGTCGAGTGACTATTACTGCGGACA
    AGTCAACATCAACTGCCTATATGGAGCTGTCTTCTTTGAGGTCAG
    AGGATACAGCAGTTTACTACTGCACTAGAAATTACGATGGTTAT
    TCACGGACCTTCGATTATTGGGGTCAAGGCACTCTGGTGACCGT
    GAGTTCCGCTTCAACCAAGGGACCTTCTGTCTTTCCTCTGGCCCC
    TTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCACTCGGGTGCC
    TTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTGGAATT
    CAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGTGCTTC
    AGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGTGCCGT
    CCTCTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAATCATA
    AGCCTTCTAATACCAAGGTGGACAAGAAGGTGGAACCCAAATCA
    TGTGACAAGACCCACACCTGTCCGCCCTGTCCGGCACCCGAACT
    GCTGGGTGGCCCTTCCGTGTTCCTTTTCCCTCCAAAGCCGAAGGA
    CACTCTTATGATTTCTCGCACTCCCGAAGTGACTTGCGTCGTGGT
    GGATGTGTCCCATGAGGATCCAGAGGTCAAGTTCAACTGGTACG
    TGGACGGTGTGGAAGTCCACAACGCCAAGACTAAGCCGAGAGA
    GGAACAGTACAATTCAACCTATCGGGTGGTGAGCGTCCTGACCG
    TGCTGCACCAGGACTGGCTTAACGGAAAGGAGTACAAGTGCAA
    AGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGACCATTA
    GCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATACCCTT
    CCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCACTCAC
    TTGTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCGAATG
    GGAGTCCAATGGTCAGCCAGAGAACAACTACAAAACCACCCCTC
    CCGTGCTGGACAGCGACGGGTCTTTCTTTCTCTACTCAAAGCTGA
    CCGTGGATAAGTCTCGCTGGCAGCAAGGGAATGTGTTTTCCTGTT
    CAGTGATGCATGAGGCCCTTCATAATCATTACACCCAAAAGTCA
    CTGAGCCTGTCTCCCGGA (SEQ ID NO: 47)
    KE94 Hu03 HC CAGGTTCAGCTGGTACAATCTGGCGCGGAAGTCAAAAAGCCAGG
    CGCAAGTGTTAAAGTGTCTTGCAAGGCTTCAGGATCTACCTTTAC
    AGATTTTGAAATCCACTGGGTAAGACAAGCACCTGGCCAGGGGC
    TGGAATGGATTGGTGCCATAGACCCTGAGACGGGAGGAACCGC
    ATATAACCAGAAATTCCAAGGTCGAGTGACTATTACTGCGGACA
    AGTCAACATCAACTGCCTATATGGAGCTGTCTTCTTTGAGGTCAG
    AGGATACAGCAGTTTACTACTGCACTAGAAATTACGATGGTTAT
    TCACGGACCTTCGATTATTGGGGTCAAGGCACTCTGGTGACCGT
    GAGTTCCGCTTCAACCAAGGGACCTTCTGTCTTTCCTCTGGCCCC
    TTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCACTCGGGTGCC
    TTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTGGAATT
    CAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGTGCTTC
    AGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGTGCCGT
    CCTCTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAATCATA
    AGCCTTCTAATACCAAGGTGGACAAGAAGGTGGAACCCAAATCA
    TGTGACAAGACCCACACCTGTCCGCCCTGTCCGGCACCCGAACT
    GCTGGGTGGCCCTTCCGTGTTCCTTTTCCCTCCAAAGCCGAAGGA
    CACTCTTATGATTTCTCGCACTCCCGAAGTGACTTGCGTCGTGGT
    GGATGTGTCCCATGAGGATCCAGAGGTCAAGTTCAACTGGTACG
    TGGACGGTGTGGAAGTCCACAACGCCAAGACTAAGCCGAGAGA
    GGAACAGTACAATTCAACCTATCGGGTGGTGAGCGTCCTGACCG
    TGCTGCACCAGGACTGGCTTAACGGAAAGGAGTACAAGTGCAA
    AGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGACCATTA
    GCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATACCCTT
    CCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCACTCAC
    TTGTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCGAATG
    GGAGTCCAATGGTCAGCCAGAGAACAACTACAAAACCACCCCTC
    CCGTGCTGGACAGCGACGGGTCTTTCTTTCTCTACTCAAAGCTGA
    CCGTGGATAAGTCTCGCTGGCAGCAAGGGAATGTGTTTTCCTGTT
    CAGTGATGCATGAGGCCCTTCATAATCATTACACCCAAAAGTCA
    CTGAGCCTGTCTCCCGGA (SEQ ID NO: 48)
    KE94 Hu04 HC CAGGTTCAGCTGGTACAATCTGGCGCGGAAGTCAAAAAGCCAGG
    CGCAAGTGTTAAAGTGTCTTGCAAGGCTTCAGGATCTACCTTTAC
    AGATTTTGAAATCCACTGGGTAAGACAAGCACCTGGCCAGGGGC
    TGGAATGGATTGGTGCCATAGACCCTGAGACGGGAGGAACCGC
    ATATAACCAGAAATTCCAAGGTCGAGTGACTATTACTGCGGACA
    AGTCAACATCAACTGCCTATATGGAGCTGTCTTCTTTGAGGTCAG
    AGGATACAGCAGTTTACTACTGCACTAGAAATTACGATGGTTAT
    TCACGGACCTTCGATTATTGGGGTCAAGGCACTCTGGTGACCGT
    GAGTTCCGCTTCAACCAAGGGACCTTCTGTCTTTCCTCTGGCCCC
    TTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCACTCGGGTGCC
    TTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTGGAATT
    CAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGTGCTTC
    AGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGTGCCGT
    CCTCTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAATCATA
    AGCCTTCTAATACCAAGGTGGACAAGAAGGTGGAACCCAAATCA
    TGTGACAAGACCCACACCTGTCCGCCCTGTCCGGCACCCGAACT
    GCTGGGTGGCCCTTCCGTGTTCCTTTTCCCTCCAAAGCCGAAGGA
    CACTCTTATGATTTCTCGCACTCCCGAAGTGACTTGCGTCGTGGT
    GGATGTGTCCCATGAGGATCCAGAGGTCAAGTTCAACTGGTACG
    TGGACGGTGTGGAAGTCCACAACGCCAAGACTAAGCCGAGAGA
    GGAACAGTACAATTCAACCTATCGGGTGGTGAGCGTCCTGACCG
    TGCTGCACCAGGACTGGCTTAACGGAAAGGAGTACAAGTGCAA
    AGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGACCATTA
    GCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATACCCTT
    CCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCACTCAC
    TTGTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCGAATG
    GGAGTCCAATGGTCAGCCAGAGAACAACTACAAAACCACCCCTC
    CCGTGCTGGACAGCGACGGGTCTTTCTTTCTCTACTCAAAGCTGA
    CCGTGGATAAGTCTCGCTGGCAGCAAGGGAATGTGTTTTCCTGTT
    CAGTGATGCATGAGGCCCTTCATAATCATTACACCCAAAAGTCA
    CTGAGCCTGTCTCCCGGA (SEQ ID NO: 49)
    KE94 Hu01 LC GATATAGTTATGACACAGAGCCCTGACTCTCTGGCTGTGAGTTTG
    GGCGAGCGAGTAACCATTAATTGTAAGAGTTCTCAATCCGTCCT
    CTACTCAAGCAACCAGAAAAATTACCTCGCGTGGTACCAGCAAA
    AACCAGGACAGAGCCCCAAACTCTTGATCTATTGGGCGTCCACC
    CGAGAGAGTGGCGTGCCAGATCGGTTTTCAGGTTCTGGATCTGG
    TACCGACTTCACCCTTACAATCTCAAGCCTGCAAGCAGAGGATG
    TCGCAGTTTATTATTGCCATCAGTACCTGAGCAGCTACACATTCG
    GACAAGGAACGAAACTGGAAATCAAACGCACTGTGGCAGCCCC
    TTCTGTGTTTATCTTCCCACCCTCCGACGAGCAGCTCAAGTCCGG
    TACCGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCCAAGAGA
    GGCCAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCGGT
    AATTCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCA
    CCTACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACG
    AAAAGCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTT
    TCTAGCCCTGTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ
    ID NO: 50)
    KE94 Hu02 LC GACATAGTAATGACCCAAAGTCCAGATTCTTTGGCCGTATCTTTG
    GGTGAGCGCGTTACCATCAACTGTAAGTCTTCCCAGTCTGTGTTG
    TACTCATCTAATCAAAAAAACTACCTCGCTTGGTACCAGCAGAA
    GCCAGGTCAAAGCCCGAAACTGCTTATTTATTGGGCGTCTACGC
    GAGAGTCTGGGGTCCCCGATCGGTTTTCAGGGTCAGGCTCTGGC
    ACTGATTTTACTCTGACTATTTCATCCCTCCAAGCCGAAGACGTG
    GCAGTGTATTACTGCCACCAGTATTTGAGCCCTTACACGTTTGGG
    CAGGGGACTAAACTTGAAATCAAGCGCACTGTGGCAGCCCCTTC
    TGTGTTTATCTTCCCACCCTCCGACGAGCAGCTCAAGTCCGGTAC
    CGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCCAAGAGAGGC
    CAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCGGTAAT
    TCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCACCT
    ACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACGAA
    AAGCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTTTC
    TAGCCCTGTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ ID
    NO: 51)
    KE94 Hu03 LC GATATTGTGATGACTCAGTCACCTGACAGTCTGGCGGTTTCTTTG
    GGCGAAAGAGTGACTATAAATTGCAAAAGCAGCCAGTCAGTTCT
    CTATTCCGACAATCAAAAGAACTATCTCGCATGGTATCAGCAGA
    AGCCAGGGCAATCCCCAAAATTGCTTATATACTATGCATCAACG
    CGCGAAAGCGGTGTACCCGATCGGTTTTCAGGAAGTGGCAGTGG
    GACCGACTTTACGCTGACAATCTCTTCCCTTCAAGCGGAGGATGT
    CGCGGTTTATTATTGTCATCAGTATCTGAGTCCTTACACCTTTGG
    TCAAGGGACGAAGTTGGAGATCAAACGCACTGTGGCAGCCCCTT
    CTGTGTTTATCTTCCCACCCTCCGACGAGCAGCTCAAGTCCGGTA
    CCGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCCAAGAGAGG
    CCAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCGGTAA
    TTCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCACCT
    ACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACGAA
    AAGCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTTTC
    TAGCCCTGTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ ID
    NO: 52)
    KE94 Hu04 LC GACATCGTAATGACCCAGTCCCCCGATAGTCTGGCTGTGTCTTTG
    GGCGAGAGGGTAACGATAAACTGTAAATCAAGTCAGTCAGTGCT
    TTACTCAGATAACCAGAAGAACTATCTTGCGTGGTATCAGCAAA
    AGCCCGGACAGTCTCCAAAACTTCTTATATATTTCGCTTCTACCA
    GAGAATCAGGTGTACCAGACCGCTTTTCTGGAAGCGGCTCTGGT
    ACTGACTTTACCCTGACAATTAGTAGCTTGCAAGCTGAAGATGTT
    GCGGTATATTATTGTCACCAATACTTGAGTCCCTATACTTTTGGC
    CAAGGGACAAAACTGGAAATAAAGCGCACTGTGGCAGCCCCTTC
    TGTGTTTATCTTCCCACCCTCCGACGAGCAGCTCAAGTCCGGTAC
    CGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCCAAGAGAGGC
    CAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCGGTAAT
    TCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCACCT
    ACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACGAA
    AAGCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTTTC
    TAGCCCTGTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ ID
    NO: 53)
  • Affinities of the humanized KC18 antibodies to human and mouse FGFR3 were determined and are shown in Table 10 below. The affinities of these humanized antibodies are comparable to the parental KC18 antibody.
  • TABLE 10
    Affinities to human and mouse FGFR3 of the humanized KC18 antibodies
    KC18 hFGFR3 mFGFR3
    Variants ka kd KD ka kd KD
    Hu7 1.96E+05 1.06E−3 5.41E−09 1.98E+05 1.26E−3 6.36E−09
    Hu10 2.78E+05 1.32E−3 4.73E−09 2.86E+05 1.47E−3 5.15E−09
    Hu12 3.27E+05 5.27E−04 1.61E−09 3.37E+05 5.83E−04 1.73E−09
    Hu13 1.89E+05 8.57E−04 4.52E−09 1.93E+05 1.02E−3 5.28E−09
    Hu16 2.76E+05 1.04E−3 3.76E−09 2.78E+05 1.18E−3 4.23E−09
    Hu18 3.34E+05 4.17E−04 1.25E−09 3.37E+05 4.79E−04 1.42E−09
    Hu19 2.25E+05 6.75E−04 2.99E−09 2.35E+05 8.85E−04 3.78E−09
    Hu23 2.41E+05 6.48E−04 2.68E−09 2.54E+05 8.50E−04 3.35E−09
    Hu27 2.14E+05 8.34E−04 3.90E−09 2.20E+05 1.01E−3 4.60E−09
    Hu28 2.13E+05 9.49E−04 4.46E−09 2.10E+05 1.14E−3 5.41E−09
    Hu33 1.66E+05 1.14E−3 6.89E−09 1.68E+05 1.54E−3 9.15E−09
    Hu34 1.55E+05 1.06E−3 6.85E−09 1.64E+05 1.34E−3 8.14E−09
    KC18 2.13E+05 5.80E−04 2.73E−09 2.20E+05 8.32E−04 3.78E−09
  • Humanized antibodies KC18_Hu42 to KC18_49 were designed based on the sequence of KC_Hu18 to further remove liability sites, such as oxidation sites in FRWH3 and CDRH3, a deamidation site in CDRL1, and an oxidation site in CDRL2 (Table 11). At the end, two additional variants each for VH and VL were designed, which resulted in 8 more variants (KC18_Hu42-49) in addition to KC18_Hu18 (Table 12).
  • TABLE 11
    Liability motifs in KC18_Hu18. The IMGT definition was
    used. Liability residues are underlined in the sequences.
    Liability Modi- Involved Proposed
    Motif fication Region Sequence in binding mutations
    W Oxidation HFW2 IHWVQQAPGKGLEWIGD No Y
    (SEQ ID NO: 340)
    M Oxidation HFW3 AYAEKFQGRATLTADRSTD No L
    TAYMELSSLRSEDTAVYYC
    (SEQ ID NO: 341)
    W Oxidation HFW4 WGQGTLVTVSS No Y
    (SEQ ID NO: 342)
    NNN Deamidation LCDR1 QSVLYSNNNKNY Yes DNQ
    (SEQ ID NO: 302)
    W Oxidation LCDR2 WAS (SEQ ID NO: 74) Yes Y and F
  • A sequence alignment of Hu18 and the newly designed variants (Hu42-49) is shown in FIG. 7 . Mutations of Hu18 residues are underlined.
  • TABLE 12
    Human and mouse germline identity percentage of the desiged KC18 variants.
    KC18_VL_3 KC18_VL_14 KC18_VL_15
    KC18 (SEQ ID NO: 59) (SEQ ID NO: 60) (SEQ ID NO: 61)
    Human 95.05% 92.08% 92.08%
    Mouse 86.14% 87.13% 87.13%
    KC18_VH_6 83.67% 72.45% KC18_Hu18 KC18_Hu42 KC18_Hu43
    (SEQ ID NO: 56)
    KC18_VH_15 82.65% 71.43% KC18_Hu44 KC18_Hu45 KC18_Hu46
    (SEQ ID NO: 57)
    KC18_VH_16 81.63% 70.41% KC18_Hu47 KC18_Hu48 KC18_Hu49
    (SEQ ID NO: 58)
  • TABLE 13
    Designed KC18 variant amino acid sequences.
    Antibody ID Sequence
    KC18_VH_6 EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSS (SEQ ID NO: 56)
    KC18_VH_15 EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSS (SEQ ID NO: 57)
    KC18_VH_16 EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSS (SEQ ID NO: 58)
    KC18_VL_3 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSNNNKNYLAWYQQKPGQSP
    KLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSY
    RTFGGGTKVEIK (SEQ ID NO: 59)
    KC18_VL_14 DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSDNQKNYLAWYQQKPGQSP
    KLLIYYASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYR
    TFGGGTKLEIK (SEQ ID NO: 60)
    KC18_VL_15 DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSDNQKNYLAWYQQKPGQSP
    KLLIYFASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYR
    TFGGGTKLEIK (SEQ ID NO: 61)
  • TABLE 14
    Designed KC18 variant sequences.
    Antibody ID Sequence
    KC18 Hu44 GAGGTTCAGTTGGTGCAAAGTGGGGCCGAGGTTAAAAAACCAGGTGC
    Heavy chain AACCGTGAAACTGTCCTGCAAGGCGAGTGGTGATACATTTACAGATTT
    nucleic acids TGAAATTCATTGGGTACAGCAGGCACCCGGAAAGGGATTGGAATGGAT
    (with constant AGGAGATGTGGACCCGGAGACTGGCGGAACCGCGTACGCGGAGAAAT
    region) TTCAGGGCAGAGCCACTTTGACGGCGGATAGAAGTACGGATACTGCCT
    ACCTTGAACTGAGTTCCTTGCGGTCCGAAGATACGGCAGTTTACTATTG
    TACTCGCACGTATGATGGCTACCCATACGCTTTCGATTATTGGGGACAA
    GGCACTCTCGTGACCGTATCTTCAGCTTCAACCAAGGGACCTTCTGTCT
    TTCCTCTGGCCCCTTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCAC
    TCGGGTGCCTTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTG
    GAATTCAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGTGCTT
    CAGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGTGCCGTCCT
    CTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAATCATAAGCCTTC
    TAATACCAAGGTGGACAAGAAGGTGGAACCCAAATCATGTGACAAGA
    CCCACACCTGTCCGCCCTGTCCGGCACCCGAACTGCTGGGTGGCCCTTC
    CGTGTTCCTTTTCCCTCCAAAGCCGAAGGACACTCTTATGATTTCTCGC
    ACTCCCGAAGTGACTTGCGTCGTGGTGGATGTGTCCCATGAGGATCCA
    GAGGTCAAGTTCAACTGGTACGTGGACGGTGTGGAAGTCCACAACGCC
    AAGACTAAGCCGAGAGAGGAACAGTACAATTCAACCTATCGGGTGGT
    GAGCGTCCTGACCGTGCTGCACCAGGACTGGCTTAACGGAAAGGAGTA
    CAAGTGCAAAGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGA
    CCATTAGCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATACCC
    TTCCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCACTCACTT
    GTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCGAATGGGAGT
    CCAATGGTCAGCCAGAGAACAACTACAAAACCACCCCTCCCGTGCTGG
    ACAGCGACGGGTCTTTCTTTCTCTACTCAAAGCTGACCGTGGATAAGTC
    TCGCTGGCAGCAAGGGAATGTGTTTTCCTGTTCAGTGATGCATGAGGC
    CCTTCATAATCATTACACCCAAAAGTCACTGAGCCTGTCTCCCGGA
    (SEQ ID NO: 62)
    KC18 Hu44 EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    Heavy Chain DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    amino acids YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    (with constant KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    region) YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK
    DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
    STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
    VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
    DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    (SEQ ID NO: 63)
    KC18 Hu46 GAGGTTCAGTTGGTGCAAAGTGGGGCCGAGGTTAAAAAACCAGGTGC
    Heavy Chain AACCGTGAAACTGTCCTGCAAGGCGAGTGGTGATACATTTACAGATTT
    nucleic acids TGAAATTCATTGGGTACAGCAGGCACCCGGAAAGGGATTGGAATGGAT
    (with constant AGGAGATGTGGACCCGGAGACTGGCGGAACCGCGTACGCGGAGAAAT
    region) TTCAGGGCAGAGCCACTTTGACGGCGGATAGAAGTACGGATACTGCCT
    ACCTTGAACTGAGTTCCTTGCGGTCCGAAGATACGGCAGTTTACTATTG
    TACTCGCACGTATGATGGCTACCCATACGCTTTCGATTATTGGGGACAA
    GGCACTCTCGTGACCGTATCTTCAGCTTCAACCAAGGGACCTTCTGTCT
    TTCCTCTGGCCCCTTCAAGCAAGAGCACTTCCGGAGGGACTGCCGCAC
    TCGGGTGCCTTGTGAAAGATTACTTCCCAGAGCCTGTCACCGTCAGCTG
    GAATTCAGGCGCTCTGACTAGCGGAGTGCACACCTTCCCCGCTGTGCTT
    CAGTCCTCCGGACTCTACTCTCTGAGCAGCGTGGTGACCGTGCCGTCCT
    CTTCTCTGGGGACCCAGACTTATATCTGCAACGTCAATCATAAGCCTTC
    TAATACCAAGGTGGACAAGAAGGTGGAACCCAAATCATGTGACAAGA
    CCCACACCTGTCCGCCCTGTCCGGCACCCGAACTGCTGGGTGGCCCTTC
    CGTGTTCCTTTTCCCTCCAAAGCCGAAGGACACTCTTATGATTTCTCGC
    ACTCCCGAAGTGACTTGCGTCGTGGTGGATGTGTCCCATGAGGATCCA
    GAGGTCAAGTTCAACTGGTACGTGGACGGTGTGGAAGTCCACAACGCC
    AAGACTAAGCCGAGAGAGGAACAGTACAATTCAACCTATCGGGTGGT
    GAGCGTCCTGACCGTGCTGCACCAGGACTGGCTTAACGGAAAGGAGTA
    CAAGTGCAAAGTGTCAAACAAGGCACTGCCCGCTCCGATCGAAAAGA
    CCATTAGCAAAGCTAAGGGCCAGCCCAGAGAACCCCAAGTCTATACCC
    TTCCACCCAGCCGGGACGAGCTGACCAAAAACCAGGTGTCACTCACTT
    GTCTCGTGAAGGGTTTCTACCCCTCAGACATCGCCGTCGAATGGGAGT
    CCAATGGTCAGCCAGAGAACAACTACAAAACCACCCCTCCCGTGCTGG
    ACAGCGACGGGTCTTTCTTTCTCTACTCAAAGCTGACCGTGGATAAGTC
    TCGCTGGCAGCAAGGGAATGTGTTTTCCTGTTCAGTGATGCATGAGGC
    CCTTCATAATCATTACACCCAAAAGTCACTGAGCCTGTCTCCCGGA
    (SEQ ID NO: 64)
    KC18 Hu46 EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    Heavy Chain DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    amino acids YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    (with constant KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    region) YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK
    DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
    STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
    VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
    DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    (SEQ ID NO: 65)
    KC18 Hu44 GACATTGTAATGACACAATCTCCCGACTCTCTTGCAGTCAGCTTGGGTG
    Light Chain AACGAGCAACTATAAATTGTAAAAGCAGCCAGTCTGTACTCTACTCTA
    nucleic acids ATAACAACAAGAACTACCTCGCATGGTATCAGCAGAAACCGGGGCAA
    (with constant AGTCCTAAACTTTTGATCTATTGGGCAAGTACCAGGGAGAGCGGAGTA
    region) CCCGACAGATTCAGCGGGTCTGGATCAGGCACCGATTTTACTCTCACC
    ATTTCTTCAGTTCAAGCTGAAGACGTCGCAGTCTACTACTGCCAGCAGT
    ATTACAGTTACCGAACTTTTGGCGGTGGAACAAAAGTGGAAATAAAGC
    GCACTGTGGCAGCCCCTTCTGTGTTTATCTTCCCACCCTCCGACGAGCA
    GCTCAAGTCCGGTACCGCCTCTGTCGTCTGCCTGCTGAACAATTTCTAC
    CCAAGAGAGGCCAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAG
    CGGTAATTCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCA
    CCTACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACGAAAA
    GCACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTTTCTAGCCCT
    GTGACCAAGAGCTTCAACAGAGGCGAATGC (SEQ ID NO: 66)
    KC18 Hu44 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSNNNKNYLAWYQQKPGQSP
    Light Chain KLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSY
    amino acids RTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
    (with constant QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
    region) VTHQGLSSPVTKSFNRGEC (SEQ ID NO: 67)
    KC18 Hu46 GACATAGTTATGACCCAGTCTCCAGACTCCCTCGCAGTTTCTCTCGGCG
    Light Chain AGAGAGTAACAATCAACTGTAAGTCATCACAGTCCGTACTCTACTCTG
    nucleic acids ACAACCAAAAGAATTATTTGGCTTGGTATCAGCAAAAGCCAGGACAAA
    (with constant GCCCCAAACTTCTTATCTATTTTGCCAGCACTAGGGAGTCCGGGGTACC
    region) CGACCGCTTTAGTGGCTCAGGTTCTGGGACAGACTTTACACTGACCATT
    TCTAGCGTACAGGCTGAAGACGTTGCAGTCTACTACTGCCAGCAATAC
    TATTCTTACAGAACGTTTGGCGGGGGCACAAAGTTGGAGATCAAACGC
    ACTGTGGCAGCCCCTTCTGTGTTTATCTTCCCACCCTCCGACGAGCAGC
    TCAAGTCCGGTACCGCCTCTGTCGTCTGCCTGCTGAACAATTTCTACCC
    AAGAGAGGCCAAGGTGCAGTGGAAGGTGGACAACGCACTGCAAAGCG
    GTAATTCACAAGAGTCAGTCACCGAACAAGACTCAAAGGACAGCACCT
    ACTCACTGTCATCCACCCTGACTCTCTCAAAGGCTGACTACGAAAAGC
    ACAAAGTGTATGCTTGTGAAGTCACTCATCAGGGCCTTTCTAGCCCTGT
    GACCAAGAGCTTCAACAGAGGCGAATGC (SEQ ID NO: 68)
    KC18 Hu46 DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSDNQKNYLAWYQQKPGQSP
    Light Chain KLLIYFASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYR
    amino acids TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
    (with constant WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
    region) THQGLSSPVTKSFNRGEC (SEQ ID NO: 69)
  • TABLE 15
    Humanized Anti-FGFR3 Fab fragment heavy chain amino
    acid sequences.
    Antibody ID Sequence
    Fab Heavy chain QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 141)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 143)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 145)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 147)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 149)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDEEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 151)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 153)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 155)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 156)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKS (SEQ ID NO: 164)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKS (SEQ ID NO: 165)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKS (SEQ ID NO: 166)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKS (SEQ ID NO: 167)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDEEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKS (SEQ ID NO: 168)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDNEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKS (SEQ ID NO: 169)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKS (SEQ ID NO: 170)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKS (SEQ ID NO: 171)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKS (SEQ ID NO: 172)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPK (SEQ ID NO: 173)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPK (SEQ ID NO: 174)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPK (SEQ ID NO: 175)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPK (SEQ ID NO: 176)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPK (SEQ ID NO: 177)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDNEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPK (SEQ ID NO: 178)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPK (SEQ ID NO: 179)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPK (SEQ ID NO: 180)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPK (SEQ ID NO: 181)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEP (SEQ ID NO: 182)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEP (SEQ ID NO: 183)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEP (SEQ ID NO: 184)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEP (SEQ ID NO: 185)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEP (SEQ ID NO: 186)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEP (SEQ ID NO: 187)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEP (SEQ ID NO: 188)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEP (SEQ ID NO: 189)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEP (SEQ ID NO: 190)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVE (SEQ ID NO: 191)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVE (SEQ ID NO: 192)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVE (SEQ ID NO: 193)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVE (SEQ ID NO: 194)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVE (SEQ ID NO: 195)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVE (SEQ ID NO: 196)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVE (SEQ ID NO: 197)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVE (SEQ ID NO: 198)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVE (SEQ ID NO: 199)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKV (SEQ ID NO: 200)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKV (SEQ ID NO: 201)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKV (SEQ ID NO: 202)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKV (SEQ ID NO: 203)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKV (SEQ ID NO: 204)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKV (SEQ ID NO: 205)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKV (SEQ ID NO: 206)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKV (SEQ ID NO: 207)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKV (SEQ ID NO: 208)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKK (SEQ ID NO: 209)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKK (SEQ ID NO: 210)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKK (SEQ ID NO: 211)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKK (SEQ ID NO: 212)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKK (SEQ ID NO: 213)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKK (SEQ ID NO: 214)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKK (SEQ ID NO: 215)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKK (SEQ ID NO: 216)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKK (SEQ ID NO: 217)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDK (SEQ ID NO: 218)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDK (SEQ ID NO: 219)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDK (SEQ ID NO: 220)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDK (SEQ ID NO: 221)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDK (SEQ ID NO: 222)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDK (SEQ ID NO: 223)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDK (SEQ ID NO: 224)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDK (SEQ ID NO: 225)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDK (SEQ ID NO: 226)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 227)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 228)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 229)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 230)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 231)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 232)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 233)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 234)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 235)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHTC (SEQ ID NO: 236)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTHTC (SEQ ID NO: 237)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTHTC (SEQ ID NO: 238)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKSCDKTHTC (SEQ ID NO: 239)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHTC (SEQ ID NO: 240)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHTC (SEQ ID NO: 241)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTHTC (SEQ ID NO: 242)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHTC (SEQ ID NO: 243)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHTC (SEQ ID NO: 244)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 245)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 246)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 247)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 248)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 249)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 250)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 251)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 252)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 253)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 254)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 255)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 256)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 257)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 258)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 259)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 260)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 261)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 262)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 263)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 264)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 265)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 266)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 267)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 268)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 269)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 270)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 271)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDK (SEQ ID NO: 272)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDK (SEQ ID NO: 273)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDK (SEQ ID NO: 274)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKSCDK (SEQ ID NO: 275)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDK (SEQ ID NO: 276)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDFEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDK (SEQ ID NO: 277)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCDK (SEQ ID NO: 278)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDK (SEQ ID NO: 279)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDK (SEQ ID NO: 280)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWIGD
    IDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYCTRTY
    DGYPYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCD (SEQ ID NO: 281)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWI
    GYINPNNGGTRYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCA
    RERDYDGAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCD (SEQ ID NO: 282)
    EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLQWI
    GYINPNNGGTNYNQNFKDKATLTVNKSSTTAYMELRSLTSEDSAVYYCA
    RERDYDGSMDFWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCD (SEQ ID NO: 283)
    EVQLQQSGPDLVKPGASVKISCKASGYTVTDYYMNWVKQSHGKSLEWIG
    DINPNNGVTTYNQKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARE
    EDFDGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
    YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKSCD (SEQ ID NO: 284)
    QVQLQQSGAELVRPGASVTLSCKASGSTFSDFEIHWVKQTPVHGLEWIGG
    IDPETGGTAYNQKFKGKAILTADRSSSTAYMELRSLTSEDSAVYYCTRNY
    DGYSQTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCD (SEQ ID NO: 285)
    QVQLQQSGAELVRPGASVTLSCKASGSTFTDNEIHWVKQTPVHGLEWIGA
    IDPETGGTAYNQKFKGKAILTAVKSSSTAYMGLRSLTSEDSAVYYCTRNY
    DGYSRTMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCD (SEQ ID NO: 286)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYMELSSLRSEDTAVYYCTR
    TYDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
    TYICNVNHKPSNTKVDKKVEPKSCD (SEQ ID NO: 287)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEWIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCD (SEQ ID NO: 288)
    EVQLVQSGAEVKKPGATVKLSCKASGDTFTDFEIHWVQQAPGKGLEYIG
    DVDPETGGTAYAEKFQGRATLTADRSTDTAYLELSSLRSEDTAVYYCTRT
    YDGYPYAFDYYGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCD (SEQ ID NO: 289)
  • TABLE 16
    Humanized Anti-FGFR3 Fab fragment light chain amino acid
    sequences.
    Antibody ID Sequence
    Fab Light chain DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSNNQKNYLAWYQQKPGQS
    PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY
    RTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
    QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
    VTHQGLSSPVTKSFNRGEC (SEQ ID NO: 142)
    DIQMTQSPSSLSASLGGKVTITCKASQDINKFIAWYQHKPGKGPRLLIHYTS
    TLQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLLWTFGGGTKL
    EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
    QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
    VTKSFNRGEC (SEQ ID NO: 144)
    DIQMTQSPSSLSASLGGKVTITCKASQDINKFIAWYQHKPGKGPRLLIHYTS
    TLQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYFCLQYDNLLWTFGGGTKL
    EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
    QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
    VTKSFNRGEC (SEQ ID NO: 146)
    DIVMTQSHKFMSTSVGDRVSITCKASQDVSTGVAWYQQKPGQSPQLLIY
    WASTRHTGVPDRFTGSGSGTDYILTIRSVQAEDLALYYCQQHYSTPLTFG
    AGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK
    VDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
    GLSSPVTKSFNRGEC (SEQ ID NO: 148)
    NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLYSSNQKNYLAWYQQKPGQS
    PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCHQYLSS
    YTFGGGTKLEMKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
    VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
    EVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 150)
    NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLYSSNQKNYLAWYQQKPGQS
    PKLLIYWASTRESGVPDRFTGSGSGTDFSLSISSVQTEDLAVYYCHQYLSS
    YTFGGGTRLEMKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
    QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
    VTHQGLSSPVTKSFNRGEC (SEQ ID NO: 152)
    DIVMTQSPDSLAVSLGERATINCKSSQSVLYSNNNKNYLAWYQQKPGQSP
    KLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSY
    RTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
    QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
    VTHQGLSSPVTKSFNRGEC (SEQ ID NO: 67)
    DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSDNQKNYLAWYQQKPGQSP
    KLLIYFASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYR
    TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
    WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
    THQGLSSPVTKSFNRGEC (SEQ ID NO: 69)
    DIVMTQSPDSLAVSLGERVTINCKSSQSVLYSDNQKNYLAWYQQKPGQSP
    KLLIYYASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYR
    TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
    WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
    THQGLSSPVTKSFNRGEC (SEQ ID NO: 154)
  • In certain embodiments, an anti-FGFR3 F(ab) fragment of the present application comprises a heavy chain of Table 15, and a light chain in Table 16.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 141, 164, 173, 182, 191, 200, 209, 218, 227, 236, 245, 254, 263, 272, or 281, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 142.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 143, 165, 174, 183, 192, 201, 210, 219, 228, 237, 246, 255, 264, 273, or 282, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 144.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 145, 166, 175, 184, 193, 202, 211, 220, 229, 238, 247, 256, 265, 274, or 283 and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 146.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 147, 167, 176, 185, 194, 203, 212, 221, 230, 239, 248, 257, 266, 275, or 284, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 148.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 149, 168, 177, 186, 195, 204, 213, 222, 231, 240, 249, 258, 267, 276, or 285, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 150.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 151, 169, 178, 187, 196, 205, 214, 223, 232, 241, 250, 259, 268, 277, or 286, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 152.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154.
  • In certain embodiments, the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
  • In Vitro Analysis
  • Antibodies were screened for binding and specificity to FGFR3. Activity was assessed using a Homogenous Time-Resolved Fluorescence (HTRF) assay to evaluate the level of inhibition on Erk phosphorylation using mouse primary rib chondrocytes. Briefly, primary mouse rib chondrocyte cells isolated from the achondroplasia mouse model were pretreated for 2 hours with anti-FGFR3 antibodies with a concentration ranging from 0.016 μg/ml to 100 μg/ml. Cells were then stimulated with FGF18 for 5 minutes. The reaction was then stopped, total Erk was measured using the HTRF assay, and Phospho-Erk (Thr202/Tyr204) was measured in a separate HTRF assay. The percent inhibition of Erk phosphorylation was measured by taking the ratio of Phospho-Erk over total Erk and multiplying by 100. Particularly, mouse antibodies KC18, KE63, and KE94 and their corresponding Fab fragments were tested in the HTRF assay, all of which inhibited Erk phosphorylation (FIG. 9A and FIG. 9B).
  • To determine the effects of different mouse antibody formats on inhibition of Erk phosphorylation, KC18 mouse antibody in various formats, including full-length antibody (IgG), Fab, a one-armed, monovalent antibody (MetMab), and pegylated (PEG) Fab fragment were tested in the HTRF assay and compared to isotype control (Iso). Also, KC18 Fab with half-life extension using a human albumin nanobody (KC18 Fab-HLE) was tested, with and without human serum albumin (HSA) or mouse serum albumin (MSA).
  • The full-length KC18 mouse antibody has a heavy chain of SEQ ID NO: 291 (with mIgG2a Fc sequence), and a light chain of SEQ ID NO: 292. The KC18 mouse Fab antibody has a heavy chain of SEQ ID NO: 293, and a light chain of SEQ ID NO: 294.
  • (SEQ ID NO: 291)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWI
    GDIDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYC
    TRTYDGYPYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVT
    LGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTS
    STWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPPVAGP
    SVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHT
    AQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKGLPSSIER
    TISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWT
    NNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHE
    GLHNHHTTKSFSRTPGK
    (SEQ ID NO: 292)
    DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSNNQKNYLAWYQQKPGQ
    SPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQ
    YYSYRTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNF
    YPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYE
    RHNSYTCEATHKTSTSPIVKSFNRNEC
    (SEQ ID NO: 293)
    QVQLQQSGAELVRPGASVTLSCKASGDTFTDFEIHWVKQTPVHGLEWI
    GDIDPETGGTAYNQKFRGRAMLTADRSSSTAYMELRSLTSEDSAVYYC
    TRTYDGYPYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVT
    LGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTS
    STWPSQSITCNVAHPASSTKVDKKI
    (SEQ ID NO: 294)
    DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSNNQKNYLAWYQQKPGQ
    SPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQ
    YYSYRTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNF
    YPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYE
    RHNSYTCEATHKTSTSPIVKSFNRNEC
  • All formats inhibited Erk phosphorylation (FIG. 10A to FIG. 10C). The antibody format referred to in FIG. 10A as “MetMab” is described in further detail in Merchant et al. (PNAS. 110(32): E2987-E2996. 2013).
  • Humanized FGFR3 antibodies, including Hu18, Hu44, and Hu46, were also tested in the HTRF assay, and found to inhibit Erk phosphorylation (FIG. 11 ). The IC50s of these humanized antibodies were determined, as well (FIG. 8A to FIG. 8C, respectively).
  • In Vivo Analysis
  • For in vivo evaluation of the antibodies, an achondroplasia mouse model (Ach) was used. The achondroplasia mouse is a transgenic mouse that overexpresses the mouse FGFR3 protein having the G380R mutation under control of the collagen II promoter (Shazeeb et al., (2018) Sci Rep 8, 469). The mice were genotyped at 1 day of age, and randomized to either a control (i.e., saline) group or an antibody dosed group. Achondroplasia mice (G380R) received a daily dose subcutaneously (SC) from 3 days of age to 20 days of age. The mice were then euthanized, and bones were collected at 21 days of age for microCT analysis. Tibias, femurs, vertebrae and skulls were used for the analysis, and lengths were measured using 3D microCT analysis. AMIRA (V6.0.1, FEI, Hillsboro, OR, USA) was used for all numerical analysis of bone lengths. The lengths of leg bones were measured using seed points along the bone, and a 3D length tool in AMIRA. The results indicated that achondroplasia (Ach) mice treated with KC18 Fab had a significantly increased tibia and femur length (FIG. 12A and FIG. 12B), a significantly increased vertebra and skull length (FIG. 13A and FIG. 13B), a significantly increased brain volume (FIG. 14 ), and corrected vertebral abnormalities as measured by Kyphosis Index (FIG. 15A-FIG. 15B). Ach mice treated with KC18 Fab also had several improved bone parameters, including femur growth plate volume, and femur diameter (FIG. 16A and FIG. 16B). Ach mice treated with KC18 Fab also had improved bone age as shown by more developed secondary ossification center in tibia (FIG. 17 ) compared to those treated with vehicle.
  • In summary, achondroplasia is the most common form of dwarfism due to activating mutations in the FGFR3 gene. FGFR3 protein is expressed in the growth plate and its function is to regulate proper growth. However, the activating mutations lead to excessive inhibition of chondrocyte proliferation and differentiation which is the main cause for the short stature and other skeletal deformities. The antibodies generated herein are specific to FGFR3 and inhibit FGFR3 activity. The mechanism of action of the antibody is to inhibit ligand binding and prevent activation of the receptor. The antibodies described herein can block ligand activation and subsequently inhibit downstream signaling measured by the decrease in Erk phosphorylation. This translates into inhibition of receptor activity. In vivo testing of anti-FGFR3 antibodies in the Ach mouse model demonstrated efficacy on the axial and appendicular skeleton. More specifically, a significant increase in femur and tibia length, skull length as well as lumbar length were observed.

Claims (28)

1. An antigen-binding protein or antigen-binding fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein:
(a) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GX1TFTDX2E (SEQ ID NO: 157), wherein X1 is Y or D and X2 is F or Y;
a CDR-H2 sequence comprising the amino acid sequence of IDPETGX3T (SEQ ID NO: 158), wherein X3 is G or S; or a CDR-H2 sequence comprising the amino acid sequence of INPNNGX4T (SEQ ID NO: 159), wherein X4 is G or V; or a CDR-H2 sequence comprising the amino acid sequence of VX5PETGGT (SEQ ID NO: 160), wherein X5 is D or E;
a CDR-H3 sequence comprising the amino acid sequence of TRX6YX7GYX8X9X10X11DY (SEQ ID NO: 161), wherein X6 is T or N, X7 is D or E, X8 is S or P, X9 is Q, R, or Y, X10 is T or A, X11 is F or M; and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QSX12LYSX13NX14KNY (SEQ ID NO: 162), wherein X12 is L or V, X13 is N, D, or S, and X14 is Q or N;
a CDR-L2 sequence comprising the amino acid sequence of X15AS (SEQ ID NO: 163), wherein X15 is W, Y, or F;
a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75), LQYDNLLWT (SEQ ID NO: 81), or HQYLSX16YT (SEQ ID NO: 290) wherein X16 is P or S;
(b) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82);
a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83);
a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGAMDY (SEQ ID NO: 78); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85);
a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86);
a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
(c) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82);
a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83);
a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGSMDF (SEQ ID NO: 84); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85);
a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86);
a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
(d) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GYTVTDYY (SEQ ID NO: 88);
a CDR-H2 sequence comprising the amino acid sequence of INPNNGVT (SEQ ID NO: 89);
a CDR-H3 sequence comprising the amino acid sequence of AREEDFDGFDY (SEQ ID NO: 90); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QDVSTG (SEQ ID NO: 91);
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104);
a CDR-L3 sequence comprising the amino acid sequence of QQHYSTPLT (SEQ ID NO: 93);
(e) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GSTFSDFE (SEQ ID NO: 94);
a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101);
a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTX17DY (SEQ ID NO: 308), wherein X17 is M or F; and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QSVLYSX18NQKNY (SEQ ID NO: 309, wherein X18 is S or D;
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104);
a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105); or
(f) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GSTFTDFE (SEQ ID NO: 100);
a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101);
a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTX17DY (SEQ ID NO: 308), wherein X17 is M or F; and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QSVLYSX18NQKNY (SEQ ID NO: 309), wherein X18 is S or D;
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104);
a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105).
2. The antigen binding protein or antigen-binding fragment thereof of claim 1, wherein:
(a) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GDTFTDFE (SEQ ID NO: 70), GDTFTDYE (SEQ ID NO: 295), or GYTFTDFE (SEQ ID NO: 296);
a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101), VDPETGGT (SEQ ID NO: 297), IDPETGST (SEQ ID NO: 298), or VEPETGGT (SEQ ID NO: 299);
a CDR-H3 sequence comprising the amino acid sequence of TRTYDGYPYAMDY (SEQ ID NO: 72), TRTYEGYPYAMDY (SEQ ID NO: 300), or TRTYDGYPYAFDY (SEQ ID NO: 301); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QSLLYSNNQKNY (SEQ ID NO: 73), QSVLYSNNNKNY (SEQ ID NO: 302), or QSVLYSDNQKNY (SEQ ID NO: 306);
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, 104), YAS (SEQ ID NO: 303), or FAS (SEQ ID NO: 304);
a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75);
(b) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82);
a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83);
a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGAMDY (SEQ ID NO: 78); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85);
a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86);
a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
(c) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82);
a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83);
a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGSMDF (SEQ ID NO: 84); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85);
a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86);
a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
(d) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GYTVTDYY (SEQ ID NO: 88);
a CDR-H2 sequence comprising the amino acid sequence of INPNNGVT (SEQ ID NO: 89);
a CDR-H3 sequence comprising the amino acid sequence of AREEDFDGFDY (SEQ ID NO: 90); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QDVSTG (SEQ ID NO: 91);
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104);
a CDR-L3 sequence comprising the amino acid sequence of QQHYSTPLT (SEQ ID NO: 93);
(e) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GSTFSDFE (SEQ ID NO: 94);
a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101);
a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTMDY (SEQ ID NO: 96) or TRNYDGYSQTFDY (SEQ ID NO: 305); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY (SEQ ID NOs: 97 and 103) or QSVLYSDNQKNY (SEQ ID NO: 306);
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104);
a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105); or
(f) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GSTFTDFE (SEQ ID NO: 100);
a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101);
a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSRTMDY (SEQ ID NO: 102) or TRNYDGYSRTFDY (SEQ ID NO: 307); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QSVLYSSNQKNY (SEQ ID NOs: 97 and 103) or QSVLYSDNQKNY (SEQ ID NO: 306);
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104);
a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105).
3. The antigen binding protein or antigen-binding fragment thereof of claim 1, wherein:
(a) the VH domain comprises an amino acid sequence selected from the group consisting of:
SEQ ID NO: 6, SEQ ID NO: 18, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 10, SEQ ID NO: 110, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, and SEQ ID NO: 122; and
the VL domain comprises an amino acid sequence selected from the group consisting of:
SEQ ID NO: 7, SEQ ID NO: 19, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, and SEQ ID NO: 132;
(b) the VH domain comprises the amino acid sequence of SEQ ID NO: 8; and
the VL domain comprises the amino acid sequence of SEQ ID NO: 9;
(c) the VH domain comprises the amino acid sequence of SEQ ID NO: 10; and
the VL domain comprises the amino acid sequence of SEQ ID NO: 11;
(d) the VH domain comprises the amino acid sequence of SEQ ID NO: 12; and
the VL domain comprises the amino acid sequence of SEQ ID NO: 13;
(e) the VH domain comprises an amino acid sequence selected from the group consisting of:
SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 23; and
the VL domain comprises an amino acid sequence selected from the group consisting of:
SEQ ID NO: 15, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27;
(f) the VH domain comprises an amino acid sequence selected from the group consisting of:
SEQ ID NO: 16, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31;
the VL domain comprises an amino acid sequence selected from the group consisting of:
SEQ ID NO: 17, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
4. The antigen binding protein or antigen-binding fragment thereof of claim 1, wherein the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 63 or 65, and the antibody light chain comprises the amino acid sequence of SEQ ID NO: 67 or 69.
5. The antigen binding protein or antigen-binding fragment thereof of claim 3, wherein the VH domain is at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, or SEQ ID NO: 122, and
wherein the VL domain is at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132.
6. The antigen binding protein or fragment thereof of claim 5, comprising an antibody heavy chain at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 63 or 65, and an antibody light chain at least about 90% identical or at least about 95% identical to the amino acid sequence of SEQ ID NO: 67 or 69.
7-32. (canceled)
33. The antigen binding protein or antigen-binding fragment thereof of claim 1, wherein the antigen binding protein or antigen-binding binding fragment thereof comprises one or more full-length antibody heavy chains comprising an Fc region, optionally wherein the Fc region is a human IgG1 Fc region.
34. (canceled)
35. The antigen binding protein or antigen-binding fragment thereof of claim 1, wherein the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab), F(ab′)2, Fab′-SH, Fv, or scFv fragment.
36. The antigen binding protein or antigen-binding fragment thereof of claim 1, wherein the antigen binding protein or antigen-binding binding fragment thereof comprises an antibody F(ab) fragment.
37. The antigen binding protein or antigen-binding fragment thereof of claim 36, wherein the antibody F(ab) fragment comprises a heavy chain comprising SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58 and the first about 100 amino acids of SEQ ID NO: 54.
38-39. (canceled)
40. The antigen binding protein or antigen-binding fragment thereof of claim 36, wherein the antibody F(ab) fragment is selected from the group consisting of:
(a) an antibody F(ab) fragment wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 141, 164, 173, 182, 191, 200, 209, 218, 227, 236, 245, 254, 263, 272, or 281, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 142;
(b) an antibody F(ab) fragment wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 143, 165, 174, 183, 192, 201, 210, 219, 228, 237, 246, 255, 264, 273, or 282, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 144;
(c) an antibody F(ab) fragment wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 145, 166, 175, 184, 193, 202, 211, 220, 229, 238, 247, 256, 265, 274, or 283, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 146;
(d) an antibody F(ab) fragment wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 147, 167, 176, 185, 194, 203, 212, 221, 230, 239, 248, 257, 266, 275, or 284, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 148;
(e) an antibody F(ab) fragment wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 149, 168, 177, 186, 195, 204, 213, 222, 231, 240, 249, 258, 267, 276, or 285, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 150;
(f) an antibody F(ab) fragment wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 151, 169, 178, 187, 196, 205, 214, 223, 232, 241, 250, 259, 268, 277, or 286, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 152;
(g) an antibody F(ab) fragment wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67;
(h) an antibody F(ab) fragment wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154;
(i) an antibody F(ab) fragment, wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 153, 170, 179, 188, 197, 206, 215, 224, 233, 242, 251, 260, 269, 278, or 287, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69;
(j) an antibody F(ab) fragment, wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67;
(k) an antibody F(ab) fragment, wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154;
(l) an antibody F(ab) fragment, wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 155, 171, 180, 189, 198, 207, 216, 225, 234, 243, 252, 261, 270, 279, or 288, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69;
(m) an antibody F(ab) fragment, wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 67;
(n) an antibody F(ab) fragment, wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 154; and
(o) an antibody F(ab) fragment, wherein the antibody F(ab) fragment heavy chain comprises the amino acid sequence of SEQ ID NO: 156, 172, 181, 190, 199, 208, 217, 226, 235, 244, 253, 262, 271, 280, or 289, and the antibody F(ab) fragment light chain comprises the amino acid sequence of SEQ ID NO: 69.
41-65. (canceled)
66. A pharmaceutical composition comprising the antigen binding protein or antigen-binding fragment of claim 1, and a pharmaceutically acceptable carrier.
67. An isolated nucleic acid molecule encoding the antigen binding protein or antigen-binding fragment thereof of claim 1.
68. An expression vector comprising the nucleic acid molecule of claim 67.
69. A host cell comprising the expression vector of claim 68.
70. A method for treating a FGFR3-mediated disease or disorder in a subject, comprising administering to a subject in need thereof the antigen binding protein or antigen-binding fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising an antibody heavy chain variable (VH) domain and an antibody light chain variable (VL) domain, wherein:
(a) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GX1TFTDX2E (SEQ ID NO: 157), wherein X1 is Y or D and X2 is F or Y;
a CDR-H2 sequence comprising the amino acid sequence of IDPETGX3T (SEQ ID NO: 158), wherein X3 is G or S; or a CDR-H2 sequence comprising the amino acid sequence of INPNNGX4T (SEQ ID NO: 159), wherein X4 is G or V; or a CDR-H2 sequence comprising the amino acid sequence of VX5PETGGT (SEQ ID NO: 160), wherein X5 is D or E;
a CDR-H3 sequence comprising the amino acid sequence of TRX6YX7GYX8X9X10X11DY (SEQ ID NO: 161), wherein X6 is T or N, X7 is D or E, X8 is S or P, X9 is Q, R, or Y, X10 is T or A, X11 is F or M; and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QSX12LYSX13NX14KNY (SEQ ID NO: 162), wherein X12 is L or V, X13 is N, D, or S, and X14 is Q or N;
a CDR-L2 sequence comprising the amino acid sequence of X15AS (SEQ ID NO: 163), wherein X15 is W, Y, or F;
a CDR-L3 sequence comprising the amino acid sequence of QQYYSYRT (SEQ ID NO: 75), LQYDNLLWT (SEQ ID NO: 81), or HQYLSX16YT (SEQ ID NO: 290) wherein X16 is P or S;
(b) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82);
a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83);
a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGAMDY (SEQ ID NO: 78); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85);
a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86);
a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
(c) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GYTFTDYN (SEQ ID NOs: 76 and 82);
a CDR-H2 sequence comprising the amino acid sequence of INPNNGGT (SEQ ID NOs: 77 and 83);
a CDR-H3 sequence comprising the amino acid sequence of ARERDYDGSMDF (SEQ ID NO: 84); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QDINKF (SEQ ID NOs: 79 and 85);
a CDR-L2 sequence comprising the amino acid sequence of YTS (SEQ ID NOs: 80 and 86);
a CDR-L3 sequence comprising the amino acid sequence of LQYDNLLWT (SEQ ID NOs: 81 and 87);
(d) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GYTVTDYY (SEQ ID NO: 88);
a CDR-H2 sequence comprising the amino acid sequence of INPNNGVT (SEQ ID NO: 89);
a CDR-H3 sequence comprising the amino acid sequence of AREEDFDGFDY (SEQ ID NO: 90); and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QDVSTG (SEQ ID NO: 91);
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104);
a CDR-L3 sequence comprising the amino acid sequence of QQHYSTPLT (SEQ ID NO: 93);
(e) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GSTFSDFE (SEQ ID NO: 94);
a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101);
a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTX17DY (SEQ ID NO: 308), wherein X17 is M or F; and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QSVLYSX18NQKNY (SEQ ID NO: 309), wherein X18 is S or D;
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104);
a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105); or
(f) the VH domain comprises
a CDR-H1 sequence comprising the amino acid sequence of GSTFTDFE (SEQ ID NO: 100);
a CDR-H2 sequence comprising the amino acid sequence of IDPETGGT (SEQ ID NOs: 71, 95, and 101);
a CDR-H3 sequence comprising the amino acid sequence of TRNYDGYSQTX17DY (SEQ ID NO: 308), wherein X17 is M or F; and
the VL domain comprises
a CDR-L1 sequence comprising the amino acid sequence of QSVLYSX18NQKNY (SEQ ID NO: 309), wherein X18 is S or D;
a CDR-L2 sequence comprising the amino acid sequence of WAS (SEQ ID NOs: 74, 92, 98, and 104);
a CDR-L3 sequence comprising the amino acid sequence of or HQYLSSYT (SEQ ID NOs: 99 and 105).
71. The method of claim 70, wherein the FGFR3-mediated disease or disorder is achondroplasia, optionally wherein:
the achondroplasia is FGFR3G380R+ achondroplasia; and/or
the subject suffering from achondroplasia comprises one or more symptoms selected from the group consisting of shortened proximal limbs, brachydactyly, large head with prominent forehead frontal bossing, small midface with a flattened nasal bridge, spinal kyphosis, spinal lordosis, varus, valgus, ear infections, sleep apnea, and hydrocephalus.
72-73. (canceled)
74. The method of claim 70, wherein the FGFR3-mediated disease or disorder is cancer, optionally wherein the cancer is bladder cancer melanoma, urothelial cancer, and endometrial cancer.
75. (canceled)
76. A method for treating achondroplasia in a subject or preventing or alleviating one or more symptoms of achondroplasia in a subject, comprising administering to a subject in need thereof an antigen-binding protein fragment that specifically binds to FGFR3, wherein the antigen binding protein fragment does not bind to one or more of FGFR1, FGFR2, and FGFR4.
77. A method for inhibiting one or both of FGFR3 activity and expression in a bone growth plate of a subject, comprising administering to a subject the antigen-binding protein fragment of claim 1.
78. The method of claim 77, wherein the subject is a child, optionally wherein the child is an infant, optionally wherein the infant is a newborn.
79-81. (canceled)
US18/045,995 2020-08-21 2022-10-12 Fgfr3 antibodies and methods of use Pending US20230303704A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/045,995 US20230303704A1 (en) 2020-08-21 2022-10-12 Fgfr3 antibodies and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068575P 2020-08-21 2020-08-21
US17/407,774 US11505611B2 (en) 2020-08-21 2021-08-20 FGFR3 antibodies and methods of use
US18/045,995 US20230303704A1 (en) 2020-08-21 2022-10-12 Fgfr3 antibodies and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17/407,774 Division US11505611B2 (en) 2020-08-21 2021-08-20 FGFR3 antibodies and methods of use

Publications (1)

Publication Number Publication Date
US20230303704A1 true US20230303704A1 (en) 2023-09-28

Family

ID=77774991

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/407,774 Active US11505611B2 (en) 2020-08-21 2021-08-20 FGFR3 antibodies and methods of use
US18/045,995 Pending US20230303704A1 (en) 2020-08-21 2022-10-12 Fgfr3 antibodies and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US17/407,774 Active US11505611B2 (en) 2020-08-21 2021-08-20 FGFR3 antibodies and methods of use

Country Status (14)

Country Link
US (2) US11505611B2 (en)
EP (1) EP4200019A1 (en)
JP (1) JP2023538098A (en)
KR (1) KR20230052963A (en)
CN (1) CN116323666A (en)
AR (1) AR123306A1 (en)
AU (1) AU2021327387A1 (en)
BR (1) BR112023002455A2 (en)
CA (1) CA3189470A1 (en)
CO (1) CO2023001559A2 (en)
IL (1) IL300623A (en)
MX (1) MX2023002106A (en)
TW (1) TW202229343A (en)
WO (1) WO2022040560A1 (en)

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3039802B2 (en) 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア Receptor for fibroblast growth factor
AU686566B2 (en) 1992-06-18 1998-02-12 Whittier Institute For Diabetes And Endocrinology, The Process for detection of neoplastic disease
WO1994021813A1 (en) 1993-03-17 1994-09-29 The Whittier Institute For Diabetes And Endocrinology Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
EP1208231B2 (en) 1999-05-05 2009-12-30 Institut Curie Means for detecting and treating pathologies linked to fgfr3
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
DE122010000021I1 (en) 1999-10-06 2012-09-06 Tigenix Nv IN VIVO ASSAY FOR THE TESTING OF PHENOTYPIC STABILITY
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN100531796C (en) 2002-01-31 2009-08-26 马普科技促进协会 FGFR agonists
CN1678734B (en) 2002-06-27 2012-12-12 韦尔瓦制药有限公司 Differentiation modulating agents and uses thereof
WO2004022095A1 (en) 2002-09-04 2004-03-18 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
EP1579218A2 (en) 2002-12-20 2005-09-28 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
DK1611252T3 (en) 2003-03-26 2009-11-23 Progenika Biopharma Sa In vitro method for detecting transitional cell carcinoma of the bladder
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
US20070248605A1 (en) 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
DE60319240D1 (en) 2003-12-19 2008-04-03 Charite Universitaetsmedizin Use of ligands of CD52 antigen for the treatment of solid tumors and bone cancers
US7598027B2 (en) 2004-02-24 2009-10-06 Allergan, Inc. Botulinum toxin screening assays
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
AU2005302083A1 (en) 2004-11-04 2006-05-11 Fibron Limited Treatment of B-cell malignancies
EP1659175A1 (en) 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
KR20130105885A (en) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP2316847A3 (en) 2005-03-15 2012-01-18 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2007014123A2 (en) 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007045243A2 (en) 2005-10-17 2007-04-26 Enkam Pharmaceuticals A/S Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
BRPI0619548A2 (en) 2005-12-08 2011-10-04 Novartis Ag fgfr3 inhibitory effects on gene transcription
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US20100255004A1 (en) 2007-04-13 2010-10-07 Dana Farber Cancer Institute Receptor tyrosine kinase profiling
WO2009025846A2 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
NZ587420A (en) 2008-02-25 2012-07-27 Prometheus Lab Inc Drug selection for breast cancer therapy using antibody-based arrays
WO2009146033A2 (en) 2008-03-31 2009-12-03 Sma Foundation Compositions and methods for modulating smn activity
KR101590495B1 (en) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 Monoclonal antibodies to basic fibroblast growth factor
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
TWI381848B (en) 2008-10-20 2013-01-11 Imclone Llc Anti-fibroblast growth factor receptor-3 (fgfr-3) antibodies and pharmaceutical composition comprising the same
LT3702371T (en) 2009-03-25 2023-01-10 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
MX2012008222A (en) 2010-01-14 2012-08-17 Univ Yale Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof.
ES2660151T3 (en) * 2010-11-17 2018-03-21 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen binding molecule that has an alternative function to the function of blood coagulation factor VIII
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
US9481911B2 (en) 2012-03-08 2016-11-01 Astellas Pharma Inc. Methods for detecting FGFR3/TACC3 fusion genes
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US20150292030A1 (en) 2012-11-27 2015-10-15 Board Of Regents, The University Of Texas System Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
CN105209607B (en) 2013-04-05 2020-02-07 大学健康网络 Methods and compositions for producing chondrocyte lineage cells and/or cartilage-like tissue
TWI541022B (en) 2013-12-18 2016-07-11 應克隆公司 Compounds to fibroblast growth factor receptor-3 (fgfr3) and methods of treatment
MX2017010595A (en) 2015-02-19 2018-11-12 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer.
KR20200026787A (en) 2017-02-06 2020-03-11 레이니어 테라퓨틱스, 인크. Methods, Compositions, and Kits for Cancer Treatment

Also Published As

Publication number Publication date
CA3189470A1 (en) 2022-02-24
KR20230052963A (en) 2023-04-20
JP2023538098A (en) 2023-09-06
US20220056142A1 (en) 2022-02-24
BR112023002455A2 (en) 2023-03-28
AR123306A1 (en) 2022-11-16
WO2022040560A1 (en) 2022-02-24
CN116323666A (en) 2023-06-23
AU2021327387A1 (en) 2023-05-04
CO2023001559A2 (en) 2023-02-16
EP4200019A1 (en) 2023-06-28
US11505611B2 (en) 2022-11-22
IL300623A (en) 2023-04-01
MX2023002106A (en) 2023-03-15
AU2021327387A9 (en) 2023-07-06
TW202229343A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
US11512129B2 (en) TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
DK2513147T3 (en) Hitherto UNKNOWN ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF
WO2020098599A1 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
US11440954B2 (en) Optimized anti-TL1A antibodies
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
US20220098304A1 (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN103547594A (en) Anti-notch1 antibodies
CN110431231A (en) Anti-CD 3 antibodies and molecule comprising the antibody
KR20150002679A (en) Antibodies to bradykinin b1 receptor ligands
US20240076398A1 (en) Antibody Molecules to C5AR1 and Uses Thereof
JP2024504124A (en) Novel anti-gremlin 1 antibody
TW201922798A (en) Therapeutic antibody targeting RANKL
WO2022228183A1 (en) Anti-siglec15 antibody, preparation method therefor and use thereof
TW202235443A (en) Anti-trka antibody or antigen-binding fragment thereof, preparation method therefor, and application thereof
US20220251193A1 (en) Semaphorin 3a antibodies and uses thereof
WO2020244540A1 (en) Anti-connective tissue growth factor antibody and application thereof
TW202334220A (en) Human tumor necrosis factor alpha antibodies
US11505611B2 (en) FGFR3 antibodies and methods of use
CA3227972A1 (en) Anti-pvrig/anti-tigit bispecific antibodies and applications thereof
CN116323664A (en) Anti-beta-cytokine antibodies, fragments thereof, and multispecific binding molecules
RU2807484C2 (en) Antibody to pd-1, its antigen-binding fragment and its pharmaceutical use
US11655292B2 (en) Anti-human NGF antibodies and methods using same
CA3211727A1 (en) Novel pd-1 binding domains
TW202300526A (en) Antibodies directed against gdf-15

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEMOINE, CENDRINE;REEL/FRAME:061396/0355

Effective date: 20210630

Owner name: GENZYME CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRONDYK, WILLIAM;CHEN, YANGDE;CHO, HYUNSUK;AND OTHERS;SIGNING DATES FROM 20210615 TO 20210701;REEL/FRAME:061396/0170

Owner name: GENZYME CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT;REEL/FRAME:061396/0463

Effective date: 20210630

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION